An analysis of ototoxicity in children: Audiological detection, clinical practice and genetic susceptibility by Al-Malky, GMA
 1 
 
 
 
An analysis of ototoxicity in children:  
Audiological detection, clinical practice 
and genetic susceptibility 
 
 
Dr. Ghada Al-Malky,  
MBChB, MD.AVM, PG-CLTHE, HCPC CS 
Submitted for the degree of Doctor of Philosophy 
University College London (UCL) 
Ear Institute 
2014 
 
 2 
 
Declaration: 
 
‘I, Ghada Al-Malky, confirm that the work presented in this thesis is my 
own. Where information has been derived from other sources, I confirm 
that this has been indicated in the thesis. I, the candidate, designed all 
experiments with assistance from my supervisors. As part of MSc 
projects that were supervised by the candidate, the following students 
collected the data for some of the studies reported in this work: Suparna 
Bali (Theme A: Control Study), Anne Abiodun (Theme C: Study 1) and 
Miranda De Jongh & Mirijam Kikic (Theme C: Study 2). The remaining 
testing and all analyses were conducted by the candidate.’ 
  
 3 
Abstract:  
Ototoxicity is the damage to the ear from exposure to medications. The inner ear is the 
commonest site of damage where cochlear and/or vestibular functions are affected. Ototoxic 
medications can cause irreversible toxicity, with aminoglycosides (AGs) and cisplatin being 
the most established agents. A series of studies are reported in this research under three main 
themes. Theme A focused on audiological assessments and assessment tools; Theme B 
focused on causation; and Theme C focused on the impact of ototoxicity and current service 
provision. The main Theme A study was a clinical observational study with a cross-sectional 
design assessing the auditory status of children with cystic fibrosis (CF) exposed to AGs. 
Theme B investigated potential risk factors and aspects in genetics that may be associated 
with increasing patient susceptibility to the ototoxic effect of AGs. Theme C assessed the 
effect of ototoxicity on the quality of life (QoL) of children surviving cancer. It also included 
a survey of current UK practice regarding auditory monitoring for ototoxicity. 
The novel outcomes of these studies included showing that the prevalence of AG ototoxicity 
in children with CF is higher than previously reported and evaluating the efficacy of auditory 
assessment tools. They stressed the importance of choosing appropriate criteria to define 
ototoxicity and identified potential risk factors associated with it. The genetic studies 
highlighted a rare case of normal hearing in a child with the m.1555 A>G mutation despite 
exposure to AGs. They complemented the limited research on the impact of ototoxicity in 
children on their QoL and on current practice. The latter identified gaps in the provision of 
ototoxicity monitoring services in the UK, especially due to the absence of nationally agreed 
guidelines. 
This research has generated recommendations for several future studies and has informed the 
clinical management of patients with CF.  
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  Introduction Chapter 1:
1.1 Overview 
Ototoxicity is damage to the ear following exposure to drugs or chemicals.  There are 
hundreds of drugs and chemicals that can cause either reversible or irreversible damage, with 
some established groups such as the aminoglycoside antibiotics and chemotherapeutic 
cisplatin. Despite their well known ototoxic effects there are still many research questions 
that have not been addressed enough, such as why there is a significant variation in the 
reported ototoxic effect of these drugs, what are the most appropriate auditory monitoring 
tools that should be used for early detection of this effect and what genetic mutations or 
variations effect patients’ susceptibility to this side effect.  
This research project will aim to address some of these questions through a series of 
clinical audiological and laboratory-based genetics studies to further our 
understanding of this important field and translate these findings into clinical practice 
to improve patient care and enhance their quality of life.   
1.2 Ototoxicity 
1.2.1 Definition of Ototoxicity 
Ototoxicity (“ear-poisoning”) is damage to the hearing or balance functions of the ear by 
drugs or chemicals. The most commonly affected parts of the ear are the cochlea with the 
associated vestibulo-cochlear nerve and the vestibular apparatus in the inner ear.  
Ototoxicity can result in temporary or permanent disturbances of hearing, balance, or both. It 
is one of the main preventable causes of deafness and one that is most directly influenced by 
managing clinicians that make vital decisions regarding what, when, how much and how 
often these medications are prescribed. Many chemicals have ototoxic potential, including 
over-the-counter drugs, prescription medications and environmental chemicals.  
1.2.2 Overview of ototoxic agents 
Generally, there are more than 200 medications and chemicals known to cause hearing and 
balance problems. It has even been reported that at least 743 drugs, 30 herbs and 148 
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chemicals include known ototoxic substances (Bauman, 2003). The main classes of drugs 
and chemicals that have been implicated as having ototoxic potential include aminoglycoside 
antibiotics, chemotherapeutic agents such as cisplatin, non-steroidal anti-inflammatory drugs 
(NSAID) like aspirin, antimalarial drugs and diuretics.  Some of these drugs mainly affect 
the cochlear function leading to hearing loss and tinnitus and are therefore classified as 
cochleotoxic drugs; others mainly affect the vestibular function leading to oscillopsia, 
imbalance or even vertigo and are classified as vestibulotoxic drugs. Some drugs may affect 
both functions. Ototoxic drugs can also be classified according to whether they cause a 
reversible or irreversible permanent damage to the ear. Drugs known to have a reversible 
ototoxic effect may only induce a temporary threshold shift with return to normal thresholds 
following stoppage of intake. These include salicylates and loop diuretics. Aminoglycosides 
and cisplatin mainly produce irreversible permanent damage and continue to have an 
ototoxic effect even after weeks and months of intake (Campbell, 2007). 
Cochleotoxicity can manifest as hearing loss in one or both ears, range from a mild to a 
severe-profound impairment, and have temporary or long-lasting effects. Regardless of the 
type or severity, drug-induced hearing loss can have devastating effects on communication 
and can lead to difficulties in educational, vocational, and social settings for both children 
and adults (ASHA, 1994b). It also represents one of the main preventable causes of deafness, 
in the sense that it is an outcome that can perhaps be most directly influenced by healthcare 
professionals (Yorgason et al., 2006). 
1.2.3 Type of ototoxic agents 
The most well established substances known to cause ototoxicity include:      
Aminoglycoside antibiotics: include gentamicin, streptomycin, kanamycin, tobramycin, 
neomycin, amikacin, netilmicin, dihydrostreptomycin, and ribostamycin. All members of 
this family are known for their potential to cause permanent ototoxicity and nephrotoxicity. 
They may enter into the inner ear through the blood system or through inhalation by 
unknown mechanisms, which may include being secreted into the perilymph by the spiral 
ligament or endolymph by the stria vascularis (Forge and Schacht, 2000, Rybak and 
Ramkumar, 2007, Schacht et al., 2012, Wu et al., 2002). They may also diffuse from the 
middle ear through the round window membrane into the inner ear when administered 
topically for management of middle ear infections or specifically for chemical 
labyrinthectomy for treatment of unilateral Meniere’s disease (McCall et al., 2010, Perez et 
al., 2003). They enter the blood stream in largest amounts when given intravenously (i.v). 
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Aminoglycosides are excreted by the kidney. These are one of the drugs of interest in this 
research project. 
Other possible ototoxic but much less established antibiotics include, macrolides like 
erythromycin possibly causing reversible hearing loss; vancomycin, which is effective 
against gram-positive infections such as Staphylococcus aureus and reported to be ototoxic 
and nephrotoxic but with limited evidence (Vella-Brincat et al., 2011, Forouzesh et al., 2009, 
Shields et al., 2009); and penicillin, sulphonamides and cephalosporins, which may be 
associated with minor topical ototoxicity when administered in large doses to the middle ear 
(Brown et al., 1989).  
Anti-neoplastic (anti-cancer /chemotherapeutic drugs): include platinum compounds such as 
cisplatin and carboplatin, bleomycin and vincristine. Cisplatin is most known to cause 
hearing loss with incidence as high as 62%-81% and even up to 100% in some children 
(Knight et al., 2005, Knight et al., 2007). It has a similar histopathological mechanism of 
cochlear damage as aminoglycosides. Clinically, it is associated with bilateral high 
frequency symmetric SNHL, which is usually not reversible and cumulative in nature. Risk 
factors include age extremes, cranial irradiation, high dose or cumulative therapy and 
concomitant use with other ototoxic drugs. Carboplatin has been implicated as well but is 
reported to be less ototoxic so that ototoxicity is usually only associated with intake of large 
doses (Musial-Bright et al., 2011, Taudy et al., 1992).      
Loop diuretics: include furosemide (Lasix), bumetanide (Bumex) and ethacrynic acid 
(Edecrin). They are examples of reversible ototoxic medications with a reported incidence at 
6-7%. Clinically a common presentation includes tinnitus, temporary and reversible SNHL 
and rarely vertigo, possibly occurring within minutes of intake. High doses can cause 
irreversible SNHL. The highest risk is co-administration of aminoglycosides due to the 
associated synergistic effect (Bates et al., 2002, Hirose and Sato, 2011). 
Salicylates (Aspirin) and NSAIDs (non-steroidal anti-inflammatory drugs):  here the 
cochlea is histologically normal with no hair cell loss and is therefore another example of 
reversible ototoxic medications. The mechanism of ototoxicity is probably due to decreased 
blood flow and decreased enzymes. Clinically, the commonest presentation is tonal, high 
frequency (HF) tinnitus (7-9 kHz) with reversible mild to moderate HF-SNHL that is rarely 
permanent (Brien, 1993). 
Antimalarial quinine products: these may cause temporary ototoxicity, particularly tinnitus, 
but may also reduce hearing. The mechanism, which is similar to salicylates, includes 
decreases in cochlear blood flow through vasoconstriction. Reversible changes within outer 
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hair cells also seem to play an important role. Also, one of quinine's main actions, which 
involve antagonism of calcium-dependent potassium channels, has not been confirmed for its 
possible role in ototoxicity (Jung et al., 1993, Koegel, 1985, Hennebert and Fernandez, 1959). 
Environmental chemicals, including butyl nitrite, mercury, carbon disulphide, styrene, 
carbon monoxide, tin, hexane, toluene, lead, trichloroethylene, manganese, and xylene. Most 
are associated with hearing disturbances that may be permanent; mercury has also been 
linked to permanent balance problems in addition to evidence showing that it produces 
peripheral and/or central damage (Hoshino et al., 2012, Hoet and Lison, 2008, Fechter et al., 
1998, Counter and Buchanan, 2002).   Workplace exposure to some of these organic 
solvents, such as toluene, was shown to increase the risk of hearing impairment especially 
when associated with concomitant noise exposure where a synergistic interaction was 
confirmed (Lund and Kristiansen, 2008, Lataye and Campo, 1997, Johnson et al., 1990).    
1.2.4 Aminoglycoside antibiotics 
As these are one of the ototoxic agents of interest in this current research, aminoglycosides 
(AGs) will be further discussed in detail in the following sections. They are potent water-
soluble antibiotics, with peak concentration-dependent bactericidal activity against many 
pathogenic aerobic gram-negative bacteria as Pseudomonas aeruginosa and including many 
multi-drug resistant bacilli, mycobacterium tuberculosis and to a lesser extent against gram-
positive bacteria as Staphylococcus aureus. They have a bactericidal effect, i.e. they actually 
kill the bacteria not just weaken them. AGs probably have more than one mechanism of 
action on bacterial cells beginning at the plasma membrane followed by internalization and 
interference with several intracellular processes (Forge and Schacht, 2000). They bind to the 
16S ribosomal RNA and the 30S ribosome leading to misreading of the RNA code and 
subsequent inhibition of essential protein synthesis and cell death (Aronson, 2006).  
The common route of administration for systemic therapy is parenteral (intravenously (i.v) or 
intramuscularly (i.m)). If possible, they are given in localized form to decrease side effects, 
e.g. as topical eardrops for treatment of otitis media or inhaled through nebulization for 
treatment of chest infections. The most significant side effects include trough concentration-
dependent reversible nephrotoxicity and more commonly irreversible ototoxicity (Kumana 
and Yuen, 1994). Generally, ototoxicity is bilaterally symmetrical, but it may be 
asymmetrical, affecting the basal turn of the cochlea first then progressively extending 
towards the apex. This leads to appearance of high frequency sensorineural hearing loss 
(SNHL) first which gradually affects lower frequencies. The usual onset time of ototoxicity 
is often unpredictable, with reports that significant hearing loss can occur even after a single 
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dose. In addition, ototoxicity may not manifest until several weeks, months or years after 
completion and cessation of antibiotic therapy. This is because AGs are cleared more slowly 
from inner ear fluids than from serum, making continued monitoring for evidence of 
ototoxicity after cessation of treatment important. (Matz, 1993, Rizzi and Hirose, 2007, 
Schacht, 1998, Selimoglu, 2007, Waguespack and Ricci, 2005). 
1.2.4.1 Types and Epidemiology:  
Streptomycin was the first of the aminoglycosides to be discovered in the 1940s by Selman 
Waksman (Jones et al., 1944). It was a long-awaited cure for tuberculosis (TB) and became 
widely popular in the 1940s and 1950s and remains a first/second-line treatment choice for 
this condition to date, particularly in developing countries where the prevalence of TB has 
increased (Wu et al., 2002). Over the following years, new AGs were isolated or derivatives 
synthesized including amikacin, gentamicin and tobramycin, kanamycin, neomycin, 
netilmicin, and dihydrostreptomycin are currently available in most countries. The 
combination of high efficiency with low cost makes them still one of the most highly used 
antibiotics. This is especially still the case in developing countries where the prevalence 
exceeds the 20-25% reported for ototoxicity in developed countries. In certain countries such 
as China reports that 2/3 (66%) of all deaf-mutism was due to the administration of 
aminoglycosides to children, highlighting the impact of this condition on the general 
population (Forge and Schacht, 2000, Lu, 1987). In developing countries of sub-Saharan 
Africa, diseases such as TB and HIV/AIDs go hand-in-hand, which necessitates the intake of 
antiretroviral and TB medications simultaneously. It has been reported that HIV-positive 
multidrug-resistant (MDR) TB patients, requiring 2
nd
 line ototoxic drugs such as 
streptomycin and kanamycin, who are also receiving highly active antiretroviral therapy 
(HAART) were more likely to present with ototoxic hearing loss than HIV-negative MDR-
TB patients. In addition, treating HIV-associated opportunistic infections and malignancies 
with aminoglycosides, amphotericin B, and platinum-based antineoplastic drugs, such as 
cisplatin, increase the incidence of ototoxicity in these populations (Harris et al., 2012).  
On the other hand, aminoglycosides’ prominent chronic side effects of nephrotoxicity and 
ototoxicity have led to a steep decline in their use in developed industrial countries since the 
1970s and 80s. Here, prescription of these antibiotics has been restricted to certain 
population groups where they are most needed. These include children, even neonates, 
hospitalized within intensive care units (ICU) for serious infections like septicaemia caused 
by aerobic gram-negative bacteria; cystic fibrosis patients with chronic chest infections; 
multi-drug resistant TB patients; surgical prophylaxis during operations such as urological, 
vascular or cardiac surgery where only a single dose of gentamicin is given; empirical 
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therapy (pathogen unknown) for severe conditions such as intra-abdominal infections, acute 
cholecystitis, genito-urinary infections, infective endocarditis or hospital acquired 
pneumonia where gentamicin is always used in combination with other antibiotics for <48 
hours; and directed therapy (pathogen known) for conditions such as prosthetic valve 
infective endocarditis, enteric organism bacteraemia and pseudomonas aeruginosa infections 
where different types of aminoglycosides are almost always used in combination with other 
antibiotic groups for prolonged durations (often weeks) (Avent et al., 2011).     
1.2.4.2 Differences in ototoxicity between different types of AGs 
The ototoxic effect of aminoglycosides occurs either in the form of vestibulotoxicity or 
cochleotoxicity depending on the type of aminoglycoside used. Gentamicin and streptomycin 
are known to be mainly vestibulotoxic with an element of cochleotoxicity; whereas others 
like tobramycin, amikacin, neomycin, dihydrostreptomycin and kanamycin are mainly 
cochleotoxic.  
Damage to the vestibular organ presents with symptoms associated with chronic bilateral 
vestibular insufficiency i.e. ataxia and oscillopsia and possibly nystagmus, but not vertigo 
due to its common bilateral symmetrical affect. However, it can rarely cause unilateral 
damage even when administered systemically where in this case patients may complain of 
vertigo due to the asymmetrical nature of the damage (Selimoglu, 2007, Waterston and 
Halmagyi, 1998). Vestibulotoxicity can occur in up to 15% of patients following exposure to 
AGs (Fee, 1980). Whereas cochleotoxicity first presents as a high frequency sensorineural 
hearing loss (SNHL) due to the selective damage of outer hair cells (outer layers first) 
followed by inner hair cells of the basal coil of the cochlea, where tonotopically high 
frequency sounds are represented, before gradually extending towards the apex. 
Several studies have been performed to rank AGs in order of their probability of auditory 
toxicity including animal (Parravicini et al., 1983, McCormick et al., 1985) and clinical 
studies (Lerner and Lorber, 1983, Rybak et al., 1999, Lerner et al., 1986). Comparisons of 
ototoxicity with antibacterial activity have shown that netilmicin is the least toxic and has the 
highest therapeutic index followed by tobramycin then by gentamicin. A clinical study 
showed that the average incidence of cochlear toxicity was 13.9% for amikacin, 8.3% for 
gentamicin, 6.1 % for tobramycin, and 2.4% for netilmicin (Kahlmeter and Dahlager, 1984) 
whereas another study comparing amikacin and gentamicin indicated that amikacin is just as 
effective against severe infections caused by gram-negative bacteria as Pseudomonas 
auroginosa and is not significantly more or less ototoxic or nephrotoxic than gentamicin 
(Smith et al., 1977).  
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In general, gentamicin is usually considered the agent of choice for most conditions, 
tobramycin is shown to be slightly more potent against Pseudomonas aeruginosa infections, 
amikacin is the most resistant to break down by bacterial enzymes and therefore is more 
suitable for use in hospital settings where gentamicin resistance is high, and netilmicin is 
possibly the least toxic whereas neomycin is considered to be the most toxic (Kumana and 
Yuen, 1994).  
1.2.4.3 Risk factors: 
Identification of risk factors associated with occurrence of AG ototoxicity is one of the main 
aims of many research studies. Identifying these risk factors can prove most useful especially 
if they can be realistically avoided or stopped and consequently decrease the incidence of 
ototoxicity. Some of these findings are reported below. 
Patient susceptibility to ototoxicity depends on a number of factors, such as route of 
administration (systemic vs. transtympanic perfusion), genotype and existing medical 
conditions (Guthrie, 2008). Factors related to the drug administration regimens such as 
intake of larger doses, higher blood levels, longer duration of therapy, or intake of 
cumulative courses with short intervals between courses that don’t allow for complete 
clearance of the drugs from the inner ear, are all associated with increased incidence of 
ototoxicity. Other high-risk patients include elderly patients especially if they have other 
inner ear disorders such as noise-induced hearing loss or presbyacusis, those with renal 
insufficiency as this impairs the excretion of the drugs and higher blood levels, those with 
pre-existing hearing problems, those with a family history of ototoxicity, and those receiving 
other ototoxic, e.g. loop diuretics, or nephrotoxic medications (Gatell et al., 1987, Moore et 
al., 1984). The remaining part of this section will present some of the literature that 
identified some of these risk factors.  
The route of administration has been shown to affect the levels of ototoxicity. Transtympanic 
administration, commonly used for treatment of incapacitating vertigo in Meniere’s disease, 
manifests with a lower incidence and less severe cochleotoxicity than systemic parenteral 
administration. Bottrill et al. reported that only one patient developed a profound hearing 
loss from a total of 83 patients who received transtympanic gentamicin to treat incapacitating 
vertigo secondary to Meniere’s disease (Bottrill et al., 2003). Wu and Minor also reported 
one case of profound hearing loss in 34 patients treated in the same way for the same 
condition (Wu and Minor, 2003). Both authors concluded that the risk of transtympanic 
gentamicin is minimal and does not outweigh the benefit.  
 27 
Many studies have suggested that certain individuals may be at a greater risk of developing 
hearing loss due to the existence of genetic mutations. Molecular studies revealed a 
mitochondrial DNA (mtDNA) 1555A>G point mutation in the 12S ribosomal RNA gene to 
be significantly associated with increased susceptibility to aminoglycoside ototoxicity and 
non-syndromic sensorineural hearing loss. A single parenteral injection of aminoglycosides 
could lead to a severe-profound hearing loss in subjects with this mutation (Stergaard et al., 
2002, Estivill et al., 1998, Gallo-Teran et al., 2004, Kokotas et al., 2009, Shohat et al., 1999). 
More studies related to genetic susceptibility to aminoglycosides will be discussed in more 
detail later. 
Pre-existing medical conditions are also associated with increased incidence of ototoxicity. 
Deutsch et al. reported an incidence of hearing loss of 12% in 125 liver transplant children 
taking aminoglycosides (Deutsch et al., 1998) and Naunton and Ward reported an 
association between renal dysfunction and kanamycin ototoxicity (Naunton and Ward, 1959). 
Li and Steyger reported that noise exposure had a synergistic effect even when there is no 
simultaneous exposure to aminoglycosides (Li and Steyger, 2009). They reported that prior 
acoustic insult, which does not result in permanent threshold shifts, potentiates 
aminoglycoside ototoxicity and conversely, exposure to sub-damaging doses of 
aminoglycosides aggravates noise-induced cochlear damage so that the damage caused is 
more than the damage caused by each of them individually. 
Gunther et al. (1988) reported that treatment of Mg-deficient rats with gentamicin induced a 
more severe and irreversible hearing loss compared to a milder reversible hearing loss in 
normally fed rats. They also found that Zn-deficient rats had a stronger yet still reversible 
hearing loss with salicylic acid. The authors concluded that Mg and Zn deficiencies 
enhanced ototoxicity of both gentamicin and salicylic acid (aspirin) (Gunther et al., 1988).   
Aronson recommended strategies for minimizing aminoglycoside toxicity which all include 
avoiding risk factors. Therefore  advice was given for early bedside detection of hearing and 
vestibular dysfunction, which should lead to prompt withdrawal, use of shorter durations of 
treatment, increasing dosing intervals to at least 12 hours, monitoring of serum 
concentrations, and awareness of potential risk factors, such as renal or liver dysfunction, old 
age, pre-existing hearing loss, and previous recent AG exposure (Aronson, 2006). 
In summary, this wide range of risk factors highlights the importance of identifying, 
monitoring and accurately recording all possible aspects that may increase the prevalence of 
side effects such as ototoxicity in patients. Part of the research conducted and presented 
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within this thesis specifically investigates some of these risk factors in the study population 
and presents difficulties encountered with accurate recording of the data required.    
1.2.5 Ototoxic chemotherapeutic agents – Cisplatin 
Platinum group of drugs, including cisplatin, carboplatin and oxaliplatin, are effective 
chemotherapeutic/ anti-neoplastic drugs commonly used for a variety of paediatric and adult 
cancers.  These include germ cell tumours (ovarian and testicular), non-small cell lung 
cancer, malignant mesothelioma, bladder and cervical cancers, liver tumours, squamous cell 
carcinomas of the head and neck and some brain tumours including neuroblastomas (NCI, 
2011). Carboplatin has slightly more limited use than cisplatin and is used against specific 
types of cancer of the breast and in combination therapy for treating lung cancer; oxaliplatin 
is the least known and is used in combination therapy against colorectal cancer. Cisplatin is 
known to be the most ototoxic but carboplatin is also ototoxic when administered in large 
doses for example when myeloablative doses are given during bone marrow transplantation 
or when given in conjunction with other drugs that open the blood-brain barrier (Neuwelt et 
al., 1998). Both cisplatin and carboplatin are shown to cause oxidative stress to the cochlear 
hair cells  (Ravi et al., 1995, Rybak et al., 2009, Taudy et al., 1992, Saito et al., 1989). As 
with aminoglycosides, cisplatin is shown to affect the outer layer of the outer hair cells 
(OHCs) at the basal turn of the cochlea then gradually extends to the inner layers and inner 
hair cells (IHCs) and apically. However, several animal studies have shown carboplatin to 
cause species-specific, dose-dependent high-frequency SNHL attributed to primary damage 
of the inner hair cells instead of the OHCs (Wake et al., 1994). With both drugs, due to the 
tonotopic organization of the cochlea, high frequencies are affected first followed by the 
lower frequencies containing the speech frequencies. These platin group of drugs however, 
tend to be cochleotoxic only and not vestibulotoxic, as some of the aminoglycosides. Other 
toxicities include nephrotoxicity, which is the most significant side effect. This is especially 
substantial in older patients but which can also be reversible to some extent through good 
hydration using saline or mannitol diuresis (Rybak et al., 2009). They may also be associated 
with neurotoxicity, anorexia, nausea vomiting, thrombocytopenia with bleeding tendencies 
and hair loss (Schacht et al., 2012). Hearing loss tends to be permanent, bilateral 
symmetrical SNHL affecting 75-100% of patients especially if they are children or elderly, 
exposed to head and neck radiotherapy as well, exposed to larger doses of cisplatin (150–225 
mg/m
2
), concomitant use of other ototoxic medications, or exposed to noise (Reddel et al., 
1982, Bokemeyer et al., 1998, Kopelman et al., 1988, McKeage, 1995). 
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1.2.6 Ototoxic effect of aminoglycosides and cisplatin on the 
inner ear: 
As mentioned earlier, aminoglycosides and cisplatin affect the basal turn of the cochlea first 
and then spread their effect apically. Figure 1-1 shows the tonotopic distribution of 
frequencies along the cochlear basilar membrane, where the highest frequencies are 
represented at the basal turn and the lower frequencies are represented more apically. The 
outer layer of the OHCs is affected first followed by the middle then the inner layer of OHCs 
with the IHCs being the last hair cells to show damage. This is demonstrated in Figure 1-2, 
which shows scanning electron microscopy pictures of different levels of cochlear damage to 
a rat organ of corti following exposure to aminoglycosides. Figure 1-3 shows the rate of hair 
cell loss along the basilar membrane.  
 
Figure 1-1: Schematic representation of the tonotopic organization of the cochlea. 
The higher frequencies  (starting at 20,000Hz) are represented at the basal turn of the cochlea with the 
lower frequencies represented more apically. (From: http://quizlet.com/15959363/splh-120-physic-of-
speech-midterm-flash-cards (accessed: 18/03/2014). 
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Figure 1-2: Scanning Electron microscopy (SEM) pictures of the surface of a rat cochlea demonstrating 
different levels of inner ear hair cell damage following exposure to ototoxic drugs 
A: shows normal inner ear with 3 healthy rows of OHCs and one row of IHCs 
B: early damage affecting mainly the outer row of OHCs at the basal turn of the cochlea.  
     i, inner hair cells; o, outer hair cells 
C: More significant damage affecting all layers of OHCs 
D: Total damage affecting OHCs and IHCs. The red arrow points to the only remaining steriocilia of one IHC. 
The supporting cells fill up the entire surface where hair cells were lost. 
(Adapted from: http://www.neuroreille.com/promenade/english/pathology/amino/famino.htm pictures 
by M. Lenoir (accessed: 18/03/2014))  
A	
D	C	
B	
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Figure 1-3: Showing the percentage hair cell survival along the length of the basilar membrane following 
exposure to Amikacin. 
The chart shows that the outer layer of OHCs (3) demonstrates the most significant loss followed by the 
middle layer of OHCs (2) then the inner layer of OHCs (1). The IHCs are the least damaged with the loss 
only affecting the basal part of the cochlear basilar membrane (from: (Hawkins and Johnssen, 1981) 
 
At the cellular level, different reactions lead to cell death through apoptosis following 
exposure to ototoxic medications. Figure 1-4 and Figure 1-5 illustrate a simplified version of 
the intracellular mechanisms of cell death from aminoglycosides and cisplatin (Rybak et al., 
2000). Both drugs actively cross the blood-labyrinth barrier mainly through the stria 
vascularis into the endolymph (Steyger and Karasawa, 2008). They then enter the sensory 
hair cells through the apical mechano-electrical transducer channels (Marcotti et al., 2005, 
Gale et al., 2001). Aminoglycosides form AG-iron complexes that attract electron donors 
like arachidonic acid, which form reactive oxygen species (ROS), mainly superoxide anion 
(O2
• −
), hydrogen peroxide (H2O2), and hydroxyl radical (
•
OH) that are commonly also 
referred to as ‘oxygen radicals’. ROS then activate c-Jun-N-terminal kinase (JNK), which 
translocate into the nucleus activating cell death pathway genes. These then translocate to the 
mitochondria activating cytochrome-c, which activates a cascade of caspases causing hair 
cell death through apoptosis. Another caspase-independent pathway is also identified with 
aminoglycosides. Cisplatin only follows a caspase-dependent pathway by first forming a 
cisplatin-monohydrate complex which activates NADPH oxidase (NOX3) forming ROS 
which activate JNK which then translocate into the nucleus and follows a similar pathway as 
aminoglycosides (Rybak and Ramkumar, 2007). In addition to targeting the hair cells 
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(mainly OHCs), these reactions also affect different cochlear tissues including the stria 
vascularis, spiral ligament and spiral ganglionic cells (Clerici et al., 1995, Clerici and Yang, 
1996, Kopke et al., 1997).  
 
Figure 1-4: Intracellular mechanisms of aminoglycoside and cisplatin-induced cell death. 
AG, aminoglycoside; AG-FE, AG-iron complex; ROS, reactive oxygen species; JNK, c-Jun N-terminal kinase; 
Cyt c, cytochrome c. (b) CP, cisplatin; CP-MHC, cisplatin-monohydrate complex; (From (Rybak and 
Ramkumar, 2007)  
 
 
This ROS-induced apoptosis is counteracted within the cell by mechanisms to detoxify the 
reactive intermediates causing oxidative stress with the aim of supporting cell recovery and 
survival. Figure 1-5 (part B) illustrates some of these intracellular antioxidant cellular 
mechanisms, which involve production of Heat Shock Proteins, reduction of glutathione, 
utilization of intracellular antioxidants such as Vitamin C & E and trophic factors and 
targeting genes encoding antioxidant enzymes and detoxifying enzymes such as Superoxide 
Dismutase (SOD), Peroxidases and Catalases. An imbalance between the ROS pathways and 
the detoxification processes causes oxidative stress and cell death through apoptosis (Wu et 
al., 2002). 
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Figure 1-5: Illustration of drug-induced hair cell injury and death at the cellular level.  
A. Shows the formation of damaging reactive oxygen species (ROS) e.g. superoxide (O2- ) and hydroxyl 
anion (OH-) that are initiated by entry of ototoxic drugs into the hair cells.  
B. Shows some of the internal antioxidant mechanisms that sensory hair cells use to control ROS-induced 
damage. These include production of heat shock proteins, reduced glutathione, use of antioxidant factors 
such as Vitamins C & E and production of antioxidant enzymes.  
C. If antioxidant mechanisms fail to balance the reactions towards cell survival, ROS will irreversibly 
damage cell membranes, mitochondria, nuclear DNA and proteins, which signals cell death through 
apoptosis. (From:http://www.soundpharmaceuticals.com/technology.html (accessed 18/03/2014)) 
 
 
Figure 1-6: Illustration of the chemical reactions occurring within the mitochondrion where initiation of 
apoptosis occurs. (From (Wallace, 2005b) 
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To describe this complicated process in more detail, reactions occurring at the level of the 
organelles, specifically the mitochondria are presented. The mitochondrion is defined as “a 
cellular organelle of endosymbiotic origin that resides in the cytosol of most nucleated 
(eukaryotic) cells and which produces energy by oxidizing organic acids and fats with 
oxygen by the process oxidative phosphorylation (OXPHOS) and generates oxygen radicals 
(reactive oxygen species, ROS) as a toxic by-product” (Wallace, 2005b). Figure 1-6 
illustrates the complex chemical reactions continuously occurring within the mitochondria 
where the three main functions of the mitochondria are carried out. These functions include: 
i) energy production through formation of ATP (adenosine triphosphate); ii) formation of 
Reactive Oxygen Species (ROS); and iii) initiation of controlled cell death through apoptosis 
from reactions at the mitochondrial permeability transition pore (mtPTP) when an imbalance 
between the anti-apoptotic and pro-apoptotic reactions occurs. The reactions shown on the 
right-hand side of the figure are the ones associated with apoptosis. The pro-apoptotic Bax in 
the mtPTP interacts with the anti-apoptotic Bcl2 and the benzodiazepine receptor (BD) 
leading to the opening of the mtPTP and release of numerous pro-apoptotic proteins. 
Cytochrome-c (cyt c) then interacts with cytosolic Apoptotic protease activating factor 1 
(Apaf-1) and activates it, which consequently activates caspase-9 that activates a down-
stream reaction to activate caspase-3 and caspase-2 initiating proteolytic degeneration of 
cellular proteins. Apoptosis initiating factor (AIF) and endonuclease G (EndoG) are released 
to the nucleus where they target nuclear peptides and degrade the nuclear chromosomal 
DNA leading to cell death (Wallace, 2005b) as shown in part C of Figure 1-5. 
1.3 Current practice in monitoring for toxicities 
There is a widespread variability in monitoring for toxicities. The deficiency in monitoring 
for both nephrotoxicity and ototoxicity exists even in developed countries, especially for 
ototoxicity, and is reported in the literature. Al-Aloul et al. reported that the commonly used 
glomerular filtration rate (GFR) monitoring tool is not effective in detecting nephrotoxicity 
(Al-Aloul et al., 2007).  They investigated different methods for measuring renal function in 
CF and concluded that equations and 24-hr urine collections were inaccurate and that 
monitoring of renal function using more sensitive methods and increased vigilance were 
needed to reduce toxicity. Whereas in regards to ototoxicity, in the UK, Tan et al. undertook 
a questionnaire study of all UK CF specialist centers to determine prescribing practice and 
surveillance of AG antibiotics where 23 out of 28 centres responded (82%; 17 paediatric, 6 
adult). Of these, only 3/23 (13%) centers reported routinely assessing hearing function, and 
even then, only standard pure-tone audiometry up to 8 kHz was used to detect the 
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cochleotoxic aspect of ototoxicity (Tan et al., 2002). Wilkinson & Mora performed another 
questionnaire survey of just the Paediatric CF units in the UK to audit hearing surveillance in 
these services. They had a response from 22/27 centers who all administered i.v. AGs to 
their patients. Despite providing more encouraging results in that most centers provided 
some form of audiological screening and verbal/written information regarding ototoxicity, 
they showed that only 9/22 (41%) centers reported having an established protocol for 
audiological screening with only 2/22 (9%) centers carrying out baseline hearing 
assessments prior to i.v. AG treatment. They concluded that: “There seems to be a lack of 
consensus regarding audiological screening procedures and methods of information sharing” 
(Wilkinson and Mora, 2009). 
In the US, Van Meter et al. performed a similar survey where 84 out of 195 (43%) Cystic 
Fibrosis Foundation-accredited care centers and affiliated programs (CFFACCs) completed 
the survey of which 43 (51%) were paediatric only centers. They reported that audiometric 
evaluation was performed routinely in only 22 (26%) centers with annual assessment 
performed in only 14 (64%) of these 22 centers (Van Meter et al., 2009). In Australia a 
survey in 1999 by Phillips and Bell showed that despite confirmation from 23/26 (88%) of 
the CF centers responding to the questionnaire that they undergo creatinine monitoring for 
nephrotoxicity, only 4/26 (15%) monitored for auditory and vestibular toxicity. Of these 
centers 19%, 27% and 12% reported evidence of nephrotoxicity, cochleotoxicity and 
vestibulotoxicity respectively. Soulsby et al. repeated this survey in 2006 where an 
improvement in the number of centers monitoring for ototoxicity was reported, with 17/27 
(63%) confirming that they do monitor yet more detailed questioning showed that the 
methods of monitoring were varied and crude. They stated that 13 units only used standard 
audiometry, 3 just asked the patient about their hearing and one unit undertook monitoring 
only during the conduct of a study. Frequency of testing was again varied ranging from each 
admission to when considered necessary which invariably would lead to a lower reporting of 
incidence of these toxic effects (Phillips and Bell, 2001, Soulsby et al., 2009). 
There were no available survey studies reporting the current provision for ototoxicity 
monitoring in oncology patients, yet published clinical research indicates that it is highly 
variable and inconsistent. The ASHA 1994 recommendations and criteria for ototoxicity 
monitoring for oncology patients are very comprehensive. They recommend baseline testing 
before commencement of ototoxic chemotherapy like cisplatin, or within the first 48 hours of 
the first dose if that was not possible. Auditory monitoring following every cisplatin cycle is 
adviced as well as post-treatment follow-up for late-onset hearing impairment. Figure 1-7 is 
the flow-chart published by ASHA summarizing the recommended ototoxicity monitoring 
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protocol for oncology patients (ASHA, 2013). The American Academy of Audiology (AAA) 
has also published a position statement and clinical guidlelines for ototoxicity monitoring in 
2009. There it was highlighted that ototoxicity monitoring goes beyond conventional 
methods used in routine clinical practice so that compreshensive baseline and follow-up 
assessments, including extended high-frequency audiometry, OAEs, speech audiometry and 
tympanometry, were required to allow for early detection of ototoxicity. It also highlighted 
the significant need for audiologists to take the lead in developing ototoxicity-monitoring 
programs, as they are best placed to achieve the main goals of such programs of both 
preventing or minimizing hearing loss before speech frequencies are affected and helping the 
patient to maintain the most effective hearing communication possible if ototoxicity is 
inevitable (Durrant et al., 2009). One of the aims of the current research presented in this 
thesis aimed to assess current practice in the UK regarding monitoring for ototoxicity in 
oncology and cystic fibrosis patients and assessing how well this matches with the 
recommended ASHA guideline for monitoring.  
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Figure 1-7: The ASHA recommended ototoxicity monitoring protocol for oncology patients (from (ASHA, 2013) 
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1.3.1  Overview of auditory monitoring for ototoxicity 
Review of the literature has indicated that a wide variation exists between the available 
recommended audiological tools for ototoxicity monitoring and the ones actually used in 
practice. In general practice, the standard method for ototoxicity monitoring is the baseline 
and serial measurement of pure-tone hearing thresholds within the conventional standard 
frequency range, 0.25 to 8 kHz. Research has shown that extended high-frequency (EHF) 
audiometry and evoked otoacoustic emissions (OAEs) are audiological tests that are more 
sensitive to initial ototoxic damage (Rybak et al., 2009, Lonsbury-Martin and Martin, 2003, 
Fausti et al., 1992b, Campbell et al., 2003). They were shown to detect early changes in 
auditory function before ototoxicity affects hearing at frequencies important for speech 
recognition when patients actually start complaining of deterioration in hearing. However 
many studies report only using standard pure-tone audiometry (PTA) instead (Riethmueller 
et al., 2009, Mulherin et al., 1991, Mulheran et al., 2001). A more detailed review of the 
literature in support of more detailed audiological assessment, beyond standard audiometry, 
for ototoxicity monitoring is provided below.  
Standard conventional PTA has been the traditional method for monitoring decreased 
auditory sensitivity due to aminoglycoside treatment (Greenwood, 1959). However, 
Lancaster et al. reported that despite having high plasma gentamicin levels in 16 patients 
treated with topical gentamicin for chronic otitis media, pre- and post-treatment audiometric 
assessments revealed no statistically significant differences. They concluded that 
conventional audiometric assessments might not be sensitive enough to monitor 
aminoglycoside ototoxicity (Lancaster et al., 1999). Several studies reported that otoacoustic 
emissions (OAE) appear to better monitoring tools for early detection of aminoglycoside 
ototoxicity than conventional audiometry. Stavroulaki et al. performed pre and post-
treatment auditory assessment using conventional audiometry and OAEs in 13 children 
treated with gentamicin (4 mg/kg per day, i.v) for 8–29 days. They reported that audiometry 
showed no statistically significant pre-post treatment changes while OAEs revealed a 
significant difference (Stavroulaki et al., 1999). The same authors underwent another study 
(Stavroulaki et al., 2002) where they tested children with cystic fibrosis (CF) treated with 
gentamicin (4 mg/kg for 14 days). Again, the audiometric assessments revealed normal 
thresholds at pre-post treatment recordings whereas pre-post-measurements of transient 
evoked (TE) OAE, distortion product (DP) OAE-gram and DPOAE input/output (I/O) 
function showed statistically significant deteriorations compared to a control group. 
Katbamna et al. assessed both children and adults who received tobramycin (<1250 mg/kg). 
They also reported that pre-post conventional audiometry was normal and similar to the 
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control group while OAE latency and growth (I/O) function thresholds were significantly 
different from the controls. Therefore, these authors concluded that OAEs should be 
recommended as more effective measures for monitoring cochlear function during 
aminoglycoside ototoxicity than conventional audiometry (Katbamna et al., 1999, 
Stavroulaki et al., 2002).  
Extended high frequency (EHF) audiometry (>8 kHz up to 20 kHz) has also been shown to 
be effective as early detectors of aminoglycoside and cisplatin ototoxicity. Fausti et al. (1992 
and 2003) have shown a high frequency 1/6th-octave protocol to significantly improve the 
detection of ototoxicity. They identified the highest frequency that a patient can hear and the 
frequency region of one octave below this to be the most sensitive region to early damage 
from ototoxic drugs and called it the Sensitive Range for Ototoxicity (SRO). They proposed 
that identifying this region pre-treatment and then monitoring it at 1/6
th
 octave intervals 
would be the most sensitive and least time and cost consuming method of monitoring for 
ototoxicity (Fausti et al., 2005, Fausti et al., 1992b, Fausti et al., 2003). This approach was 
most appropriate for adults; especially elderly patients that are more liable to show evidence 
of progressive high frequency hearing loss due to presbyacusis or noise induced hearing loss 
leading to variability in their limit for high frequency hearing even before exposure to 
ototoxic agents. Knight et al. reported on ototoxicity monitoring of 32 patients aged 8 
months to 20 years receiving platinum-based chemotherapy. Baseline and serial 
measurements of conventional audiometry and distortion-product (DPOAEs) was performed 
with extra EHF audiometry recording in 17 of these patients. Their results showed evidence 
of bilateral ototoxicity in 20 (62.5%) using conventional audiometry, in 26 (81.3%) using 
DPOAEs and in 16/17 (94.1%) using EHF audiometry. They concluded that EHF 
audiometry and DPOAEs have the potential to reveal earlier changes in auditory function 
than conventional frequency audiometry during platinum chemotherapy in children (Knight 
et al., 2007). The reliability of EHF audiometry especially in younger age groups was 
considered an important factor to establish before advocating its use in ototoxicity 
monitoring. Frank et al. and Schmuziger et al. both assessed the test-retest reliability of EHF 
audiometry at 1/6
th
 octave frequencies ranging between 8 and 16 kHz in normal-hearing 
adults (Schmuziger et al., 2004, Frank, 2001). The intersubject test-retest variability was 
shown to be within the accepted ±10 dB range in at least 94% of all the recorded inter-
session measurements made for these frequencies. They also measured the changes in 
thresholds against the ASHA 1994 criteria for ototoxicity and indicated that the false positive 
rates where <3% for all the assessed ears. Beahan et al. performed a study with a similar aim 
but assessed children at three different age groups (4-6 yrs., 7-9 yrs. and 10-13 yrs.). Good 
test-retest variability within the ±10 dB range was demonstrated in 89.9%, 93.0% and 97.0% 
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for the three age groups respectively. They calculated this to equate to false-positive rates 
when compared to the ASHA 1994 criteria for ototoxicity to 24.6%, 11.0% and 7.6% 
respectively. This was deemed acceptable for the two older age groups of >7years of age but 
not for the younger age group (4-6 yrs.) as the false-positive rate was too high. It was 
recommended to supplement the EHF audiometry testing with an objective test such as 
DPOAE to confirm that a genuine threshold shift had occurred especially in this age group 
(Beahan et al., 2012). 
These reports all supported the hypothesis that the inclusion of non-standard assessment 
tools, such as EHF audiometry and DPOAE testing, for audiological monitoring would be 
more sensitive to detection of early or mild evidence of ototoxicity. Confirmation of this 
hypothesis in a population of cystic fibrosis children exposed to aminoglycosides but never 
monitored for occurrence of ototoxicity was also one of the main aims of this current 
research project. Results are presented in section 4.1.  
1.3.2 Criteria for detecting/grading ototoxicity 
It is highlighted from the section above, that despite the presence of evidence in the literature 
supporting specific audiological assessment tools as effective monitoring tools for 
ototoxicity, there is no clear ‘gold standard’ protocol of monitoring for ototoxicity. More 
critically, this section highlights that there is a variation in the criteria used to define the 
occurrence of ototoxicity. Some define an initial indication of hearing loss as a drop of more 
than 10 dB at one or more frequencies when assessed by pure-tone audiometry (PTA) 
(Wright et al., 1998); while others specify a hearing loss of 20 dB at two or more adjacent 
test frequencies (Forge & Schacht, 2000) and others follow even more stringent detailed 
criteria such as the ASHA (1994) criteria of a 20 dB or greater increase in pure-tone 
threshold at a single test frequency, 10 dB or greater increase in threshold at two adjacent 
frequencies, or the loss of response at three consecutive frequencies where responses were 
previously obtained (Table 1-1) (ASHA, 1994a). Within the field of oncology several 
grading systems for defining ototoxicity criteria have been developed and used to identify 
different classes of hearing loss especially in children with cancer. The grading systems were 
either based on measuring absolute hearing levels specifically for children, such as Brock’s 
scale (Table 1-2) (Brock et al., 1991), the more recently Chang scale, a modification of the 
Brock scale proposed by Chang and Chinosornvatana which took into account the mild 
degrees of hearing loss (Table 1-3) (Chang and Chinosornvatana, 2010), or the latest new 
International Society of Paediatric Oncology Boston Ototoxicity Scale (SIOP Boston scale: 
Table 1-4). The latter is based on the recommendations made by a variety of experts, 
including international paediatric oncologists, audiologists and basic scientists, at the 42
nd
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Congress of the International Society of Paediatric Oncology (SIOP) in Boston in 2010 
(Brock et al., 2012a). The other grading systems are based on identifying changes in hearing 
from baseline including National Cancer Institute Common Toxicity Criteria for Adverse 
Effects (CTCAE) which specify an extensive range of side effects including hearing 
impairment from ototoxicity (Table 1-5) (Knight et al., 2005), the WHO Common toxicity 
Criteria (Gallegos-Castorena et al., 2007) and the Children’s Hospital Boston (CHB) scale  
(Lewis et al., 2009). As seen in the examples provided in the tables below these grading 
systems are quite variable and may partly account for the differences reported in incidence of 
ototoxicity and make comparing research outcomes very difficult. The recently proposed 
SIOP Boston Scale is aiming to provide uniformity between different international groups 
especially those performing clinical trials in order to compare results appropriately. It was 
aimed to make it simple, easy to use and avoided disadvantages of other scales such as the 
Brock’s scale where the mild levels of hearing loss (20-40 dB) were completely ignored. 
However it still only considered frequencies within the conventional standard audiometry 
range up to 8kHz and excluded outcomes of EHF audiometry.  Brock’s grading was used in 
the assessment of the study population of cystic fibrosis children included in this current 
research to evaluate the effect of using these criteria on determination, identification and 
estimation of severity of ototoxicity.  
DPOAEs are faced with a similar hindrance where absence of universally accepted criteria 
for ototoxicity also exists. Reavis et al. recently highlighted that interpreting DPOAE 
findings in the context of ototoxicity monitoring requires that their accuracy be determined 
in relation to a clinically accepted gold standard test. Knight et al. performed regular pre-and 
post-treatment recordings and considered decreases in DPOAE greater than 8 dB SPL a 
significant clinical change. This was based on the work of Beattie et al. who reported that 
differences in DPOAE amplitudes must exceed 7 dB SPL at 1 to 4 kHz to be statistically 
significant at the 0.05 level of confidence. Reavis et al. defined that DPOAE change criteria 
in their study as a ≥4 dB reduction in amplitude or loss of response (i.e. reduction in DPOAE 
amplitude level to below -10 dB SPL) at ≥2 adjacent f2 frequencies, with a false-positive 
rate of around 5% to be expected. Constantinescu et al. also recommended serial DPOAE 
measurements to accurately monitor for aminoglycoside ototoxicity (Beattie et al., 2003, 
Constantinescu et al., 2009, Knight et al., 2007, Reavis et al., 2011, Reavis et al., 2008). 
Another aim of the current research was to determine the range of intersubject variability of 
DPOAE recordings in ears of children on repeated testing, in order to determine the limit 
beyond which a change in DPOAE amplitudes is considered true evidence of inner ear 
damage and not just a standard error of measurement. Results of this work are presented in 
section 4.2. 
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Examples of different criteria for ototoxicity reported in the 
literature 
ASHA criteria for ototoxicity (1994) 
(A) 20 dB or greater increase (worsening) in pure tone threshold at one test frequency  
OR 
(B) 10 dB or greater increase at two adjacent test frequencies  
OR 
(C) Loss of response at 3 consecutive test frequencies where baseline responses were 
previously obtained, signifying a decrease in hearing following treatment 
Table 1-1: ASHA 1994 criteria for a significant threshold shift due to ototoxicity from (ASHA, 1994a) 
Brock’s grading criteria for ototoxicity  
Grade Thresholds 
0 < 40 dB at 500 - 8,000 Hz 
1 ≥ 40 dB at 8,000 Hz 
2 ≥ 40 dB at 4,000-8,000 Hz 
3 ≥ 40 dB at 2,000-8,000 Hz 
4 ≥ 40 dB at 1,000-8,000 Hz 
Table 1-2: Brock’s grading criteria for ototoxicity from (Brock et al., 1991)    
Chang’s grading criteria for ototoxicity  
Grade Thresholds (Sensorineural hearing thresholds by AC/BC with normal tymmps) 
0 ≤20 dB at 1,000; 2,000 & 4,000 Hz 
1a ≥ 40 dB at any freq. 6,000 - 12,000 Hz 
1b 
2a 
>20 dB & <40 dB at 4,000 Hz 
≥ 40 dB at 4,000 Hz and above 
2b >20 dB & <40 dB at any freq. <4,000 Hz 
3 ≥ 40 dB at 2,000/ 3,000 Hz and above 
4 ≥ 40 dB at 1,000 Hz and above 
Table 1-3: Chang’s grading criteria for ototoxicity from (Chang and Chinosornvatana, 2010) 
SIOP Boston Ototoxicity Scale 
Grade Parameters 
0 ≤ 20 dB HL at all frequencies 
1 > 20 dB HL (i.e. 25 dB HL or greater) SNHL above 4,000 Hz (i.e. 6 or 8 
kHz) 
2 > 20 dB HL SNHL at 4,000 Hz and above 
3 > 20 dB HL SNHL at 2,000 Hz or 3,000 Hz and above 
4 > 40 dB HL (i.e. 45 dB HL or more) SNHL at 2,000 Hz and above 
Table 1-4:  The recently proposed and agreed SIOP Boston Ototoxicity Scale from (Brock et al., 2012a) 
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Table 1-5: CTCAE criteria for hearing impairment for ototoxicity  
(Table extracted from published document at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf- accessed 12/10/2013)
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1.4 Patients with Cystic Fibrosis (CF) as a study 
population: 
Several reasons have supported the decision to make children with cystic fibrosis as the 
study population of choice to investigate certain aspects of ototoxicity. These reasons are 
briefly presented in this section. 
As mentioned earlier, the early confirmation of the chronic complications of AGs led to 
significant restrictions in the use of these antibiotics, especially in developed countries. CF 
populations are still one of the few populations that are exposed to a large number of 
cumulative repeated AG courses, in order to combat pulmonary exacerbations due to chronic 
pseudomonas chest infections, making them an ideal study population for investigating 
ototoxicity. Research has shown that the pharmacokinetics of antimicrobial drugs in CF 
patients is abnormal when compared to normal individuals. This is mainly in the form of 
increased volume of distribution of highly hydrophilic medications such as AGs, as 
expressed in liters/kg body weight, in addition to an increased total body clearance through 
renal excretion. The increased volume of distribution is mainly explained by the fact patients 
with CF are largely undernourished and have a scarcity of body fat leading to an increased 
amount of lean tissue/kg bodyweight. The justification for the increased renal excretion is 
not clear but may be attributed to increased glomerular filtration and tubular secretion of 
AGs in the kidney or to the occurrence of sub-clinical renal toxicity (Touw, 1998). These 
factors mean that patients with CF have to be prescribed larger doses of AGs that are given 
over longer durations of time/course in order to achieve the appropriate therapeutic drug 
levels. Courses are usually given over a period of at least 14 days with tobramycin or 
gentamicin usually prescribed at a once daily dose of 10mg/kg bodyweight/day and amikacin 
at 30mg/kg bodyweight/day compared to a dosage of 3-8 mg/kg bodyweight/day over 7-10 
days in non-CF patient groups (Doring et al., 2000, Govaerts et al., 1990, Kahlmeter and 
Dahlager, 1984, Tan et al., 2003). It may be hypothesized that the increased volume of 
distribution and larger, longer and cumulative intake of AGs in this population may be 
associated with more accumulation of aminoglycosides in the inner ear and consequently 
with a higher incidence of ototoxicity. 
The other main reason for choosing patients with CF was due to the controversy in the 
reported prevalence of ototoxicity in this patient group, especially in children. This point is 
discussed in more detail in section 1.4.2 below. Patients with CF are also regularly reviewed 
within dedicated CF centers distributed all over the UK with a well-established network 
coordinated through the UK CF Trust. This may aid in being able to access and retrieve 
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better documentation of patient management regimens (e.g. information regarding the type, 
number of courses, duration of intake of AG antibiotics and information regarding any other 
associated potential risk factors); it may also aid in better distribution of significant outcomes 
of the research and implementation of recommendations for practice if these are achieved. 
Currently there are no guidelines to managing or monitoring ototoxicity in CF patients even 
following repeated exposure to AGs. As overall management of this condition has resulted in 
improvements in general well-being, through adequate use of antibiotics and respiratory 
physiotherapy, the patients’ average survival rate has risen in the past decades from around 4 
years of age up to around 40 years. This improvement has placed more emphasis on 
improving the quality of life of these patients. Hearing impairment caused by ototoxicity can 
have significant deleterious effects on the patients’ health, social, educational, psychological 
and emotional well-being especially when it affects a young age. Therefore further 
investigation of ototoxicity in this patient group was warranted.   
The final reason for choosing this study population was due to an observation made by some 
previous researchers that ‘lower-than-expected’ results for acute or chronic ototoxicity were 
obtained from their study CF patients compared to non-CF patients. Their possible 
explanation for this observation was either due to the rapid clearance of AGs in CF patients 
or possibly, secondary to the fact that the CF condition actually bestows some form of 
protection against AG-induced cochleotoxicity (Mulheran et al., 2001, Mulheran et al., 2006, 
Pedersen et al., 1987). It was interesting to investigate whether a lower-than-expected 
prevalence of ototoxicity truly existed in patients with CF and if it did, if factors associated 
with this possible CF-induced otoprotection effect could be investigated.     
1.4.1 Overview of CF as a disease 
Cystic fibrosis affects different ethnic groups worldwide but is identified as the commonest 
life threatening autosomal recessive hereditary disorder affecting Caucasians. The incidence 
of clinical disease is  ~1 in 2500 live births with 1 in 25 being heterozygous carriers of the 
mutation. There is a prevalence of ~70,000 patients (Ramsey et al., 2011) worldwide 
including over 10,078 CF patients in the UK (UK CF Trust, 2013). This disease is caused by 
mutations in a single gene on the long arm of chromosome 7, which encodes the CF 
transmembrane conductance regulator (CFTR) protein (Bear et al., 1992). The CFTR protein 
is an epithelial ion channel that is involved in the regulation of liquid volume on epithelial 
surfaces through chloride secretion and inhibition of sodium absorption in a variety of 
tissues, including the lung, sweat glands, gastrointestinal tract and pancreas, (Rowe et al., 
2005). Abnormal CFTR protein leads to impaired transport of chloride ions leading to 
depletion of chloride in the pericilliary layer and reduction of the pericilliary fluid volume. 
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This consequently impairs the movement of water in and out of cells. As a result, the cells 
that line the passageways of organs such as the lungs, pancreas, and others produce mucus 
that is abnormally thick and sticky (Davies et al., 2007). 
The commonest cause of morbidity and mortality is repeated respiratory infections and 
consequent respiratory failure. The ‘low volume’ hypothesis is the commonly accepted 
explanation for respiratory disease in CF where the reduced volume of airway surface fluid 
leads to a significant reduction in mucociliary clearance and failure to sufficiently clear 
inhaled bacteria and other airborne harmful viruses or pollutants. There is also a reported 
abnormally excessive inflammatory response where patients with CF were shown to have 10 
times more inflammatory response to a given bacterial load compared to other patient groups 
with lower respiratory tract disease (Davies et al., 2007). More than 1,700 different 
mutations have been identified so far (Ashlock and Olson, 2011), however, a deletion of 
phenylalanine at codon 508, commonly known as F508 (recently known as phe508del), is 
present in ~66% of all CF patients worldwide. The different mutations produce different 
gene products leading to formation of different classes of mutation depending on how the 
protein function is affected. These different classes have a prognostic significance as is 
shown in Table 1-6 below. This table was presented by Bush and Harcourt who identify 
classes 1-3 to be the ones with severe mutations. These are usually associated with 
pancreatic insufficiency and significantly poorer survival (Bush and Harcourt, 2007). 
Patients with the G551D genotype are the first to be involved in a genomically guided 
therapy using an FDA approved ‘orphan drug’ called Ivacaftor (Kalydeco) marking a new 
frontier in the management of CF (Ramsey et al., 2011, Barrett et al., 2012) with CF patients 
in the UK being also involved. 
Mutation 
class 
Nature of defect Example of genotype 
 
Class 1 No synthesis of CFTR mRNA    Nonsense, G542X 
Frame shift, 394delTT 
Class 2 Block in intracellular processing of CFTR protein, leading to 
destruction before reaching the apical membrane 
 
ΔF508 (most common) 
 
Class 3 Block in regulation of CFTR on arrival at the apical cell 
membrane 
 
G551D 
 
Class 4 Altered conductance of the ion channel function of CFTR at 
the apical cell membrane 
 
R117H 
 
Class 5 Reduced synthesis of CFTR A455E 
Alternative splicing, 
3849+10 kbC → T 
Table 1-6: Different classes of cystic fibrosis transmembrane conductance regulator (CFTR) mutations 
(From (Bush and Harcourt, 2007)   
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Respiratory infections and need for repeated intake of AG to 
combat gram-negative infections: 
The commonest cause of death from CF is respiratory failure secondary to bronchiectasis. 
Chronic lung infection and inflammation rapidly develops despite the lung being essentially 
normal at birth. This is mainly explained by the ‘low volume’ hypothesis and the higher than 
normal inflammatory response, as mentioned earlier. Early on, common pathogens include 
Staphylococcus aureus, Haemophilus influenza, and Burkholderia cepacia, with chronic 
infection with mucoid Pseudomonas aeruginosa affecting around 80% of patients at a very 
young age. Infection with methicillin-resistant S. aureus (MRSA) is also increasingly 
common. Aggressive treatment of infection, and airway clearance techniques, are essential. 
Usually, the child will be doing two sessions of chest physiotherapy per day with antibiotics 
commonly prescribed prophylactically in addition to active treatment for any positive 
respiratory culture of pathogens. Infection with P. aeruginosa is frequently described as the 
most opportunistic infection in CF. Currently the recommendation for intravenous (i.v) 
antibiotic treatment of pulmonary exacerbations with P. aeruginosa is a combination of two 
antibiotics with different mechanisms of action (UK CF Trust, 2009). Combination antibiotic 
therapy, usually of an aminoglycoside and a -lactam, has been shown to produce a 
synergistic effect in vitro (Weiss and Lapointe, 1995), and may limit the emergence of 
antibiotic resistant strains of P. aeruginosa (Cheng et al., 1996). Table 1-7 is cited from 
Doring et al. which displays the recommended antibiotic treatment for CF respiratory 
infections (Doring et al., 2000).  
As aminoglycosides are considered to be an essential part of the 1
st
 line treatment regimen 
for P. aeruginosa infections and because this infection commonly affects CF patients even at 
a young age, audiological monitoring for ototoxicity would logically need to be considered 
as an essential component of management of these patients. On contacting several key 
clinicians of the UK CF Trust and CF units it was quite clear that there was limited 
audiological monitoring or even assessment of CF patients, which was also confirmed 
through review of the UK CF-related literature. This confirmed that a CF population was an 
ideal one to include as the study population to investigate ototoxicity. CF children were 
specifically chosen because the reported prevalence of ototoxicity was characteristically low 
as shown in the following section. Research with this population in the UK would aid in 
raising the awareness of this aspect of patient management and contribute to the extensive 
efforts of a limited number of UK clinicians in this field (Mulheran et al., 2001, Mulherin et 
al., 1991, Mulrennan et al., 2009, Prayle et al., 2010, Prescott, 2011, Smyth, 2010, Smyth 
and Bhatt, 2012, Smyth and Campbell, 2013, Tan et al., 2003).      
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Antibiotics  
 
Route of 
administration 
Dose 
mg/kg/day 
 
Administrations 
per day (n) 
 
Maximum daily 
dose (g) 
 
Amikacin* i.v. 30 1 or 2  - 
Tobramycin* i.v. 10 1 or 2 - 
 Inhaled (TOBI) 150±300# 1±2 0.6 
Aztreonam i.v. 150 4 8 
 i.v. 100 Continuously 8 
Cefepime i.v. 100±150 2±3 6 
Ceftazidime i.v. 150±250 3±4 12 
Ciprofloxacin p.o. 30 2±3 1.5±2.25 
Colistin Inhaled 80±160# 1±2 0.320# 
Sulphomethate i.v. 160# 3 0.48 
Imipenem/cilastatin i.v. 50±100 3±4 4 
Meropenem i.v. 60±120 3 6 
 i.v. 60 Continuously 3 
Netilmicin* i.v. 10 2 - 
Ticarcillin i.v. 500±750 4 30 
*Dose based on measurements of serum concentrations; #: absolute dose (dependent on age and situation).  
i.v, intravenous; p.o, per os (by mouth).  
 
Table 1-7: Recommended dosages for antibacterial agents in the management of P. aeruginosa lung 
infections in CF patients. 
(From (Doring et al., 2000) 
 
1.4.2 Controversy in reported prevalence of AG ototoxicity 
There is variability in the reported prevalence of ototoxicity in patients with CF ranging from 
0 to 51% (Mulheran and Degg, 1997a, Mulheran et al., 2001, Haddad et al., 1994, Ozcelik et 
al., 1996, Piltcher et al., 2003, Cheng et al., 2009, Martins et al., 2010) and no clear 
consensus among clinicians on the diagnostic tests that would be most suitable for 
monitoring ototoxicity. Mulheran et al. have reported the prevalence of hearing loss in 70 
young (10–18 years, n = 27) and adult (18–37 years, n = 43) patients with CF using standard 
and high frequency pure tone audiometry to be 17% (12/70 including 1 paediatric case). The 
prevalence of hearing loss in the pediatric population was generally reported to be lower (0–
6%), which may be interpreted to reflect less AG exposure and less environmental damage 
(Mulheran and Degg, 1997b, Mulheran et al., 2001, Mulheran and Degg, 1997a). 
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However, there was no agreement over a low prevalence of hearing loss in children. Cheng 
et al. (2009) performed a retrospective study of all CF children seen in the Department of 
Otolaryngology and Communication Enhancement at Children's Hospital Boston during a 
period of 13 years. Their aim was to determine the prevalence of sensorineural hearing loss 
(SNHL) in CF patients and its relationship to antibiotic use. A total of 171 CF patients were 
identified but only 50 of them had received audiological assessments, which were only 
performed on the discretion of the physicians with absence of a systematic protocol for 
follow-up monitoring. Only standard audiometry was performed with criteria of ototoxicity 
defined as thresholds >15 dB at two or more adjacent frequencies. A 14% (7/50) prevalence 
of SNHL was reported. The children had received courses of intravenous aminoglycosides, 
nasal aminoglycoside irrigations or macrolides. They reported a higher significant 
prevalence of hearing loss when patients received >10 courses of i.v aminoglycosides, >5 
courses of nasal irrigations or >5 courses of macrolides. The authors concluded that CF 
patients receiving aminoglycosides are at a high risk of developing SNHL.  
When reporting prevalence of a specific condition it is quite important to identify a control 
group that can exclude false negative and positive cases. This control group could be healthy, 
normal and age-matched to the study population or, for example in this condition, have CF 
but no history of exposure to aminoglycosides. However, this is usually quite difficult to 
achieve, especially if avoiding any confounding factors, is required. Cipolli et al. conducted 
a study that actually compared auditory function of 75 CF children (mean ageSD: 9.93.6 
years) to 50 healthy normal age-matched children (mean ageSD: 9.34.2 years). They 
performed otoscopy, standard audiometry (up to 8kHz), speech audiometry and 
tympanometry with reflexes to both groups of patients. They reported a 25.4% and 18% 
prevalence of hearing loss, using an original scoring system, in the CF and normal groups 
respectively. They concluded this to be statistically non-significant at p>0.05 and stated that 
CF was not associated with an increased risk of ear disease despite the associated pulmonary 
disease, radiological sinusitis, nasal polyposis or even the use of parenteral aminoglycosides. 
However the study does have a few flaws, which may affect this conclusion. First, the 
‘original’ scoring system that they used attributed only 20% of the score to the audiometry 
result of both ears with 50% attributed to otoscopy and tympanometry. This allows for a lot 
of weighting to be placed on conductive middle ear problems, which may explain the 18% 
prevalence of hearing loss in the normal healthy group, as it’s a common occurrence in 
children. They also only used standard conventional audiometry and not extended high 
frequency audiometry, which has been shown to miss early cases of aminoglycoside 
ototoxicity and therefore reduced the prevalence of hearing loss in the CF group (Cipolli et 
al., 1993). This highlights the difficulties that may be faced when conducting similar 
 50 
research and the need not just to accurately identify the appropriate population but also to 
have clear measurement criteria and effectively exclude confounding factors. Critical 
analysis of this article also presents some of the points that have led to possible reasons for 
under-reporting of ototoxicity where conservative figures of clinical prevalence may 
generally be reported.     
1.5 Children with cancer as a study population 
Ototoxic chemotherapeutic agents as platinum compounds like cisplatin and high dose 
carboplatin are primary therapies for a wide range of childhood malignancies including 
germ-cell tumours, neuroblastomas, osteosarcomas, hepatoblastomas, Wilm’s tumour and 
brain tumours such as medulloblastomas. Here, ototoxicity is more common and has more 
significant effects in children compared to adults (McHaney et al., 1983). Due to increased 
susceptibility to ototoxicity from platinum compounds in children the maximum cisplatin 
cumulative dosage is limited to 400mg/m
2
 to avoid unacceptable hearing loss. However, this 
may not always be possible as with neuroblastomas where triple this dose is needed. 
Increased risk for ototoxicity is also associated with concomitant use of head and neck 
irradiation or other ototoxic drugs, brain tumours, renal impairment and younger age groups 
(<5 years) (Walker et al., 1989, Schell et al., 1989).  
Hearing loss starts at the high frequencies at the basal turn of the cochlea and then progresses 
to the lower frequencies to include the speech frequencies. The effect of hearing loss in 
young children is more detrimental compared with adults as they have a higher need for 
more audibility to allow speech recognition and comprehension. Prelingual children or even 
those that have just started developing speech and language do not have an established 
language base and CNS maturity to allow them to fill in the gaps of missing speech 
components or to be able to communicate in complex acoustic environments with 
background noise. Even with hearing loss affecting only the high frequencies, children will 
miss the ability to distinguish high-frequency fricative consonants (/s/, /sh/, /t/, /z/, /th/, /h/, 
/k/, /p/) occupying the 4-8kHz tones as seen in Figure 1-8. These are essential for clarity of 
speech and discrimination in the presence of background noise. This would also affect 
essential grammatical aspects of speech e.g. identifying plurals such as /s/ in ‘ducks’ and /z/ 
in ‘girls’ with verbal errors and delays in speech and language development will occur 
(Crandell, 1993, Finitzo-Hieber and Tillman, 1978). Stelmachowicz et al. highlighted that 
even mild-moderate high frequency loss in children will cause delays in acquisition of all 
phonemes especially fricatives and increased difficulty in understanding female or child 
speech compared to male speech. They also drew attention to the fact that due to the limited 
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bandwidth of many of the available behind-the-ear hearing aids, where gain cannot be 
provided above 5kHz, amplification would not help in restoring audibility of these sounds. 
They suggested that frequency transposition/compression aids may be useful but are not 
suitable for all patients, and that cochlear implants do not really have this problem as the 
high frequency representation is much better due to usually guaranteed basal cochlear turn 
stimulation (Stelmachowicz et al., 2004). Ototoxic permanent progressive loss in children 
has been shown to cause significant emotional, educational and developmental difficulties. 
Gurney et al. showed that the 43/137-neuroblastoma survivors with hearing loss had twice 
the rate of educational difficulties and need for special education compared to their normal 
hearing peers in addition to reporting a significantly poorer quality of life (Gurney et al., 
2007). There is limited research assessing the effect that ototoxic hearing loss has on the 
quality of life of paediatric cancer patients. These children already suffer from many other 
aspects of their disease that significantly deteriorates their health related quality of life 
(HRQL). Therefore this is an aspect of interest in this research project.   
 
Figure 1-8: Frequency representation and approximate intensities of different categories of speech sounds  
(From (Hall and Mueller, 1997) 
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1.6 Common tools used for measuring quality of life 
of patients 
The WHO published a position paper in 1995 related to Quality of Life (QoL) assessment. In 
it they defined QoL as ‘individuals' perception of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns’ (WHOQOL Group, 1995). Measurements of QoL need to be 
multidimensional and applicable under all people to include different circumstances in life. 
QoL is generally defined as a person’s satisfaction or contentedness with life and is therefore 
affected by multiple factors including emotional well-being, expectations and environment. 
Health Related Quality of Life (HRQL) represents the domains of QoL associated with a 
person’s health (Lin and Niparko, 2006).   
Measurement of HRQL can be made through two different types of instruments: health index 
surveys and health utility instruments. Health index surveys contain groups of items 
organized into scales each measuring a domain of HRQL such as physical, mental, and 
social well-being domains. Scores are compiled from questions associated with each domain 
and a single score or domain-specific domain score can be presented. These can be either 
generic or disease-specific aimed at understanding the health status of patients and assess the 
impact of a specific disease on the overall QoL of these patients. An example of this disease-
specific health index survey is the Paediatric Audiology Quality of Life (PAQL) 
questionnaire, which was developed by Edwards et al. to assess aspects of QoL impacted by 
childhood deafness (Edwards et al., 2012). Health utility instruments try to capture a 
patient’s estimation of well-being by assigning a value to their current health status using a 
measure ranging between 0 -1 where 0 is equivalent to the death and 1 to perfect health. 
Health utility is measured through one of three utility metrics, which include visual analogue 
scales (VAS), time trade off or standard gamble (Froberg and Kane, 1989, Torrance, 1986). 
Health utilities provide a common metric to allow for comparisons to be made of the impact 
of different health interventions. A well-established popular measure is the Health Utilities 
Index (HUI) family of generic health profiles developed over many years at the McMaster 
University in Canada. Some health utility instruments have been adapted for children such as 
the EuroQoL EQ-5D and parent-proxy forms of the HUI. One of the studies in this research 
will utilize these instruments to assess the QoL of children with cancer suffering from 
ototoxicity and will be discussed in more detail later.   
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1.7 Genetic susceptibility to AG ototoxicity 
1.7.1 Mitochondrial DNA (mtDNA)  
The mitochondrial DNA is the only extra-nuclear component of the DNA in eukaryotic cells. 
It is much shorter than the nuclear DNA, being composed of around 16,600 base-pairs (bps) 
containing 37 genes and having a circular rather than a double helix structure (Figure 1-9). 
The other difference between it and the nuclear DNA, where there is only a single copy 
within each cell nucleus, is that there are 2-10 copies of the mtDNA within each 
mitochondrion. As there are hundreds to thousands of copies of mitochondria within each 
cell, there are thousands of mtDNAs in each cell.  Mitochondria are the power source of the 
cell producing energy through a process called oxidative phosphorylation (OXPHOS). They 
are also involved in multiple cellular activities including regulation of apoptosis. Thirteen of 
its genes code for enzymes involved in oxidative phosphorylation whereas the remaining 
genes provide instructions for making transfer RNAs (tRNA) and ribosomal RNA (rRNA), 
which are needed for protein formation. Variations within the 12S rRNA gene have been 
repeatedly reported to be associated with non-syndromic deafness in addition to increased 
susceptibility to aminoglycoside ototoxicity. The most well documented mutation within the 
12S rRNA gene is the A1555G (Shohat et al., 1999, Kupka et al., 2002b, Chen et al., 2012, 
Bottger, 2010, Prezant et al., 1993b). If the mutation is affecting all copies of mtDNA in the 
cell this is called ‘homoplasmy’  (i.e. present in all mitochondria of a cell and/or tissue), but 
if it only affects a fraction of these copies it is called ‘heteroplasmy’. mtDNA mutations are 
transmitted through the mother (matrilineal inheritance) with no father to son transmission.  
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Figure 1-9: An illustrated diagram of the mtDNA 
 (From en.wikipedia.org) 
1.7.2 mtDNA mutations and sensorineural hearing loss 
(SNHL) 
Mitochondrial DNA has been associated with a wide variety of disorders of genetic origin 
including non-syndromic deafness and increased susceptibility to aminoglycosides leading to 
ototoxicity.  Figure 1-10 shows a display of these associated disorders. Mutations in either 
the 12S rRNA (also called MT-RNR1) or the tRNA serine 1 (also called MT-TS1 or tRNA-Ser 
(UCN)) genes are associated with non-syndromic mitochondrial hearing loss and deafness. 
Mutations encoded in the 12S rRNA genes have been associated with predisposition to AG 
ototoxicity and/or late-onset non-syndromic SNHL. Mutations in tRNA-Ser (UCN) are 
usually associated with childhood onset of non-syndromic SNHL (although sometimes they 
are also associated with other manifestations such as palmoplanter keratoderma in some 
families). SNHL associated with AG ototoxicity is commonly bilateral, severe to profound, 
irreversible but not progressive, occurring within a few days to weeks following 
administration of any quantity of an AG antibiotic even when it’s still within the therapeutic 
drug levels. The hearing loss can even occur even after administration of a single dose of an 
aminoglycoside. Association with signs of vestibular ototoxicity is uncommon (Pandya, 
1993, Bates, 2003, Bravo et al., 2006).  
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As mentioned earlier, the commonest 12S rRNA gene disease-causing mutation associated 
with AG ototoxicity is a homoplasmic single base-pair substitution from A to G at nucleotide 
1555. Two further changes in this gene, m.961_962delTinsC(n), T1095C, T1291C, A827G, 
and a homoplasmic C-to-T transition at position 1494 (m.1494C>T), have also been 
associated with AG ototoxicity in some populations. The A1555G or the m.1494C>T 
mutations were reported to form a novel 1494C-G1555 or 1494U-A1555 base-pair (bp) at 
the highly conserved A-site of 12S rRNA making the human mitochondrial ribosomes more 
bacteria-like and altering binding sites for AGs (Guan, 2011, Human et al., 2010). 
Mutations of tRNA-Ser (UCN) causing mitochondrial nonsyndromic hearing loss and 
deafness include m.7443A>G, m.7444G>A, m.7445A>C, m.7510T>C, m.7511T>C (Sevior 
et al., 1998, del Castillo et al., 2002, Hutchin et al., 2000, Pandya, 1993) in addition to other 
less common mutations. 
 
 
 
Figure 1-10: The disorder association with different parts of the mitochondrial genome.  
The variant type and position on the mtDNA is presented in association with each disease (i.e. 
transition/transversion, or insertion/deletion). LHON, leber’s hereditary optic neuropathy; MELAS, 
mitochondrial encephalopathy lactic acidosis with stroke-like episodes; MERRF, myoclonic epilepsy and 
ragged-red fiber; T2DM, type II diabetes mellitus. (From (Wallace, 2005a). 
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1.7.3 A1555G mutation in the 12S rRNA gene and AG 
ototoxicity 
Prezant et al. first proposed the connection between this mutation and non-syndromic 
deafness or increased susceptibility to aminoglycoside ototoxicity in 1993 (Prezant et al., 
1993b). Changes in the structure of the 12S rRNA gene due to the A1555G mutation make it 
similar to the bacterial 16S rRNA gene providing an AG antibiotic binding site (A) and 
therefore allowing the AG to have its destructive bactericidal effect on the cells by disrupting 
the OXPHOS and increasing production of reactive oxygen species (ROC) activating 
apoptotic cell pathways and causing hair cell death. The mutation predisposes 
aminoglycosides-induced permanent SNHL reaching severe to profound levels that is 
independent of dose i.e. presenting with the SNHL phenotype from the first exposure to the 
antibiotic. This mutation is also associated with non-syndromic deafness and increased effect 
of age-related hearing loss (presbyacusis) even if the patient was not exposed to AGs 
(Vandebona et al., 2009). However, Bravo et al. showed that even though cochlear 
alterations, in the form of lowered DPOAE amplitudes, were present in all carriers of 
A1555G mutation, the phenotypic expression of this mutation was extremely variable. They 
varied with age of onset and severity of hearing loss, ranging from profound deafness to 
subclinical presentations of normal hearing (Bravo et al., 2006).  
Prevalence of A1555G mutation: 
The reported prevalence of the A1555G mutation varied mainly due to whether the 
prevalence was reported in population-based versus pedigree studies investigating the 
prevalence of this mutation in patients with hearing loss and their families. Prevalence also 
varied with different ethnic groups. Regarding the reported prevalence in population-based 
studies; in the UK Bitner-Glindzicz et al. genotyped the A1555G variant in the Avon 
Longitudinal Study of Parents and Children (ALSPAC) birth cohort, a cohort of 7-9 years 
old children who were not selected for hearing loss (Bitner-Glindzicz et al., 2009). They 
found the mutation in 18 children out of 9371 equivalent to a prevalence of 0.19% (95% CI, 
0.10 to 0.28) i.e. 1/520. Rahman et al. also found the mutation 19/7350 of the British 1958 
birth cohort of 44-45 years old adults reporting a prevalence of 0.26% (95% CI, 0.14 – 
0.38%) i.e. 1/385 (Rahman et al., 2012). Vandebona et al. identified a positive genotype in 
6/2856 in an Australian population (Blue Mountains hearing study cohort) equating a similar 
prevalence of 0.21% (95% CI, 0.08 to 0.46) i.e. 1/500 (Vandebona et al., 2009). In a control 
group of 439 South African subjects representing the major four ethnic groups in South 
Africa (n=93Afrikaner, n=104 Caucasian, n=112 Black and n=130 Mixed ancestry) a 
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prevalence of the A1555G mutation of 1/112 (0.9%) of the Black and 1/93 (1.1%) of the 
Afrikaner ethnic groups was recorded (Human et al., 2010). 
On the other hand, pedigree studies involving patients with hearing loss reported a higher 
prevalence of this mutation. The most extensive research on this topic was reported from 
China with variability in prevalence and penetrance identified. An example includes research 
by Dai et al. who examined 16 Chinese pedigrees (a total of 246 matrilineal relatives) with 
AG-induced hearing impairment reporting a prevalence of 0.4-1.8%, with an average of 
0.8% (19/246) but also reported an prevalence of very low penetrance of hearing loss with 
this mutation yet confirming that aminoglycosides are the major modifier factor for the 
development of deafness. In addition, Lu et al. identified 69 subjects harboring the A1555G 
mutation in a cohort of 1642 hearing-impaired Han Chinese pediatric subjects from Zhejiang 
Province, China with AG-induced and non-syndromic deafness equivalent to 3.96% 
prevalence (Lu et al., 2010a, Dai et al., 2006). The highest prevalence was reported in 
Spanish populations where Estivill et al. studied 70 families with SNHL and reported that 19 
families had the m.1555 A>G mutation of which 12 had history of AG exposure. Gallo-
Terán et al. also reported a frequency of A1555G mutation in 6/21 (29%) patients affected 
by late-onset non-syndromic SNHL from Cantabria and in 15/72 (20.8%) maternal relatives 
of subjects with non-syndromic deafness (Gallo-Teran et al., 2002, Gallo-Teran et al., 2003, 
Estivill et al., 1998). However, the A1555G mutation was not detected in 45 familial and 77 
sporadic cases of nonsyndromic hearing loss in an Austrian Caucasian ethnic group and in 
3/955 (0.3%) deaf probands ascertained throughout the United States. This confirmed that 
the prevalence is not generally high in Caucasians as was reported in the Spanish hearing 
loss population (Ramsebner et al., 2007, Arnos, 2003) 
Regarding the prevalence of A1555G mutations in CF patients, Conrad et al. sequenced the 
12S rRNA gene in 157 North American adult CF patients and identified two (1.3%) subjects 
with the mutation exhibiting severe-profound SNHL from non-toxic exposure to tobramycin 
and identified other known and new variations in the gene which were associated with 
deafness. They commented that this prevalence was higher than the commonly reported 
0.2% (Conrad et al., 2008). As this was the only study identified to actually assess the 
prevalence of mitochondrial mutations in CF patients it would be really interesting to see if 
the same conclusions would be reached when assessing the prevalence of A1555G mutation 
in a group children with CF. 
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 Penetrance and expressivity of A1555G mutation: 
Penetrance is a calculation of the proportion of subjects in a population who carry the 
disease-causing mutation of interest and those who express the disease phenotype. In this 
case it is the proportion of individuals that carry the A1555G mutation and are affected by 
hearing impairment. Variable expressivity is when the phenotypic presentation of the disease 
varies between different individuals having the same genotype e.g. in the degree/severity of 
hearing loss, age of onset, and response to different levels of exposure to aminoglycosides. 
Research has shown that several factors have been identified that affects the penetrance, age 
of onset and the phenotypic expression of individuals harboring this mutation. As presented 
earlier, exposure to aminoglycosides was shown to be one of the most significant modifying 
factors leading to expression of hearing loss even with exposure to a single dose and up to 
100% penetrance of this mutation (Bitner-Glindzicz et al., 2009, Pandya, 1993). Individuals 
with the mutation but no history of exposure to AGs may still present with non-syndromic 
hearing loss at a median age of 20 years with around 40% exhibiting hearing loss by the age 
of 30 years and 80% by the age of 65 years (Estivill et al., 1998). Other modifying factors 
include different mitochondrial haplotypes, major nuclear modifier genes, mtDNA variations 
and environmental factors. Many other researchers confirmed 100% penetrance in subjects 
with positive genotype and confirmed exposure to AGs (Veenstra et al., 2007, Pandya et al., 
1997, Fischel-Ghodsian et al., 1997, Estivill et al., 1998, Bitner-Glindzicz et al., 2009, 
Ballana et al., 2006). Even the articles that reported a low penetrance of hearing loss in 
specific populations such as the Han Chinese pedigrees (average penetrance 5.3%, range 0-
17%), it was still reaffirmed that aminoglycosides appeared to be a major modifying factor 
for the phenotypic expression of the A1555G mutation in these Chinese families. It is also 
worth noting that these studies were not actually designed to calculate penetrance as they 
were retrospectively analyzing data from hearing loss groups and their matrilineal relatives 
and therefore were biased towards subjects who express the disease phenotype (Tang et al., 
2007, Guan, 2011, Dai et al., 2006).   
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 Association between A1555G mutation and ototoxicity but not 
nephrotoxicity 
Rahman et al. hypothesized that the main reason why this mutation is mainly associated with 
cochleotoxicity and not vestibulotoxicity or nephrotoxicity is related to the cochlea’s unique 
endocochlear potential (EP) and function of the stria vascularis.  The stria vascularis is the 
epithelial layer of cells lining the lateral wall of the cochlear duct and is highly metabolically 
active with cells rich in mitochondria. Its main role is the active energy-dependent transport 
of ions, mainly potassium, into the endolymph to produce a positively charged EP of +80 
mV, which is essential for inner hair cell transduction. AGs are normally at lower 
concentrations within the endolymph because there are positively charged, as is the 
endolymph. The presence of the A1555G mutation has a significant effect on the 
mitochondria rich stria vascularis cells leading to decreased OXPHOS, accumulation of ROS 
and initiation of apoptosis, which decreases the EP. This in turn aids in the attraction and 
accumulation of the positively charged AGs inside the endolymph. They are then transported 
through the apical mechano-transduction channels of the hair cells where they accumulate 
and have a long half-life lasting up to six months following the last intake of these drugs 
causing ototoxicity from what appears as ‘normal’ drug levels (Marcotti et al., 2005, Gale et 
al., 2001). The AGs again attach to the mutation site in the hair cells’ mtDNA and reduce 
OXPHOS, increase ROC and generate AG-iron complexes, which induce hair cell death. As 
the EP is unique to the cochlea and not in the vestibular or renal apparatus the effect of the 
mutation appear to be restricted to enhancing cochleotoxicity (Usami et al., 1997, Rahman et 
al., 2012). 
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Figure 1-11: Mechanism that is proposed for enhanced sensitivity of the cochlea to aminoglycosides. 
In the cochlea: (A) Normal function of stria vascularis with maintenance of active K+ transport into the 
endolymph to keep the EP positively charged at +80mV. (B) Main effect is on stria vascularis->decrease in 
ATP and inaccurate translation of OXOPHOS proteins -> decrease in K+ and EP (norm +80mV) -> increase 
in AG uptake -> (C) increase entry into hair cells through mechanotransduction channels -> more ROS & 
generation of iron species (toxic Fe-AG complex) -> apoptosis. Half-life of AG in hair cells is very long (6 
mths). AG, aminoglycosides; I–V represents complexes I–V of the mitochondrial OXPHOS system. (From: 
(Rahman et al., 2012) 
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1.7.4 Drug metabolizing genes and ototoxicity 
Pharmacogenetics is the study of the role of inheritance in individual variation in drug 
response. This individual variation can result in a phenotype spectrum that can range 
between adverse drug reaction at one end and a lack of therapeutic efficiency at the other end. 
Pharmacogenetics has quickly evolved into pharmacogenomics due to rapid development in 
human genomics (Wang and Weinshilboum, 2008, Weinshilboum, 2006, Weinshilboum and 
Wang, 2005, O'Kane et al., 2003). For many medications, these inter-individual 
dissimilarities result in part from polymorphisms in genes that encode drug-metabolizing 
enzymes, drug transporters, and/or drug targets (such as drug receptors or enzymes). 
Pharmacogenomics is a growing field aimed at revealing the genetic basis of differences in 
drug efficacy and toxicity through the use of genome-wide or candidate-gene approaches to 
identify the group of genes that govern an individual's reaction to drug therapy (Evans and 
Relling, 2004).  
There is substantial inter-individual variation in ototoxicity in individuals receiving similar 
doses of ototoxic drugs like cisplatin and aminoglycosides. This may be explained by the 
hypothesis behind pharmacogenomics in that some individuals have polymorphisms in genes 
encoding drug-metabolizing enzymes that render them more or less susceptible to the 
ototoxic effect of these drugs.  
Ross et al. published in Nature Genetics in 2009 a study on the pharmacogenomics of 
cisplatin and ototoxicity. This study used a candidate gene approach and tested the top 220 
genes associated with the absorption, distribution, metabolism and elimination (ADME) of 
drugs. They used an Illumina GoldenGate assay to genotype 1,949 SNPs of these drug-
metabolizing genes to assess if any of these variants were associated with cisplatin 
ototoxicity within two study groups of children with cancer in Canada. They used an initial 
discovery cohort of 54 children treated in a paediatric oncology unit at the BC Children’s 
hospital in Vancouver and then ran the same assay with a second replication cohort of 112 
children recruited through a national surveillance network of adverse drug reactions in 
Canada. By using this tiered analysis strategy they were aiming to increase power in the 
discovery cohort as there was less biasing and then used the replication cohort to ensure 
generalizability of the clinically significant findings and minimize the likelihood of false 
positives. Variants in two genes were discovered. TPMT gene (thiopurine S-
methyltransferase) variants rs12201199, rs1142345 and rs1800460 (confer odds ratio OR: 
16.9, 11.0 and 18.0 respectively) and COMT gene (catechol O-methyltransferase) variants 
rs9332377 and rs4646316 (OR: 5.5 and 15.0 respectively) were found to be significantly 
(p<0.01) associated with cisplatin ototoxicity. COMT gene is present on Chromosome 22 
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and the TPMT gene is on Chromosome 6 (Ross et al., 2009). Similar involvement with 
aminoglycoside ototoxicity was investigated in this current research.  
 
 TPMT and COMT are methyltransferases dependent on the S-adenosylmethionine (SAM) 
methyl donor substrate in the methionine pathway. The TPMT gene encodes the thiopurine 
S-methyltransferase enzyme, which is known to have a significant role in the metabolism of 
thiopurine cytotoxic drugs such as azathioprine, 6-mercatopurine (6MP) and 6-thioguanine 
through AdoMet-dependent S-methylation. Variants of this gene that are associated with 
decrease or loss of function can lead to accumulation of these thiopurine drugs leading to 
bone marrow toxicity which consequently leads to anaemia, leucopenia, bleeding tendencies 
and infections due to myelosuppression (Fujita and Sasaki, 2007, Evans, 2004).  The COMT 
gene is known to regulate catecholamines such as epinephrine, norepinephrine and dopamine, 
which have important functions as hormones and neuromodulators in the brain.  
The variants implicated in cisplatin ototoxicity included TPMT rs12201199, rs1142345 
(TPMT*3C Tyr240Cys) and rs1800460 (TPMT*3B Ala154Thr) – with carriers of both of 
the latter two being defined as carriers of the TPMT*3A haplotype, and COMT rs4646316 
and rs9332377. These variants were described as loss-of-function variants that decrease the 
function of normal TPMT and COMT enzyme activity. This reduced function leads to 
increased levels of S-adenosylmethionine (SAM), which was also previously shown to 
increase nephrotoxicity by 3-6.2 fold when administered with cisplatin (Ochoa et al., 2009). 
Cisplatin normally causes cell death in rapidly dividing cancer cells by forming intra- and 
interstrand DNA cross-links when binding thiol-containing compounds and purines and 
inducing apoptosis. The authors proposed that TPMT and COMT are involved in reduced 
inactivation of cisplatin-purine compounds, which consequently enhances cisplatin cross-
linkage and therefore cytotoxic effect on inner hair cells. However, cisplatin is not a 
thiopurine drug and a direct mechanistic pathway linking the TPMT and COMT 
polymorphisms and cisplatin toxicity was not clearly presented in the Ross et al. study. Other 
concerns were raised regarding the statistical analysis of some of the data in this study. One 
of the main concerns was related to the concept that no significance was given to the fact that 
more than half the ototoxicity cases had concomitant exposure to vincristine, which has also 
been linked to ototoxicity and therefore should have been considered as a confounding factor 
(Boddy, 2013). On the other hand, this publication had significant impact as the US Food 
and Drug Administration (FDA) has recognized this work by implementing a change in the 
Cisplatin product label in 2011 to include a new safety warning related to the association of 
TPMT gene variants and risk of cisplatin-induced ototoxicity in children. 
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 The same Canadian group in a new cohort of 155 children with cancer replicated this work. 
The associations were replicated for genetic variants in TPMT (rs12201199, p = 0.0013, OR 
6.1) and for other variants including the ATP-binding cassette transporter C3 (ABCC3) 
(rs1051640, p = 0.036, OR 1.8). They also showed that the prediction of the risk of hearing 
loss was improved using a novel predictive model including genetic (TPMT, ABCC3 and 
COMT variants) in addition to clinical variables (patient’s age, vincristine treatment, germ-
cell tumour, and craniospinal irradiation) compared to a model with clinical variables alone 
(Pussegoda et al., 2013). Conversely, a separate group from the USA also replicated the 
work in 213 children with medulloblastomas and another independent cohort of 41 children 
with solid-tumours, however they failed to establish any significant association between 
TPMT or COMT variants and cisplatin-induced hearing loss. They also performed laboratory 
investigations with TPMT knockout (KO) vs. wild-type mice and found no difference in 
functional hearing loss or hair cell damage between the two following cisplatin treatments. 
They also showed that neither TPMT nor COMT variants were associated with cisplatin 
cytotoxicity in lymphoblastoid cell lines (Yang et al., 2013). The Yang et al. study doesn’t 
just contradict the two Canadian studies but it stresses the critical need for independent 
validation studies especially when outcomes are associated with possibilities of major 
changes in clinical management.    
 I was interested in whether these enzymes were also associated with aminoglycoside 
ototoxicity. The authors’ proposed mechanism of action of these TPMT and COMT variants 
is not fully established and a clear definition of how they induce, or are linked, with cisplatin 
ototoxicity is not proved. Additionally the fact that many other studies have shown that there 
are common apoptotic cell death pathways induced by cisplatin, aminoglycoside and even 
noise-induced hearing loss (Cheng et al., 2005, Rybak, 2007), offers a rationale for 
investigating the role of TPMT and COMT polymorphisms in aminoglycoside ototoxicity.    
 
 Other possible evidence of involvement of TPMT and COMT with 
ototoxicity: 
A better understanding of the normal function of these enzymes may be useful in identifying 
how they are linked with ototoxicity.  
Du et al. identified a previously annotated gene on chromosome 7 which had a similar 
function as COMT (chromosome22q11), which they called COMT2 (Du et al., 2008). 
COMT2 was shown to be highly expressed in inner ear sensory hair cells (OHCs, IHCs and 
vestibular hair cells) without detectable expression elsewhere in the nervous system. Mice 
homozygous for a missense mutation in COMT2 show vestibular impairment, profound 
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sensorineural deafness and progressive degeneration of the cochlea. They showed that 
defects in catecholamine modification by COMT are not just implicated in the development 
of schizophrenia, but identified a role for catecholamines (specifically dopaminergic 
neurotransmitters) in the function of auditory and vestibular sense organs in mice and 
humans. Whether or not these dopaminergic neurotransmitters are affected by the apoptotic 
or necrotic cell death pathways induced by cisplatin and aminoglycosides is the next 
question that needs to be answered.   
Pharmacogenomic studies have shown that TPMT has 21 already described polymorphisms 
or mutations that may have an effect on its function. Studies have shown that the functional 
effects are primarily caused by a decrease in the levels of TPMT enzyme protein. Further 
work (Salavaggione et al. 2005) has shown that the level and quality of enzyme protein of 
wild type (WT) TPMT was much higher than for different described allozymes like TPMT 
*3A variants which showed little or no protein. Other common genetic polymorphisms that 
alter only one or two amino acids have also been observed to be associated with a similar 
phenomenon (Weinshilboum, 2006). This led to the following question of: what caused the 
drop in protein levels in these polymorphisms? Several studies have reported that it may be 
due to decreased production, increased mRNA instability or increased protein degradation.  
These studies have implicated the accelerated protein degradation to be the major contributor 
to this outcome (Weinshilboum and Wang, 2004, Tai et al., 1999).  This then led to the 
question of how one or two amino acid mutations within; for example, the 245 amino acids 
constituting the TPMT protein are ‘recognized’ by the cell leading to its degradation. Wang 
et al. showed that there are associated molecular chaperones such as heat shock protein 90 
(hsp90) and hsp70 and heat shock organizing protein (hop) that are much more highly 
associated with TPMT allozymes as TPMT*3A than with WT variants. This also agreed 
with the more generalized observation that complexes involving molecular chaperones and 
their client proteins participate in a cellular ‘protein quality control’ mechanism that can 
either lead to proper folding of the client protein or target the misfolded protein for 
proteasome-mediated degradation (Wang et al., 2005). 
Molecular chaperones, specifically hsp70, hsp27 and hsp32 have been shown to have an 
inhibitory effect with cisplatin and aminoglycoside ototoxicity. Taleb et al. showed that heat 
shock results in significant inhibition of both cisplatin- and AG-induced hair cell death as it 
can inhibit JNK- and caspase-dependent apoptosis. They showed that Hsp70 is the most 
strongly induced Hsp, which was unregulated over 250-fold at the level of mRNA 2 hours 
after heat shock. Hsp70 overexpression inhibits aminoglycoside-induced hair cell death in 
vitro (Taleb et al., 2009). Therefore, the relationship between heat shock proteins and TPMT 
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polymorphisms may offer a possible explanation for a pathway linking these genetic 
variations with ototoxicity.   
1.8 Conclusion: 
As seen from the topics introduced above, research in the field of ototoxicity is extensive and 
varied assessing multiple aspects of this important and preventable cause of inner ear 
damage. The current research aimed to assess some of these avenues of research in 
ototoxicity, specifically in children, to improve understanding and possibly make 
recommendations for better clinical management of this condition if needed.  
To summarize, it is established that ototoxic medications, especially aminoglycosides and 
chemotherapeutic agents such as cisplatin, significantly damage hearing yet there is still a 
discrepancy in the recommended and commonly used audiological tests used to detect this 
effect. It would be beneficial to establish whether a test battery including extended high 
frequency audiometry and DPOAEs would be better at detecting early or milder cases of 
ototoxicity than the commonly used standard audiometry. It has been established that 
patients with cystic fibrosis are potentially exposed to high and repeated levels of 
aminoglycosides to combat pulmonary exacerbations yet the reported prevalence of 
ototoxicity in this patient groups is highly variable, ranging from 0 to 51% in adults and 0 to 
6% in children. Some literature even implies that the prevalence of ototoxicity in this group 
is much lower than expected suggesting that a possible ‘otoprotective’ function of this 
genetic disorder may exist.  
Several factors have highlighted the need for more investigation into the assessment of 
ototoxicity in CF patients in the UK. These include: (i) The variability in reported 
prevalence; (ii) the minimal guidelines provided within the UK CF Trust document on 
‘Antibiotic Treatment for cystic fibrosis’ recommending that only ‘An annual pure tone 
audiogram should be considered for patients receiving frequent courses of an intravenous 
aminoglycoside’; and (iii) the absence of UK national guidelines for ototoxicity monitoring. 
It must however be acknowledged that there is excellent research already undertaken in this 
field in the UK but there is a need to confirm whether the recommended outcomes of this 
research is actually translated into clinical practice.  
Assessment of prevalence; the benefits of use of different audiological tools; and the search 
for possible factors that increase the risk of ototoxicity in these patients are all areas of 
research that could be investigated further. The possible risk factors increasing susceptibility 
to ototoxicity suggests investigating the prevalence of genetic mutations or variations that 
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may be associated with this increased susceptibility. As discussed above, mitochondrial 
DNA mutations, specifically A1555G mutation of the 12S rRNA gene have been associated 
with increased susceptibility to aminoglycoside ototoxicity and yet only one research article 
investigated this prevalence in patients with CF (Conrad et al., 2008). This article only 
presented data from adult CF patients, it would be interesting to assess the prevalence of this 
mutation in a group of children with CF. There was also only one article published that 
established a significant association between specific drug-metabolizing genes and 
ototoxicity in children with cancer receiving cisplatin. It would therefore be interesting to 
investigate whether a similar association is established with AG ototoxicity.   
Patients with cancer receiving ototoxic chemotherapeutic drugs such as cisplatin are also an 
important and interesting group of patients to investigate. Ototoxicity monitoring in this 
patient group is slightly more established yet there is very limited research investigating the 
effect the extra disability of hearing loss has on the general well-being and quality of life of 
these patients. This is an especially important question for children as a permanent hearing 
loss can potentially affect their speech and language development, social and psychological 
development and their ability to effectively communicate within their usually highly noisy 
and distracting environments. As higher numbers of these patients, who also have evidence 
of auditory monitoring to confirm ototoxicity, can be accessed, a good sample size can be 
achieved to assess if a significant change in the quality of life of these patients occurs due to 
the hearing loss. It would be interesting to see if similar outcomes could be extrapolated for 
other patient groups such as those with CF. It would also be very interesting to establish the 
current practice in the UK regarding monitoring for ototoxicity in these patient groups to 
identify if more work is needed to actually translate research evidence into clinical practice.  
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  Aims of the research Chapter 2:
2.1 Overview 
This research project aimed to identify and investigate the different elements that affect the 
management of patients at risk of ototoxicity. The work undertaken had three main themes. 
The first theme aimed to observe the prevalence of ototoxicity in a population of children 
with CF, who are commonly exposed to ototoxic aminoglycosides, with the added aim of 
validating and applying the most appropriate tools for the audiological detection of 
ototoxicity. The second theme aimed to identify possible causative factors that may be 
responsible for wide-ranging susceptibilities of these children to ototoxicity, with two main 
areas of investigation: i) analyzing patients’ history and ii) testing for genetic variants 
commonly associated with increased susceptibility to ototoxicity. The third and final theme 
aimed to assess the clinical impact of ototoxicity on patients, in addition to assessing the 
current practice in monitoring ototoxicity from the clinicians’ perspective. The ultimate aim 
of the whole study was to gain a better understanding of these aspects of ototoxicity in order 
to make informed, clear recommendations for the implementation of the best and most 
suitable ototoxicity monitoring service for susceptible patients. 
2.2 Themes of the research project:  
2.2.1 Theme A: Audiological assessment and assessment 
tools 
A clinical observational study investigated aminoglycoside ototoxicity in patients with CF. 
The main aims of this work were: 
 To assess the auditory status of children with CF with different levels of exposure to 
aminoglycosides using an audiological test battery of objective and subjective tests 
in order to identify the prevalence of ototoxicity in this cohort. 
 To compare the performance of the different audiological tests used and identify the 
most effective audiological tools in early identification of ototoxicity. 
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The second aim prompted further research into factors that may affect the reliability of 
DPOAE testing as an objective audiological tool for monitoring ototoxicity. A control study 
were undertaken to: 
a. Investigate the short-term repeatability of DPOAE recordings in school-aged normal 
hearing children. This aimed to assess the repeatability of DPOAE recordings after 
removal and re-insertion of the OAE probe.  
b. It also aimed to calculate the standard error of measurement (SEM) beyond which a 
change would be considered as a true change in OHC function due to ototoxicity or 
any other inner ear disorder. 
2.2.2 Theme B: Causation 
Aimed at identifying possible causative factors that can be associated with the occurrence of 
ototoxicity in the population of children with CF included in the audiological observational 
study above. The two main areas of investigation were: 
i) Analysis of the clinical history of the CF patients with the aim of identifying 
factors such as age or drug dosage that may be significantly associated with 
occurrence of their ototoxicity.  
ii) Genetic analysis of biological samples obtained from these children in order to 
identify if an association between previously reported mutations, known to 
increase susceptibility to ototoxicity, and children with ototoxicity in this study 
population existed. The genetic analysis aimed to: 
 To assess the prevalence of the A1555G mutation in the 12S rRNA gene 
in the mitochondrial DNA in children with CF and assess its association 
with aminoglycoside ototoxicity. This mutation is the most well 
documented mutation to be associated with increased susceptibility to 
aminoglycoside ototoxicity.  
 To sequence the 12S rRNA gene in the children identified with the 
A1555G genotype to identify any other known or new variations within 
this gene were present.  
 To assess the prevalence of variants rs12201199 of TPMT and 
rs4646316 of COMT genes in CF children and assess if they are 
associated with aminoglycoside ototoxicity. These two variants were 
shown to be significantly associated with cisplatin ototoxicity.  
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2.2.3 Theme C: Impact of ototoxicity and current service 
provision 
Aimed at assessing the impact of ototoxicity on patients in order to assess if more effective 
ototoxicity monitoring would be justified by the benefits. An investigation into the effect of 
hearing loss on the quality of life of paediatric cancer survivors receiving ototoxic 
chemotherapeutic agents was undertaken. The aim was to assess the difference in the 
reported quality of life of oncology children with and without associated ototoxicity using 
validated parent-proxy generic and customized quality of life questionnaires.   
A further aim of this theme also included assessing current clinical practice in the UK in 
relation to ototoxicity monitoring. A survey of Oncology, Audiology and CF services in the 
UK was done to assess the current UK practice regarding auditory monitoring for ototoxicity, 
in the absence of nationally agreed guidelines, using online questionnaires. 
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  Material and Methods Chapter 3:
3.1 Study populations 
The main study populations were recruited at Great Ormond Street Hospital (GOSH) to 
address several aims of this project. They included children with CF from the CF Unit, 
Respiratory Medicine Department (for Themes A and B) and the children with cancer from 
the Oncology Department (for Theme C).  
Two control groups were recruited for the studies in Theme A investigating the short-term 
repeatability of DPOAE recordings in normally hearing school-aged children and 
investigating the effect of changes in ear canal pressure on OAE recordings. For the former 
study, 60 normal hearing healthy primary school-aged children (7-11 year-olds) were 
recruited from Abbey Meads community primary school in Swindon. For the later study, 
eight normal hearing healthy adults were recruited from students and staff members of the 
Ear Institute  
In addition to the recruited subjects or patients mentioned above, healthcare professionals 
including audiological professionals, oncology and CF clinicians were included in the final 
survey study in Theme C, which aimed at evaluating the current provision of ototoxicity 
monitoring services in the UK.   
Ethics approval was obtained from the appropriate ethical committees before commencing 
any of the studies. These are all listed with each equivalent part of the methodology below.  
3.2 Materials: 
Typically equipment used for audiological assessment in all studies: 
 Otoscopy: 
 Welch Allen Otoscope (Guymark UK Limited, UK) 
 Tympanometry:  
 Grason-Stadler GSI TympStar diagnostic tympanometer, version 1 
OR 
 Grason-Stadler GSI 33 middle ear analyzer 
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 Audiometry: 
o Standard:  
 GSI-61 diagnostic audiometer with Telephonics TDH-39 supraural 
headphones (Guymark UK Limited, UK) OR 
 Kamplex KC50 clinical Audiometer with TDH-39P headphones 
(Interacoustics, PC Werth, UK) 
o High-frequency: 
 GSI-61 diagnostic audiometer with Sennheiser HDA200 
circumaural headphones (Guymark UK Limited, UK) 
 DPOAE & TEOAE 
 Otodynamics ILO292: USB DP-Echoport equipment (Otodynamics, 
Hatfield, UK) 
Equipment used in the Genetics Study (Theme B) is listed in section: 3.5.2.2.  
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3.3 Methods: 
The methodology used for each of the studies undertaken will be presented under the three 
corresponding themes highlighted in the aims section. The same layout will also be used for 
the results/discussions chapters that will follow.  
3.4 Theme A: Audiological assessments and 
assessment tools  
3.4.1 Clinical observational study investigating 
aminoglycoside ototoxicity in patients with CF  
Ethics approval was granted for this study through the NHS ICH/GOS Research Ethics 
Committee, REC reference number: 07/Q0508/21 
This study aimed to assess the auditory function of children with CF with a variable history 
of exposure to aminoglycosides: 
 To assess the prevalence of ototoxicity in this patient group,  
 To recommend the most appropriate audiological test battery to allow for early 
identification of ototoxicity, 
 To assess the possible risk factors that would make the affected children more 
susceptible to the ototoxic effect of these antibiotics (results of this aim were 
presented within Theme B) 
A cross-sectional study design of this observational study was adopted. 
3.4.1.1 Subjects for Theme A: 
Children with confirmed CF (positive sweat test or genetics) (De Boeck et al., 2006) aged 4 
– 16 years, were recruited from the paediatric CF clinic at Great Ormond Street Hospital 
(GOSH), London, UK. Inclusion criteria were limited to the child being ≥4 years old; have a 
confirmed diagnosis of CF irrespective of whether they already received aminoglycosides or 
not; with a negative history of previous ear infections or surgery; for parent and child to 
voluntarily consent to join the study and to come for the audiological assessment at the 
Audiology department, GOSH. There was no requirement to have a specific history of 
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exposure to aminoglycosides. Children with negative history of exposure were considered as 
a control group and were assessed to confirm whether CF as a disorder was associated with 
increased prevalence of hearing loss, compared to normal healthy subjects, or not.  Informed 
consent was obtained from the parents and the child (where appropriate). Full ethical 
approval was obtained for the study from the hospital ethics committee. 
3.4.1.2 Retrieval of patient information in relation to ototoxicity:  
This data was obtained through verbal interviews with the children’s parents/carers; through 
review of annual review reports, discharge letters and clinical notes; and through review of 
patient records of haematological tests for therapeutic drug monitoring (TDM) of the 
aminoglycosides administered while the children were admitted to GOSH. History taking 
was performed and the following information was obtained for each patient through their 
parent/carer by a verbal interview: number and type (e.g. amikacin, tobramycin and 
gentamicin) of i.v. AG courses received and duration of exposure; history of hearing 
problems (including hearing loss, tinnitus or ear infections), balance problems, nasal, sinus 
or renal problems and intake of other ototoxic medication. The history of having nasal 
polyps or sinus disease were not exclusion criteria but were asked about as they are 
conditions that may be associated with or predispose the occurance of middle ear infections. 
Measurements of forced expiratory volume in 1 second (FEV1) obtained within the previous 
year were recorded and confirmation of AG drug type, number of courses, years of exposure 
and drug trough levels for TDM, were obtained from hospital records.  Drug trough levels 
were obtained from a blood sample drawn within 30 minutes before the intake of the 2
nd
 and 
8
th
 doses of AG using a once-daily (pulse dosing) regimen. The UK Cystic Fibrosis Trust 
recommended measuring a trough level, specifying that a trough/pre-dose tobramycin 
concentration of < 1 μg/mL should be accepted as per the TOPIC study (Smyth et al., 2005) 
while the goal trough concentrations for gentamicin was considered to be <0.5–1 μg/mL 
(Mohamed et al., 2012, Rao et al., 2011) and 4-10 μg/ml for Amikacin (Begg et al., 2001). 
3.4.1.3 Audiological Test Battery 
Each patient underwent the following hearing tests: 
3.4.1.3.1 Otoscopy and tympanometry with acoustic reflexes 
Otoscopic examination, tympanometry and stapedial reflex thresholds using Grason-Stadler 
(GSI-33) immittance equipment (Guymark, UK Ltd) were performed to exclude external and 
middle ear problems. Normal middle ear function was defined as a type ‘A’ Tympanogram 
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with the BSA agreed pediatric normative range of -150 to +50 daPa peak pressure and 0.3 to 
1.6 cm
3
 static compliance (BSA, 1992). 
Both ipsilateral and contralateral acoustic reflex thresholds for frequencies 0.5, 1, 2 and 4 
kHz were recorded.  Patients were retested on a separate occasion if they had evidence of 
middle ear disease. If there was persistent evidence of middle ear disease as seen by 
abnormal Otoscopy or tympanometry results, the patient was excluded from further analysis. 
Assessment of middle ear function of the CF patients was made to investigate the rate of 
occurrence of middle ear infections (otitis media) in this group and compare the results with 
previously published data of presumably ‘normal hearing children’ such as the Avon 
Longitudinal Study of Parents and Children (ALSPAC) birth cohort, a cohort of children 
who were not selected for hearing loss (Bitner-Glindzicz et al., 2009) .   
3.4.1.3.2 Standard and extended high frequency pure-tone audiometry (PTA) 
Standard PTA frequencies of 0.25-8 kHz were tested at 1-octave steps using a GSI-61 
diagnostic audiometer (Guymark, UK Ltd) and Telephonics TDH-39 supra-aural earphones. 
Regular calibration of the audiometer using the TDH-39 earphones for frequencies (0.125-8 
kHz) was performed in accordance with the EN 60645-1:1995 specification and for the 
EarPhone SPL’s: Reference equivalent threshold sound pressure levels (RETSPL) + 60dB + 
NPL Correction using the ISO 389-1 specification.  
Extended high-frequency (EHF) audiometry was performed to measure hearing
 
thresholds 
for frequencies ranging from 9-16 kHz at 1/6
th
 octave test frequencies, using the same GSI-
61 audiometer and Sennheiser HDA200 circumaural high frequency earphones. Regular 
calibration of the Sennheiser HDA200 earphones for high frequencies (8-16 kHz) was 
performed using the EN 60645-1:1995 specification and for the EarPhone SPL’s: RETSPL + 
Reference HL level + NPL Correction + LD2559 mic Correction using the ISO 389-5:1998 
specification.  
Testing was carried out in standard soundproof rooms of the hospital audiology department 
satisfying the criteria for ambient noise levels of <30dBA during audiometric testing. Care 
was taken to allow for accurate placement of the headphones so that the diaphragm was in 
line with the concha then the headband was tightened accordingly. This was done to decrease 
the test-retest differences to within the clinically acceptable range of ±10dB (Hunter et al., 
1996).  Thresholds were defined as the quietest sound that the child could hear 50% percent 
of the time with a minimum of two ascending responses at each frequency using conditioned 
play audiometry, or standard methods, depending on the child’s age and development.  
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3.4.1.3.3 Distortion-product otoacoustic emissions (DPOAE) testing 
This was measured using commercial Otodynamics ILO292:USB DP-Echoport equipment. 
Two simultaneous pure-tone
 
signals were presented at 2 different frequencies
 
(f1 and f2, 
where f2>f1) with f1:f2 ratio of 1.22 and at intensity of 65 and 55 dBSPL respectively. The 
intensity of the 2f1 - f2 intermodulation distortion product components were measured as a 
function of f2 frequency
 
at 1/2-octave frequency intervals ranging between 1 and 8 kHz and 
were presented in the form of DP-grams. 
Calibration of the probe was performed regularly using the manufacturer’s recommended 
procedure and the small cavity provided. The total duration of recording per ear was ~2 
minutes. As the recording was performed in a quiet room at the audiology department, the 
noise floors during the measurements were typically quite low ranging between -20 ± 5 
dBSPL over the 1-8 kHz regions. DPOAE responses were considered valid when 
signal/noise ratio was >6 dBSPL. The children were asked to sit quietly while a small probe, 
placed in the ear canal, recorded the DPOAEs.  
3.4.1.4 Procedure 
3.4.1.4.1 Recruitment 
CF children were recruited with the aid of the CF nurse specialists and other members of the 
CF unit. They were approached while they attended the CF 3-monthly or annual review 
clinics. The CF outpatient clinic is held on a weekly basis and takes place in the Outpatient 
Department on the first floor of the Royal Homeopathic Hospital on Great Ormond Street on 
Tuesday afternoons. Patients were also approached while being admitted to Badger Ward at 
GOSH, usually for a planned course of i.v. antibiotics.  
At that initial introduction, the patients and their parents were given the age-appropriate 
information sheet and consent form and a verbal explanation of the study aims and 
procedures to be done. The parents were adviced to read the information sheets at home and 
once they are satisfied were instructed to complete the written consent form and to send it 
back in the enclosed stamped envelope.  
On receipt of the consent form, the date of the patient’s next CF outpatient appointment was 
checked and an extra appointment for audiological assessment was booked either one hour 
before or after their CF clinic. This avoided patients having to undertake an extra journey to 
the hospital just for the audiological assessment.  With regards to the DNA sample needed 
for the genetics part of the research (Theme B), the blood samples were collected through 
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coordination with the outpatients’ phlebotomist responsible for these clinics or with the ward 
nurse responsible for the child.    
3.4.1.4.2 Audiological assessment 
On arrival to the audiology department at GOSH, history taking was done followed by a full 
test battery of audiological assessments as previously detailed in section: 3.4.1.3.  
At the end of the assessment, all the test results were explained to the patient and their 
parent/s and two copies were made of the test results – one for the parent to keep for future 
reference and the other to add to the patient hospital notes (investigations section).   
3.4.1.4.3 Reporting back to the CF Unit 
If any patient fulfilled the criteria for ototoxicity through the audiological tests, as stated 
below, this information was relayed directly to the supervisory consultant (Dr. Ranjan Suri) 
who would then take the necessary action of reviewing the patient’s current medications and 
ensure continuous monitoring of their audiological status.  
3.4.1.5 Patient Grouping 
In accordance with the history of exposure to i.v AGs, each patient was placed into one of 
three groups: the first is the ‘non-exposure’ group for patients with no previous history of 
exposure to AGs; the second is the ‘low-exposure’ group for patients with history of 
exposure to <10 i.v AG courses in their lifetime. The last group is the ‘high-exposure’ 
group with history of intake of ≥10 i.v AG courses in their lifetime. The cut-off threshold of 
10 i.v. AG courses to divide groups into low and high exposure groups was based on 
previous studies including Mulheran and Degg who showed that the median number of i.v. 
AG courses received in patients with CF and normal hearing was 9 whereas it was 20 for 
those with evidence of ototoxicity (Mulheran and Degg, 1997a, Mulheran et al., 2001, Tan et 
al., 2003). Following the audiological assessment of the patients, they were further grouped 
into ‘ototoxic’ and ‘non-ototoxic’ groups.  
Determination of Occurrence and Severity of Hearing Loss  
Hearing loss was assessed using the ASHA criteria for both standard and EHF PTA (Table 
1) with severity of hearing loss determined using the British Society of Audiology (BSA) 
audiometric descriptors (BSA, 2011), which define that pure-tone average thresholds of ≤20 
dBHL is considered normal hearing; 21-40 dBHL is mild hearing loss (HL); 41-70 dBHL is 
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moderate HL, 71-95 dBHL is severe HL and >95 dBHL is profound HL. Therefore, the 
criteria of ototoxicity used included an increase in audiometric hearing thresholds of 
>20dBHL in two or more of the high frequencies using either standard or EHF audiometry.  
A drop in the DPOAE amplitudes determined evidence of ototoxicity using DPOAEs so that 
the difference between the DPOAE amplitude and the noise floor (also termed signal-to-
noise ratio) was ≤6dB at two or more higher f2 frequencies that are at least ½ octave or more 
apart. Standard audiograms were analysed and assigned numeric grades to describe the 
degree of acquired hearing loss. Grades were assigned according to the ototoxicity grading 
systems developed by Brock et al. (Table 1-2) with the grading and thresholds illustrated for 
clarity in Figure 3-1. In cases of asymmetric hearing loss, the Brock’s hearing loss grade 
was based on results from the ear with better hearing (Brock et al., 1991).  
 
 
Figure 3-1: A graphic representation of a typical audiogram with areas shaded to illustrate the different 
Brock’s grades.  
(Keeping in mind that each grade includes the specified frequency and all the higher frequencies above it. 
Note that the results of the better ear were the ones considered when grading.) 
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3.4.2 A control study investigating the short-term 
repeatability of DPOAE recordings in school-aged 
normal hearing children 
Ethics approval was granted for this study through the UCL Ethics Committee (Ref.ID: 
2476/001) 
This control study observed the short-term repeatability of DPOAE recordings in school-
aged children using a repeated measures cross-sectional study design. This was to assess 
whether probe positioning/re-insertion had a significant effect on DPOAE level outcomes 
and therefore should be considered as a contributing factor for inaccurate test results in study 
populations of this age group. Calculation of the standard error of measurement, beyond 
which a change would be considered as a true change in inner ear OHC function due to inner 
ear disorders such as ototoxicity, was also made to help inform more accurate guidelines for 
ototoxicity monitoring when using DPAOE measurements. 
3.4.2.1 Procedure 
3.4.2.1.1 Recruitment and set-up: 
Children aged 7 – 11 years attending Swindon, Abbey Meads community primary school 
were recruited.  
The school headmaster was approached in order to get approval to conduct the study on the 
school premises. All the relevant paperwork was presented and enquiries addressed. A CRB 
check was undertaken by the school administration for the audiologist testing the children 
before commencing with the study. The audiologist undertaking the testing and collecting 
the data was Mrs Bali (an MSc student and audiologist) under my (the candidate) sole 
supervision.   
Copies of the Parent/Patient information sheet, the consent form and an associated pre-
assessment questionnaire were given to the school administrators in order to distribute them 
to the children to take home. Written consent by the parents/guardians was requested. 150 
copies were sent off with the children.  
The Parent/Patient information sheet included details about: the aim of the study; 
explanation of tests that will be performed on the day; confirmation that recruitment is 
voluntary and that the parents/children are free to withdraw at any time without having to 
provide an explanation; that all data anonymized and stored and assessed in a secure fashion. 
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Confirmation that the tests will be performed within the school premises within school hours 
and that a copy of the hearing tests results will be given to each child was also provided in 
addition to provision of details of the audiologist’s contact details. The pre-assessment 
questionnaire attached to the consent form asked if the child had any history of known 
hearing loss, had a recent ear infection within the last three months, any history of ear 
surgery or having ventilation/Grommet tube insertion in their ears. 
To encourage children and parents to consent to the study, ‘Free hearing tests’ fliers were 
displayed at different locations on the school premises. The flier clearly highlighted that the 
hearing test was free; tests were quick and non-invasive and that they are to be conducted by 
a qualified NHS audiologist. 
An agreement with the school to conduct the test on 100 children over a mutually agreed 
period of 3 weeks was made.  A small quiet room was made available within the school 
premises for testing within this period.  
Each test was conducted over a period of 10-15 minutes. A simple Hearing test report clearly 
indicating if the child has passed both tests was issued for the child to give to the parents. In 
case of failure of one or both tests, the parents were adviced to have further detailed 
assessment of child’s hearing through their GP and local Hospital if they had any concerns. 
3.4.2.1.2 Inclusion criteria 
These included the following: (1) based on the information provided by the 
parents/guardians through the pre-assessment questionnaire: - absence of previous history of 
hearing loss, recent history of ear infections or ear surgery including Grommet’s tube 
insertion. (2) Normal otoscopic examination to confirm absence of external or middle ear 
infections, occluding wax, foreign bodies or perforation of the ear drum. (3) Confirmation of 
normal middle ear function through tympanometry. (4) Collection of the signed written 
consent form with verbal confirmation of the child that he/she is happy to have their ears 
tested.  
3.4.2.2 Test Battery 
3.4.2.2.1 Tympanometry 
Tympanometry was performed with a Grason-Stadler GSI 33 middle ear analyzer using a 
226 Hz probe tone with a sound pressure level of 85 dB SPL to exclude external and middle 
ear problems using the same criteria as described in section: 3.4.1.3.1 
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3.4.2.2.2 DPOAE repeated recordings with probe removal and replacement 
DPOAEs were recorded simultaneously in both ears of all the test subjects as described 
previously in section: 3.4.1.3.3 
Three short-term within subject - within session repeats of the recordings were performed 
per ear for each child giving a total of six recordings per child. The probe was removed and 
refitted before each recording.   
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3.5 Theme B: Causation  
3.5.1 Investigation to identify potential risk factors that can 
be associated with ototoxicity in CF children 
Ethical approval is included within the same study referenced in section 3.4.1. 
As section 3.4.1 mainly aimed to assess the audiological status of the chosen population of 
CF children exposed to aminoglycosides to identify the prevalence of ototoxicity and the 
most appropriate audiological tools to detect it, this section aimed to analyze the patient and 
treatment factors that may be associated with ototoxicity. Separating the analysis of this data 
from the earlier section is to highlight the main theme of the second part of this research, 
which involved investigating possible causative factors associated with ototoxicity.    
3.5.1.1 Procedure: 
All the factors retrieved from taking the patient history from the parent/carer or from 
information obtained from clinical records as specified in section 3.4.1.1 were statistically 
analyzed after grouping the patients into two groups (with and without ototoxicity) according 
to the outcomes of the audiological assessment of these children (as shown in Theme A). 
The statistical package SPSS version 17.0 was used where the p-value of <0.05 was 
considered to be significant.   
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3.5.2 Genetic studies investigating susceptibility to 
aminoglycoside ototoxicity in patients with CF 
Ethical approval is included within the same study referenced in section 3.4.1. 
The aim of these genetic investigations was to assess whether genetic mutations known to 
increase susceptibility to ototoxicity could be associated with ototoxicity detected in the 
study population of CF children exposed to aminoglycosides.  
The best known and most frequent susceptibility factor of the A1555G mutation in the 12S 
rRNA gene (GenBank GI: 251831106) of the mitochondrial DNA (mtDNA) was genotyped 
to see if this explained some of the variance in ototoxicity between the CF children. Further 
search for other mutations/variations in the mtDNA 12S rRNA gene was also performed if 
cases with the A1555G genotype were discovered.  
Genotyping of variants in the drug-metabolizing genes TPMT rs12201199 (thiopurine S-
methyltransferase) and COMT rs4646316 (catechol-O-methyltransferase), which were 
previously reported by Ross et al. to be significantly associated with cisplatin ototoxicity in 
patients with cancer (Ross et al., 2009), was undertaken to assess if they were also 
significantly associated with aminoglycoside ototoxicity in patients with CF and could 
therefore be included as a possible causative factor for ototoxicity. A pilot study to gauge the 
frequency of the TPMT variant in a UK population and assess whether it is linked to hearing 
loss using the 1958 British cohort was also performed, as these samples were already 
available.  
3.5.2.1 Patient samples: 
DNA was obtained from the children with CF either through collection of a blood or saliva 
sample.  
Peripheral venous blood samples were collected in BD vacutainer blood tubes (Becton, 
Dickson and Company) containing EDTA (red-top tubes) to avoid coagulation.  2-5 ml were 
collected by the hospital phlebotomist in the outpatients’ clinic or by the ward nurse if the 
child was an in-patient for administration of i.v. antibiotics. Samples were pipetted into 
1.5ml aliquots and stored at -80 C freezers until DNA extraction was performed. 
Saliva samples were collected using the DNA Genotek collection kits while the children 
were in the CF review outpatients’ clinic.    
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All samples and data were analyzed under the anonymized-linked procedure and allocated 
codes ‘CF001’ onwards.  
3.5.2.2 General Equipment: 
Applied Biosystems  
7500 Real-Time PCR System 
Eppendorff 
Centrifuges: 5417R, 5417C, 5804R 
Thermal Cycler for PCR: Mastercycler gradient 
Jenway 
6305 UV/Vis Spectrophotometer 
Millipore 
Elix and Milli-Q
® 
water purification system 
Nanodrop® 
ND-1000 spectrophotometer 
Sorvall 
RC 5C plus centrifuge 
UVP 
3UV™ Transilluminator; GelDoc-it imaging system 
3.5.2.3 General Reagents: 
50x TAE (Stock solution diluted to 1x for use) 
 2M  Tris 
 1M  Glacial acetic acid 
 50mM  EDTA pH 8.0 
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2% Agarose Gel 
 2g  Agarose powder 
 100ml  1x TAE  
 3l  Ethidium Bromide 
3.5.2.4 Procedures 
3.5.2.4.1 DNA extraction 
DNA Extraction from the Blood samples: 
Qiagen (20) QIAamp blood Midi kit (Midispin protocol) for DNA extraction from whole 
blood was used according to manufacturer’s instructions. All thirteen steps in the 
recommended protocol for 
(http://www.immunoseq.com/wpcontent/uploads/manual/QIAamp_DNA_Blood_ 
Midi_Maxi_Handboo.pdf) were followed to obtain a maximum yield of ~600l using step 
13b of the protocol. 
To summarize; 1-2 ml blood per sample were equilibrated to room temperature (15-25
0
C). 
200 l QIAGEN Protease was pipetted into a 15ml centrifuge tube to which the blood was 
added and mixed. 2.4ml Buffer AL was then added followed by vigorous shaking for at least 
1 min to ensure adequate lysis. The tubes were incubated at 70
0
C for 10 minutes. 2 ml 100% 
ethanol was added per sample and mixed by vigorous shaking to ensure efficient binding. 
Half the solution was transferred onto the QIAamp Midi column in a 15 ml centrifuge tube 
and centrifuged at 1850 x g (3000 rpm) for 3 minutes.  The filtrate was discarded and the 
remaining solution was again transferred and centrifuged. After discarding the filtrate again, 
2 ml Buffer AW1 was added and centrifugation at 4500 x g (5000 rpm) was performed for 1 
min. 2 ml of Buffer AW2 was then added followed by centrifugation at the same speed but 
for 25 minutes. After placing the QIAamp Midi column in a clean 15 ml centrifuge tube, 300 
l Buffer AE was pipetted directly onto the membrane of the QIAamp Midi column, 
incubated at room temperature for 5 minutes then centrifuged at 4500 x g (5000 rpm) for 2 
minutes. To maximize yield, 300 l more Buffer AE was pipetted and the same steps were 
followed. Around 500-600 l were eluted from the column containing the purified DNA.  
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DNA Extraction from the Saliva samples: 
Oragene
®
 DNA saliva kits (Ref.no. OG-100) were used to collect 2-4ml of saliva from 
children with CF. The children were instructed to spit into the special vials up to a specified 
marked line on the container. Once the specified amount was collected the cap of the 
container was screwed on which broke a seal on the cap and released Oragene.DNA, which 
immediately stabilized the saliva solution.  
The samples, once mixed with Oragene.DNA are stable at room temperature for years 
without processing but it is preferable to store them at a -20
o
C freezer for long-term storage. 
This is done after transferring the sample into a 15ml centrifuge tube with incubation at 50
 
o
C for at least 1 hour in a water bath. The protocol for manual purification for each of the 
collected samples was followed as per manufacturer’s instructions 
(http://www.dnagenotek.com/ROW/pdf/PD-PR-006.pdf) and is summarized as follows: - 
1/25
th
 volume Oragene.DNA Purifier was added to the sample (i.e. 40µl/1ml of the sample); 
mixed by vortexing and incubated on ice for 10 minutes. Samples were then spun in a SS34 
rotor in a RC 5Cplus Sorvall centrifuge for 20 minutes. 
An equal volume of 100% ethanol was added to the supernatant and left to stand for 15 
minutes at room temperature to allow the DNA to fully precipitate. DNA was then pelleted 
by centrifugation at 20
 o
C for 15 minutes at 5,000 rpm. Most of the supernatant was carefully 
removed without disturbing the DNA pellet, which was then transferred into 1.5ml 
eppendorff tubes. Centrifugation at 20
 o
C for 10 minutes at 13,600 rpm resulted in a compact 
pellet of DNA. An ethanol wash step was performed by adding 1ml of 70% Ethanol to the 
DNA pellet followed by further centrifugation at 20
 o
C for 5 minutes at 13,600 rpm. The 
supernatant was again discarded carefully and the DNA pellet was left to dry for 3 minutes. 
Rehydration of the DNA was then done by adding an appropriate volume of 0.1X TE pH8.0 
(200µl or 400 µl is added depending on the size of the pellet- larger volume for bigger pellet) 
and then gently pipetting and placed on a rotor at 4
 o
C with speed set at 0.2-0.3 for 48 hours 
to allow for gentle mixing and full dissolving of the DNA. After 48hrs: the sample was 
briefly centrifuged at maximum speed and then gently pipetted 15-20x with a p200 filter tip 
to ensure the DNA has dissolved. If the DNA was too viscous, more 0.1xTE was added and 
the sample was returned to the rotor for another 24 hours. Once dissolved fully, the DNA 
sample was centrifuged at 20
 o
C for 15 minutes at 13,000 rpm, to maximize DNA recovery 
and ensure complete rehydration and removal of any remaining turbid material. The 
supernatant containing the DNA was moved to a 1.5ml sterile screw-top tube leaving the 
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pellet of remaining impurities behind. Quantification of the DNA was then performed using 
the Nanodrop ND-1000 spectrophotometer. 
 Assessing DNA purity and concentration: Nanodrop ND-1000 spectrophotometer was 
typically used to assess the concentration and purity of the DNA eluted solutions. Qiagen 
Buffer AE solution (blood samples) and 0.1X TE solution (saliva samples) were used as the 
blanking solution (2l) followed by the same quantity of the sample to be tested. The 
260/280 ratio was recorded (should range between 1.7-1.95) in addition to the concentration 
(measured in ng/l) as seen in Figure 3-2.  
 
Figure 3-2: A screen shot of the information displayed by the Nanodrop test  
– The single peak at 260 nm wavelengths is an indication of presence of DNA with absence of impurities. 
The 331.1-ng/l is the concentration for this sample. 
 
The yield of the samples varied quite significantly to range between 55-486ng/l (Figure 
3-3). 
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Figure 3-3: Scatter plot of the Nanodrop yield of the extracted DNA. 
Samples were obtained for all CF patients’ blood and saliva samples (n=105). Yield from all samples ranged 
between 55-486ng/µl. 
 
 
3.5.2.4.2 Agarose gel electrophoresis: 
This is a procedure used to separate fragments of DNA of different sizes (bps) by passing an 
electrical current through the DNA mix placed in an agarose gel. Typically 5-10l DNA 
solutions were electrophoresed on a 2% agarose gel containing 0.03% ethidium bromide at 
approximately 80mA for 45 minutes. The gel was then visualized using the UVP 3UV™ 
Transilluminator where the gel is exposed to ultraviolet light. This procedure is used 
following Polymerase Chain Reactions (PCR) or Restriction Fragment Length 
Polymorphism (RFLP), as discussed below, in order to verify outcomes of these procedures. 
A 100bp ladder by Promega was used as a marker to help identify the fragment sizes (Figure 
3-4). 
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Figure 3-4: Promega 100 bp DNA Ladder 
(Electrophoresis shown with 0.5 μg/lane, 2% agarose gel stained with ethidium bromide used as a marker 
to define the fragment sizes of the samples). 
 
3.5.2.4.3 Polymerase Chain Reaction (PCR)  
Table 3-1: Primers used for PCR amplification of the DNA segments containing the different target genes or mutations.  
    Primers were purchased from Eurofins and re-suspended at 100μM in ddH2O.  
 
 
Variant/ 
Mutation 
 
Forward primer (5’- 3’) 
 
Reverse primer (5’- 3’) 
A1555G GCTCAGCCTATATACCGCCATCTTCAGCAA (30) TTTCCAGTACACTTACCATGTTACGACTG (30) 
12S rRNA 
(Fragment 1) 
 
12S rRNA 
(Fragment 2) 
GAACCAACCAAACCCCAAAG (20) 
 
 
TGGCTTTAACATATCTGAACACA (23) 
TGAGCAAGAGGTGGTGAGGT (20) 
 
 
CTCCTAAGTGTAAGTTGGGTGCT (23) 
TPMT  
rs12201199 
CTCAGTTTCCCATAGTTTGGGAG (23) GCAGTGCAGGCATGGGAGTGG (21) 
COMT  
rs4646316 
CAGCCTCAGCCTCTCCAAAGAGCC (24) GAGTGAGGCTAGACAGCGGGTG (22) 
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The Eppendorff Gradient Mastercycler was used for all the PCR reactions. PCR was used for 
amplification for all the different genomic DNA segments containing the specific 
variants/mutations of interest within each study. Table 3-1 contains the primers used for each 
reaction. 
PCR parameters: 
The following is a typical cocktail recipe used to produce a total of 25l/sample for each of 
the reactions that are described below: 
 0.2l dNTPs (25mM) 
 5l   5X GoTaq Green Buffer 
 1.25l  Forward Primer 
 1.25l  Reverse Primer 
 2l   MgCl2  (2mM) 
 0.125l  GoTaq Polymerase (0.025U) 
 10.175l  Water (Milli-Q dd H2O) 
 5l   Genomic DNA (250ng) 
Varying the MgCl2, dNTP, and genomic DNA quantities and the annealing temperature in 
order to ensure specific amplification of the required amplicons was undertaken to optimize 
the PCR reactions. 
The following is a typical PCR thermal cycler program used: 
1. 95°C  5 minutes   (initial denaturation) 
2. 95°C  1 minute    (denaturation) 
3. 62.4°C*  30 seconds   (annealing) 
4. 72°C  30 seconds   (extension) 
5. Repeat Steps 2 to 4 for 35 Cycles 
6. 72°C  5 minutes   (final extension) 
7. 4°C   Hold 
*Typically this annealing temperature is the only parameter changed for the different 
reactions to provide the optimal setting for each reaction. 
5l of the samples were then electrophoresed on a 2% Agarose gel and visualized as 
described in section: 3.5.2.4.2 
3.5.2.4.3.1  PCR for A1555G mutation 
The A1555G 12S rRNA gene mutation in mitochondrial DNA (mtDNA) has been repeatedly 
reported in the literature to be associated with increased susceptibility to AG ototoxicity and 
with non-syndromic deafness (Prezant et al., 1993b, Li et al., 2005, Kupka et al., 2002a). To 
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amplify the segment of the mtDNA containing the A1555G mutation in the 12S rRNA gene 
(also called MTRNR1 gene: GenBank GI: 251831106), forward and reverse primers 
previously specified by Estivill et al. and Kokotas et al. were used as shown in Table 3-1 
(Estivill et al., 1998, Kokotas et al., 2009, Kokotas et al., 2011). The PCR reaction was 
performed using the same typical recipe and thermal cycle settings as those mentioned above. 
Successful amplification of the required mtDNA 339-bp segment was confirmed through 2% 
agarose gel electrophoresis and visualization under UV light. 
 
 
Figure 3-6: 2% agarose gel electrophoresis of 10 PCR amplicons for the mtDNA segment containing the 
1555A/G variants.  
Lane 1 contains 100bp ladder maker with the 500 and 300bp bands highlighted with the arrows and the 
last lane (11) contains the no template control. 
 
 
3.5.2.4.3.2  PCR for mtDNA 12S rRNA gene 
In order to detect further mutations or variations in the 12S rRNA gene that may be 
significantly associated with ototoxicity in the study group, PCR amplification of two 
overlapping fragments of the mtDNA, containing the whole of the 12S rRNA gene, were 
prepared using the two sets of primer pairs as shown in Table 3-1.  
The first fragment reaction was performed as above but with 500ng genomic DNA, 0.2M 
(0.5l) of each primer and 1.5l MgCl2. The PCR thermal cycle settings were the same as 
the typical reaction above with the exception of an annealing temperature of 54.3°C.  The 
second fragment PCR reaction used the same components and thermal cycler settings as the 
first fragment with the exception of an MgCl2 concentration of 2l and an annealing 
temperature at 52.3°C. 
 
 
500 
300 
336 bp 
M   1    2     3      4      5       6      7      8      9      10    11 
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The first fragment yielded a product of 707 bp spanning from mtDNA positions 545 to 1251 
and the second fragment yielded a product of 616 bp from positions 1028 to 1644. These 
products were then purified and sequenced as described later in section 3.5.2.4.5. 
3.5.2.4.3.3 PCR for TPMT rs12201199 variant 
Primers TPMT-F and TPMT-R (for sequence see Table 3-1) were designed to generate a 
PCR fragment of 168 bp of the intron region of the TPMT gene (NCBI Reference Sequence: 
NM_000367.2) containing the SNP rs12201199 of interest. The amplified PCR fragment 
was confirmed by 2% agarose gel electrophoresis where visualizing of a single band of the 
correct size was made. Reactions were performed using the typical 25l recipe stated above 
with the exception of using 10l  (500ng) genomic DNA, 2.5l (1M) of each primer and 
1l MgCl2 (water quantities were adjusted accordingly).  Thermal cycling was performed as 
stated above with only the annealing temperature changed to an optimal temperature of 58
0
C 
for 30 seconds. 
3.5.2.4.3.4  PCR for COMT variant: 
Primers COMT-F and COMT-R (for sequence see Table 3-1) were used in a typical PCR 
reaction, as described in above, to generate a 496 bp PCR fragment of the intron region of 
the COMT gene (NCBI reference sequence: NM_000754.3.) containing the SNP rs4646316 
(RefSNP Alleles: C/T). The PCR was performed using the typical recipe and standard 
reaction as specified above with the only difference being the annealing temperature of 
63.8
0
C.    
3.5.2.4.4 Genotyping by Restriction Fragment Length Polymorphism (RFLP)  
Restriction fragment length polymorphism is a procedure used to aid detection of differences 
between homologous DNA sequences. A specific restriction enzyme, also called restriction 
endonuclease, is used to divide the DNA sample into different restriction fragments. This 
reaction is also called ‘digestion of the DNA fragment’. The digested fragments of varying 
sizes can then be visualized using agarose gel electrophoresis. RFLP is capable of detecting 
the different alleles of a single nucleotide polymorphism (SNP) or mutation so that the wild-
type (WT) homozygous, heterozygous and mutant homozygous variants can be differentiated 
from each other.  
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RFLP parameters: 
The following is a typical cocktail recipe used to produce a total of 20l/sample for each of 
the reactions that are described below: 
 2l    10X Buffer (Promega or NEB) 
 6.5l  Water 
 1.5l  Restriction endonuclease enzyme 
 10l   DNA (PCR amplicons) 
To ensure complete digestion the RFLP mixture was placed in a 37°C water bath 
overnight.  
RFLP was used to identify the A1555G mutations and to identify TPMT and COMT SNPs 
under investigation as follows:  
3.5.2.4.4.1 For A1555G mutation: 
RFLP was performed using the restriction enzyme HaeIII as specified by Estivill et al. and 
Kokotas et al. where HaeIII with the 1555A wild-type produces two fragments of 216 bp and 
123 bp, while the patients affected with the A1555G mutation have three fragments of 216 
bp, 93 bp and 30 bp owing to the creation of a HaeIII site by the A1555G mutation.  (Estivill 
et al., 1998, Kokotas et al., 2009, Kokotas et al., 2011). Table 3-2 below summarises these 
expected outcomes. 
Mutation Enzyme Amplified fragment (bp) Normal sample (bp) Mutant sample (bp) 
 
A1555G  
 
HaeIII 
 
339 
 
216, 123 
 
216, 93, 30 
Table 3-2: Summary of the expected outcomes of RFLP using HaeIII restriction enzyme on the 12S rRNA 
(MTRNR1) segment of the mtDNA. 
(Estivill et al. 1998; Kokotas et al. 2009 and Kokotas et al. 2011). 
 
 
3.5.2.4.4.2  For TPMT rs12201199 variant: 
A restriction mapper website (http://www.restrictionmapper.org/) was used to identify the 
restriction endonuclease (RE) enzyme that can differentiate between the ‘A’ wild-type and 
the ‘T’ variant SNP of the TPMT rs12201199 SNP by producing different digestion 
fragments with each. Table 3-3 shows the restriction endonuclease MnLI that was identified 
and the cut positions occurring with each SNP variant. The table shows that the sample with 
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an A-wild type homozygous allele will be digested into four fragments of sizes 116, 12, 27 
and 13 bp whereas the T- variant homozygous allele would only be digested into three 
fragments of 128, 27 and 13 bps.  
TPMT with MnLI  Sequence  Overhang  Frequency  Cut Positions  Fragments  
‘A’ WT SNP CCTC  3_prime  3  116, 128, 155 116, 12, 27, 13 
‘T’ variant SNP  CCTC  3_prime  2  128, 155 128, 27, 13 
Table 3-3: Describing action of the restriction enzyme MnLI used for digestion of the TPMT amplicon and its 
cutting positions for both ‘A’ or ‘T’ alleles. 
Restriction enzyme digestion using MnLI enzyme was performed. A 20l digest mixture 
using 10l of the TPMT PCR product was prepared as described above.  The restriction 
fragments were visualized on the 2% agarose gels and under UV light using the 20 l Digest 
solution + 4 l 6X Xylene Blue loading dye (LD). 
3.5.2.4.4.3  For COMT rs4646316 variant 
The restriction mapper website (http://www.restrictionmapper.org/) was used again to 
identify the RE that can differentiate between the ‘C’ wild-type (WT) and the ‘T’ variant 
SNP of the COMT rs4646316 SNP. The restriction enzyme XcmI was identified as the 
suitable enzyme to use. Table 3-4 shows the different digestion sites and fragment sizes 
produced.  
COMT with XcmI Sequence Overhang Frequency Cut Positions Fragments 
‘C’ WT SNP CCANNNNNNNNTGG 3_prime 1 79 417, 79 
‘T’ variant SNP CCANNNNNNNNTGG 3_prime 2 79, 250 246, 171,79 
Table 3-4: Describing action of the restriction enzyme XcmI used for digestion of the COMT amplicon and its 
cutting positions for both ‘C’ or ‘T’ alleles. 
As described above, A 20l digest mixture using 10l of the COMT PCR product was made. 
The restriction fragments were visualized on 2% agarose gels and under UV light using the 
20 l Digest solution + 4 l 6X Xylene Blue LD. 
3.5.2.4.5 Sequencing for mtDNA 12S rRNA gene 
In an attempt to identify differences between the cases where the mtDNA A1555G mutation 
was found, sequencing of the whole 12S rRNA gene was performed. The 12S rRNA gene 
(GenEmbl AF346971) was amplified, using PCR, in two overlapping fragments using two 
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sets of primer pairs (Table 3-1) as described previously in Gurtler et al. (Gurtler et al., 2005), 
yielding a product of 707 base pairs and 616 base pairs for each of the two fragments 
respectively. The fragments encompassed nucleotides 545–1251 and 1028–1644, 
respectively. Each fragment was purified using the QIAquick PCR Purification Kit (Qiagen) 
and subsequently analyzed by direct sequencing at Source Bioscience Sequencing 
Cambridge UK [sequencing.cambridge@ sourcebioscience. com]. Bidirectional sequencing 
was carried out using the forward and reverse PCR amplification primers presented above. 
Therefore, each fragment was sequenced twice after independent PCR amplification to 
detect and confirm sequence changes. The resultant sequence data were compared with the 
updated consensus Cambridge sequence (GenBank accession number: NC_012920 
gi:251831106) (Andrews et al., 1999). 
3.5.2.4.6 Real-time PCR for TPMT variant: 
Unfortunately, the agarose gel electrophoresis was not sensitive enough to differentiate 
between the T/T-homozygous and the A/T heterozygote genotypes due to the similarity and 
small sizes of the produced fragments. Only the A/A-wild type homozygous genotype was 
differentiated from the other two on the 2% agarose gel. Real time PCR was used instead to 
identify all three alleles.  
Reagents & Equipment used: 
Custom TaqMan® SNP Genotyping Assay for TPMT rs12201199 SNP was ordered through 
Applied Biosystems. The ordered 40x SNP Genotyping Assay contained: 
 Sequence-specific forward and reverse primers to amplify the polymorphic sequence 
of interest. 
 Two TaqMan® MGB probes: 
– One probe labelled with VIC® dye detects the Allele 1 sequence 
           – One probe labelled with FAM™ dye detects the Allele 2 sequence 
These dyes emit fluorescence during the PCR reaction to indicate which allele is being 
amplified. In this case the VIC dye detected the Wild-type ‘A’ allele and the FAM dye 
detected the variant ‘T’ allele. If both alleles are amplified, then this sample was a 
heterozygote ‘A/T’.  All TaqMan SNP Genotyping Assays are designed and optimized to 
work with TaqMan® Universal PCR Master Mix (with or without AmpErase® UNG) using 
the same thermal cycling conditions. They require only one PCR amplification step and an 
endpoint reading to obtain results. 
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The equipment used was Applied Biosystems 7500 Real-Time PCR System.  This 
instrument allows real-time analysis of PCR, which is helpful for troubleshooting. Cross-
referencing the real-time dye output with the final endpoint plate read can be done to 
correctly identify each sample SNP.  
The total volume of each component needed for each assay was calculated as shown in the 
Table 3-5 below: 
 Working stock for a 96-well plate 
TaqMan Universal PCR Master Mix (2x),  
No AmpErase UNG 
5 µl 
20✕ working stock of SNP Genotyping Assay 0.5 µl 
DNase-free water 0.5 µl 
DNA sample @ 2.5ng/ µl  4 µl 
TOTAL 10 µl 
Table 3-5: Formula used for preparation of 10 µl/sample reaction mix for Real-time PCR using a 96-well plate. 
Amplification cycles protocol to perform the Real-time PCR used the following specified 
thermal cycling conditions: 
The Standard Protocol was used 
AmpliTaq Gold Enzyme Activation PCR (50 cycles) 
HOLD  Denature Anneal/Extend 
10 min at 95 °C 15 sec at 92 °C 1 min at 60 °C 
Table 3-6: The thermal cycles conditions used for Real-time PCR. 
After PCR amplification, an endpoint plate read was performed using the Applied 
Biosystems 7500 Real-Time PCR System. The Sequence Detection System (SDS) Software 
used the fluorescence measurements made during the plate read to plot fluorescence (Rn) 
values based on the signals from each well. The plotted fluorescence signals indicated which 
alleles were in each sample. Manual allele calls or reviewing automatic allele calls was 
performed then the allele calls were converted to genotypes. The data was also exported into 
excel sheets in order to save and analyze it further.  
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3.6 Theme C: Impact of ototoxicity and Current 
service provision 
3.6.1 Investigating the effect of hearing loss on the quality of 
life of paediatric cancer survivors receiving ototoxic 
chemotherapeutic agents. 
This study was registered as a clinical audit with the Research and Development (R&D) 
office at Great Ormond Street Hospital (GOSH) for Children 
This audit was aiming to assess if the quality of life of a cancer patient deteriorates even 
further if the patient has the added complication of ototoxicity. It also aimed to assess 
whether both generic quality of life questionnaires, such as the Health Utility Index 3 (HUI3) 
questionnaire, or disease-specific quality of life questionnaires, such as the Paediatric 
Audiology Quality of Life (PAQL) questionnaire, were able to accurately detect this effect 
or if one type was more sensitive than the other.  
As the main aim of this research theme was to highlight the importance of early and accurate 
identification of ototoxicity, assessing the impact of ototoxicity on the quality of life of 
patients suffering from it was an important factor in completing this argument. 
3.6.1.1 Recruitment 
Patients were recruited retrospectively from an assessment of auditory ototoxicity 
monitoring records of oncology patients assessed through a dedicated ototoxicity clinic at the 
Audiology department at GOSH during the past three years. The following inclusion and 
exclusion criteria were used to identify two groups of children: those who received ototoxic 
chemotherapy but still had normal hearing and those who received ototoxic chemotherapy 
and showed evidence of ototoxicity.  
Inclusion criteria: 
Children aged 5-18 years with confirmed diagnosis of cancer and proofs of intake of 
chemotherapeutic medication such as cisplatin were included in the study. All included 
subjects had to have records of baseline audiological assessment before the intake of any 
chemotherapeutic drugs and of post treatment audiological follow up.  
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Exclusion criteria: 
Children outside the above mentioned age range were excluded (n=339); other exclusion 
criteria included: children with recorded cognitive/psychological problems pretreatment 
(n=3), private non-NHS patients residing outside the UK (n=25), types of chemotherapeutic 
agents used not included in the record (n=59), absence of a baseline audiological assessment 
record (n=30) and death of the patient as shown through the hospital database (n=23).  
The hospital medical records were examined to extract the following information: The 
patients’ age, gender, age at diagnosis, cancer diagnosis confirmed by histopathology and the 
treatment protocol used. The ototoxicity clinic records were used to extract data regarding 
the baseline and post-treatment pure-tone standard audiometric results and to document 
records of auditory rehabilitation through amplification.  
Identification of hearing loss 
Patients were divided into two groups according to their post-treatment audiometric 
assessment into normal hearing and ototoxic hearing loss groups using the BSA audiometric 
descriptors of hearing loss and evidence of high frequency sloping hearing loss associated 
with ototoxicity caused by chemotherapeutic drugs. Brock’s grading was also used to 
describe the severity of ototoxicity with grades as seen in Table 1-2 and Figure 3-1.  
3.6.1.2 Assessment of quality of life using questionnaires: 
Once patients were identified to satisfy the inclusion criteria, parents were sent the 
parent/patient information sheet, consent forms and a copy of two questionnaires: the Health 
Utilities Index Mark 3 (HUI3) and the Paediatric Audiology Quality of Life (PAQL) 
Questionnaires. These were sent either through the mail with a pre-stamped return envelope 
enclosed or sent through email with a link to the questionnaires being available through the 
UCL Opinio survey software to allow for online completion of the questionnaire. Miss 
Abiodun (MSc student) collected this data under my (the candidate) sole supervision.  
The Health Utilities Index Mark 3 (HUI3) questionnaire:  
A parent-proxy version of this questionnaire was sent for completion by parents/carers of the 
children aged 5 years and above (not suitable for younger children). The questionnaire is a 
health utility measure of generic health-related quality of life (HRQOL) (Horsman et al., 
2003). It consists of a 15-item questionnaire (15Q) with answers set in a multiple-choice 
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format with four to six choices given for the different questions and usually takes 
approximately 5–10 minutes to complete (Hawthorne and Richardson, 2001). The answers 
are arranged so that the first one (level one) is always the ‘normal’ best possible condition 
(e.g. ‘Able to hear what is said without a hearing aid or cochlear implant’), which then 
gradually get worse so that the last answer is the ‘most disabled’ worst possible condition 
(e.g. ‘Unable to hear at all’). 
The questionnaire covers eight attributes:  vision, hearing, speech, emotion, pain/discomfort, 
ambulation, dexterity, and cognition (Appendix 9.2 and 9.3). The HUI responses were 
converted to utilities as defined by Feeny et al. (Feeny et al., 2002) with scores from each 
subscale aggregated to calculate the final utility score.  
The final multiplicative, multi-attribute utility score was based on the variation of responses 
across the eight attributes and was expressed on an interval scale ranging from –0.36 
(representing the ‘most disabled’ health state with the lowest level of function for all 
attributes i.e. worse than death, which is attributed a score of 0.00) to 1.00 (representing the 
‘maximum perfect health’ state with the highest level of function for all attributes).  
The Paediatric Quality of Life (PAQL) Questionnaire: 
This questionnaire is used to assess the Quality of Life (QOL) of children as young as 3 
years. Parents/carers provided the answers to the questionnaire, which was divided into three 
sections (Appendix 9.4). The main first part of the questionnaire consisted of 22 questions’ 
assessing ‘how concerned or worried parents felt about’ issues covering four subscales: 
communication and independence (6 items), emotional well-being (7 items), peer 
comparisons (5 items) and acceptance by peers (4 items).  Communication and 
Independence refers to the child’s ability to communicate with his/her peers, family 
members and teachers and the extent to which they are able to be independent. Emotional 
well-being refers to his/her emotional state on a daily basis and the extent to which negative 
emotions are under control. Peer comparisons and acceptance by peers refers to how well 
the child gets along with his/her peers and how their peers view them.  
Each question was given a ranked score ranging from 1-to-5 with the highest score of 5 
being attributed to a response of ‘Not at all concerned’ and the lowest score of 1 attributed to 
a response of ‘Extremely concerned’. Due to the difference in the number of questions 
included in each subscale, the weighting of subscales differed as follows: 
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1. Communication and Independence: questions 4, 8, 13, 14, 20 and 22 – with 
maximum score of 30 
2. Emotional Well-being: questions 9, 10, 15, 17, 18, 19 and 21 – with maximum score 
of 35 
3. Peer Comparisons: questions 1, 2, 3, 7 and 16 – with maximum score of 25 
4. Acceptance by peers: questions 5, 6, 11 and 12 – with maximum score of 20 
The Total Quality of life (QOL) score was calculated from the sum of the four subscales. 
The highest total score that could be achieved was 110. 
The second part of the questionnaire was specifically tailored for those with a hearing loss 
who do wear hearing aids; here only two questions were presented with responses again in 
the form of a tick box with three alternative answers (N/A applied to those who do not have 
a hearing loss or do not wear hearing aids even if a hearing loss is present).   The last part of 
the questionnaire was designed to obtain some demographic information about the child and 
ascertain the length of hearing aid use. 
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3.6.2 Survey of Oncology, Audiology and CF services in the 
UK to assess current practice of auditory monitoring 
for ototoxicity 
Ethics approval was granted for this study through the NHS City Road and Hampstead 
Research Ethics Committee, REC reference number: 13/LO/0624. 
This study aimed to assess the current UK practice in regards to auditory monitoring for 
ototoxicity from the perspective of both the audiology professionals and clinicians managing 
the patients exposed to ototoxic medication (in this case oncologists and CF clinicians). This 
would help identify deficiencies in existing clinical practice, which should be addressed 
when making recommendations for appropriate UK-wide ototoxicity monitoring guidelines 
in order to improve clinical practice.   
3.6.2.1 Questionnaires’ design and delivery: 
Review of the literature revealed that there were no previous survey studies investigating 
ototoxicity monitoring from the oncology or audiology professionals’ perspective except for 
a small pilot study of two oncology centers in South Africa (de Andrade, 2009). There were 
a few studies reporting on ototoxicity monitoring for CF patients as part of surveys 
investigating aminoglycosides usage and monitoring in CF patients in the UK (Tan et al., 
2002) , the USA (Van Meter et al., 2009) and in Australia (Phillips and Bell, 2001, Soulsby 
et al., 2009).  Therefore custom questionnaires (Appendices 9.6, 9.7 and 9.8) were 
specifically designed for each of the three professions (audiology, oncology and CF 
clinicians) with the MSc students (MDJ and MK) and with feedback from clinicians (Drs 
Suri, Sirimanna, Rajput and Brock) in order to ensure that it contained appropriate content 
and detail to suit each of the professional groups.   
The questionnaires mainly followed a multiple-choice format with some open-ended 
questions included to allow respondents to elaborate on some of their answers. Table 3-7 
shows a summary of the overall structure of the questionnaires. The surveys were delivered 
electronically using a web-based survey tool called ‘Opinio’, which is available to UCL staff 
and graduate students, that provides a framework for authoring and distributing surveys 
(http://www.ucl.ac.uk/isd /staff/e-learning/core-tools/opinio).  This format allowed for ease 
of access and quick response. The hyperlink to the survey was sent through an invitation 
email. This message highlighted that answering the survey would only take 5 minutes to 
complete, which the consulted clinicians stressed was a vital requirement to ensure more 
cooperation. It also included a brief explanation of the main aims and purpose of the study 
and provided reassurance that the anonymity of all the respondents would be maintained. 
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Audiology Survey Oncology Survey CF clinicians Survey 
No. of 
questions 
19 25 13 
Section I 
Demographics: 
 Clinical role; 
 Type of service; 
 Location 
Section II 
N/A Chemotherapy used Aminoglycosides used 
 
 Proportion of patients receiving ototoxic medication; 
 Cisplatin/Carboplatin as first line treatments; 
 Receive head and neck radiotherapy; 
 TDM 
 AG type as 1st line treatment; 
 Frequency of administration; 
 TDM 
Section III 
Auditory monitoring for ototoxicity 
 Verification whether auditory monitoring was performed or not 
 Pre-treatment counselling and baseline assessments 
 Protocols/other measures for when, what, and where audiological assessments are performed 
Section IV 
Significance of ototoxicity monitoring 
 Criteria for confirming evidence of ototoxicity 
 If and how changes in management are made 
 If other measurements of ototoxicity are undertaken 
 If monitoring is considered important 
 If genetic screening for A1555G was performed (only in CF survey) 
 
Table 3-7: Summary of the structure of the three surveys 
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3.6.2.2 Survey participants and data collection: 
As email was the route of delivery of the survey hyperlinks, the method accessing these 
email addresses defined who the invited participants were going to be. It was possible to 
obtain a list of all the UK CF centers from the 2010 CF Trust Registry available on the CF 
Trust website (www.cftrust.org.uk). There were 48 CF centers, including both adult and 
paediatric services.  The lead clinician of each CF center was identified through the CF Trust 
website and they were contacted. This made calculation of a response rate possible.  
On the other hand, it was not possible to identify the oncology and audiology centers and 
therefore a different approach was taken. Audiology professionals (including audiologists, 
clinical scientists, Audiovestibular physicians, and ENT doctors) and oncology professionals 
(including oncology physicians, specialist nurses and pharmacists) were invited to participate.  
The British Academy of Audiology (BAA), the British Society of Audiology (BSA), the UK 
Oncology Nursing Society, the Children’s Cancer & Leukaemia Group and the CHAIN 
support network were contacted and they agreed to send the invitation email with the survey 
hyperlinks to members on their mailing lists. The anonymity of the respondents was 
maintained for all the surveys.  
The surveys were available for three months. Follow-up reminder emails were sent. The 
Opinio survey tool generated data reports that provided information related to the frequency 
of responses to each of the questions. Integration of all the outcomes of all three surveys was 
undertaken to identify common trends and obtain a better understanding of current practice.    
  
 105 
3.7 Statistical Analyses of studies included within 
all three themes: 
Software used in all studies: 
 Microsoft Excel for Windows 2000 and for Mac 2011.  
 SPSS statistical package version 17- Significance was two-tailed and set at 5% level 
(p<0.05) for all statistical tests.    
 MATLAB (only used in ‘Effect of ECP changes on OAE recordings’ study)  
 G*Power online software version 3.1was used for sample size and power 
calculations.  
 Genetic Power Calculation was used in Theme B using online software at 
http://pngu.mgh.harvard.edu/~purcell/gpc/ (Purcell et al., 2003). 
3.7.1 Theme A: Audiological assessments and tools- 
Statistical analysis 
Clinical observational study described in section 3.4.1:  Descriptive 
analysis including frequency plots for AG use and plots of mean ± standard deviations (SD) 
of the audiological assessments were performed and statistically significant differences 
between non-ototoxic vs. ototoxic groups were analyzed using a repeated measures analysis 
of variance (ANOVA) with post-hoc pairwise comparisons with Bonferroni adjustment for 
multiple comparisons.  
A priori sample size calculation was performed for this clinical observational study using the 
G*Power v.3.1 software. Mean and standard deviation (SD) data was based on the work of 
Stavroulaki et al. (2002).  This study used paired samples 2-tailed t-test to compare the 
baseline audiometric and otoacoustic emissions (TEOAE and DPOAE) recordings for CF 
patients with those following gentamicin treatment. Significant differences were found 
between the pre-treatment and post-treatment DPOAE amplitudes at all frequencies above 3 
kHz.  The outcomes for DPOAEs at f2 frequency 5042 Hz were used as the group 
parameters to generate the effect size (dz). The mean pre-treatment amplitude (mean group 
1) mean was 17.68 dBSPL with SD of 5.47 dBSPL and the mean post-treatment amplitude 
(mean group 2) was 10.80 dBSPL with SD of 9.54 dBSPL (Stavroulaki et al., 2002). This 
produced an effect size of 0.63 as shown in Table 3-8. This is considered a moderate-to-large 
effect size according to Cohen's index of effect size for t-tests where 0.2 is considered a 
small effect size, 0.5 a medium and 0.8 a large effect size (more detailed explanation of the 
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meaning of effect size and power is provided below in section 3.7.2).  A power estimate of 
0.95, and a significance level of 0.05 (two-tailed) were used. According to the calculation 
below, a total of 36 patients with CF and history of exposure to aminoglycosides were 
required for this study (Table 3-8).  
 
G*Power Sample size calculation: t tests - Means: Difference between two dependent 
means (matched pairs) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                         = Two 
   Effect size dz                  = 0.6256 
   α err prob                      = 0.05 
   Power (1-β err prob)           = 0.95 
Output:  Noncentrality parameter δ      = 3.7538 
   Critical t                      = 2.03011 
   Df                              = 35 
   Total sample size              = 36 
   Actual power                    = 0.9544 
Table 3-8: A priori sample size calculation performed to assess the number of subjects needed to detect an 
effect of ototoxicity. 
Control Study assessing repeatability of DPOAE recordings 
described in section 3.4.2: A one-way repeated measures analysis of variance 
(ANOVA) was conducted to analyze the variance in the DPOAE amplitudes and signal-to-
noise ratios (SNR) between the three repeated recordings at all eleven f2 frequencies tested. 
A Pearson’s Interclass Correlation Coefficient (ICC) was also computed for the different f2 
frequencies tested between the three repeats. The strongest and weakest correlations were 
presented as scatter charts with r
2
 values and trend lines displayed. 
Standard error of measurement (SEM) was calculated using ICC values using the following 
formula SEM = s*√ (1−ICC) where ‘s’ is the standard deviation (combined SD of the three 
recordings) across all the measurements. The SEM values were used to calculate the 
minimum detectable difference (MDD), which can be taken into consideration as an actual 
change above the measurement error in a subject's score. MDD95% equals 1.96*a√2*SEM.  
3.7.2 Theme B: Causation- Statistical analysis 
Study assessing potential risk factors for aminoglycoside described 
in section 3.5.1: Risk factors were analyzed using non-parametric tests including chi-
squared test for categorical data, with χ2 or Fisher’s exact test used where appropriate; and 
 107 
Mann Whitney U-test for continuous numerical variables. The null hypothesis that there was 
no significant difference in distribution across the two groups was rejected when the level of 
significance of p<0.05 was reached. Further analysis of the risk factors was performed using 
Binomial Logistic Regression to confirm which factors were significantly associated with 
ototoxicity.  A non-parametric Spearman’s rho correlation test was performed to test the 
correlation between the average lung function (FEV1 scores) and number of i.v AG courses 
administered and between the type of AG used and the occurrence of high frequency hearing 
loss. A statistician from Institute of Child Health (ICH) (Mr. Manolis Bagkeris) provided 
advice regarding some of the results of statistical analysis presented within this section  
Genetics studies described in section 3.5.2: Descriptive analysis and Chi-
squared statistical analyses correlating the frequency of the different 
polymorphisms/mutations with the audiometric analysis were carried out using the SPSS 
version 17 statistical software packages. A Test for deviation from Hardy-Weinberg 
equilibrium and association analysis was performed to assess the level of significance of 
association between the frequencies of the genotypes/alleles of the TPMT rs12201199 and 
COMT rs4646316 variants and the occurrence of ototoxicity in the CF children. A power 
calculation was performed for both gene variants using the online genetic power calculator at 
http://pngu.mgh.harvard.edu/~purcell/gpc/ (Purcell et al., 2003). The case-control for 
discrete traits option was used. The data from Table 2 of the Ross et al. 2009 article was used 
to derive reference information for the number of cases and genotypic relative risk Aa and 
AA values. The high risk allele frequency (A) data was derived from the population genetics 
1000-Genome Study allele frequencies information presented in the e!Ensembl website at 
http://www.ensembl.org/Homo_sapiens.  Power is the probability of correctly rejecting the 
null hypothesis when the null hypothesis is truly false (i.e. the probability of not making a 
Type II error, which is also known as a false negative rate (β). Therefore power is also 
referred to as 1-β. A power value of 80% or 0.8 is considered acceptable but studies may aim 
to achieve a higher probability of finding a true difference by choosing a value of 95% or 
0.95 instead. Power usually increases as the sample size or the effect size increase. The 
effect size is a measure of the size of difference or association recorded when comparing 
independent variables. It is equivalent to the amount of change that occurs in order to 
successfully differentiate between groups. It is also known as the expression variance. 
Common measures of effect size include the r or R-value calculated in correlation/regression 
analysis, the Cohen’s d or dz calculated in t-tests, partial eta-squared (η2) calculated in 
ANOVA tests and phi (θ) calculated in chi-squared goodness of fit tests. Cohen provided 
rules of thumb for interpreting these effect sizes. According to Cohen's index of effect size 
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for the goodness of fit test a small effect size is equivalent to 0.10, a medium effect size is 
equivalent to 0.30, and a large effect size is equivalent to 0.50 (Walker, 2008). 
3.7.3 Theme C: Impact and current service provision- 
Statistical analysis 
Study on the affect of ototoxicity on quality of life described in 
section 3.6.1: Descriptive analysis of the age, gender, type of tumour, chemotherapeutic 
drugs administered, Brock’s ototoxicity grading and presence of other disabilities/not was 
presented. The HRQL and total QOL scores and scores of the different subscales were 
compared between the two groups of cancer patients, those with and those without hearing 
loss. As the data was not normally distributed, a Mann Whitney U test was performed to 
assess whether the differences between the groups were statistically significant or not. 
Correlation analysis between the outcomes of the two questionnaires was also performed. 
Survey study on current practice described in section 3.6.2: Descriptive 
analysis and graphical representation of the outcomes of the questionnaires was presented in 
clear formats to highlight the results and integrate the responses from all three professional 
groups. 
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 Results & Discussion of Theme A: Chapter 4:
Audiological assessment and assessment tools 
 
This part of the research assessed the prevalence of ototoxicity in a group of children with 
CF exposed to aminoglycosides and validated a sensitive audiological test battery that allows 
for reliable detection of early/mild ototoxicity.  
The rationale for this theme is a follow up of previous reports that the prevalence of 
ototoxicity in CF patients is quite variable (McRorie et al., 1989, Mulheran et al., 2001, 
Mulheran et al., 2006, Mulrennan et al., 2009, O'Donnell et al., 2010, Pedersen et al., 1987, 
Prayle et al., 2010, Scheenstra et al., 2010, Smyth and Bhatt, 2012) and specifically low in 
children (Cheng et al., 2009, Crifo et al., 1980).  
 
4.1 Clinical observational study investigating AG 
ototoxicity in children with CF 
4.1.1.1 Study groups and demographics: 
The study population of interest was the children with CF who were under the care of the CF 
unit, department of Respiratory Medicine at Great Ormond Street Hospital (GOSH). 76 
children with CF aged 4-16 years old (median: 11.4; range: 4.3 - 16.4 years) were recruited. 
The main inclusion criteria, other than having CF, were mainly that they are willing to be 
assessed and did not have previous history of ear infections or surgery with more details 
included in section 3.4.1.1. Six (8%) patients were excluded from the analysis; five had 
middle ear disease, with negative tympanometric pressures ≤ -100daPa, and one was unable 
to produce reliable audiometric test results, leaving 70 children whose results were analyzed. 
The patients were divided into 3 groups based on the number of courses of i.v AG they had 
received during their lifetime: Non-exposure group - those who had never received IV AG 
(n=7); low-exposure group - those who had received <10 courses of IV AG (n=38); high-
exposure group - those who had received ≥ 10 courses of IV AG (n=25). Patients in the 
high exposure group had received between 10 to 40 courses of IV AG (median: 20; range: 
10-40). Figure 4-1 shows the distribution of number of i.v AG courses across all 70 children. 
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Figure 4-1: Histogram showing the distribution of cases according to the number of AG i.v courses taken 
over their lifetime. 
4.1.1.2 Results of Standard and EHF audiometry and DPOAE 
testing: 
As ototoxicity is known to cause high frequency sensorineural hearing loss, the first aim of 
the audiological assessment was to exclude external and middle ear pathologies. Otoscopy 
and tympanometry with acoustic reflex testing was performed for all the children in order to 
achieve this aim and exclude causes of conductive hearing loss (not related to ototoxicity).  
Standard audiometry (0.25-8.0 kHz at one-octave intervals) and extended high-frequency 
(EHF) audiometry (9.0-16.0 kHz at 1/6
th
 octave intervals) were then used to assess the 
children’s hearing status. A recording of their DPOAEs followed this.  
Reviewing the distribution of audiometric threshold levels recorded at each of several 
different frequencies showed a clear dichotomy in the results. Figure 4-2 demonstrates this 
bimodal/double-peaked distribution shown over six of the twelve frequencies tested. This 
figure also shows that as the frequencies increase the number of children having higher 
thresholds increases, which is in line with the evidence that ototoxicity first affects the higher 
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frequencies at the basal turn of the cochlea, and then gradually extends apically damaging 
the lower frequencies. Inspection of the audiograms revealed a bimodal/ double-peaked 
distribution, with one group of children having thresholds of ≤20 dBHL, indicating normal 
hearing, and the other group having thresholds >20 dBHL extending up to 95 dBHL in the 
high frequencies. 
The BSA has defined audiometric descriptors (BSA, 2011) and the ASHA criteria of 
ototoxicity (ASHA, 1994a), including an increase in thresholds of ≥20dB HL at one or more 
frequencies, to differentiate between normal and abnormal hearing.  Using  <20 dBHL cut-
off criteria for normality, as defined by these bodies, the children were grouped into ‘non-
ototoxic’ and ‘ototoxic groups’.  
 Figure 4-3 shows the mean ±SD thresholds of the right and left ears of these two groups 
which confirms the presence of these two distinct groups with the non-ototoxic group of 
children showing normal, even exceptionally good, hearing and the ototoxic group showing 
decrease in hearing thresholds mainly at frequencies at and above 8 kHz.  
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Figure 4-2: Frequency plots of the number of cases (children) displaying the different threshold intensities 
at a range of frequencies recorded using standard and EHF pure-tone audiometry.  
Note a clear bimodal /double-peaked distribution is shown at the lower frequencies and as the frequency 
increases the number of cases exceeding the normal hearing thresholds (≤20 dBHL) increase. X-axis shows 
the threshold intensity range at each of the specified frequencies; Y-axis shows the number of cases.  
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Figure 4-3: Line graph showing mean ±SD thresholds of audiometric results of the right and left ears of the 
ototoxic vs. non-ototoxic groups. 
Standard PTA: 
On applying these criteria for ototoxicity to the standard audiometric frequencies only 
(frequency range 0.25 to 8 kHz), 13 of the 70 children showed evidence of ototoxicity, i.e. 
18.6 % with 95% confidence interval (95% CI: 9.5% to 27.7%). This included three children 
showing unilateral hearing loss confined to the right ears only. All of the children in the non-
exposure group (7/70) fell into the non-ototoxic group. Despite this representing a small 
number of children, absence of ototoxicity in all the non-exposure children confirmed that 
CF as a disorder was not commonly associated with hearing loss and that other causes were 
most likely to be associated with appearance of hearing loss in these patients, taken here to 
be ototoxicity. Therefore, standard PTA identified 13/63 (20.6%) children who had 
previously received i.v AGs and satisfied the criteria of ototoxicity. In 5 cases evidence for 
ototoxicity was only found at the highest standard frequency of 8kHz. The remaining eight 
children showed frank threshold elevations in ≥2 consecutive standard PTA frequencies. In 
contrast to the BSA/ASHA criteria, Brock’s grading uses an increase in thresholds of ≥40 
dBHL in the better ear at different frequencies to grade ototoxicity (criteria shown in Table 
1-2).  When Brock’s grading was applied using this data, 5/13 of these children scored grade 
0 (absent ototoxicity) and 6 scored grade 1 (mild ototoxicity) (Table 4-1). Figure 4-4 shows 
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the audiological results of four children with ototoxicity, a variable level of AG exposure and 
the corresponding Brock’s grading as examples to demonstrate the non-linear relationship 
between these factors. In this figure, examples 4-4A and 4-4B show audiometric outcomes of 
two children that had similar exposure to >10 i.v. AG courses and similar normal standard 
PTA and Brock’s grading but with a significant difference in the EHF PTA results where the 
second child has a moderate sloping SNHL. Example 4-4C has a history of high exposure 
(26 i.v. AG courses) and a moderate-to-severe EHF PTA SNHL. However, within the 
standard PTA the hearing loss is confined to the 8 kHz frequency point and therefore has a 
Brock grading of 1. Thus if only standard PTA and Brock’s grading were used a significant 
underestimation of the extent of ototoxicity affecting this child would occur.  Example 4-4D 
is of a child that had a history of low exposure of only 3 courses yet significant sloping 
SNHL in both standard and EHF PTA frequencies and a Brock’s grade 4 rating. Thus 
Figure 4-4 demonstrates when accepted criteria are applied to the standard audiograms of 
these children there is some ambiguity about ototoxic vs. non-ototoxic group of children.    
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Extended high-frequency (EHF) PTA 
The High frequency audiometry is an extension of the standard PTA, which adds 
information from PTA 9 kHz to PTA 16 kHz at 1/6
th
 octave intervals. Frequencies 18 and 20 
kHz were also tested but it was very clear early on that responses to these two frequencies 
were very unreliable and so they were excluded from the analysis.  
The EHF PTA data indicated that 15 of the 70 children developed ototoxicity i.e. 21.4 % 
(95% CI: 11.8% to 31.0%). Again all the non-exposure group of children did not show 
evidence of ototoxicity. The three children who showed unilateral hearing loss with standard 
PTA continued to display the same pattern of unilateral loss. EHF audiometry identified 
15/63 of the AG exposed children as having ototoxicity (23.8%).  That included two extra 
children with early signs of ototoxicity at frequencies ≥9 kHz, not identified by standard 
PTA. In relation to the AG exposure history, 11 of the 15 children (73%) with ototoxicity 
identified by EHF audiometry belonged to the ‘high exposure’ group (≥10 courses of i.v AG) 
and only 4 children (27%) with ototoxicity belonged to the low-exposure group, each 
receiving between 3 to 8 courses of i.v AG, (median: 17; range: 3-40 across all ototoxic 
group). Therefore 44% (11/25 children) of the ‘high exposure’ group had ototoxicity (Figure 
4-5). Their hearing loss ranged between 25 and 85 dBHL (mean ±SD: 57.5±25.7dBHL) 
across all the EHF audiometry frequencies.  
An important observation was that 14 children in the high-exposure group (56%) were in the 
non-ototoxic group.  Many demonstrated exceptionally good hearing, where thresholds were 
in the range of 0 to -10/-20 dBHL rather than in the 0 to 20 dBHL range which is still within 
the normal hearing range, across all frequencies despite having a similar history of high 
exposure to i.v AG (median: 17.5; range: 10-38 courses). This again highlighted that high or 
cumulative AG exposure was not always sufficient to cause ototoxicity and that other factors 
must be associated with making some children more susceptible to it’s effect.  
As with standard PTA, three children showed unilateral signs of ototoxicity, with the hearing 
loss occurring only in their right ears at the EHF audiometric frequencies. In addition, eight 
of these children reported absence of any hearing problems, while four complained of both 
tinnitus and hearing loss; two reported hearing impairment only and one only complained of 
tinnitus (Table 4-1).  
The threshold data from these two audiometrically identified groups (non-ototoxic vs. 
ototoxic) were analyzed using a repeated measures analysis of variance (ANOVA) for the 
effect of ear (right vs. left) and the audiometric frequencies (0.25–16 kHz). The overall 
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between-subjects effect of the ototoxic grouping (ototoxic vs. non-ototoxic) was significant 
(F1, 68= 277.5, p<0.001, partial η
2
= 0.810). The non-ototoxic group threshold means for the 
right and left ears respectively were 3.85 and 3.52 dBHL (95% CI: 1.78 to 5.93 and 0.83 to 
6.22 respectively) and were 47.78 and 46.65 dBHL (95% CI: 43.33 to 52.22 and 37.88 to 
49.41 respectively) for the ototoxic group. The audiometric thresholds did not differ 
significantly between the groups at the lower frequencies (≤4 kHz) but differed significantly 
from one another at p<0.05 for frequencies 8 to 16 kHz with related t-tests when Bonferroni 
adjustment was made for the number of comparisons. 
Figure 4-5 shows the distribution of children in each of these two groups (as defined by both 
standard and EHF audiometry) in relation to their level of lifetime exposure to i.v AGs. None 
of the seven (0%) children with absent history of exposure to IV AGs had any signs of 
ototoxicity confirming, as stated earlier, that CF as a disease is not commonly associated 
with hearing loss. This increased to 4/38 (11%) of the low exposure (<10 IV AGs) group and 
then showed even more dramatic increase in the high exposure (≥10 IV AGs) group with 
11/25 (44%) children showing evidence of ototoxicity.  
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Figure 4-4: Audiometric data (Standard and EHF) of four children with Brock’s grading and level of AG 
exposure stated as examples to demonstrate the non-linear relationship between these factors.  
(A) Normal hearing non-ototoxic child with Brock’s grade 0 yet history of intake of 14 i.v AG courses;  
(B)  Ototoxicity only in EHF PTA, normal Standard PTA and Brock’s grade 0 with history of intake of 15 i.v 
AG courses;  
(C) Ototoxicity clear in EHF PTA, only at 8kHz in standard PTA, Brock’s grade 1 with history of intake of 
26 i.v AG courses;  
(D) Frank ototoxicity with Brock’s grade 4 with history of intake of only 3 i.v AG courses.   
The grey shaded areas represent the normal hearing range. 
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Figure 4-5: The distribution of identified non-ototoxic vs. ototoxic group of children using both standard 
and EHF audiometric data presented according to their lifetime exposure to i.v AG courses.   
Most of the ototoxic group of children were within the high exposure group (≥10 courses) with 44% of this 
group showing evidence of ototoxicity. 
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Results of DPOAE recordings: 
Only 65/70 children underwent DPOAE testing, as it was not possible to test five patients. 
These five children included 3 of the 15 children identified with ototoxicity using EHF 
audiometry. The main reason for not performing the test was the presence of infections such 
as MRSA, where it is a contraindication to perform this test to avoid cross-contamination 
through the probe, or it was due to lack of availability of the equipment on the day.   
Unlike PTA there are no generally agreed criteria for determining pathological DPOAEs, 
other than their complete absence.  DPOAEs are considered to show evidence of a functional 
deficit when the DPOAE amplitude levels (dBSPL) are below the normal range at any two or 
more adjacent f2 test frequencies with consequent decrease in the signal-to-noise ratio (SNR) 
(Robinette, 2003, Dille et al., 2007, Durrant et al., 2009, Lonsbury-Martin and Martin, 2003, 
Lonsbury-Martin et al., 1993b, Mulheran and Degg, 1997a).   For the purposes of this study 
a small SNR was used. There is general consensus that SNR can be used to assess the 
presence of a DPOAE but no clear consensus as to what this limiting SNR should be.  Cut-
off SNR values of both <3dB and <6dB were explored in the analysis. When cut-off SNR 
levels of <6dB was used 12/65 (18.5%; 95% CI: 7.8% to 26.0%) children showed evidence 
of ototoxicity and when SNR levels of <3dB cut=off was used this decreased to 7/65 (10.8%; 
95% CI: 3.3% to 18.4%).    
Figure 4-6 shows the mean DPOAE amplitudes of right and left ears of each of the two 
groups (non-ototoxic vs. ototoxic as determined by the audiometric assessments) displayed 
against the corresponding noise floor levels which were shown to be at low levels so that a 
low SNR score meant that the DP amplitude level was abnormally low too. Figure 4-7 shows 
the mean corresponding SNR scores. The mean SNR scores for both ears were clearly poorer 
in the audiometric ototoxic group compared to the non-ototoxic group especially at f2 
frequencies 4-8 kHz. In 7/15 children with ototoxicity identified by EHF audiometry there 
was an associated drop in DPOAE amplitudes, confirming ototoxicity using both cut-off 
SNR values. The decrease in the left ear mean DPOAE amplitudes in the ototoxic patients 
was more prominent, occurring across all the f2 frequencies tested (0.8-8 kHz) whereas in 
the right it was limited to the higher f2 frequencies of 3-8 kHz. Statistical analysis of the 
difference in DPOAE amplitudes between the two groups was performed using a repeated 
measures analysis of variance (ANOVA) for the effect of ear (right vs. left) and the f2 
frequencies (0.8-8 kHz). The overall between-subjects effect of the ototoxic grouping 
(ototoxic vs. non-ototoxic as defined by the PTA criteria) was significant (F1, 63= 21.7, 
p<0.001, partial η2= 0.262). There was a significant difference between the ears within the 
groups (F1, 63= 7.62, p= 0.008, partial η
2
= 0.111). The non-ototoxic group DPOAE means for 
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the right and left ears respectively were 7.47 and 7.70 dBSPL (95% CI: 6.19 to 8.75 and 6.10 
to 9.30 dBSPL) and were 2.06 and -3.32 dBSPL (95% CI: -1.30 to 5.42 and -7.51 to 0.88 
dBSPL) for the ototoxic group. The f2 frequencies also differed significantly between the 
groups in the right ears at f2 frequencies 4–8 kHz & left ears at f2 frequencies 1.3–6.3 kHz 
(p<0.05) with related t-tests when Bonferroni adjustment was made for the number of 
comparisons.   
Table 4-1 displayed the characteristics of the fifteen children that were included in the 
ototoxic group and presented the differences in the audiological outcomes when each of the 
three audiological assessment tools was used. It highlighted that EHF audiometry was the 
assessment tool that was able to clearly detect ototoxicity for all 15 children; and that 7/15 
also showed evidence of ototoxicity using DPOAEs (low amplitude levels and SNR scores), 
3/15 where not tested using DPOAEs and 5/15 demonstrated within normal DPOAE results. 
If the five children that demonstrated normal DPOAEs were compared with standard PTA 
outcomes it shows that 1/5 also had normal thresholds and another 2/5 showed hearing loss 
only at 8 kHz. This shows that there is a reasonable agreement between audiometric and 
DPOAE testing with EHF PTA showing the most loss. 
Figure 4-6: DP-Gram showing DPOAE mean amplitudes for right and left ears of the two audiometrically 
defined groups (ototoxic vs. non-ototoxic) and the corresponding noise floor recordings.  
The grey-areas in the background show the normal range of DPOAE and Noise floor recordings. ANOVA 
test showed a statistically significant difference in distribution of DPOAE Amplitudes across the two 
categories in RT ears at Frequencies 4 – 8 kHz & LT ears at frequencies 1.25 – 6.3 kHz (p<0.05).  (RT, right; 
LT, left; NF, noise floor) 
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Figure 4-7: Showing the SNR scores of the audiometric non-ototoxic vs. ototoxic group for the Rt and Lt 
ears respectively.  
The SNR scores were significantly poorer in the ototoxic group at f2 frequencies 4-8 kHz. 
 
Patient 
Age 
(yrs.) 
Gender 
Auditory 
symptoms 
No. 
IV 
AGs 
Ear 
Affected 
Assessment tools for ototoxicity 
Standard 
PTA 
Brock’s 
Grade 
EHF 
PTA 
DPOAE 
CF035 15.9 M HL 3 RT + 0 ++ ++ 
CF062 14.6 F HL & T 3 Both ++ 3 ++ ++ 
CF067 15.1 F None 4 Both -ve 0 ++ -ve 
CF046 12 F None 8 RT ++ 0 ++ -ve 
CF032 5.5 F None 14 RT + 0 ++ -ve 
CF096 10.8 F HL & T 14 Both ++ 2 ++ ++ 
CF011 14 M None 15 Both -ve 0 ++ ++ 
CF003 16.4 F None 17 Both ++ 1 ++ -ve 
CF014 12.5 M HL 18 Both + 1 ++ 
Not 
tested 
CF066 13.8 F HL & T 24 Both ++ 4 ++ 
Not 
tested 
CF026 16.2 F None 26 Both + 1 ++ -ve 
CF022 12.9 F None 30 Both ++ 1 ++ ++ 
CF006 14.4 M HL & T 32 Both ++ 2 ++ 
Not 
tested 
CF004 11.8 F T 37 Both + 1 ++ ++ 
CF034 10.6 F None 40 Both ++ 1 ++ ++ 
Table 4-1: Characteristics and audiological results of the fifteen children with ototoxicity with comparison 
of diagnosis based on different assessment tools.  
HL, hearing loss; T, tinnitus; freq, frequency; RT, Right ear. Hearing loss is bilateral unless otherwise stated. 
For assessments: ‘+’ indicates ototoxicity recorded at one frequency only (8kHz at standard PTA); ‘++’ 
indicated ototoxicity recorded at ≥ 2 consecutive frequencies and ‘-ve’ indicate normal non-ototoxic 
response. Brock’s hearing loss grading (0 to 4): 0=No ototoxicity, 4=severe ototoxicity. 
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4.1.1.3 Relationship between the three audiological assessment tools: 
In the previous section, the differentiation of patients into an ototoxic and a non-ototoxic 
group was dependent on the outcomes of the audiometric assessments (both standard and 
EHF PTA) and then the outcomes of the DPOAEs within this two pre-determined groups 
was assessed. In this section, a statistical analysis of the relationship between the three 
audiological assessment tools is presented. The aim was to determine whether or not all tools 
were able to identify ototoxicity in the CF children and to identify how well the outcomes of 
each of the tools correlated with each other. An appropriate statistical test to use in order to 
assess the reliability of different assessment tools is the ‘Kappa statistic’. A reliability 
analysis using the Kappa statistic was performed to determine consistency among methods 
(Landis and Koch, 1977). Cohen's kappa coefficient is a statistical measure of agreement for 
binary outcomes that can be used to address agreement of the three different methods in 
identifying a patient’s hearing loss. A 2x2 contingency table was used to analyze the 
categorical data obtained from two methods at a time to calculate the Kappa statistic. An 
example of these tables is shown in Table 4-2, Table 4-3 and Table 4-4. The interrater 
reliability comparing the Standard and EHF PTA method was found to be Kappa = 0.911 (p 
<0.001), 95% CI (0.77, 1.0). This has indicated that a significant agreement above that 
expected by chance between the two methods was present. As EHF PTA indicated more 
children had ototoxicity, this method was used as a ‘gold standard’ to compare with the 
DPOAE tool using the two SNR cut-off criteria. The interrater reliability comparing EHF 
PTA and DPOAE with cut-off SNR value of <6dB was found to be Kappa = 0.707 (p 
<0.001), 95% CI (0.57, 0.95) (Table 4-3) which increased to Kappa = 0.754 (p <0.001), 95% 
CI (0.58, 0.96) when the cut-off SNR value of <3dB was used. This has also indicated that a 
significant agreement above that expected by chance between the two methods was present 
yet to a slightly lesser extent than that between the two audiometric tests. 
 EHF PTA Total 
Non ototoxic Ototoxic 
Standard PTA 
Non ototoxic 55 2 57 
Ototoxic 0 13 13 
Total 55 15 70 
Table 4-2: A 2x2 contingency table of outcomes using Standard PTA vs. EHF Audiometry.  
The interrater reliability comparing Standard and EHF PTA method was found to be Kappa = 0.911(p 
<0.001), 95% CI (0.77, 1.0). There is significant agreement above that expected by chance between the 
two methods. 
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 EHF PTA Total 
DPOAE not done Non ototoxic Ototoxic 
DPOAE 
SNR 
6dB 
Non ototoxic 2 51 5 58 
Ototoxic 3 2 7 12 
Total 5 53 12 70 
Table 4-3: A 2x2 contingency table of outcomes using DPOAEs vs. EHF Audiometry. 
The interrater reliability comparing DPOAEs with 6dB SNR and EHF PTA method was found to be Kappa = 
0.707 (p <0.001), 95% CI (0.57, 0.95). There is significant agreement above that expected by chance 
between the two methods. 
 Standard PTA Total 
DPOAE not done Non ototoxic Ototoxic 
DPOAE 
SNR 
6dB 
Non ototoxic 2 52 4 58 
Ototoxic 3 3 6 12 
Total 5 55 10 70 
Table 4-4: A 2x2 contingency table of outcomes using DPOAEs vs. Standard Audiometry. 
The interrater reliability comparing DPOAEs with 6dB SNR and EHF PTA method was found to be Kappa = 
0.488 (p <0.001), 95% CI (0.03, 0.56). There is significant agreement above that expected by chance 
between the two methods. 
Receiver operating characteristics (ROC) analysis was also performed using the EHF PTA 
data as the gold standard to determine the ototoxicity detection rate (sensitivity) and the non-
ototoxicity detection rate (specificity) of the other two methods compared to it. The Area 
under the curve (AUC) corresponding to Standard PTA, DPOAE with SNR cut-off at <6dB 
and of <3dB were 0.909, 0.824 and 0.827 respectively, with sensitivity levels of 81.8%, 
70.4% and 65.4% and specificity levels of 100%, 95.5% and 100% respectively. It is 
worth noting that, ‘Sensitivity’ defines the percentage of cases accurately detected to have 
ototoxicity by the different audiological assessment tools compared to those detected by 
EHF audiometry. Whereas, ‘Specificity’ defines the percentage of cases that were accurately 
confirmed to NOT have ototoxicity (i.e. normal hearing) by the different audiological 
assessment tools compared to those detected by EHF audiometry. Therefore, this analysis 
confirmed that despite all methods having significant agreement above that expected by 
chance, the ototoxic-induced DPOAE reduced amplitudes and SNR scores occurred at lower 
rates than those shown with behavioral threshold changes especially when compared with 
those at the EHF range. This was especially more apparent with the relatively low levels of 
sensitivity of the DPOAE test (especially when cut-off <3dB (65.4%) was used). Yet it is 
also worth considering that the two and three patients that showed evidence of ototoxicity 
with DPOAEs and not with EHF audiometry (Table 4-3) or standard audiometry (Table 4-4) 
respectively may be actually early subclinical evidence of functional damage of the OHCs 
not yet detected through audiometry (even EHFs). 
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A correlation test was then performed between the high frequency PTA and DPOAE at 
frequencies where there was a statistically significant difference between groups (Table 4-5). 
This showed a significant correlation between PTA thresholds and DPOAE amplitudes. The 
correlation was negative because patients with increased audiometric thresholds tended to 
have smaller DPOAEs amplitude levels. Many frequency pairs showed a highly statistical 
significance at p<0.001. The strongest negative correlation was seen between the DPOAEs 
results at 5 kHz f2 frequency and all the PTA results, for example, with the mean 8-12.5 kHz 
averaged result (r= -0.729, df=129, p<0.001). These correlation calculations were corrected 
from biasing due to multiple comparisons using the bootstrap method as shown in more 
detail in Table  4-6. Therefore, as PTA thresholds increased, in this case due to ototoxicity, 
the DPOAE amplitudes decreased. This confirmed that even though the sensitivity of 
DPOAE recordings to audiometric loss were shown to be lower than expected using the 
Kappa statistic or the ROC analysis, when specifically looking at the higher frequency 
recordings, they were actually highly correlated with the higher PTA frequency recordings. 
An analysis of audiological data in relation to different patient and treatment related factors 
that were assessed for an association with occurrence of ototoxicity are presented in section: 
5.1 as part of Theme B of this research which is focused on investigating ‘causation’ of 
ototoxicity.  
 DP 3.2 kHz DP 4 kHz DP 5kHz DP 6.3 kHz 
 
Pearson 
Correlation 
Sig.  
Pearson 
Correlation 
Sig.  
Pearson 
Correlation 
Sig.  
Pearson 
Correlation 
Sig.  
Mean PTA 
8 - 12.5kHz 
 
-.463** <.001 -.637** <.001 -.729** <.001 -.527** <.001 
PTA: 4kHz -.402** <.001 -.588** <.001 -.592** <.001 -0.328** <.001 
PTA: 8kHz -.381** <.001 -.573** 
<.001 -.630** <.001 -.455** <.001 
PTA: 9kHz -.443** <.001 -.631** 
<.001 -.721** <.001 -.511** <.001 
PTA: 10kHz -.463** <.001 -.638** <.001 -.730** <.001 -.544** <.001 
PTA: 11.8kHz -.465** <.001 -.627** <.001 -.735** <.001 -.518** <.001 
PTA: 12.5kHz -.490** <.001 -.629** 
<.001 -.723** <.001 -.531** <.001 
PTA: 14kHz -.482** <.001 -.605** 
<.001 -.725** <.001 -.570** <.001 
PTA: 16kHz -.468** <.001 -.624** <.001 -.709** <.001 -.528** <.001 
** Correlation is significant at the 0.01 level (2-tailed) 
* Correlation is significant at the 0.05 level (2-tailed). 
Table 4-5: Correlation between the audiometric thresholds and DPOAE amplitudes at frequency recordings 
that showed significant changes in outcomes indicating ototoxicity.
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 DP_3.2 DP_4 DP_5 DP_6.3 
PTA_AV8_12.5 Pearson Correlation -.463** -.637** -.729** -.527** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .013 .010 .006 -.003 
Std. Error .110 .072 .065 .090 
BCa 95% Confidence 
Interval 
Lower -.645 -.773 -.832 -.682 
Upper -.185 -.396 -.541 -.386 
PTA_4 Pearson Correlation -.402** -.588** -.592** -.328** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .017 .011 .007 -.002 
Std. Error .129 .094 .090 .103 
BCa 95% Confidence 
Interval 
Lower -.617 -.748 -.746 -.513 
Upper -.105 -.387 -.405 -.128 
PTA_8 Pearson Correlation -.381** -.573** -.630** -.455** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .012 .008 .004 -.006 
Std. Error .122 .093 .088 .104 
BCa 95% Confidence 
Interval 
Lower -.570 -.729 -.784 -.657 
Upper -.095 -.360 -.406 -.294 
PTA_9 Pearson Correlation -.443** -.631** -.721** -.511** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .012 .010 .006 -.003 
Std. Error .104 .071 .066 .091 
BCa 95% Confidence 
Interval 
Lower -.608 -.761 -.838 -.679 
Upper -.195 -.386 -.531 -.362 
PTA_10.5 Pearson Correlation -.463** -.638** -.730** -.544** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .012 .011 .007 -.003 
Std. Error .110 .073 .066 .089 
BCa 95% Confidence 
Interval 
Lower -.635 -.762 -.837 -.696 
Upper -.190 -.407 -.514 -.388 
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PTA_11.2 Pearson Correlation -.465** -.627** -.735** -.518** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .015 .013 .007 -.002 
Std. Error .112 .073 .064 .095 
BCa 95% Confidence 
Interval 
Lower -.659 -.761 -.840 -.681 
Upper -.162 -.394 -.521 -.355 
PTA_12.5 Pearson Correlation -.490** -.629** -.723** -.531** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .011 .009 .005 -.001 
Std. Error .106 .072 .064 .086 
BCa 95% Confidence 
Interval 
Lower -.676 -.765 -.830 -.664 
Upper -.188 -.390 -.543 -.370 
PTA_14 Pearson Correlation -.482** -.605** -.725** -.570** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .016 .012 .005 .001 
Std. Error .098 .074 .061 .080 
BCa 95% Confidence 
Interval 
Lower -.669 -.729 -.829 -.681 
Upper -.180 -.348 -.548 -.418 
PTA_16 Pearson Correlation -.468** -.624** -.709** -.528** 
Sig. (2-tailed) .000 .000 .000 .000 
N 131 131 131 131 
Bootstrapc Bias .014 .010 .006 .002 
Std. Error .097 .069 .063 .085 
BCa 95% Confidence 
Interval 
Lower -.629 -.730 -.814 -.670 
Upper -.184 -.429 -.549 -.350 
**. Correlation is significant at the 0.01 level (2-tailed). 
c. Unless otherwise noted, bootstrap results are based on 131 bootstrap samples, BCa 95% CI= Bias-corrected and accelerated (BCa) 
Table  4-6:  Detailed Bivariate Correlation analysis with boostrap corrections between the higher PTA and DPOAE frequencies that previously showed significant 
differences between the two groups (non-ototoxic vs. ototoxic group of children)
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4.1.2 Discussion of the audiological observational study of 
CF children: 
4.1.2.1 Summary of the main findings 
This study has shown a high prevalence (23.4%) of ototoxicity in children with CF who have 
previously received i.v AG courses (median: 5; range: 1-40 courses). This prevalence was 
significantly higher than the previously reported 0-6% prevalence in CF children (Crifo et al., 
1980) and closer to that reported in adult CF patients (Mulheran et al., 2001, Mulherin et al., 
1991, O'Donnell et al., 2010). This was particularly the case for those who have received at 
least 10 courses (high-exposure group) where 11/15 children showed evidence of ototoxicity. 
These children received an average of 18.2 courses (median: 16.0; range: 10-40) indicating 
that even at this young age repeated cumulative high exposure was common (Table 4-1). 
This is contrary to previous reports that CF children are less prone to ototoxicity because of 
the low exposure to aminoglycosides (Mulheran et al., 2001). However a clear dichotomy 
was seen in both the low and high exposure groups where some children showed evidence of 
ototoxicity while others showed normal, sometimes even exceptionally good, hearing. 
Just under half (44% -11/25) of CF children in the high-exposure group had evidence of 
ototoxicity. Thus it may be concluded that repeated exposure to i.v AGs represents a 
significant risk factor for ototoxicity in some children with CF and probably has a 
cumulative effect.  This is in agreement with previous studies such as Cheng et al. who 
investigated the prevalence of SNHL in 50 children with CF and reported that 3% in those 
who received ≤10 AG courses had evidence of ototoxicity versus 43% in those who received 
>10 courses (Mulheran et al., 2001, Mulheran and Degg, 1997a, Smyth and Tan, 2006, Tan 
et al., 2003, Cheng et al., 2009). In contrast, the remaining 4/15 children with ototoxicity 
received only three to eight i.v AG courses during their lifetime. It is possible that these 
individuals may be at increased risk of ototoxicity by being carriers of mutations known to 
confer increased susceptibility to AG ototoxicity such as the A1555G mutation in the 
mitochondrial 12S rRNA gene (Bitner-Glindzicz et al., 2009, Fischel-Ghodsian et al., 2004, 
Guan, 2011, Li et al., 2005, Conrad et al., 2008). These possible ‘risk factors’ and others 
were specifically investigated further in this patient cohort and the results were reported in 
section: 5.1 (Theme B) results. The lack of occurrence of ototoxicity in the other children 
receiving similar numbers of AG courses, especially the high-exposure group (14/25), is 
worthy of attention and again highlights that other factors may be involved in increased 
susceptibility to ototoxicity in addition to AG exposure.      
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4.1.2.2 Complaints of auditory symptoms: 
Another finding of this study is that more than half the children with ototoxicity did not 
complain of any hearing problems. Symptom presentation is therefore not a substitute for 
actively monitoring hearing through audiological testing. Children, in general, do not 
complain of hearing loss until the speech frequencies (mainly 0.5-6 kHz) become affected. 
At this point other serious consequences, including delayed speech and language 
development, will occur with associated adverse effects on social, educational and 
psychological wellbeing (Pimperton and Kennedy, 2012, Theunissen et al., 2013). Results of 
the survey study in section: 6.2 showed that patients’ complaints of hearing loss, tinnitus or 
dizziness were the most commonly used criteria for referral for audiological assessment by 
clinicians. This needs to be avoided and an appropriate ototoxicity monitoring protocol 
should be implemented instead. Results of further investigation into the effect that hearing 
loss due to ototoxicity has on the quality-of-life of children are presented within Theme C of 
this research in section: 6.1 of chapter six.    
4.1.2.3 Assessment of standard PTA vs. EHF PTA and DPOAEs as 
monitoring tools for ototoxicity 
Overall, EHF audiometry was shown to be most sensitive in detecting ototoxicity in children 
with CF, and superior to the more commonly used standard PTA. DPOAEs showed a lower 
than expected degree of sensitivity with respect to EHF PTA yet an equal degree of 
specificity in identifying ototoxicity compared to EHF audiometry.  
When compared with standard PTA, EHF audiometry detected two additional children with 
mild or early ototoxicity and showed a significant drop in hearing thresholds (25-85 dBHL) 
across several adjacent frequencies, whereas with standard PTA hearing loss was confined to 
only the highest (8 kHz) frequency in 33.3% (5/15) of the subjects identified with ototoxicity. 
Threshold changes that occur only at a single frequency are subject to much greater 
variability in interpretation. Consequently when Brock’s hearing loss grading was employed 
to the standard PTA results, as much as 73% of these children were given a low Brock’s 
grade of 0 or 1 equating to absent or mild hearing impairment respectively, even though 
increased EHF audiometric thresholds provided evidence that a large proportion of the basal 
turn of the cochlea had already been damaged.  
DPOAE results showed a prevalence of loss of 18.5% and 10.8% respectively when SNR 
cut-off scores of <6dB and <3dB were used. A significant drop in DPOAE amplitudes at 
higher f2 frequencies in 7/15 children diagnosed with ototoxicity by the EHF audiometry 
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was recorded whereas DPOAE was not performed in another 3/15 of these children. Despite 
the kappa scores showing that this tool had a significantly higher agreement with EHF PTA 
above chance, results using this method were shown to be less sensitive than audiometry, 
especially EHF PTA. DPOAE sensitivity of 70.4% and specificity of 95.5% with the SNR 
cut-off of <6dB was obtained when compared to EHF PTA. This was similar to the hit rate 
of 78% reported by Reavis et al. who also indicated that DPOAEs were less sensitive to 
ototoxic injury compared with behavioral audiometry especially the 1/6th octave EHF PTA 
(Reavis et al., 2008). However, they also highlighted that the timing of DPOAE changes 
relative to behavioral threshold changes differed between patients. Roughly equal proportion 
(33-34%) of patients had DPOAE changes preceding, occurring during and lagging behind 
behavioral changes. They could not explain the reason for this difference on examining 
several independent variables but did state that DPOAE sensitivity increased when patients 
had better measureable pre-exposure hearing and larger magnitudes of post-exposure hearing 
change. As the current study had a cross-sectional design, further investigation into the 
relationship between DPOAE and behavioral thresholds was not possible but this 
explanation could offer a possible explanation for the patients identified to have ototoxicity 
by DPOAEs and not by the audiometric tests (Table 4-3 and Table 4-4). Here DPOAE 
changes preceding behavioral threshold changes could explain these results. This also 
supports that a recommendation should be made to use the outcomes of both the EHF PTA 
and DPOAEs as a ‘test battery’ and consider that to be a gold standard instead of EHF PTA 
alone and definitely instead of standard PTA alone if the main aim of monitoring is early 
identification of ototoxicity.  If this was the case and if ototoxicity was identified using 
results of both/either of the EHF PTA or DPOAE showed evidence of ototoxicity 14/65 
(21.5%) of this cohort that underwent both tests would have been identified versus 12/65 
(18.5%) with EHF PTA alone or 10/65 (15.4%) with standard PTA alone (Table 4-3 and 
Table 4-4). However, as the results of the survey of current ototoxicity monitoring in the UK 
presented in section 6.2 demonstrated that a significant percentage of clinicians don’t 
monitor for ototoxicity at all and others provide a very variable service, considerations to 
providing the minimum level of assessment with just standard audiometry may be an 
important starting point to establish. More details of the implications of this survey are 
presented later.  
To support this recommendation, analysis of the outcomes of the higher frequencies, where 
early evidence of ototoxicity is expected to occur, showed a highly significant negative 
correlation between the DPOAE amplitudes and the audiometry thresholds (Table 4-5). Thus 
indicating that both tools produce similar outcomes at the more important higher frequencies. 
This was in agreement with Arnold et al. and Reavis et al. who reported that DPOAEs at the 
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4-8 kHz range were significantly correlated with the EHF PTA results at the 8-20 kHz range 
indicating that high-frequency hearing influences DPOAEs recorded at significantly lower 
frequencies even when the corresponding PTA thresholds at these 4-8 kHz were still within 
the normal thresholds (Arnold et al., 1999, Reavis et al., 2008). This may be because the 
emissions are sensitive to subtle changes in outer hair cells not yet detected by pure-tone 
thresholds in this region or because alterations in the basal cochlea affect the generation of 
lower-frequency DPOAEs originating from more apical cochlear regions. As such, DPOAEs 
should be considered to be good markers for early detection of high-frequency hearing loss 
caused by ototoxicity. The strong correlation between high frequency DPOAE amplitudes 
and PTA high-frequencies shown in Table 4-5 supports this conclusion yet the cross-
sectional design of the current study do not aid in clearly demonstrating this point.  
A relative drawback to DPOAE testing was that it could not be measured in the presence of 
middle ear pathology, or in a child who is crying, vocalizing, or moving. Five children who 
were recruited in this current study had middle ear disease and DPOAEs could not be validly 
measured in them. On the other hand, DPOAE measurement is objective, non-invasive and 
does not require the patient’s active participation and therefore has the advantage of being 
very effective in monitoring ototoxicity in young children or any difficult to test patients 
who may not consistently provide reliable, ear-specific pure-tone threshold responses 
(Beattie et al., 2003, Knight et al., 2007). This fact again supported the conclusion that EHF 
audiometry and DPOAE testing complemented each other and provided a test battery that 
would be more superior than standard audiometry alone in detecting early/mild ototoxicity in 
children of this age group where crying and vocalizing in no longer an issue. Standard 
audiometry is usually used as the only audiological tool for ototoxicity monitoring despite 
repeated evidence showing that it is less sensitive than the other two tools used as a test 
battery (Al-Malky et al., 2011, Knight et al., 2007, Konrad-Martin et al., 2010, Lonsbury-
Martin and Martin, 1990, Reavis et al., 2011, Stavroulaki et al., 2002).  
The question of how reliable EHF audiometry is in children and what DPOAE testing can 
add to monitoring for ototoxicity may be posed. Investigations into the test-retest reliability 
of EHF audiometry in children have been limited (Margolis et al., 1993, Reuter et al., 1998, 
Schmuziger et al., 2004, Dreschler et al., 1989) but an important study by Beahan et al. was 
recently published specifically evaluating this issue in relation to criteria for ototoxicity 
(Beahan et al., 2012). They tested 125 children aged between 4–13 years with normal 
hearing in the 0.25–4 kHz range and divided them up into three age groups (4-6; 7-9 and 10-
13 years). They investigated the test-retest reliability of EHF PTA at frequencies 8-16 kHz. 
Their results demonstrated that a slight age effect was evident by reporting that normal 
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variability in thresholds (within ±10 dB) occurred in 89.9%, 93% and 97% of the three age 
groups respectively. It was also reported that a significant deterioration in hearing thresholds 
across test-retest conditions in relation to the ASHA (1994) ototoxicity criteria in the three 
age groups demonstrated false-positive rates of 24.6%, 11% and 7.6% respectively. They 
therefore concluded that EHF PTA demonstrated high test-retest reliability in all but the 4-6 
year-old groups and recommended that testing should be supplemented with an ‘objective’ 
test of auditory function, such as DPOAEs, to confirm the diagnosis of ototoxicity with serial 
monitoring of hearing. This again endorsed the conclusion that these two tests are 
complementary to each other and should be used as a test battery.  
Overall, EHF audiometry and DPOAE as a complementary (subjective and objective) test 
battery were shown to be sensitive in diagnosing ototoxicity in children with CF, and 
superior to the commonly used standard PTA alone. As DPOAE was shown to be a valuable 
objective tool in detecting or monitoring ototoxicity further effort was invested in trying to 
improve this technique. Results of this study and previous research have shown that DPOAE 
maybe affected by middle ear problems and probe fitting, and do not have universally 
accepted criteria for diagnosing ototoxicity as criteria for DPOAE strength is not 
standardized (Knight et al., 2007, Beattie et al., 2003). Further investigation into factors, 
such as repeatability of recordings or impact of differences in probe placement on OAE 
recordings was undertaken within a control study whose results are presented in section 4.2.      
4.1.2.4 Effect of ototoxicity on patients and the importance of 
accurate criteria for ototoxicity 
The importance of setting the appropriate criteria for determining ototoxicity was highlighted 
by using Brock’s grading as an example of the significant difference in outcomes that can be 
obtained when different criteria are used (Figure 4-4). When Brock’s grading was applied 
using the standard audiometry data, 5/13 of these children scored grade 0 (absent ototoxicity) 
and 6 scored grade 1 (mild ototoxicity) (Table 4-1). Brock’s grading is only one example of 
numeric grading systems that are at risk of under-estimating the degree of drug-induced 
hearing loss. Knight et al. compared the ASHA criteria (Table 1-1) with the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE - Table 1-5) used in 
assessment of chemotherapeutic ototoxicity (Knight et al., 2005). They concluded that the 
commonly used reporting of toxicity data (CTCAE) had under-reported ototoxicity, did not 
correlate with the ASHA criteria outcomes and minimized the significance of hearing loss in 
children as it did not specifically consider high frequency hearing loss. The problems of 
clinical interpretation of the PTA data may be addressed by use of EHF, which detected a 
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much greater loss across a number of adjacent consecutive frequencies in this cohort (Figure 
4-3) or through the use of more accurate criteria for ototoxicity. The recently proposed 
International Society of Pediatric Oncology Boston Ototoxicity Scale (SIOP Boston Scale: 
Table 1-4) appears to be a good scale to use, as there is a drive to have a consensus from all 
different professionals to use it, with the aim to have internationally common criteria for 
ototoxicity (Brock et al., 2012a). This scale is easy to interpret and takes into account mild 
levels of hearing loss at the high frequencies allowing for early identification of ototoxicity. 
It is also is dependent on absolute thresholds so that if baseline assessment were not 
performed for any reason (the child was very ill/not cooperative) later assessments can be 
made independently.  
Hearing loss in childhood has major implications on speech and language, social and 
psychological development in patients and may significantly affect quality of life. Therefore 
it is recommended to perform serial auditory monitoring using EHF audiometry and 
DPOAEs in all children with CF especially those who receive frequent courses of i.v AG for 
early detection of signs of ototoxicity. Early detection allows the managing clinicians to 
make informed decisions about the different antibiotics regimens they are using with each 
patient, weighing their risk/benefits in relation to their recorded side effects. Appropriate 
management might allow for more conservative use of these antibiotics and initiate early 
auditory rehabilitation to decrease the impact of hearing loss on quality of life.  
4.1.3 Conclusions: 
This study showed that ototoxicity due to exposure to aminoglycosides in children with 
cystic fibrosis was more common than previously reported. It affected one in five (23.4%) of 
the children tested and this prevalence went up to around two in five (44%) when only the 
high exposure children were assessed. This prevalence was closer to the previously reported 
prevalence in adults. It was also shown that despite their young age, many children were 
exposed to a large number of repeated cumulative aminoglycoside courses with some 
recorded to have received up to 40 courses before the age of 16 years. Many of the children 
were admitted to hospital for prophylactic intake of i.v antibiotics every 2-3 months in order 
to combat chronic pseudomonas chest infections. This confirms that the misconception that 
CF children are not at risk of ototoxicity because of limited exposure to AGs is not true. It 
was also shown that even when audiological assessment confirmed the existence of 
ototoxicity most of the children affected did not complain of any auditory symptoms 
therefore waiting for the child to complain before assessing them would not detect early or 
mild ototoxicity.  It could also be concluded that in order to protect their quality of life, 
which would be affected by ototoxicity and the possible consequent problems such as 
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deterioration of speech and language abilities, regular active monitoring of their hearing 
status is needed. This would allow clinicians to make informed decisions regarding 
treatments regimens with the aim to protect hearing from progression of ototoxicity.  
On comparing the different audiological assessment tools it was concluded that a test battery 
including EHF audiometry and DPOAE testing would be more sensitive for ototoxicity 
monitoring than the commonly used standard audiometry. However, the lower than expected 
sensitivity of DPOAEs as an independent monitoring tool compared to EHF audiometry 
prompted further investigations into possible factors that may account for this outcome. 
These are presented below in sections 4.2 and Error! Reference source not found.. A 
major finding was the dichotomy in audiological outcomes of the CF children. Some 
children with both low and high exposure had exceptionally good hearing whereas others 
had substantial hearing loss.  This is clear evidence that multiple factors are involved in the 
causation of ototoxicity, which needs to be investigated further.      
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Assessment of DPOAE testing as an audiological 
tool - rationale behind the control studies: 
o Significance of DPOAE as a monitoring tool for 
ototoxicity in children: 
Review of the literature has confirmed that DPOAE measurements have an important yet 
underutilized role in the monitoring of ototoxicity (Biro et al., 2006, Cevette et al., 2000, 
Konrad-Martin et al., 2012). The results reported above and other studies have shown that it 
is a quick non-invasive objective test that can be well recorded in children. It provides 
information regarding the integrity of OHCs and preservation of the non-linearity of the 
inner ear. As the OHCs are one of the first cells to be damaged by ototoxic drugs, this would 
be the ideal test to use for early detection of ototoxicity. However, this test was not found to 
be as sensitive as EHF PTA – but maybe this could be improved by research.    
o Pilot study on DPOAEs in school-aged children vs. 
adults: 
Identification of some gaps in the literature regarding research in DPOAE measurements in 
the school-aged group of children prompted investigation of this aspect as a possible 
explanation for the recorded lower sensitivity when using this tool with the CF children 
exposed to aminoglycosides. There had been extensive research regarding DPOAE testing in 
neonates and also in adults. They showed that there was a variation in outcomes of each of 
these subject groups, even within normal hearing subjects, yet there was limited research in 
the school-aged children’s group (Gorga et al., 2000b, Lonsbury-Martin et al., 1993a, 
Lonsbury-Martin et al., 1993b, Zhao and Stephens, 1999). A pilot study where repeated 
DPOAE testing for two normal-hearing children aged 6 years and 8 years and two normal-
hearing adults aged >18 years over a period of four weeks was undertaken. Testing was 
repeated on average ten times/day at different times of the day and at different positions (i.e. 
sitting up or lying down). Preliminary analysis of these results showed that there was 
significantly more variability in the DPOAE results of the children compared to the adults 
despite all the results still being considered within the normal range of >6dB SNR scores. 
The DPOAE amplitudes and noise levels varied more with the children. On trying to identify 
the possible causes for this in line with previous research it was decided that the two main 
factors that may have caused this variability were differences in the positioning and 
placement of the OAE probe into the ear canal and possible changes in the children’s middle 
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ear pressure due to the higher probability of nasal congestion or susceptibility to otitis media 
with effusion in children.        
o Generation of research questions: 
On the basis of this small pilot study it was decided to undertake a control study. This study 
was to assess the effect of probe re-insertion on the repeatability of DPOAE recordings in 
school-aged children. The results of this study is presented below.   
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4.2 A control study assessing the short-term test-
retest repeatability of DPOAE recordings in 
normal hearing school-aged children 
The aim of this study was to assess the short-term repeatability of DPOAE recordings in 
school-aged children after removal and re-insertion of the OAE probe. The aim was also to 
calculate the minimum detectable difference (MDD), which is the ‘band of error’ beyond 
which a change is considered to be a true sign of abnormality.  
4.2.1.1 Study group: 
150 patient information sheets and consent forms were sent home with the children from 
Swindon, Abbey Meads community primary school to obtain parental approval to test the 
children. 83 consent forms were returned. Assessments were undertaken in a dedicated quiet 
room in the school. Otoscopy and tympanometry were performed to confirm normal external 
and middle ear function. 23 (28%) children were excluded as they had occluding earwax or 
Type B or C tympanograms. Therefore a total of 60 children were included in the study.  
The ages of the 60 children ranged between 7 and 12 years (mean ±SD: 10.1 ±5.3) with 37 
boys and 23 girls. Figure 4-8 shows the distribution of children according to age. All 
children had normal otoscopy and tympanometry with mean ±SD: -17.9 ±24.0 daPa and 0.78 
±0.49 ml peak pressure and compliance respectively.  
 
Figure 4-8: Distribution of the recruited children according to age (years) 
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 DPOAE results: 
DPOAE recordings were obtained from both right and left ears (120 recordings), which were 
repeated three times.  DPOAE recordings at eleven ¼-octave f2 frequencies ranging between 
0.8 and 8 kHz were made. Figure 4-9 shows the mean ± standard error (SE) DPOAE 
amplitudes for all f2 frequencies for the three recordings. All three recordings were very 
similar with mean DPOAE amplitudes ranging between 5.2 and 13.1 dB SPL (±6.2 to 9.2 
SD) across all f2 frequencies with the exception of responses at 8 kHz, which were the only 
responses with negative mean amplitudes of -14.5 (±11.5) dB SPL. Responses peaked at 
frequencies 1.6 and 5 kHz. The equivalent noise floor, as seen in Figure 4-10 showed 
gradual decrease in mean amplitudes as frequencies increased with mean levels highest at 
0.8 kHz at 1.1 dB SPL and lowest at frequency 8 kHz at -16.4 dB SPL. This higher noise 
floor at the lower frequencies contributed to diminished ability to distinguish between the 
DPOAE responses from the background noise and hence a lower SNR. This affects the 
reliability of the recordings at f2 frequencies <1.3 kHz (Figure 4-11). Reliability improves, 
as defined by the larger SNR, at f2 frequencies ≥1.3 kHz due to the decreased noise floor 
levels and associated increase in DPOAE amplitudes. A minimal SNR score of 3dB, i.e. a 
DPOAE amplitude of ≥3 dB above the mean noise floor + 2 SDs, is considered as a true 2f1-
f2 DPOAE response.  A repeated measures analysis of variance (ANOVA) was performed to 
assess if the difference between the three recordings was significant or not. Results showed 
no significant within-subject differences between the three recordings across all 11 f2 
frequencies (F2, 118 = 2.609, p=0.078, partial η
2
= 0.042). Pairwise comparison of 
combinations of each pair of repeats showed absence of significance in any of the 
combinations (p>0.05). This absence of significant differences was also confirmed by Post 
Hoc tests with Bonferroni correction (p>0.05). 
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Figure 4-9: Mean ±SE DPOAE amplitudes for each f2 frequency for each of the repeated three recordings.  
The three recordings were similar at all f2 frequencies, which were all positive values except for the 8kHz 
frequency recordings. 
 
 
In an attempt to explain the reason for the significantly low 2f1-f2 DPOAE amplitudes at 8 
kHz, as seen in Figure 4-9 and Figure 4-10 compared to all the other responses, it was 
discovered that the average level of the actual output of L1/L2 primary tones was 
significantly lower than the target L1/L2: 65/55 dB SPL. From a random sample of 60 
recordings obtained from 10 of the recruited children, the average L1/L2 values at 8 kHz 
were actually 52/40 dB SPL  ± SD: 5/7 dB SPL and at 6 kHz were 58/45 dB SPL ± SD: 8/5 
dB SPL. This was not the case for the other f2 frequencies where the target L1/L2: 65/55 dB 
SPL were achieved in most cases with a small degree of variance. This, in addition to the 
theory of standing waves in the ear canal cancelling DPOAE responses at the higher 
frequencies, may explain the low amplitudes at 8 kHz and to a lesser extent at 6 kHz. This 
information was fed back to the manufacturing company (Otodynamics ltd.), which then 
took action and modified the recording algorithm for responses at frequencies >5 kHz by 
introducing correction factors to overcome this problem (see Appendix 9.1 for report from 
Otodynamics) 
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Figure 4-10: Mean ±SD of the three repeated recordings of DPOAE amplitudes and its associated noise 
floor recordings.  
The grey background shows the average range of DPOAE amplitudes and noise floor of adult patients. The 
mean values were so similar that they overlapped.   
 
 
Figure 4-11: Mean ±SD of the signal-to-noise ratios (SNR) of the 3 repeated DPOAE recordings as a function 
of the f2 frequencies.  
The recordings are shown to be strongly repeatable leading to overlap of the results. 
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4.2.1.2 Statistical analysis of DPOAE repeatability and Calculation 
of the SEM: 
An interclass correlation coefficient (ICC) analysis was made to assess the degree of 
correlation between the three repeated recordings at each of the DPOAE f2 frequencies 
recorded. A strong ICC was obtained for the averaged measures across all tested frequencies 
(ICC= .885, 95% CI= .838 - .919) with a stong reliability statistic in the form of Cronbach’s 
Alpha of .948 as shown in Table 4-7 and Table 4-9. When the ANOVA statistic was 
performed to assess the significance of these correlations and ensure that there is a true 
within subjects – between items significant effect, the outcomes were highly significant (F= 
165.3; df= 32,118; p<0.001) as shown in Table 4-8. Table 4-10 shows a strong correlation 
between the repeats at all f2 frequencies (p<0.01) especially at f2 frequencies 1.3 to 6.4 kHz 
(ICC: 0.791 to 0.908).  The scatter plots demonstrate the weaker correlation obtained at 
DPOAE f2 frequency 0.8 kHz (Figure 4-12) with positive regression shown at R
2
=0.30 and 
the strongest correlation obtained at DPOAE f2 frequency 5 kHz (Figure 4-13) with positive 
regression at R
2
=0.77. 
Reliability Statistics 
Cronbach's Alpha 
Cronbach's Alpha 
Based on 
Standardized 
Items N of Items 
.948 .957 33 
Table 4-7: Relaibility statistics showing a strong correlation between all 33 tested items (11 DPOAE f2 
frequencies, 3 Repeats) 
ANOVA 
 Sum of Squares df Mean Square F Sig 
Between People 85643.290 118 725.791   
Within People Between Items 197953.042 32 6186.033 165.270 .000 
Residual 141334.968 3776 37.430   
Total 339288.010 3808 89.099   
Total 424931.299 3926 108.235   
Grand Mean = 6.779 
Table 4-8: ANOVA statistic assessing the significance of the ICC calculations performed. 
Intraclass Correlation Coefficient (ICC) 
 
Intraclass 
Correlation
b
 
95% Confidence Interval F Test with True Value 0 
Lower Bound 
Upper 
Bound Value df1 df2 Sig 
Single Measures .190
a
 .135 .257 19.391 118 3776 .000 
Average Measures .885
c
 .838 .919 19.391 118 3776 .000 
Two-way mixed effects model where people effects are random and measures effects are fixed. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type A intraclass correlation coefficients using an absolute agreement definition. 
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c. This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise. 
Table 4-9: ICC calculations showing the strength of the overall correlations between the repeated 
recordings of the DPOAE f2 frequencies as single measures (as shown below) and with all the measures 
averaged together.  
 
DPOAE F2 Frequency Repeats R1 R2 R3 
0.8 kHz 
R1 1 .548
** .401** 
R2 .548
** 1 .270** 
R3 .401
** .270** 1 
1 kHz 
R1 1 .646
** .746** 
R2 .646
** 1 .799** 
R3 .746
** .799** 1 
1.3 kHz 
R1 1 .807
** .900** 
R2 .807
** 1 .791** 
R3 .900
** .791** 1 
1.6 kHz 
R1 1 .845
** .896** 
R2 .845
** 1 .836** 
R3 .896
** .836** 1 
2 kHz 
R1 1 .888
** .890** 
R2 .888
** 1 .868** 
R3 .890
** .868** 1 
2.5 kHz 
R1 1 .877
** .932** 
R2 .877
** 1 .845** 
R3 .932
** .845** 1 
3.2 kHz 
R1 1 .876
** .899** 
R2 .876
** 1 .901** 
R3 .899
** .901** 1 
4 kHz 
R1 1 .771
** .874** 
R2 .771
** 1 .812** 
R3 .874
** .812** 1 
5 kHz 
R1 1 .878
** .928** 
R2 .878
** 1 .911** 
R3 .928
** .911** 1 
6.4 kHz 
R1 1 .880
** .908** 
R2 .880
** 1 .889** 
R3 .908
** .889** 1 
8 kHz 
R1 1 .681
** .699** 
R2 .681
** 1 .683** 
R3 .699
** .683** 1 
Table 4-10: Outcome of interclass correlation coefficient (ICC) analysis assessing the correlation between 
the three repeated DPOAE recordings as a function of each f2 frequency tested- Corrections for biasing 
from multiple correlations was performed using the simple Bootstrap method. 
 ** Correlation is significant at the p< 0.01 level (2-tailed). 
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Figure 4-12: Scatter plot with trend line showing a positive weaker correlation (R2=0.30) between the 1st 
and 2nd repeat DPOAE recordings at f2 frequency 0.8 kHz. 
 
Figure 4-13: Scatter plot with trend line showing a positive strong correlation (R2=0.77) between the 1st 
and 2nd repeat DPOAE recordings at f2 frequency 5 kHz. 
The final useful calculation that was performed was to assess the standard error of 
measurement (SEM) and the minimum detectable difference (MDD). The SEM was used to 
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assess test-retest reliability and was computed using the formula: SEM = s*√ (1−ICC) where 
‘s’ is the combined standard deviation (SD) of all the three repeated recordings at each 
DPOAE f2 frequency and the ‘ICC’ is the interclass correlation coefficient also known as the 
reliability coefficient (r) for the test. The SEM results were then used to calculate MDD, 
which is considered as the minimum difference above which an actual change exceeds the 
measurement error in the score and is therefore considered abnormal i.e. it is the ‘band of 
error’ beyond which a change is a true sign of abnormality. The MDD95% is equivalent to 
1.96*a√2*SEM which is within ±2 standard errors (SEs) of the MDD calculation and 
therefore has a confidence interval of 95%. Table 4-11 shows the outcome of these 
calculations for all the DPOAE f2 frequencies tested.  
These values allow us to assess the limits above which a change can be attributed to 
deterioration in cochlear function and therefore would be vital for the use of DPOAEs as a 
monitoring tool for ototoxicity. The SEM scores averaged across the strongly correlated mid-
frequencies of 1.6 to 6 kHz equaled 2.7 dB SPL with an averaged MDD95% of 7.5 dB SPL. 
This data suggests that there is a 95% probability that a drop in DPOAE amplitudes of >7.5 
dB SPL in these frequencies signifies change in the OHC non-linear cochlear function 
secondary to exposure to ototoxic medications, or any source of inner ear insult, in these 
patients. The MDD95% average for the lower and highest f2 frequencies, of 0.8 – 1.3 kHz and 
8 kHz, is higher, giving values of 11.1 dB SPL and 18.0 dB SPL respectively.  
DPOAE f2 frequencies (kHz) 0.8 1.0 1.3 1.6 2.0 2.5 3.0 4.0 5.0 6.0 8.0 
ICC 0.3 0.7 0.8 0.8 0.9 0.9 0.9 0.8 0.9 0.9 0.7 
SEM 4.5 4.0 3.5 2.6 2.4 2.6 2.3 3.2 2.6 3.2 6.5 
MDD 95% 12.5 11.0 9.7 7.2 6.6 7.2 6.3 9.0 7.2 8.9 18.0 
Table 4-11: Showing the calculated Interclass correlation coefficient (ICC), Standard error of measurement 
(SEM) and Minimum detectable difference at 95% probability (MDD 95%) for the repeated measurements at 
each of the DPOAE f2 frequencies recorded. 
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4.2.2 Discussion of DPOAE test-retest repeatability control 
study: 
This study aimed to investigate the short-term test-retest reliability of DPOAE recordings in 
primary school-aged children, taking into account the effect of reinsertion of the probe into 
the ears. This would enable assessment of the normal variability of DPOAEs so that these 
variations can be accounted for when they are used to monitor cochlear function in children 
receiving potentially ototoxic medications or offer an explanation for their lower sensitivity 
in the clinical CF study.  
The DPOAE recordings, obtained in this study from 60 normal hearing children (120 ears), 
were shown to be highly repeatable even when the probe was removed and reinserted in each 
child’s ear. This was confirmed by absence of a significant within-subject difference 
between the three recordings at all f2 frequencies using a repeated measures ANOVA test (F 
2,118= 2.609, p=0.078, partial η
2
= 0.042) and through the strong correlation between the 
repeated recordings shown in Table 4-10. The single most significant variable influencing 
the reliability of DPOAE measurements was the f2 frequency. This was evidenced by the 
SNR scores (Figure 4-11) where the minimum 3dB SNR score required to confirm the 
presence of a true 2f1-f2 DPOAE response above a mean noise floor +2SDs was not reached 
at the lower f2 frequencies <1.3 kHz or at the highest frequency of 8 kHz. SNR scores at 
≥1.3 to 6.4 kHz were well above these pass criteria and were repeatable. Decreased SNR 
scores in the lower f2 frequencies were mainly attributed to higher noise floor levels and 
relatively lower DPOAE amplitudes in comparison with the higher f2 frequencies (Figure 
4-10). This was in agreement with Roede et al., Zhao & Stephens, and Beattie et al., who 
reported that environmental, instrumentation and internal-subject noise affected the DPOAE 
reliability mainly at the lower frequencies (Roede et al., 1993, Zhao and Stephens, 1999, 
Beattie et al., 2003).  Other researchers such as Gorga et al. hypothesized that the forward 
and reverse middle ear transmission and cochlear nonlinear function contributed to the 
significant effect of environmental noise on lower frequency DPOAEs (Gorga et al., 1994) 
On the other hand the decreased SNR scores at 8 kHz were mainly attributed to the less than 
target stimulus levels actually delivered to the ears (target L1/L2: 65/55 whereas average 
stimulus levels of only 52/40 dB SPL where actually recorded). Keppler et al. also reported 
lower DPOAE reliability at 8 kHz and confirmed that higher primary-tone level DPOAE 
combinations improved reliability of DPOAEs amplitudes (Keppler et al., 2010). This same 
issue was reported by other researchers who attributed the increased variability in stimulus 
levels at 8kHz to difficulties with calibration at f2 frequencies >6kHz (Franklin et al., 1992, 
Roede et al., 1993). The theory that the presence of standing waves in the ear canal leads to 
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systematic errors in estimating eardrum sound pressure levels by the probe microphone at the 
higher frequencies was also proposed (Siegel and Hirohata, 1994).  
One of the main drivers to performing this study was due to the fact that there is very limited 
published data on test-retest reliability of DPOAEs in the paediatric population (Gorga et al., 
2000b, O'Rourke et al., 2002, Sockalingam et al., 2007) in comparison to neonatal and adult 
populations, which are both potentially very different. The neonates were shown to have 
very robust DPOAEs attributed to healthy undamaged cochlear function but also explained 
by higher amplification of the DPOAE response within the smaller ear canal space between 
the DPOAE probe and the tympanic membrane. Conversely, they were also shown to have 
significantly high noise levels at the lower frequencies (<1.0 kHz) which were mainly caused 
by internal noises from breathing and crying (Gorga et al., 2000b). DPOAEs in adults were 
shown to be repeatable but with lower amplitudes due to more cochlear damage from noise 
exposure and ageing. Lower frequency noise was still high but was mainly attributed to 
environmental noise (Gorga et al., 2000a, Gorga et al., 1993, Keppler et al., 2010, Franklin et 
al., 1992, Roede et al., 1993). The results of the current study were an intermediate outcome 
compared to these two population groups in that the responses were robust and repeatable as 
in the neonates but will less internal noise affect as in the adult population.   
Results showed that testing the school-aged group of children in a quiet room rather than in a 
soundproof booth did not have a significant effect on the measurements. This was in 
agreement with other studies (Gorga et al., 2000b, Cone-Wesson et al., 2000) that showed 
that the external test environment did not have a significant effect of DPOAE recordings 
even when testing babies in the perinatal period as long as the test environment was 
relatively quiet.  They showed that the main source of increased noise levels with consequent 
decrease in SNRs was the baby’s own internal sounds like heavy breathing, crying, or nasal 
congestion. As these internal noises decrease, as the child gets older, this effect decreases. 
This confirms that children can have their auditory status monitored through DPOAE testing 
for evidence of ototoxicity during a hospital visit, on the ward or even in the patient’s home 
as long as the room is a relatively quiet.   
The calculations of SEM and MDD95% were very useful in assessing the test-retest reliability 
of DPOAE recordings in normal-hearing children of this age group. Ideally a test should 
produce the same results when the same subject is tested under the same conditions on two 
separate occasions. Unfortunately, in reality this goal is not met and clinical tests show less-
than-perfect reliability in test-retest conditions. The SEM is a reliability estimate that is 
capable of determining a true DPOAE from a single measurement so that if a change on 
repeated monitoring recordings is found clinicians can be confident that this is due to a 
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change in the auditory system and not simply due to measurement error (Demorest and 
Walden, 1984).  The SEM at the lower frequencies  (<1.3 kHz) averaged 4.0 dB and was 
averaged 2.7 dB at the higher frequencies (1.6-6 kHz). This was similar to results obtained in 
50 young adult women tested by Beattie et al. who reported SEMs of ~4.6 dB at 550 Hz and 
~2.5 dB at the higher frequencies (1 to 4 kHz) which was also similar to other studies 
(Beattie (2003), (Beattie and Bleech, 2000, Zhao and Stephens, 1999, Franklin et al., 1992, 
Beattie et al., 2003). The larger SEM in the lower frequencies was attributed to a more 
significant effect of changes in the position of the probe tip on the level of background noise 
in the ear canal (Zhao and Stephens, 1999) and to the middle ear changes in fluid and air 
pressure having more effect on the lower frequencies (Roede et al., 1993).  Beattie et al. 
(2003) assessed SEMs for immediate repeated recordings (on same day with no probe 
replacement), for very-short term (on same day but after a 10-20 minute break and 
replacement of probe) and for short-term recordings (5-10 days following the first recording) 
and showed that the major factor contributing to variability was the probe removal and 
reinsertion. Therefore careful probe insertion and fitting may contribute to decreasing 
variability. Reavis et al. conducted a similar study where potential occurrences for adjacent 
frequency shifts in normal ears of eight subjects were calculated and showed that a 4dB shift 
in amplitudes was only observed in 5% of the recordings (21/409). They concluded that 
DPOAE change criteria of ≥4dB level reduction or loss of response due to drop in the 
DPOAE amplitudes to < -10dB at two or more adjacent f2 frequencies would be considered 
as a true change of outcome with a 5% false positive rate to be expected (Reavis et al., 2008).   
The SEM was used to determine the confidence interval for a child’s true DPOAE to 
establish whether the DPOAE has significantly deviated from a cut-off or normal level or not. 
The 95% confidence intervals (MDD95%) averaged for the lower frequencies (<1.3kHz) were 
11.1 dBSPL and 7.5 dBSPL for the higher frequencies (1.6 – 6 kHz).  This was in agreement 
with Beattie et al. (2003) which calculated similar MDD95% of ~10 dB at 550 Hz and ~5 dB 
for 1-4 kHz suggesting that differences between DPOAE recordings should exceed 14 dB 
and 7 dB for the lower and higher frequencies respectively to be statistically significant at 
the 0.05 level of confidence. Values exceeding these limits following exposure to ototoxic 
medications are likely to represent an actual decrease in cochlear function rather than due to 
a measurement error.  
4.2.3 Conclusion: 
Review of the literature had shown that research related to DPOAE testing in ears of children 
during the primary school age was limited. As this was the prevalent age group of the 
children with CF that were included in the main study, this control study was undertaken to 
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exclude possible confounding factors that may have affected the outcomes of the main study 
group of children with CF. 
Results showed that DPOAE recordings could be highly repeatable in the ears of children 
within this age group. There was a strong correlation between repeated recordings across all 
test frequencies even after probe removal and reinsertion was performed. It therefore 
suggested that this was probably not a contributing factor to changes in sensitivity of the 
DPOAE when testing the children with CF as long as good probe insertion was maintained. 
It established that on repeated DPOAE recordings, while regularly monitoring for ototoxicity, 
a minimal change of >11.1 and >7.5 dB SPL for the lower and higher frequencies 
respectively is required to establish a true shift in auditory function with 95% confidence, 
and not to attribute a change to an error of measurement. These thresholds were similar to 
recommendations of pervious researchers. It also confirmed that accurate repeatable 
recordings could be made even when testing in a quiet room (as apposed to a soundproof 
room). This makes this tool suitable for use in a clinic room or a wardroom if the patient is 
too ill to go to an audiology department. DPOAE testing is a quick, non-invasive, repeatable 
and accurate measurement of inner ear OHC function. The outcomes of this study have 
confirmed that a recommendation to use it as serial monitoring tool to detect evidence of 
ototoxicity in children can be made with confidence.    
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 Results and Discussion of Theme B: Chapter 5:
Causation   
The aim of this theme was to investigate factors that may be associated with ototoxicity in 
CF children. The clear dichotomy seen in the hearing status of the children with CF and 
exposure to aminoglycosides suggested that there might be risk factors that make some 
children more susceptible to ototoxicity than others. The results of two studies are presented 
and discussed. The first one assessed factors in the CF children’s clinical / drug history and 
investigations that may be significant risk factors associated with ototoxicity. The second 
study was a genetic study, which initially investigated the prevalence of the mtDNA 
A1555G mutation of the 12S rRNA gene. This mutation is the commonest mutation reported 
to increase susceptibility to aminoglycoside ototoxicity and non-syndromic hearing loss 
(Bottger, 2010, Gallo-Teran et al., 2004, Shohat et al., 1999). It also investigated the 
association between certain variants of drug-metabolizing genes and aminoglycoside 
ototoxicity as they were previously shown to be significantly associated with cisplatin 
ototoxicity (Ross et al., 2009). 
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5.1 Potential risk factors associated with AG 
ototoxicity in CF children  
5.1.1.1 Study group: 
The study group consisted of the same 70 children with CF that were audiologically assessed 
for Theme A. Data obtained from the children’s clinical and drug history and from outcomes 
of investigations were statistically analyzed to investigate the relationship between them and 
ototoxicity. This data was obtained through verbal interviews with the children’s 
parents/carers; through review of annual review reports, discharge letters and clinical notes; 
and through review of patient records of haematological tests for therapeutic drug 
monitoring (TDM) of the aminoglycosides administered while the children were admitted to 
GOSH for intake of i.v. antibiotic courses.  
5.1.1.2 Analysis of potential risk factors: 
 Table 5-1 shows the factors that were tested for association with the occurrence of 
ototoxicity in this study group. As the data for these risk factors was not normally distributed, 
non-parametric Chi-square (χ2) test and Mann Whitney U-test were employed to compare the 
distribution of the categorical and numerical possible risk factors respectively, across the two 
categories of ‘ototoxicity absent ‘ and ‘ototoxicity present’. 
Results of the analysis showed that the ototoxic group had: a significantly higher age; lower 
mean FEV1 lung function; exposure to a greater number of i.v AG courses; exposure to a 
greater number of amikacin and tobramycin courses; and that they were also significantly 
associated with intake of vancomycin. However, gender, ethnicity, other AG types 
(gentamicin) and plasma AG trough levels did not show a significant difference between the 
groups (Table 5-1). A Pearson’s correlation test showed that there was a moderate negative 
correlation between lung function, recorded as the FEV1 % predicted score, and the number 
of IV AG courses received (p<0.01; r = -0.505; r
2 
= 0.218) (Figure 5-1).  
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Figure 5-1: Comparison between the number of courses of IV AG received by each of the children with CF 
and average FEV1 % predicted score.  
The bold line is the negative regression line and the dotted lines are the 95% confidence intervals. A 
significant (p < 0.01) negative Pearson’s correlation was obtained between the number of administered IV 
AG courses and average lung function with R2 = 0.218 
Risk factors 
                        Ototoxicity 
P-value  
Absent (n = 55) Present (n = 15) 
                                                   Age & Gender 
  Median age years (range)
b
 10.1 (3.1-16.2) 13.0 (5.5-16.4) 0.008 
  Female sex [n (%)]
a
 31 (56%) 11 (73%) 0.248 
  Male sex [n (%)]
a
 24 (44%) 4 (27%) 0.248 
                                                                                                       Ethnicity 
  Caucasian [n (%)]
a
 50 (91%) 13 (87%) 1.00 
  Other race [n (%)]
a
 5 (9%) 2 (13%) 1.00 
                                                                                                       Lung Function 
  Median FEV1% predicted score (range)
b
 79.1 (69.1) 54.5 (55.1) 0.004 
                                                                                                       Aminoglycoside risk factors 
  Median no. IV AG courses (range)
b
 4 (0-31) 16 (3-40) <0.001 
  Median yrs. of intake of IV AGs (range)
b
 5 (0-16) 7 (1-15) 0.235 
  Median no. of Amikacin courses (range)
b
 2 (0-21) 10 (2-26) <0.001 
  Median no. of Tobramycin courses (range)
b
 0 (0-11) 1.5 (0-18) 0.038 
  Median no. of Gentamicin courses (range)
b
 0 (0-11) 0 (0-24) 0.254 
                                                                 Other Ototoxic Agents 
  No. Receiving Vancomycin courses (n (%)]
a
 3 (5%) 4 (26%) 0.047 
  No. Receiving Cisplatin courses (n (%)]
a
 1 (2%) 2 (13%) 0.125 
Table 5-1: Assessment of potential risk factors associated with ototoxicity.  
a indicates the categorical variables with patient numbers and percentage within each group presented 
and chi-squared test used for analysis using χ2 or Fischer’s exact p-values as appropriate. b indicates the 
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numerical variables with median and range values presented and the Mann Whitney U-test used for 
analysis. Significant data (p <0.05) is shown in bold. 
 
External review of these results led to recommendations for further statistical 
analysis.   Specifically for multivariable linear mixed models to be applied for each of the 
testing methods. Multivariable linear mixed models were applied for each of the testing 
methods, Standard PTA, EHF PTA and DPOAE to quantify the association of these different 
possible risk factors on the response levels at different frequencies. This allowed modeling 
the trajectories of hearing level (dB) change according to frequency and adjusting for the 
possible risk factors, taking into account the repeated measures at different frequencies from 
different ears within person (Appendix 9.13).    
The motivation for this analysis was the possibility that adding all the frequency responses 
within each of the three audiological tools into a multivariable linear mixed model would 
take advantage of the richness of the data collected rather than just depending on the binary 
analysis of identifying ‘non-ototoxic’ versus ‘ototoxic’ groups. The binary analysis from 
each of these tools as previously presented in the Kappa analysis in Table 4-2, Table 4-3 and 
Table 4-4 or in the chi-square analysis in Table 5-1. The criteria for ototoxicity was applied 
to each frequency tested by the three tools rather than to the overall outcome of each of the 
tests. However, this analysis provided some outcomes that are contradictory to those 
previously presented and appears to be quite circular as the same individual frequencies 
within each audiological tool were the same frequencies used to define ototoxicity. In this 
analysis only the 8kHz frequency outcomes from standard audiometry showed a statistically 
significant coefficient change, which was expected from previous analysis, yet for the EHF 
audiometry only the 11.8 and 12.0 kHz frequency were significant. This was not expected as 
data presented in Figure 4-1 and Figure 4-2, which showed the clear difference in thresholds 
across all EHF audiometry responses at all 9 to 16 kHz frequencies, and from the ANOVA 
statistical analysis which showed: ‘The audiometric thresholds did not differ significantly 
between the groups at the lower frequencies (≤4 kHz) but differed significantly from one 
another at p<0.05 for frequencies 8 to 16 kHz with related t-tests when Bonferroni 
adjustment was made for the number of comparisons.’ (Section: 4.1.1.2). The analysis of the 
DPOAE responses was even more divergent from previous analysis as it showed that all f2 
frequencies (except for 8kHz) tested showed significant coefficient changes that were much 
larger than the standard or the EHF audiometry data (i.e. coefficient values range of 3.79 -
18.59 for DPOAEs vs. 0.72 - 3.74 for EHF PTA).  This was different from the DPOAE 
amplitude and SNR data presented in Figure 4-6 and Figure 4-7 respectively and in the 
kappa analysis presented in Table 4-3 and Table 4-4. These results had shown that even 
though the DPOAE results were generally in agreement with the audiometric data, the 
  153 
sensitivity of the EHF audiometry to detection of ototoxicity was higher than with DPOAE. 
This current analysis may shed more light on the possibility that DPOAEs may be more 
sensitive to inner ear ototoxic damage than previously presented. However, using the 
audiometric data, as the gold standard for audiometry was still considered a valid approach 
to analysis. For these reasons the table detailing this multivariate analysis has been removed 
from this section and added as an appendix item (Appendix 9.13) for reference.  
5.1.1.3 Significance of the type of Aminoglycoside used: 
The three AGs administered were Amikacin, Tobramycin and Gentamicin and these are 
typically prescribed as a once daily dose over an average of 14 days. Serum levels were 
monitored before the 2nd and 8th doses with pre-dose trough levels. These were always 
administered in combination with other i.v antibiotics such as ceftazidime, meropenem or 
piptazobactam. Table 5-1 shows that in this study group, there was a statistically significant 
difference (p<0.001) between the ototoxic versus the non-ototoxic group of children mainly 
in regards to Amikacin and to a lesser extent to Tobramycin (p=0.038) where both drugs 
were more associated with the ototoxic group. Pearson’s correlation analysis was performed 
between the number of Amikacin courses taken and an audiometric high-frequency pure-
tone average (8-12.5 kHz). It showed a significant mild negative correlation (p<0.05; r= -
0.247; r
2
= 0.280) between the two, where increase in intake in the number of courses was 
associated with hearing loss and deterioration in audiometric thresholds with the r
2 
value 
indicating that increased intake is responsible for 28% of the occurance of high frequency 
hearing loss. There was no significant correlation found when the same analysis was 
performed for Tobramycin intake (p=0.730; r= -0.042; r
2
= 0.038) or Gentamicin intake 
(p=0.373; r= -0.109; r
2
= 0.034). Assessment of AG trough levels used for TDM, as an 
indication of exceeding therapeutic blood levels of the AG used when higher than normal 
levels are recorded, did not show a significant difference between the ototoxic and non-
ototoxic groups (p >0.05), suggesting that ototoxicity can occur despite adherence to 
therapeutic levels. 
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5.1.2 Discussion of potential risk factors associated with AG 
ototoxicity in CF children 
5.1.2.1 Age, gender and ethnicity 
An analysis of possible risk factors predictive of ototoxicity in this study, showed a 
significant difference between the ages of the non-ototoxic and the ototoxic groups. It is 
worth noting that 14 out of 15 ototoxic group of children (Table 4-1) were over 10 years of 
age (median: 13.8; range: 5.5 - 16.4 years), suggesting that they were more likely to have 
received a larger number of courses of i.v AG and therefore age is probably more of an 
indicator of amount of AG exposure than an actual risk factor to ototoxicity. Ethnicity 
differences were not of significance between the two groups, probably because our study 
subjects were mainly Caucasians, and neither were there gender differences (Table 5-1). 
Previous studies have shown a higher prevalence of ototoxicity in Hispanic (O'Donnell et al., 
2010) and Asian (Knight et al., 2005) patients with CF compared to Caucasians.  
Children with greater disease severity (lower FEV1 indicating poorer lung function) had a 
higher risk of ototoxicity (p<0.01). There was also a negative correlation between FEV1 and 
the number of courses of i.v AG received (p<0.01; r= -0.505; r
2
= 0.218), as expected (Figure 
5-1).  Children with lower lung function would be more likely to have a greater number of 
i.v AG courses and hence at an increased risk of ototoxicity indicating, again, that poor lung 
function could be another possible confounding factor. Concomitant use of other potentially 
ototoxic medications was also assessed as risk factors for ototoxicity and Vancomycin was 
found to be significantly associated with ototoxicity in this group. O’Donnell et al. 
considered risk factors for AG ototoxicity in adult CF patients and also reported a borderline 
significance for concomitant use of Vancomycin (O'Donnell et al., 2010).  
5.1.2.2 Type of aminoglycoside taken 
The majority of patients in this study had received i.v Amikacin, compared to Tobramycin or 
Gentamicin. This was in line with the prescribing protocol at Great Ormond Street Hospital, 
which used Amikacin as the first-line treatment for pseudomonas aeruginosa infections 
since the 1990s when gentamicin-resistant strains emerged. Tobramycin was also commonly 
prescribed, but after/alternating with amikacin courses. Results of the survey study of current 
ototoxicity monitoring practice in the UK presented in section 6.2, have shown that this is 
not common practice in the UK as 97% of the responding CF clinicians indicated that 
Tobramycin was their first line of treatment (Table 6-9). A mild significant negative 
correlation between Amikacin and poor high-frequency hearing (p<0.05;r= -0.247; r
2
= 
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0.280) was found but was mostly absent for the other two AG types. Despite this finding, the 
preferential use of Amikacin did not allow for an accurate comparison of ototoxicity 
between different AGs and therefore the suggestion that Amikacin is more ototoxic than the 
other AGs studied is made with caution. However, this has been investigated previously by 
Matz et al. who reported a prevalence for ototoxicity of 18% for Gentamicin and 12.9%, 
11.5% and 2% for Amikacin, Tobramycin and Netilmicin, respectively (Matz, 1986) and 
others, have reported auditory toxicity occurring in 4.4, 10.8, and 23.5% of 187 patients 
given Netilmicin, Tobramycin, and Amikacin, respectively (Gatell et al., 1987).  
 Assessment of AG trough levels is used as an indication of exceeded therapeutic blood 
levels of AG. It did not show a significant difference between the ototoxic and non-ototoxic 
groups (p >0.05), suggesting that ototoxicity can occur despite adherence to therapeutic 
levels. O’Donnell et al. showed ototoxicity was predicted by trough serum concentrations 
>10 mg/L for Amikacin or >2 mg/L for Gentamicin and Tobramycin (O'Donnell et al., 2010). 
However, Tan et al. highlighted that tests for therapeutic drug monitoring should be 
interpreted with caution, as they are limited in sensitivity (Tan et al., 2003). 
5.1.2.3 Cumulative repeated AG courses 
This study has shown that one of the most significant risk for ototoxicity (p<0.001) in 
children with CF was history of high exposure to i.v AGs, particularly those who have 
received at least 10 courses (Table 5-1). This was also confirmed in the multivariate analysis 
where high exposure showed the highest unit increase in thresholds mainly in EHF PTA but 
also in standard PTA results (Table 5-9-1). This was in agreement with Mulheran et al. who 
assessed 70 CF patients and 91 controls and reported ototoxicity in 12 CF patients including 
1 paediatric case. The median number of AG courses in the hearing impaired group was 20 
versus only 9 in the normal hearing group (Mulheran et al., 2001). Several other studies have 
also reported on the effects of repeated AG exposure on the auditory status of CF patients 
(Mulherin et al., 1991, Crifo et al., 1980, Pedersen et al., 1987, Wood et al., 1996). This 
suggests that repeated doses have a cumulative effect and that a child that has many doses of 
AG but still hasn’t presented with ototoxicity may still develop hearing loss at a later stage 
and therefore must be monitored. However, the fact that there were children in the ototoxic 
group with history of exposure to a small number of AG courses and others with history of 
high exposure yet completely normal hearing, as demonstrated in Figure 4-4, excludes that a 
simple linear relationship exists between these two factors suggesting that other factors are 
possibly involved, including genetic predisposition, as suggested by others (Mulheran et al., 
2001, Smyth, 2010).  
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5.1.2.4 Information regarding antibiotic intake 
The most significant limitation of this study was accuracy of information about previous 
drug history and details regarding intake of AGs (i.e. number of courses in the child’s 
lifetime and the years over which these courses were taken).  The first source of information 
was obtained through the history-taking interview with the child’s parent/carer before 
audiological assessment was undertaken. It was clear at a very early stage that this was a 
variable source of information as some parents provided very accurate information and even 
kept written records of all of their child’s medications while others were very overwhelmed 
by their child’s condition and only vaguely knew what medications they were receiving. The 
second source of information was examining the patients’ hospital notes where records of 
medications when children are admitted to the hospital for i.v AGs were kept and review of 
the results of the haematological tests where the dates for trough level measurements of the 
AGs used for TDM were kept. Even though these provided a more accurate source of 
information they were not comprehensive.  Some children were admitted to their local 
hospitals for these treatments or were administered the i.v. treatments at home if they had a 
patent venous line through a portacath.  Local hospitals and the GPs were consistently 
requested to provide this information to the GOSH CF unit as this was the main center of 
care for these children, but this information was not always fed back. Finally, every Annual 
Review letter written by the CF clinician was examined in order to extract medication 
information provided for that past year. Crosschecking with any data available within 
databases that only members of the CF unit staff could access was also done. 
This highlighted a significant clinical problem in the accuracy and accessibility of this 
information not only for future ototoxicity monitoring but also for monitoring of any other 
side effects of these medications, assessment of benefit, comparison of outcome between 
treatment regimens or even identification of drug resistance. CF unit staff members 
confirmed that this is a problem especially as this is information that is submitted to the CF 
Trust database in order to produce the UK CF Registry annual data reports published online 
(https://www.cysticfibrosis.org.uk/about-cf/publications/cf-registry-reports.aspx). The 
difficulty encountered in trying to retrieve this information actually highlighted the need to 
include clear and accurate treatment records as an essential component of any ototoxicity 
monitoring service being developed whether on a local departmental, national or 
international scale. Regarding its affect on the current study, this was a limiting factor, as the 
accuracy of the drug history was not guaranteed 100% but the crosschecking of the 
information managed to keep the information as accurate as possible.    
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5.1.3 Conclusions: 
Analysis of the data related to ototoxicity in the CF children assessed has shown that 
repeated cumulative exposure to aminoglycosides is the most significant risk factor 
associated with the occurrence of ototoxicity. The older age of the child and the poorer lung 
function were also significantly associated with ototoxicity but this may be because this is 
the group with increased exposure to more i.v. AG courses. As shown in the data in the 
earlier audiological assessment study, higher audiometric frequencies (≥8 kHz) were more 
significantly associated with differentiating between non-ototoxicity and ototoxicity, as were 
the higher DPOAE f2 frequencies. It could not be categorically confirmed that Amikacin 
was more ototoxic than other AGs due to the prescription bias in this group of children 
because of the treatment protocol of GOSH, however it was the AG drug type that was most 
consistently associated with ototoxicity.  
This study has suggested that there are several possible ‘risk factors’ that may increase the 
susceptibility of CF children to ototoxicity confirming that audiological monitoring and good 
record keeping of these factors is very important if the aim is to try to prevent ototoxicity 
and avoid deterioration of the children’s quality of life. The lack of a clear linear relationship 
between ototoxicity and any of the factors assessed, even high exposure, mandates that 
further investigation into other causes that affect individual susceptibility to ototoxicity, such 
as genetic causes, may help elucidate the mechanisms involved.  
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5.1.4 Investigating susceptibility to AG ototoxicity in CF 
children through Genetic studies.  
Results from the audiological clinical study reported earlier in section 4.1, Figure 4-3 
showed a clear dichotomy in the recorded hearing of the children, with some showing 
evidence of hearing loss following the high frequency sloping SNHL representation of 
ototoxicity while others maintained exceptionally good hearing. Here, despite higher 
cumulative exposure to repeated intravenous courses of AGs being identified as a significant 
risk factor to development of ototoxicity it could not account for hearing impairment in all 
cases. It was not clear why some children manifest significant hearing impairment following 
minimal exposure to AGs while others sustained normal hearing even after multiple courses 
of intravenous AGs. This supported the aim to investigate the role of genetic variation in 
increasing susceptibility to aminoglycosides and a possible explanation for this dichotomy. 
As presented in section 1.7, genetic susceptibility to AG ototoxicity is well established 
especially in relation to mutations in the mitochondrial DNA such as the A1555G mutation 
in the 12S rRNA gene. The frequency of this mutation varies by ethnicity but two large UK-
based population studies report a prevalence of the A1555G mutation of 0.19% and of 0.26% 
respectively (Bitner-Glindzicz et al., 2009, Rahman et al., 2012). A higher prevalence of 2 to 
5% was reported in Caucasians with sensorineural deafness (Hutchin et al., 2001, Kupka et 
al., 2002b, Tekin et al., 2003). A study of a population of adult cystic fibrosis patients 
showed a prevalence of 1.3%, which was considered to be higher than expected (Conrad et 
al., 2008). 
5.1.4.1 Study group: 
The parents/carers of the children with CF recruited in the audiological observational study 
also provided consent for their children to provide either a blood or saliva sample for DNA 
extraction to test for genetic variations that may be associated with increased susceptibility 
to ototoxicity. All 70 children who underwent audiological assessment were recruited but 
three of the parents/children refused to give consent to this aspect of the research or it was 
not possible to obtain a sample from the patient. Therefore, a total of 67 DNA samples were 
collected. Two of the missing samples were from children in the ‘Non-ototoxic’ group and 
one was from the ‘Ototoxic’ group. This meant that there were 53 children with normal 
hearing and 14 children with evidence of ototoxicity included in the genetic study. 
The first aim of this study was to assess the prevalence of the mtDNA A1555G mutation in 
the 12S rRNA gene in CF children as this is the most commonly reported gene mutation to be 
associated with increased susceptibility to aminoglycoside ototoxicity (Bai et al., 2008, 
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Bottger, 2010, Casano et al., 1998, Estivill et al., 1998, Gallo-Teran et al., 2004, Gallo-Teran 
et al., 2003, Scrimshaw et al., 1999, Shohat et al., 1999). The second aim was to assess if the 
two variants in the TPMT and COMT genes (rs12201199 and rs4646316 respectively) were 
significantly associated with occurrence of aminoglycoside ototoxicity in the CF children. 
These variants were previously shown to be significantly associated with cisplatin 
ototoxicity in children with cancer (Ross et al., 2009).  The overall aim of the genetic study 
was to assess whether the presence of any of these variants in subjects might explain the 
dichotomy in outcome versus dose observed in the audiological study. 
5.2  Analysis of mtDNA A1555G and other 
variations in the 12S rRNA gene in CF patients 
5.2.1 Outcomes of genotyping for the A1555G mutation: 
Polymerase chain reaction (PCR) was used to amplify a section of the 12S rRNA gene 
containing the site of the A1555G mutation using primers as described in Table 3-1. 
Restriction fragment length polymerase (RFLP) was then used to digest the amplified 
fragment into different sized fragments according to whether the A1555G mutation was 
present or not. The HaeIII restriction endonuclease enzyme was used to genotype the 
samples for the A1555G mutation using this PCR-RFLP technique. The A1555G genotype 
was identified in 2/67 subjects and both appeared to be homoplasmic for this mutation. 
Figure 5-2 shows a representative UV image of the 2% agarose gel electrophoresis of six 
digested samples including the two samples showing A1555G mutation where three 
fragments of sizes 216 bp, 93 bp and 30 bp are visualized instead of the two fragments of 
sizes 216 and 123 bp which were seen with the wild-type m.1555A variant. Table 5-2 is a 
2x2 contingency table showing the distribution of children with and without ototoxicity 
according to the A1555G genotype where there was only one child with the A1555G 
mutation in each of the two groups. Fisher’s exact test showed a non-significant difference 
between ototoxicity and the A1555G mutation (χ2 (1, n=67) =3.84, p = 0.333). The overall 
prevalence of the A1555G mutation was equal to 3% of this study cohort. This was a 
surprising outcome of this study as this prevalence was higher than the expected prevalence 
reported in population studies. A 3% prevalence with 2/67 cases is much higher than the 
reported ~0.2% frequency of this mutation in the UK and other populations (Bitner-
Glindzicz et al., 2009, Kokotas et al., 2009). It is equivalent to a 15-fold increase in 
prevalence. In order to try to confirm if there is a higher prevalence of A1555G mutations in 
patients with CF, more DNA samples were collected from this cohort. In total 105 samples 
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were collected with the same patient information, consent and assessments performed for the 
additional subjects as for the original recruited children with the exception of 19 children 
who only provided the DNA sample but didn’t have the hearing assessments undertaken by 
the time the analysis of the data was performed. These assessments were later undertaken as 
part of the regular ototoxicity-monitoring clinic that was established as a result of this 
current research (see Appendix 9.12. for detailed ototoxicity monitoring protocol established 
for the CF and Audiology units at GOSH). Interestingly, PCR-RFLP revealed absence of any 
more A1555G mutations in any of the added cases making the prevalence 2/105 (1.9%), 
which was still found to be a non-significant difference between determination AG 
ototoxicity and occurrence of A1555G mutation  (χ2 (1, n=105) =3.84, p = 0.395) as shown 
in Table 5-3.  
 
Figure 5-2: RFLP analysis of the 12S RNA A1555G mutation using HaeIII restriction enzyme. 
Well M, 100bp DNA ladder marker. Well 1, undigested sample (339bp). Lanes 2-7, HaeIII digested samples. 
Wild type (WT) samples show 2 fragments at 216 bp & 123 bp (WT – wells 2, 5-7). The A1555G (Mut.) 
affected samples show 3 fragments at 216 bp, 93 bp and 30 bp (Mut. – wells 3-4); Well 8, non-template 
control. 
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A1555G mutation vs. ototoxicity 
 
Non-ototoxic 
(n=53) 
Ototoxic 
(n=14) 
Total OR (95% CI) p-value
a
 
Absent 
A1555G 52 (98%) 13 (93%) 65 (97%) 1 
 
Present 
A1555G 1 (2%) 1 (7%) 2 (3%) 
4.818 
(0.28-83.035) 
0.333 
Total 
53 (100%) 14 (100%) 67 (100%) 
  
a Fisher’s exact test 2-sided significance was used as 2 cells had cell count <5 
Table 5-2: Contingency table showing a record of patient numbers with and without the A1555G 
mutation in the two groups (ototoxicity was defined by the audiometric data).  
χ2- test shows non-significant difference between presence of A1555G mutation and occurrence of 
ototoxicity. Note the normal hearing case with the A1555G mutation (not reported previously in 
literature). a Fisher’s exact test (two tailed, p< 0.05). 
A1555G mutation vs. ototoxicity 
 
Non-ototoxic 
(n=67) 
Ototoxic 
(n=19) 
Hearing tests 
not 
performed 
yet (n=19) 
Total p-value
a
 
Absent A1555G 
66 (98.5%) 18 (95%) 19 (100%) 103 (98%) 
 
Present A1555G 
1 (1.5%) 1 (5%) 0 (0%) 2 (2%) 0.395 
Total 
67 (100%) 19 (100%) 19 (100%) 105 (100%) 
 
a Fisher’s exact test 2-sided significance was used as 2 cells had cell count <5 
Table 5-3: Contingency table showing a record of patient numbers with and without the A1555G 
mutation in the groups defined by the audiometric outcomes when more samples were genotyped.  
χ2- test showed no significant difference between presence of A1555G mutation and occurrence of 
ototoxicity. a Fisher’s exact test (two tailed, p< 0.05). 
 
 
 
 
5.2.2 Further analysis of the two children with the A1555G 
genotype: 
Sanger sequencing was used to confirm a positive result in the A1555G genotype. The 
audiological data and sequencing chromatograms for the two individuals with the A1555G 
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mutation are presented in Figure 5-3. Child A displayed bilateral severe high frequency 
hearing loss with diminished DPOAEs typical of AG ototoxicity. Surprisingly, child B 
showed well preserved hearing as demonstrated by thresholds across all frequencies and by 
DPOAE measurements despite repeated intravenous aminoglycoside use in the presence of 
the A1555G mutation. This finding was surprising because it has been repeatedly reported 
that exposure to AGs is one of the most significant modifying factors associated with 
increasing the penetrance of the A1555G mutation up to 100% (Bitner-Glindzicz et al., 2009, 
Pandya, 1993). The clinical characteristics of both children A and B are presented in Table 
5-4. Due to the unexpected nature of this observation a second, independent DNA sample 
was obtained from this patient to confirm the presence of the A1555G mutation. Functional 
evidence from several earlier studies suggests that the pathogenic mechanism of A1555G 
may be via an altered secondary structure of the 12S rRNA, which facilitates an interaction 
with aminoglycoside antibiotics. If so, it is possible that further mutations in the 12S rRNA 
molecule could modify the secondary structure to ameliorate this pathogenicity (Ballana et 
al., 2006). To determine whether child B, or even child A, had such a mutation the complete 
12S rRNA gene was sequenced for both children. The results confirmed the presence of the 
A1555G mutation in child A and B in addition to the identification of two other known 
polymorphisms of 750A>G and 1438A>G, which were also present in both subjects.  
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Figure 5-3: Outcomes of audiological and genetic assessments for both child A and child B.  
Ai, Bi shows standard and EHF pure tone audiometry. Child A Ai, shows a severe high-frequency sloping 
sensorineural hearing loss whereas child B, Bi shows normal hearing across all frequencies (0.25 – 16 kHz). 
Aii and Bii, show DPOAE results of each child. Child A, Aii displays an abnormal DP-gram with low DPOAE 
amplitudes and signal/noise ratio <6 dBSPL representing poor cochlear function whereas child B Bii, 
results are within normal DP-gram with high DPOAE amplitudes and a signal/noise ration ≥6 dBSPL 
representing normal cochlear function. Aiii and Biii show the sequencing chromatograms of the section of 
the mtDNA 12S rRNA gene that contains the A1555G mutation in both children, highlighted by a grey bar.
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                                                                     A1555G Positive cases 
 Ototoxic  Non-ototoxic  
Patient Child A Child B 
Age  14.1y 11.5y  
Gender Female Female 
Ethnicity Caucasian Caucasian 
CFTR Genotype ΔF508/1717-1G>T ΔF508/ΔF508 
Mean FEV1 % predicted  
(Lung Function) 
72% 104% 
12S rRNA genotype 750A>G 
1438A>G 
A1555G 
750A>G 
1438A>G 
A1555G 
 
Hearing status Severe HF-SNHL Normal  
Family history of maternal 
HL 
None None 
Vestibular toxicity None None 
IV AG courses (n, type) 3 (Amikacin) 3 (Tobramycin) 
Years during which IV 
courses were given  
1 y  3 y  
Nebulized AG (type, 
duration) 
Gentamycin (3m)   
TOBI (1y) 
TOBI (3y) 
 
 
Other IV/ ototoxic Rx Vancomycin/Azithromycin/ 
Ceftazidime/Flucloxacillin 
Vancomycin/Ciprofloxacin/ 
Flucloxacillin/Azithromycin 
 
Family history of HL Negative Negative 
CFTR, cystic fibrosis transmembrane conductance regulator gene; IV, intravenous; AG, aminoglycoside; 
FEV1%, forced expiratory volume in one second (percentage); y, years; m, months; HF-SNHL, high-frequency 
sloping sensorineural hearing loss; TOBI, nebulized tobramycin; HL, hearing loss; Rx, treatment. 
Table 5-4: Characteristic features of the two children with CF who had A1555G mutation and history of 
exposure to AGs.  
Due to the significance of this finding, another sample was collected from the child and both 
the genetic and auditory testing was repeated and findings confirmed. The child’s parents 
were informed of the outcomes of this genetic test and a more detailed history was obtained 
to confirm the absence of hearing loss in any of the family members especially the 
matrilineal relatives. The family was offered the chance to have genetic counseling and the 
managing clinician confirmed that this child should not be prescribed any AGs in the future 
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except where it was essential and recommended that regular audiological monitoring of this 
child is maintained. The same actions were also taken for Child A but additionally this child 
was referred to Audiology where she was fitted with bilateral hearing aids and offered 
rehabilitation and counseling regarding her hearing loss. Child A reported that she had 
initially refused to wear hearing aids but changed her mind later because she was struggling 
to hear in school and found it very difficult to get any part-time jobs because of her hearing 
loss. She currently wears her hearing aids and is much happier. 
  
  166 
5.2.3 Discussion of outcomes from investigating the A1555G 
mutation and sequencing the 12S rRNA gene: 
The most commonly reported mutation, as a cause of increased susceptibility to 
aminoglycoside ototoxicity, is the A1555G mutation in the 12S rRNA gene in the 
mitochondrial DNA. Results of the current study identified two children with the A1555G 
mutation in 67 CF children (Table 5-2). As this was equivalent to a 3% prevalence, which is 
a 15-fold increase in prevalence when compared to the reported population prevalence of 
0.2% (Bitner-Glindzicz et al., 2009, Rahman et al., 2012, Vandebona et al., 2009) it was 
decided to test more children from this cohort to confirm if this mutation was more common 
in children with CF than in the general population. A total of 105 samples were tested but no 
more mutations were uncovered (Table 5-3). This sample size is considered a small sample 
group in genetics studies as a ‘chance’ occurrence of two individuals can give an 
overestimation of the prevalence of this mutation. This indicated that a significantly larger 
cohort might need to be examined before such a conclusion could be made. A chi-squared 
analysis was performed to assess if the difference between the observed and expected 
frequencies of the presence of the A1555G mutation and occurrence of ototoxicity was 
significant or not. The results showed that it was not significant (χ2 (1, n=105) =3.84, 
p=0.395) (Table 5-3). However, Conrad et al. investigated the frequency of mtDNA 12S 
rRNA variants in 157 North American adult CF patients (Conrad et al., 2008). As in this 
current study, they also highlighted that the frequency of the A1555G mutation (1.27%) was 
higher that that observed in non-CF general populations where it was detected at a frequency 
of 1/385-520 (0.19-0.26%) in different studies. Conrad et al. identified five CF patients with 
homoplasmic variations in this gene with two of these patients having the A1555G mutation. 
These two patients presented with moderate-to-severe SNHL after exposure to only one and 
four courses of tobramycin respectively. The other three patients each displayed one form of 
polymorphism of 827A>G, 961T>G and 1494C>T with AG-induced auditory dysfunction 
reported as unknown, none (normal hearing) and mild hearing loss respectively. They didn’t 
observe any correlation between the CFTR genotypes and the novel 12S rRNA variants that 
they identified (Conrad et al., 2008). The Conrad et al. study was the only study reporting the 
prevalence of 12S rRNA mutations in patients with CF in addition to this current study. If the 
data of both the current study and Conrad’s study were combined, a total of 4/262 patients 
with CF would be reported to have the A1555G mutation. This would still equate to a higher 
prevalence of 1.5% compared to the reported average population prevalence of 0.2%.  This 
again highlights the importance of conducting larger scale investigations with this patient 
group especially since most of the patients with CF will need to take these antibiotics sooner 
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or later in their lifetime and so identifying subjects that are more susceptible to their side 
effects would be beneficial.  
However, the aim of this current study was not to perform an association study between the 
A1555G mutation and AG ototoxicity as this has already been established and the sample 
size was too small to detect such an effect. As stated before, previous population studies had 
shown an prevalence of 0.2%, which means that it is expected to only find around two cases 
per 1000 subjects tested. Therefore the sample size included within this current study would 
never have fulfilled this aim. The main aim of this study was to assess if this mutation could 
explain part of the causation of ototoxicity in this patient cohort and see if it could partially 
explain the dichotomy in hearing status observed. The small number of children carrying this 
mutation (only two children) could not support that this mutation was a strong cause of 
ototoxicity occurring in this cohort especially that one of these children was within the non-
ototoxic group having normal hearing. However, the other child within the ototoxic group is 
one of the few children (4/15 children with ototoxicity) that were within the low-exposure 
group.  She started complaining of tinnitus and hearing loss even after exposure to the first 
course of amikacin, which progressed to severe-profound SNHL after exposure to only three 
courses. This is an agreement with previous research, which has confirmed that the presence 
of this mutation does not just increase susceptibility to AG ototoxicity but also increases the 
occurrence of ototoxicity even after intake of one dose of AG (Pandya, 1993).    
The most significant finding of this study was the identification of a child with the A1555G 
mutation with normal hearing despite having documented evidence of AG exposure (Table 
5-4). It has been repeatedly documented that AG exposure is a major modifying factor and 
has been perceived to make the A1555G mutation 100% penetrant in the presence of AGs 
(Bae et al., 2012, Estivill et al., 1998, Li et al., 2005, Liu et al., 2006). A possible explanation 
of this finding of normal hearing despite the positive genotype and exposure to AGs may be 
due to low dosage intake of the treatment leading to diminished cochlear load of AGs 
preventing them from reaching pathogenic levels. This however cannot be the cause as it is 
well documented that a single therapeutic dose of AG is capable of causing ototoxicity in 
subjects with the A1555G mutation (Pandya, 1993). Child B reported here has documented 
evidence from the hospital records confirming that she has received three i.v courses of 
tobramycin (14 days of 10mg/kg body weight/day/i.v course) over a 3-year period in 
addition to repeated intake of nebulized tobramycin (TOBI). Delayed post-treatment onset of 
hearing loss may not be the explanation either because the child was assessed several years 
after the intake of the last AG course. If testing was confined to performing standard 
audiometry, as in common practice, it may have been hypothesized that this child had early 
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effects of ototoxicity restricted to the higher frequencies and not detected by standard PTA. 
However EHF audiometry and DPOAEs were performed, as they were shown by the earlier 
study (section 4.1) and by other previous studies to be better markers of early ototoxicity 
(Al-Malky et al., 2011, Knight et al., 2007, Stavroulaki et al., 2002). This child had normal 
audiometric thresholds up to 16kHz and normal DPOAE amplitudes (Figure 5-3) again 
excluding undiagnosed hearing loss.   
The A1555G mutation is considered the most common base change in the 12S rRNA that is 
associated with AG ototoxicity (Fischel-Ghodsian et al., 2004, Guan, 2011, Prezant et al., 
1993a). It occurs in a conserved region of the gene producing a secondary structure (Ballana 
et al., 2006) which closely resembles the bacterial E. coli 16S rRNA gene and creates an 
AG-binding site in the human 12S rRNA structure which subsequently results in decreased 
mitochondrial ribosomal function and build up of reactive oxygen species (ROS) ensuing 
initiation of apoptosis (Cheng et al., 2005, Roland, 2004). Another possible explanation for 
hearing preservation in this child may be that this child has another rare mutation(s) in the 
12S rRNA gene, which negates the A1555G pathogenic mechanism by changing this 
secondary structure. However, as presented earlier, DNA sequencing of the gene has only 
uncovered two other known nucleotide variations (750A>G and 1438A>G) which were also 
present in Child A and were not reported to have significant effects on the penetrance and 
expressivity of hearing impairment with the A1555G mutation (Bae et al., 2012, Li et al., 
2004, Lu et al., 2010b, Zhao et al., 2004). Should this point be investigated further, 
sequencing of the mtDNA tRNA gene and other reported nuclear modifier genes such as 
TRMU, MTO1 or p53 would need to be explored (Guan et al., 2006, Li et al., 2004, Li et al., 
2002).  More tentatively, it has been suggested by Mulheran et al. that the CF condition may 
provide some form of ‘protection’ of the ear from AG ototoxicity even in the presence of the 
A1555G mutation (Mulheran et al., 2001). The CFTR protein is expressed in outer hair cells 
(OHC) where it has been shown to interact with prestin, the OHC motor protein, and so it is 
not implausible that mutations in the CFTR gene might in some way vary the hair cell’s 
susceptibility to aminoglycosides (Homma et al., 2010). However, there is no tangible 
evidence to support this theory especially given that many studies report high rates of 
ototoxicity in CF patients, as exhibited by Child A here.  
The most plausible suggestion to explain this A1555G non-penetrance case has been reached 
from a detailed review of the relevant literature. Here, the true penetrance of this mutation 
with the added modifying factor of AG exposure is questioned based on the existence of a 
recruitment bias in previous studies.  A large number of studies document the frequency of 
A1555G in cohorts of families or unrelated individuals with a previous/existing diagnosis of 
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hearing loss (Abe et al., 1998, Abreu-Silva et al., 2006, Bae et al., 2012, Bai et al., 2008, 
Gallo-Teran et al., 2002, Guo et al., 2008, Kokotas et al., 2009, Malik et al., 2003, Ou et al., 
2011, Tekin et al., 2003, Zu-Jian et al., 2009). This recruitment method would not permit 
detection of non-penetrance as the phenotype is already exhibited. Many of the pedigree-
based studies also involve a retrospective characterisation of the matrilineal family members 
of a proband diagnosed with AG-induced ototoxicity.  Previous exposure of these family 
members to AGs is usually dependent on self-report. This may compromise researchers’ 
confidence in confirming this exposure in the absence of a robust source of information 
especially when people generally take a wide variety of ‘antibiotics’ during their lifetime 
without always exactly knowing which ‘type of antibiotic’ they are prescribed. In this 
scenario it is possible that non-penetrance may have been under reported. With this in mind, 
the report here of a single case of non-penetrance may be a very rare observation or it could 
represent a more frequent phenomenon, which has been overlooked due to a recruitment bias 
towards hearing impaired individuals. It is unlikely that the A1555G interaction with AGs is 
not highly penetrant, especially given that even the studies that reported low penetrance 
showed that all probands/matrilineal relatives that had a history of exposure to AGs were 
hearing-impaired (Dai et al., 2006, Tang et al., 2007). However, this case has highlighted the 
lack of studies capable of establishing the true penetrance of this effect. In addition, it has 
been reported that there are issues of publication bias where it is quite difficult to publish 
negative findings compared to positive observations. Case reports are also increasingly 
difficult to publish which makes evidence of the existence of these cases of non-penetrance 
extremely difficult to add to the literature.  This problem was highlighted by Boddy when 
commenting on the recently published literature related to the genetics of cisplatin 
ototoxicity (Boddy, 2013) as well as through personal experience when trying to publish this 
case report. 
In conclusion, providing accurate information regarding the true penetrance of this 
interaction is highly significant because clinical centres are starting to advocate screening 
patients for the A1555G mutation based on recommendations of population studies even if it 
hasn’t been deemed to be cost-effective yet (Bitner-Glindzicz et al., 2009, Vandebona et al., 
2009, Veenstra et al., 2007). This is particularly significant since avoidance of first-line 
aminoglycoside therapy based on pharmacogenetic testing for the A1555G genotype can 
cause an increased risk of morbidity or even mortality in some conditions. A large well-
characterised study with accurately documented AG exposure is urgently required.  
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5.3 Investigating the association between variants 
in the TPMT & COMT genes and AG ototoxicity: 
Ross et al. had undertaken a study where association analyses of 1,946 SNPs from 220 drug-
metabolism genes with increased susceptibility to cisplatin ototoxicity in cancer children 
treated with this drug were performed. They identified some variants of both the TPMT and 
COMT genes to be highly statistically significantly associated with cisplatin ototoxicity.  
This was the first relatively large-scale study in which this link between drug-metabolizing 
genes and ototoxicity was investigated. The aim of this part of the research was to assess 
whether a similar association was present with these identified SNPs and aminoglycoside 
ototoxicity in the study CF population.  
5.3.1 Genotyping for the rs4646316 COMT SNP: 
The DNA was extracted from the blood and saliva samples in accordance with the 
manufacturer’s instructions as described in the methods section 3.5.2.4.1. Amplification of 
the gene fragment of interest was done using Polymerase Chain Reaction (PCR) by using 
primers specific for each reaction as specified in Table 3-1. A representative gel showing the 
PCR amplified DNA fragment containing the rs4646316 SNP of the COMT gene was 457 bp 
in size and was shown in Figure 5-4.  Genotyping was performed using the Restriction 
Fragment Length Polymerase (RFLP) technique where the PCR amplified fragment is 
digested further into smaller fragments using an enzyme. The number and size of the 
digested fragments varies according to the genotype of the SNP of interest. RFLP was 
carried out for all the amplified samples where the restriction endonuclease enzyme XcmI 
was used to digest the samples. The three genotypes produced are shown in Figure 5-5. The 
wild-type (W/T) C/C genotype was digested into two fragments of sizes of 378 and 79 bp; 
the heterozygous C/T genotype was digested into four fragments of 378, 207, 171 and 79 bp; 
whereas the variant homozygous genotype T/T was digested into three fragments of 207, 171 
and 79 bp.  
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Figure 5-4: UV image of 2% Agarose gel electrophoresis of the PCR-amplified COMT gene section 
containing the rs4646316 SNP.  
PCR products (457bp each) of 13 samples are shown. The marker is the Promega 100bp ladder with the 
dark highlighted fragment representing the 500bp fragment. Lane 15- is the non-template water control. 
 
Figure 5-5: UV image of 2% Agarose gel electrophoresis of PCR-RFLP analysis of COMT rs4646316 using 
XcmI restriction enzyme for 13 samples.  
Identification of the C/C wild-type homozygous – 2 fragments at 378 bp & 79 bp (Wells 4-5,7-9,11,13); the 
heterozygous C/T – 4 fragments at 378, 207, 171 & 79 bp (Wells 2-3,6,10,12) and variant homozygous T/T 
– 3 fragments at 207, 171 & 79 bp (Well 6). Well M, 100 bp DNA ladder marker; Well 1, undigested sample 
(457 bp fragment). 
5.3.2 Genotyping for the rs12201199 TPMT SNP: 
For the rs12201199 TPMT SNP, the same PCR-RFLP procedure was used first. The PCR 
amplified DNA fragment was 168 bp in size. This was digested using the MnlI enzyme in 
RFLP, which would cut the W/T genotype A/A at positions 116, 128 and 155 and would cut 
the variant genotype T/T at positions 128 and 155.  Analysis by agarose gel electrophoreses 
produced four fragments of sizes 116, 12, 27 and 13 bp with the W/T genotype A/A. It 
produced only three fragments of sizes 128, 27 and 13 bp with the variant T/T genotype. 
These small fragments could not be distinguished with clarity so the analysis was dependent 
    M  1   2      3      4        5   6     7      8        9  10    11      12       13    14     15
  500 
 457 
 C/T T/T C/C 
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on the 116 and 128 bp fragments alone. This procedure was not able to clearly discriminate 
between the three genotypes due to the similar small band sizes, which are not easily 
visualized using agarose gel electrophoresis (fragments 116 and 128 bp had only 12 bp 
difference in size). This was shown in Figure 5-6 where it was clear that it was not easy 
differentiate between the genotypes even when a λDNA Hind III marker (M2 marker in the 
figure) was used because it had a 125 bp fragment to help differentiate between the A/A and 
T/T genotypes. Therefore, it was decided to send the fourteen samples, which were 
suspected to be either A/T or T/T, for Sanger sequencing to confirm exact genotypes, 
together with a few wild type samples as a control. Representative chromatograms obtained 
for the three different genotypes are shown in Figure 5-7. These outcomes were matched 
with the UV electrophoresis image of the same samples displayed in Figure 5-6. As the 
PCR-RFLP technique was shown to be unclear and the cost of sequencing all the samples 
was going to be too high, it was subsequently decided that Real-time PCR using TaqMan® 
SNP Allelic Discrimination Assays was to be used as it was the most cost-effective and 
accurate technique to use in order to confirm the correct allele calls for all the samples. All 
these techniques are described in the methods section 3.5.2.4. Through the Real-time PCR 
Taqman genotyping assay technique only one heterozygous A/T genotype was identified in 
the ototoxic group of children (as defined by the audiometric tests) and no homozygous 
variant T/T genotypes were identified. For the non-ototoxic group, five children had the A/T 
genotype while one child had the T/T genotype Table 5-5. This data was presented and 
further analyzed in section 5.3.3 below.    
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Figure 5-6: UV image of 2% Agarose gel electrophoresis of PCR-RFLP analysis of TPMT rs12201199 using 
MNLI restriction enzyme for 14 samples of CF children (Wells 1-14). 
The fragments obtained were small and very similar in size making it difficult to identify the different 
genotypes. The small fragments 12, 27 and 13 bp were all blurred and vaguely seen at the lower end of the 
gels. Only the relatively larger 116bp and 128 bp fragments could be seen clearly. The genotypes (A/A, A/T 
and T/T) marked on this picture were identified through the DNA sequencing as shown in figure 5-6 and 
then matched with the same samples on this UV image. The heterozygous A/T and homozygous variant 
T/T were impossible to differentiate through this technique. M1, 1kb Ladder marker; M2, λDNA Hind III 
marker used because it had a 125bp-band fragment that could differentiate between the 116bp A/A digested 
fragment and the 128bp T/T digested fragment.  
 
Figure 5-7: DNA sequencing chromatogram of TPMT rs12201199 SNP.  
Showing 3 sequencing chromatograms with the Heterozygous A/T (top), Wild-type Homozygous A/A 
(middle) and Variant Homozygous T/T (bottom) TPMT rs12201199 SNP respectively. Only 14 samples 
were sent for sequencing and only 9 of these were correctly identified through this technique (the other 
samples were too noisy). The identified samples were matched to the UV electrophoresis image displayed 
in figure 5-5.  
G 
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5.3.3 Statistical analysis of the results:  
The outcomes for both gene variants were then correlated with evidence of ototoxicity in the 
sample using Chi-squared (χ2) statistical analysis as shown in Table 5-5.  The mutant T/T 
genotype in rs12201199 TPMT SNP was only present in one (1.9%) normal hearing child 
and the mutant T/T rs4646316 COMT SNP was only present in two (3.8%) normal hearing 
children and one (7.1%) child with ototoxicity. Chi-square analysis showed that both 
variants were not statistically significantly associated with aminoglycoside ototoxicity in this 
cohort of children with CF (p=0.691 and 0.442 respectively). More detailed analysis was 
presented below.   
  
 
CF Patients Statistics 
  Genotype 
/allele 
Non-Ototoxic 
 (n=53) 
Ototoxic  
(n=14) 
OR (95% CI) p-valuea 
  
TPMT 
rs12201199 
A/A 
47 
(88.7%) 
13  
(92.9%)   
A/T  
5 
(9.4%) 
1 
(7.1%)  
0.839 
T/T 
1 
(1.9%) 
0  
(0.0%)  
0.839 
 
A 
99 
(93.4%) 
27  
(96.4%) 
0.969 
(0.887 – 1.057)  
 
T 
7 
(6.6%) 
1 
(3.6%) 
1.849 
(0.237 – 14.413) 
0.691 
 
          
COMT 
rs4646316 
C/C 
32  
(60.4%) 
11  
(78.6%)   
C/T  
19  
(35.8%) 
2  
(14.3%)  
0.287 
T/T 
2  
(3.8%) 
1  
(7.1%)  
0.287 
 
C 
83  
(78.3%) 
24  
(85.7%) 
0.914  
(0.762 - 1.095)  
 
T 
23  
(21.7%) 
4  
(14.3%) 
1.519  
(0.572 - 4.034) 
0.442 
Table 5-5: Chi-square analysis showing lack of association between SNPs in TPMT & COMT and 
ototoxicity.  
a determined using Fisher Exact Probability test as the expected cell count was <5 in some cells (p<0.05) 
5.3.3.1 Modeling under different genetic models of inheritance 
In order to further analyze the significance of association between the variant genotype and 
allele (in this case ‘T/T’ and ‘T’ respectively, for both the TPMT and COMT SNPs of 
interest) and cases with ototoxicity, further statistical analysis using the tests for deviation 
from Hardy-Weinberg equilibrium and association analysis for alleles and genotypes was 
performed. The output for the tests for deviation from Hardy-Weinberg equilibrium showed 
non-significant p-values (p>0.05) for both controls (i.e. non-ototoxic) and cases (i.e. 
ototoxic) for both SNPs. This indicated that there was no deviation of the genotype 
frequencies from those expected under the Hardy–Weinberg equilibrium.  Case-control 
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association analysis for alleles and genotypes under different genetic models of inheritance 
was performed using a χ2- test or Fisher’s exact test if the expected cell count was <5. The 
χ2–test tests the null hypothesis, which is based on the assumption that there is no 
statistically significant difference between the observed and expected results and that any 
difference is due to chance. Therefore, if there is no statistical difference obtained because 
the χ2 value is larger than the critical value corresponding to the 0.05 (5%) probability then 
the difference is due to chance, and so the null hypothesis is accepted.  The results for the 
association analysis were displayed in Table 5-6 for TPMT rs12201199 and in Table 5-7 for 
COMT rs4646316. Here the theory of the null hypothesis is that there is no significant 
relationship between each of these SNPs and the AG ototoxicity phenotype. As all the χ2 
results showed that there is no significant difference (p>0.05) then the null hypothesis was 
accepted. Therefore this data did not show an association like the one seen with the cisplatin 
ototoxicity previously reported. The risk probability associated with the presence of either or 
both COMT and TPMT variant SNPs were also shown to be non-significant. This was 
displayed in Table 5-8 in addition to the presentation of the different levels of sensitivity and 
specificity of the observed results. 
SNP 
TPMT 
rs12201199 
 
 
  NON-OTOTOXIC  
(controls n=53) 
OTOTOXIC  
(cases n=14) 
OR (95% CI) ᵪ2 p 
valuea 
(a) i- Full genotype table for a general genetic model 
 
A/A 
47 
(88.7%) 
13 
(92.9%) 
1 
  
 
A/T 
5 
(9.4%) 
1 
(7.1%) 
0.873 
(0.092-8.237) 
0.01 0.839 
 
T/T 
1 
(1.9%) 
0 
(0.0%) 
0.873 
(0.092-8.237) 
0.01 0.839 
(a) ii-Allele frequency 
 
A 
99 
(93.4%) 
27 
(96.4%) 
0.969 
(0.887 – 1.057)   
 
T 
7 
(6.6%) 
1 
(3.6%) 
1.849 
(0.237 – 14.413) 
1.71 0.691 
(b) Dominant model: allele T increases risk 
 A/A 47 13 
   
 
A/T+T/T 6 1 
1.745 
(0.299-10.205) 
0.39 0.617 
(c) Recessive model: two copies of allele T required 
 A/A+A/T 52 14 
   
 
T/T 1 0 
0.078 
(0.003 - 2.027) 
4.14 0.197 
(d) Multiplicative model: r-fold increased risk for AT,r2 increased risk for TT. Analysed by 
allele, not by genotype 
 A (2a+b) 99 27 
   
 
T (b+2c) 7 1 
2.635 
(0.587-11.823) 
1.71 0.191 
(e) Additive model: r-fold increased risk for AT, 2r increased risk for TT. Genotypes analysed 
by Armitage’s test for trend 
 Risk 
allele A   
0.421 
  
 Risk 
allele T   
5.49 1.42 0.233 
Table 5-6: TPMT association analysis for alleles and genotypes under different genetic models. 
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 SNP 
COMT 
rs4646316 
  
NON-OTOTOXIC 
(controls n=53) 
OTOTOXIC 
(cases n=14) 
OR (95% CI) ᵪ2 p value 
(a) i- Full genotype table for a general genetic model 
 
C/C 
32 
(60.4%) 
11  
(78.6%) 
1 
  
 
C/T 
19 
(35.8%) 
2 
(14.3%) 
0.174 
(0.021-1.464) 
3.157 0.287 
 
T/T 
2 
(3.8%) 
1 
(7.1%) 
0.174 
(0.021-1.464) 
3.157 0.287 
(a) ii-Allele frequency 
 
C 
83 
(78.3%) 
24  
(85.7%) 
0.914 
(0.762 - 1.095) 
0.96 0.442a 
 
T 
23 
(21.7%) 
4 
(14.3%) 
1.519 
(0.572 - 4.034) 
0.96 0.442a 
(b) Dominant model: allele T increases risk 
 
C/C 32 11 1 
  
 
C/T+T/T 21 3 
0.314 
(0.063 -1.578) 
2.135 0.191a 
(c) Recessive model: two copies of allele T required 
 
C/C+C/T 51 13 1 
  
 
T/T 2 1 
2.364 
(0.197-28.424) 
0.485 0.458 
(d) Multiplicative model: r-fold increased risk for AT, r2 increased risk for TT. Analysed by allele, 
not by genotype 
 
C (2a+b) 83 24 
   
 
T (b+2c) 23 4 
0.528 
(0.145-1.927) 
0.961a 0.407a 
(e) Additive model: r-fold increased risk for AT, 2r increased risk for TT. Genotypes analysed by 
Armitage’s test for trend 
 
Risk allele C 
  
1.351 0.92 0.337 
 
Risk allele T 
  
0.791 0.92 0.337 
Table 5-7: COMT rs4646316 association analysis for alleles and genotypes under different genetic models.  
aNumber of individuals (percentage of the group) bDetermined using Fisher's Exact Test (2-sided) cCombination 
of unique carriers of either the TPMT risk genotype (rs12201199 T/_) or the COMT risk genotype (rs4646316 
T/_). Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value. 
 
 
Gene SNP Genotyp
e 
Non-
Ototoxic 
(n=53) 
Ototoxic 
(n=14) 
OR 95% 
CI 
P 
valueb 
Sens Spec PPV NPV 
TPMT 
 
rs12201199 
 
T/_ 
6 
(11.3%) 
1 
(7.1%) 
0.73 
0.08
-
6.67 
0.63 8.3% 88.9% 14.3% 81.4% 
A/A 
47 
(88.7%) 
13 
(92.9%)        
COMT 
 
rs4646316 
 
T/_ 
21 
(39.6%) 
3 
(21.4%) 
0.31 
0.06
-
1.58 
0.19 16.7% 61.1% 8.7% 76.7% 
C/C 
32 
(60.4%) 
11 
(78.6%)       
 
Unique carriers of 
eitherc 
 
 
27 
(46.3%) 
4 
(25.0%) 
0.39 
0.09
-
1.59 
0.21 25.0% 53.7% 10.7% 76.3% 
Non-carriers 
  
29 
(53.7%) 
9 
(75.0%)        
Table 5-8: Combined effect of TPMT and COMT genotypes on AG-induced ototoxicity. 
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It was also considered that the lack of significant association with AG ototoxicity might be 
due to the sample size not being large enough to achieve enough power to reject the null 
hypothesis with confidence. To confirm if this was the case, a power calculation was 
performed for both gene variants using the online genetic power calculator at 
http://pngu.mgh.harvard.edu/~purcell/gpc/ (Purcell et al., 2003). The case-control for 
discrete traits option was used. The data from Table 2 of the Ross et al. article was used to 
derive reference information for the expected genotypic relative risk Aa and AA values. The 
high risk allele frequency (A) data was derived from the population genetics 1000-Genome 
Study allele frequencies information presented in the e!Ensembl website at 
http://www.ensembl.org/Homo_sapiens.  For the rs12201199 TPMT SNP the calculation 
suggested that a sample size of 302 cases with ototoxicity would be needed to have 80% 
power to detect an allelic association based on an allele frequency of 0.151, prevalence of 
0.21% and a 3.6 fold relative risk under an additive model. As for the rs4646316 COMT 
SNP the calculation suggested that a sample size of 42 cases with ototoxicity would be 
needed to have 80% power to detect an allelic association based on an allele frequency of 
0.764, prevalence of 0.21% and a 2 fold relative risk under an additive model. Therefore, 
these calculations confirm that the sample size of the current study was not large enough to 
assess the significance of this association with confidence and so should be considered as a 
pilot study for this effect.  
5.3.3.2 Genetic association with TPMT and hearing in the British 
1958 birth cohort  
The rs12201199 TPMT SNP was also genotyped in a sample of 351 individuals from the 
British 1958 birth cohort study group. This is a cohort of subjects born in 1958 for which 
samples were collected for a large-scale population study investigating many aspects of 
health of a representative sample of the British population. Therefore subjects were not 
selected for hearing impairment but audiological assessment was undertaken as part of an 
extensive test battery. Within this population study of 6000 individuals the top 1000 and 
bottom 1000 (16.67%) people were chosen according to their hearing scores (4kHz 
thresholds) to represent ‘good’ and ‘poor’ hearing for this 44-45 years age group. These 
samples were available in the lab and were used here to assess if a similar genotype 
representation was seen in a group of these subjects representing ‘Good’ and ‘Poor’ hearing 
as with the CF children in the study population (with and without ototoxicity).  A sample of 
subjects representing ‘Good Hearing’ (n=175; 87 females and 88 males) and others 
representing ‘Poor Hearing’  (n=176; 88 females and 88 males) were tested to confirm if 
there was an association between the variant T/T genotype and poor hearing. Table 5-9 
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shows that again there was no significant difference in the genotype or allele frequencies 
between the two groups. As shown with the CF children, there were no association between 
TPMT variants and poor hearing (p=0.298). Figure 5-8 shows the allele frequencies of both 
the 1958 cohort and CF study group data confirming the similarity in the genotype 
distributions between the two groups.   
 
 1958 British Cohort Group (n=351) for rs12201199 TPMT  
Genotype/allele 
With GH (n=175),  
n (%) 
With PH (n=176),  
n (%) 
OR (95% CI) p valuea 
A/A 150 (85.7%) 144 (81.8%)     
A/T 23 (13.1%) 29 (16.5%) 1.313 (0.726-2.377) 0.367 
T/T 2 (1.1%) 3 (1.1%) 0.640 (0.105-3.886) 0.625 
         
A 323 (92.3%) 317 (90.1%) 0.757 (0.448-1.280)   
T 27 (7.7%) 35 (9.9%) 1.321 (0.781-2.234) 0.298 
Table 5-9: Genotypes for the British 1958 birth cohort samples.  
These were used to assess the prevalence of rs12201199 TPMT variants in a sample of the general 
population of normal hearing and poor hearing subjects. GH, Good Hearing and PH, Poor Hearing.   
 
Figure 5-8: Comparison between the TPMT rs12201199 allele frequencies of the 1958 cohort study 
population representing good and poor hearing and the study CF group with and without ototoxicity (as 
defined by standard & EHF PTA outcomes).  
There was no statistically significant difference between the groups (p<0.05). 
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5.3.4 Overview for outcomes of genetic analysis of the 
children with ototoxicity 
Table 5-10 displays the genetic characteristics of the fourteen children with evidence of 
ototoxicity. The table shows that their ages ranged between 5.5 and 16.4 years; that they 
were all Caucasian, with the exception of one child; that 9/14 were affected by the ΔF508/ 
ΔF508 CFTR mutation, which is the commonest type of CFTR mutation recorded. Only 
Child A (CF062) was genotyped positive for the A1555G mutation. Only one child (CF035) 
had an A/T genotype for the TPMT SNP and only two (CF046 and CF011) had the C/T and 
one (CF026) had the T/T genotypes for the COMT SNP. None of these children had a 
positive family history for hearing loss. Overall there were no characteristic factors from the 
patients’ assessed data that separated Child A from the rest of the children that did not have 
the mutation, other than she had the less common ΔF508/1717-1G>T CFTR gene mutation. 
Pt. code Age Ethnicity CFTR mutation TPMT 
genotype 
COMT 
genotype 
A1555G 
mutation 
Family H 
of HL 
CF035 15.9 Caucasian ΔF508/ ΔF508 A/T C/C - ve - ve 
CF062 14.6 Caucasian ΔF508/1717-1G->T A/A C/C + ve - ve 
CF067 15.1 Caucasian ΔF508/ ΔF508 A/A C/C - ve - ve 
CF046 12.0 Caucasian ΔF508/ ΔF508 A/A C/T - ve - ve 
CF032 5.5 Caucasian ΔF508/ ΔF508 A/A C/C - ve - ve 
CF011 14.0 Caucasian ΔF508/ ΔF508/I507 A/A C/T - ve - ve 
CF003 16.4 Caucasian ΔF508/1154 ins TC A/A C/C - ve - ve 
CF014 12.5 Caucasian ΔF508/ ΔF508 A/A C/C - ve - ve 
CF066 13.8 Caucasian ΔF508/ G542X A/A C/C - ve - ve 
CF026 16.2 Caucasian ΔF508/ ΔF508 A/A T/T - ve - ve 
CF022 12.9 Caucasian ΔF508/ ΔF508 A/A C/C - ve - ve 
CF006 14.4 Caucasian ΔF508/ G551D A/A C/C - ve - ve 
CF004 11.8 Indian ΔF508/ ΔF508 A/A C/C - ve - ve 
CF034 10.6 Caucasian ΔF508/ ΔF508 A/A C/C - ve - ve 
CFTR, cystic fibrosis transmembrane conductance regulator; TPMT, thiopurine S-methyltransferase; COMT, Catechol-
O-methyltransferase; Family H of HL, family history of hearing loss. 
Table 5-10: Genetic characteristics of the children with ototoxicity.  
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5.3.5 Discussion of the investigation of association between 
TPMT & COMT variants and AG-ototoxicity:   
Cisplatin and aminoglycoside ototoxicity were shown to follow a similar apoptotic cell death 
pathway leading to cochlear toxicity (Hutchin and Cortopassi, 1994, Ravi et al., 1995, Rybak 
et al., 2007) and consequently typically lead to a similar phenotypic profile of permanent 
bilateral symmetrical high frequency sloping SNHL. Ross et al. proposed that variants in two 
genes, thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT), 
were significantly associated with patients having evidence of cisplatin ototoxicity (Ross et 
al., 2009). They investigated 1,949 SNPs in 220 drug-metabolizing genes identified to have 
key roles in absorption, distribution, metabolism and elimination (ADME) of medical 
treatments. They had two study groups, a discovery group of 54 children exposed to cisplatin 
from the same oncology center and an independent replication group of 112 children from 
several paediatric oncology units across Canada in order to ensure increased power and 
generalizability of any significant findings they discover.  They showed that SNPs 
rs12201199; rs1142345 and rs1800460 of the TPMT gene and rs4646316 and rs9332377 of 
the COMT gene were significantly associated with oncology children exhibiting cisplatin 
ototoxicity (p<0.01). They were all reported to be ‘loss-of-function’ variants of these genes 
leading to decrease in their enzyme activity and hypothesized to consequently increase the 
toxic effect of cisplatin. As the TPMT rs12201199 was in Linkage disequilibrium (LD) with 
the other two SNPs (LD D’=1.0 for both) and the COMT rs4646316 was in LD with the 
rs9332377 SNP (LD D’=0.94) it was decided for the current study to only investigate these 
two SNPs for association with AG ototoxicity in CF children. Results of the Ross et al. study 
had shown that the risk allele for the TPMT rs12201199 was present in 9 (27.3%) and 16 
(21.9%) of the children showing cisplatin ototoxicity in the discovery and replication cohorts 
and was not present in the controls of the discovery cohort and present in only 1 (2.4%) of 
the controls of the replication cohort. This was a significant even after Bonferroni adjustment 
for multiple testing in the combined analysis of both cohorts (Fisher exact allelic test p= 
0.00022, Bonferonni-corrected p=0.032). The COMT rs4646316 variant allele (T) was 
actually seen more in the controls with 5 (25%) and 2 (5.6%) of the controls in the discovery 
and replication cohorts presenting with it and in only 1 (1.4%) of the ototoxic cases in the 
replication cohort only. This indicated that this allele conferred a protective effect in this 
case (Fisher exact allelic test p= 0.00055, Bonferonni-corrected p= 0.076) (Ross et al., 2009).  
Results of the current study showed absence of any significant association between either 
SNPs of both genes and AG ototoxicity in the CF children (p >0.05) (Table 5-5, Table 5-6, 
Table 5-7 and Table 5-8) where the variant risk alleles (T) of both gene SNPs occurred more 
commonly in the control children. The COMT rs4646316 variant did not follow a similar 
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trend of protection as conferred in the Ross et al. study. Therefore, trend in allele frequency 
was in the same direction as the Ross et al. study with the TPMT rs12201199 SNP but was in 
the opposite direction for the COMT rs4646316 SNP.  Samples from the British 1958 cohort 
study were used as samples representative of the general UK population with ‘Good’ or 
‘Poor’ hearing to assess if similar genotype frequencies were obtained compared to those 
from the study population of CF children.   Case-control association analysis between the 
TPMT rs12201199 and ‘poor hearing’ in samples from this population was also shown to be 
not statistically significant (Table 5-9) and of a similar genotype frequency distribution as 
the CF children (Figure 5-8).  A similar association analysis using the British 1958 cohort 
study samples could not be done for the COMT rs4646316 variants. This was because there 
was not enough DNA in the available samples to identify the different variants when using 
RFLP whereas with the TPMT, Real time PCR using Taqman Allelic Discrimination assays 
was used which required much smaller quantities of DNA. 
These results confirmed that AG ototoxicity did not show a significant association with these 
two gene variants in this CF cohort and therefore did not explain the dichotomy in the 
hearing status of these children. This was contrary to the findings previously reported to 
show a highly significant relationship with cisplatin ototoxicity. Another possible 
explanation for the lack of significant association with AG ototoxicity that was considered 
was that the sample size was not large enough to achieve enough power to reject the null 
hypothesis with confidence. The genetic power calculation that was performed suggested 
that a sample size cohort of 302 and 42 cases with AG ototoxicity would be needed to have 
80% power to detect an allelic association for TPMT rs12201199 and COMT rs4646316 
SNPs respectively.  This was therefore considered as the main limitation of this study. 
Therefore, a recommendation to consider this cohort, as a pilot study group should be made 
and consideration to recruit the calculated sample size if this research question is to be 
pursued.  
It is also worth noting that this current investigation was undertaken during the period of 
2010-2012 following the initial Ross et al., 2009 article. In 2013 a number of articles were 
published with the main aim of replicating the significant outcomes of this original paper 
(Carleton et al., 2014, Yang et al., 2013, Pussegoda et al., 2013). Pussegoda et al. (who 
belong to the same Canadian group of investigators from the Ross et al., 2009 article) 
replicated the genetic findings in an independent group of 155 paediatric oncology patients 
exposed to cisplatin. They investigated the association between genetic variants in TPMT 
(rs12201199, rs1800460, rs1142345), and COMT (rs9332377, rs4646316), in addition to 
other variants, including the ATP-binding cassette transporter C3 (ABCC3) (rs1051640) and 
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cisplatin-induced ototoxicity. They were able to replicate these associations for genetic 
variants in TPMT (rs12201199, p = 0.0013, odds ratio (OR) 6.1) and ABCC3 (rs1051640, p 
= 0.036, OR 1.8) in support of the original article. They also presented evidence that a 
predictive model that combined genetic variants in TPMT, ABCC3, and COMT with clinical 
variables (patient age, concomitant vincristine treatment, germ-cell tumour, and craniospinal 
irradiation) significantly improved the prediction of ototoxicity development as compared 
with a predictive model using clinical risk factors alone (Pussegoda et al., 2013). On the 
other hand, a separate research group from St. Jude Children’s Research Hospital, Memphis, 
Tennessee, USA, replicated this work in 213 children with medulloblastomas and could not 
find any significant association between TPMT or COMT variants and cisplatin-induced 
hearing loss. Instead, they confirmed that a significant connection with ototoxicity was only 
established for younger age (p = 0.013) and additional exposure to craniospinal irradiation 
(p = 0.001). They also replicated the study with 41 other children with solid-tumours 
(neuroblastoma and osteosarcoma) to avoid confounding factors in the children with 
medulloblastomas such as being treated with craniospinal irradiation and with amifostine, an 
otoprotectant against cisplatin ototoxicity. They still did not establish a significant 
association between TPMT and COMT variants with cisplatin-induced hearing loss. 
Experimental in-vivo and in-vitro laboratory studies were also undertaken using TPMT 
knock-out (KO) mice and lymphoblastoid cell lines, which also established a lack of 
association (Yang et al., 2013). Therefore the outcomes of the Yang et al. study for cisplatin 
ototoxicity showed similar outcomes as with the current study but for AG ototoxicity where 
no significant association was found between the TPMT or COMT variants and AG 
ototoxicity.   
Publication of this conflicting data is important as it re-establishes the importance of 
replicating outcomes of such significant pharmacogenetic association studies. The US Food 
and Drug Administration (FDA) had changed the cisplatin label to indicate the association 
of TPMT with ototoxicity based on the outcomes of the original 2009 paper. This big impact 
was probably due to the fact that this article was published in the high-impact journal Nature 
Genetics and because the data presented a highly significant pharmacogenetic association 
with cisplatin-induced hearing loss. This has major implications on the clinical management 
of cancer patients needing cisplatin, where pre-treatment genotyping of patients in search of 
the TPMT and COMT variants would be needed if cisplatin treatment individualization were 
to be implemented. If cisplatin is the 1
st
 line of treatment for an individual’s type of tumour, 
risk assessment of this avoidance treatment needs to be considered on top of cost-
effectiveness of this genetic testing and the need for genetic counseling and other monitoring 
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services. These factors have large health and financial implications and therefore outcomes 
of any study have to be considered with care and caution.  
However, there is still a rationale that variants of drug-metabolizing genes could be 
significantly associated with AG ototoxicity. It is still a valid research hypothesis and should 
be investigated further for AG ototoxicity. The outcomes of the current study did not support 
this but maybe by initially replicating Ross et al.’s methodology of assessing this association 
with variants of the most common 220 drug-metabolizing genes significant outcomes may be 
achieved with other genes. This is especially pertinent as the actual mechanistic pathway 
connecting variants of the two TPMT and COMT genes and cisplatin ototoxicity was not 
really established.  Ross et al. had proposed a convoluted hypothesis that the TPMT/COMT 
variants are associated with deficiency in the functional ability of these genes, which could 
result in excess intracellular S-adenosylmethionine (SAM). Both TPMT and COMT are 
methyltransferases that are consistently dependent on SAM as a methyl-donor substrate in 
the methionine pathways occurring within many cells.  Ochoa et al. had shown that 
administration of SAM and cisplatin together is associated with 3-6.2-fold increase in 
cisplatin toxicity as substantiated by significantly increased renal dysfunction. This was an 
unexpected outcome as this study was initiated based on the concept that SAM also had 
antioxidant properties by acting as a precursor of Glutathione. This is a major cellular 
antioxidant that may have protective effects on cisplatin nephrotoxicity and ototoxicity 
without interfering with its chemotherapeutic function. The administration of SAM alone 
was not cytotoxic, and cisplatin alone resulted in a moderate increase the toxicity (Ochoa et 
al., 2009). Based on these finding, Ross et al. concluded that cisplatin-induced ototoxicity 
could be related to increased levels of SAM through reduced TPMT or COMT activity to 
explain the link between these gene variants and ototoxicity. However, Milek et al. showed 
that direct measurement of SAM in red blood cells from healthy individuals showed no 
significant difference between individuals with wild-type TPMT (*1/*1, n = 115) and those 
carrying TPMT loss-of-function variants (*1/*3; n = 44; p = 0.69),
 
thus defying the notion 
that TPMT status can substantively influence SAM homeostasis. The direct correlation 
between COMT and SAM in vivo continues to be unclear (Milek et al., 2012). A study by 
Babu et al. investigated the antioxidant effect of SAM on gentamicin-induced nephrotoxicity 
in rats confirming the common pathways involved in toxicity caused by cisplatin and 
aminoglycosides. They showed similar outcomes as the study with cisplatin where renal 
dysfunction was demonstrated through increased urea and creatinine and histopathological 
damage of the proximal tubules seen in the rats given gentamicin + SAM yet this effect was 
non-significant when compared to the saline alone or gentamicin alone conditions (Babu et 
al., 2013). Therefore if this line of investigation is to continue in the future with AG 
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ototoxicity, investigation of the mechanistic pathway of any association should take priority 
too.  
5.3.6 Conclusions from the genetic studies: 
It is established that genetic variations may offer a possible explanation for substantial inter-
individual variation in ototoxicity in individuals receiving similar doses of potentially 
ototoxic medications. Therefore, following this line of investigation was an essential aspect 
in the search for ‘causation’ of ototoxicity and to offer a possible explanation for the 
dichotomy in hearing observed in the CF study population. Specifically, we investigated 
whether some prevalences of ototoxicity after low doses of AG may be explained by a 
known genetic susceptibility. The 12S rRNA gene of the mitochondrial DNA was genotyped 
for the A1555G mutation in the CF children. This is the most commonly reported mtDNA 
mutation known to cause increased susceptibility to aminoglycoside-induced ototoxicity. 
Two out of 105 (1.9%) children had the A1555G mutation. Even though it was not an aim of 
the current study to investigate the prevalence of this mutation in CF patients, it was noted 
that the prevalence of occurrence in this study cohort was higher than the previously reported 
~0.2% in UK populations. However, if this aim were to be pursued, a larger cohort study 
would be needed to confirm if the prevalence of this mutation is truly higher than expected 
in CF patients. It is worth noting that the only previous study of A1555G in a similar sample 
size of CF cases also found a raised frequency. In the case of child A - the A1555G was 
associated with early onset severe-profound SNHL in one of the few ototoxic group of 
children that belonged to the low AG-exposure group, consistent with the well established 
effect of this mutation. In this child the presence of this mutation provided an explanation as 
to why she had severe-profound SNHL following intake of only three AG courses whereas 
other children had exceptionally good hearing even after intake of 30-40 AG courses. This 
finding, in the context of what is already established in the literature, supports the 
recommendation to screen patient groups that are known to require the intake of these 
medications (like this CF patient group) at an early stage before they start developing 
infections and need these antibiotics. This will enable the clinicians to make informed 
decisions regarding the drug regimens they will use for each patient and be able to provide 
proper counselling and management.  
The unexpected and significant finding was that one of the two children with the mutation 
was seen to have completely normal hearing despite confirmed intake of i.v and nebulized 
AGs. Exposure to AGs has been consistently identified as a major modifying factor for this 
mutation leading to increased penetrance to 100%. From a retrospective review of the 
literature many of these studies utilized hearing loss cohorts and therefore were not capable 
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of establishing penetrance. This finding was published as a case report as this was a rare 
outcome and in order to highlight the need for further studies to confirm the true penetrance 
of this mutation with exposure to AGs (Al-Malky et al., 2014)(Appendix 9.14). Genotyping 
for the A1555G mutation in CF patients is not common practice in the UK. As 
aminoglycosides are commonly used as 1
st
 line treatments of pseudomonas chest 
exacerbations, genetic testing for this mutation raises many issues including dealing with 
patient/parent anxiety, the need to provide genetic counselling and auditory monitoring 
services, and weighing up the benefits of protecting hearing versus possible increased 
morbidity due to cessation of this treatment. Therefore it is recommended that further larger 
scale investigations should be done before genotyping for this or any other mutations with 
consequent stoppage of AG prescription in CF patients becomes common practice.        
The research by Ross et al. was the first to identify a correlation between variants in two of 
the known most common 220 drug-metabolizing genes and cisplatin ototoxicity. A similar 
link between these variants and AG ototoxicity could not be established in the current study. 
There was also no significant correlation seen between the TPMT rs12201199 variant and a 
representative sample of the British population using samples from the 1958 British Cohort 
study. Yang et al. later showed that this association with cisplatin ototoxicity could not be 
replicated. As both cisplatin and aminoglycosides were shown to follow similar pathways of 
entry into the inner ear and initiation of apoptosis of its cells (Forge and Schacht, 2000, 
Koegel, 1985, Lautermann et al., 2004, Ravi et al., 1995, Roland, 2004, Rybak and 
Ramkumar, 2007, Schacht et al., 2012), it was hypothesized that a similar correlation with 
the identified variants of the TPMT and COMT drug-metabolizing genes could be established 
with aminoglycoside ototoxicity. The small sample size should be considered as a limiting 
factor within this current study, as it may be a possible cause for this absence of significant 
relationships. The genetic power calculation showed that a sample size of 302 and 42 cases 
with ototoxicity would be needed to establish an association with 80% power between AG 
ototoxicity and TPMT rs12201199 and COMT rs4646316 respectively. Conversely, even 
though this similar link could not be established, the concept that variations in drug-
metabolizing genes could offer a possible explanation for the dichotomy in hearing 
thresholds of children exposed to AGs could still be valid. These genes affect the way the 
body deals with the absorption, dissemination, metabolism, and elimination (ADME) of 
drugs and are the basis for pharmacogenomics. If variants of these genes change the rate this 
ADME occurs this will lead to consequent changes in the drug serum levels and the amounts 
that pass the blood-labyrinth barrier and therefore may account for increased individual 
susceptibility to ototoxicity. This current pilot study failed to find a correlation with the 
TPMT and COMT variants but it may still be worth replicating the Ross et al. study and 
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searching for a correlation between AG ototoxicity and variants of all the 220-commonest 
drug-metabolizing genes, as variants other than those of TPMT and COMT may be 
associated with it. In this case establishing the mechanistic pathway through which this 
occurs should also be defined.     
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 Results & Discussion of Theme C: Chapter 6:
Impact of ototoxicity and current service 
provision 
 
In this current research, results of the audiological assessment of the CF children exposed to 
AGs has shown that ototoxicity occurs in around one-fifth of the children exposed, which 
increases even further to 44% in children exposed to cumulative high doses (Figure 4-5). 
Previous research has shown that cisplatin leads to ototoxicity in 60-100% of children 
(Knight et al., 2005, Brock et al., 1991, Rybak et al., 2009). The main aims of this final 
theme of the work were firstly to assess the impact that the added disability of ototoxic 
hearing loss has on patients that are already unwell. Evidence that this would significantly 
affect their quality of life would support the need to try and prevent the occurrence of 
ototoxicity by early identification through monitoring and change in treatment regimens if 
possible. The second aim was to survey current practice regarding monitoring for ototoxicity 
in the UK from the perspective of the audiological professionals and clinicians managing 
patients vulnerable to ototoxicity. This would allow for a more informed assessment of what 
is currently available and identify what is needed in order to improve this service.    
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6.1 Investigating the effect of hearing loss on the 
quality of life of paediatric cancer survivors 
receiving ototoxic chemotherapeutic agents. 
6.1.1.1 Initial retrospective assessment of the study group: 
This study aimed to assess the effect an added disability caused by hearing loss has on the 
quality of life of children with cancer. Records of patients that were monitored for 
ototoxicity in a dedicated ototoxicity clinic for oncology patients at GOSH were reviewed. 
Within this clinic children were routinely monitored for ototoxicity with baseline and regular 
post-treatment assessments undertaken. Data for 219 patients that were assessed over the 
period from 04/2005 to 12/2012 were retrieved. The mean age of the patients that were 
reviewed was 9.7 years (±SD=3.1 years) having a mean age at cancer diagnosis of 5.5 years 
(±SD=2.9 years). 82 of the 219 (37%) patients were females. On assessing their audiological 
data, 114 patients (52%) had normal hearing with standard audiometric thresholds of ≤20dB 
across all 1-8 kHz frequencies with recordable DPOAEs and normal type ‘A’ tympanograms, 
whereas 105 (48%) demonstrated evidence of hearing loss. Only 21 (20%) of the hearing 
loss patients had conductive/mixed hearing loss whereas the majority (80%) had 
sensorineural high frequency sloping hearing loss commonly seen in cases of ototoxicity 
(36% mild-moderate, 40% severe and 4% profound high frequency sloping SNHL). 70/105 
(67%) of the patients with hearing loss wore amplification, which in most cases was in the 
form of hearing aids except for two children who were fitted with cochlear implants. Most of 
the hearing loss patients were reported to have progressively worsening SNHL, which was 
evidenced through repeated assessments (mean number of assessments 3.6 ±SD=2.8; range 
1-16) (Table 6-1). The parents of all these children were contacted by phone or though email, 
the study was explained to them and a copy of the information sheet, consent form and 
questionnaires were sent to them either through the post or electronically through an email 
with the link to the questionnaires using the UCL Opinio survey tool.  
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Descriptive Data Number of Patients (n=219) Percentage (%)  
Total PTAs Performed  
1-4 PTAs 160 73 
5-8 PTAs 38 17 
9-12 PTAs 13 6 
13-16 PTAs 3 1 
OAE results   
Intact OAEs 118 54 
Absent OAEs 74 34 
Tympanometry results  
Normal Type 'A' 152 69 
Flat Type 'B' 31 14 
Negative Type 'C' 9 4 
Hearing Status   
Normal Hearing  114 52 
Conductive HL 21 10 
Mild-Moderate HF Sloping HL 38 17 
Severe HF Sloping HL 42 19 
Profound HF Sloping HL 4 2 
Progression of HL  
Stable 67 31 
Progressive 79 36 
Table 6-1: Description of the audiological data retrieved from the records of oncology patients (n=219) 
assessed in the ototoxicity clinic.  
Some data was missing for patients in each category hence the discrepancy in the reported numbers. 
6.1.1.2 Responding participants:  
Completed questionnaires were received from 41 parents of children with ototoxic hearing 
impairment and 37 parents of children with normal hearing (total of 78 responses, 36% 
response rate). The mean age of the children was 9.8 years (±2.8 years) with a mean age at 
cancer diagnosis of 5.9 years (±2.3 years). 35/78 (45%) of the children were females. Table 
6-2 summarizes the types and distribution of the cancers affecting the children highlighting 
that a wide range of cancers require the intake of ototoxic chemotherapy or radiotherapy 
with the most common being the solid tumours (47.5%). All children were exposed to at 
least one type ototoxic agent with many exposed to more (e.g. both cisplatin and carboplatin) 
with details shown in Table 6-3. The children were divided into those with normal hearing 
(n=37) and those with audiological evidence of ototoxicity (n=41) and the responses to the 
questionnaires were analyzed and compared between the two groups. Of the 41 children with 
ototoxicity 26 (63%) had mild to moderate high-frequency (HF) sloping SNHL while 11 
(27%) and 2 (5%) had severe and profound HF sloping SNHL respectively. Thirty (73%) of 
the study children with ototoxicity were wearing hearing aids and six (15%) had other 
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disabilities, including partial sightedness, which was comparable with the normal hearing 
group (14%). 
 Number of children  
(n=78) 
Percentage 
(%) 
Leukaemias /Lymphomas 14          18.0% 
Acute Lymphoblastic Leukaemia (ALL) 2 2.6 
Acute Myeloid Leukaemia (AML) 4 5.1 
Anaplastic Large Cell Lymphoma (ALCL)  1 1.3 
B Cell Lymphoma 1 1.3 
Burkitts Lymphoma 2 2.6 
Follicular Lymphoma 1 1.3 
Hodgkin’s Lymphoma 3 3.8 
Non Hodgkin’s  0 0.0 
Solid Brain Tumours 27            34.6% 
Astrocytoma 4 5.1 
Ependymoma 2 2.6 
Glioma/Optic Glioma 5 6.4 
Medulloblastoma 15 19.2 
Pineal Tumour 1 1.3 
Solid Tumours 37            47.5% 
Adrenal Carcinoma 1 1.3 
Choriocarcinoma 1 1.3 
Ewing's Sarcoma 2 2.6 
Germ Cell Tumour 4 5.1 
Hepatoblastoma 4 5.1 
Hepatoma 1 1.3 
Immature Teratoma 1 1.3 
Neuroblastoma 7 9.0 
Neurofibromatosis 1 1.3 
Osteosarcoma 4 5.1 
Retinoblastoma 4 5.1 
Rhabdoid Tumour 1 1.3 
Wilm’s Tumour 6 7.7 
Table 6-2: Summary of types and distribution of tumours affecting the children.  
The commonest tumour was Medulloblastoma (19.2%) whereas the commonest group of tumours was the 
solid tumours (47.5%).  
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 Number Of Children 
(n=78) 
Percentage  
(%) 
Age (years)    
0-5y 6 7.7 
6-10y  42 53.8 
11-15y 30 38.5 
Age At Diagnosis   
0-5y 45 57.7 
6-10y  29 37.2 
11-15y 4 5.1 
Gender   
Male 43 55.1 
Female 35 44.9 
Ototoxic Chemotherapy received   
Single type 
  
 
32 41.0 
Multiple types 
  
 
46 59.0 
Hearing Status   
Normal 37 47.4 
Mixed HL 2 2.6 
Mild-Moderate HF Sloping SNHL 26 33.3 
Moderate-Severe HF Sloping SNHL 11 14.1 
Moderate-Profound HF Sloping SNHL 2 2.6 
Brock's Grading   
0 45 57.7 
1 5 6.4 
2* 5 6.4 
3 10 12.8 
4 13 16.7 
Hearing Aids fitted   
Yes 20 25.4 
No 58 74.4 
Other Disabilities   
No 67 85.9 
Yes 11 14.1 
Table 6-3: Summary of descriptive and audiological data of all recruited children.  
Brock’s grade 2* is the minimal grade prompting clinicians to consider changing the treatment regimenn 
e.g. switch to less ototoxic chemotherapeutics.   
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6.1.1.3 Outcomes of the responses from the questionnaires: 
Health Utilities Index Mark 3 (HUI3) Questionnaire: 
The HUI3 is a standardized set of generic health profiles and preference-based systems 
designed for the purpose of producing utility scores to report on health-related quality of life 
(HRQL) and measure health status. It was chosen because it is one of the most commonly 
used and validated measures of HRQL. The 15-Q parent-proxy version of the HUI3 
questionnaires was used. The eight attributes in the HUI3 classification (vision, hearing, 
speech, ambulation, dexterity, emotion, cognition and pain) are scored using single and 
multi-attribute utility functions so that single-attribute scores of morbidity are defined on a 
scale such that the best level has a score of 1.00 and the worst score of 0.00 and the multi-
attribute utility functions convert detailed health state descriptors into preference measures 
of overall HRQL. This again is defined such that the score for perfect health=1.00 and the 
score for death=0.00 with the HUI3 allowing for negative scores of HRQL representing 
health states considered worst than death with the lowest score being -0.36 (Horsman et al., 
2003). 
 When comparing the frequency and distribution of suboptimal levels of function in the eight 
different attributes of the HUI3 questionnaire between the normal hearing group of cancer 
patients and those with ototoxicity, two attributes showed a significant difference (Table 6-4). 
The suboptimal levels of function were defined as the less than normal function indicated by 
scores below level 1 for each attribute (see Appendix 9.3).  The two attributes that were 
significantly different between the two groups were the ‘hearing’ and ‘cognition’ attributes 
(p= <0.0001 and 0.046 respectively). The remaining six of the eight attributes were not 
statistically significantly different between the two groups of children although suboptimal 
levels were present in a higher percentage of the ototoxic group children compared to those 
in the normal hearing group across all attributes (Table 6-4). 
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 Normal Hearing Group  
(n=37), n (%) 
Ototoxic Group 
(n=41), n (%) 
p-value
a
 
Vision 3    (8.1%) 8    (19.5%) 0.199 
Hearing 1    (2.7%) 33  (80.5%) <0.001 
Speech 11  (29.7%) 19  (46.3%) 0.132 
Ambulation 15  (40.5%) 18  (43.9%) 0.764 
Dexterity 9    (24.3%) 14  (34.1%) 0.342 
Emotion 13  (35.1%) 17  (41.5%) 0.566 
Cognition 17  (45.9%) 28  (68.3%) 0.046 
Pain 13  (35.1%) 18  (43.9%) 0.429 
Suboptimal levels of function are defined as below level 1 scores indicating less than normal function for each attribute.  
a Calculated using chi-square test (Fischer’s exact test when cells have <5) comparing all children with normal hearing 
with those with ototoxicity (p<0.05). 
Table 6-4: Number of children in each group with suboptimal levels of function in each attribute of the 
HUI3. 
 
 
Figure 6-1: Shows mean with 95% CI error bars for the HUI3 single attribute responses for each of the two 
normal hearing and ototoxic oncology groups.  
The Hearing and Cognition attributes were significantly worse in the ototoxic group (* p<0.05). 
 * * 
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A comparison of the single-attribute response scores in the two groups again showed a 
significantly lower mean (error bars=95% CI) score in the ototoxic group for the Hearing 
and Cognition attributes (Figure 6-1) 
Figure 6-2 and Table 6-5 show the distribution of the multi-attribute utility scores of the 
children with normal hearing and those with evidence of ototoxicity. There was a significant 
difference in the median and range values between the two groups with only one outlier in 
the normal hearing group. The difference was shown to be statistically significant using the 
non-parametric Mann Whitney U test  (Mann-Whitney U=419.0, p=0.001). This indicates an 
overall recorded reduction in the health-related quality of life (HRQL) of children with 
cancer when hearing loss is an added disability.   
 
 
Figure 6-2: A Boxplot showing the multi-attribute utility scores of HUI3 for both the normal hearing and 
ototoxicity group of cancer children.  
The central line inside the box represents the median score and the lower and upper edges of the box 
represent the 25th and 75th percentile scores. 
 
  
  195 
 Normal Hearing Group  Ototoxicity Group  p-value 
N 37 41  
Mean 0.734 0.539  
Median 0.849 0.598 0.001
a
 
Minimum -0.155 -0.264  
Maximum 1.000 0.931  
Range 1.155 1.195  
Std. Deviation 0.297 0.276  
Table 6-5: Descriptive data of the multi-attribute HUI3 utilities scores for both groups (including the 
outlier).  
a Calculated using the Mann-Whitney U test (p<0.05). 
Paediatric Audiology Quality of Life Questionnaire (PAQL): 
The PAQL 22-item questionnaire, which was developed by Edwards et al. (Edwards et al., 
2012) to specifically assess the aspects of Quality of Life (QoL) affected by childhood 
deafness while still being appropriate for hearing children, was the second parent-proxy 
questionnaire used in this study. The scores of the four PAQL subscales and total QoL score 
(i.e. the sum of all four subscale scores) were compared for children with cancer who had 
normal hearing and those showing evidence of ototoxic hearing loss using the non-
parametric independent samples Mann-Whitney U -test. The results shown in the boxplots in 
Figure 6-3 and in the analysis in Table 6-6 demonstrated that a highly statistically significant 
difference was present between the two groups across all four subscales and in the overall 
total QoL score at p<0.001, therefore rejecting the null hypothesis that the distribution of any 
of these scales is the same across the two patient categories. All the scores of the ototoxic 
group were poorer than those of the normal hearing group. The highest mean difference 
between the two groups was seen in the ‘communications and independence’ subscale, 
which was also shown to be the most important subscale in differentiating between the two 
groups. This was because it was responsible for 89% of the variance between them when 
factor analysis was performed to identify the significance of each of the subscales (% of 
variance of 6%, 3% and 2% was shown for the other three subscales respectively). Despite 
the presence of a wider range of scores in all subscales of the ototoxic group, there were 
significantly more extreme scores in the subscale scores of the normal hearing group as 
shown in Figure 6-3 as the outliers.    
 
  196 
 
Figure 6-3: A Boxplot showing the distribution of scores for all four subscales of the PAQL for each of the 
two groups of children.  
Outliers were only seen in the Normal Hearing group. 
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 Communication 
& independence 
 
Emotional 
wellbeing 
 
Peer 
comparisons 
 
Acceptance Total QoL 
scores  
 
 
Normal Hearing Group 
N 37 37 37 37 37 
Mean 27.70 31.81 22.54 18.57 100.62 
Median 30.00 34.00 24.00 20.00 107.00 
Minimum 16.00 19.00 9.00 11.00 63.00 
Maximum 30.00 35.00 25.00 20.00 110.00 
Std. Deviation 3.79 4.36 3.72 2.39 13.11 
Variance 14.38 19.05 13.81 5.70 171.96 
 
Ototoxic Group 
N 41 41 41 41 41 
Mean 22.51 27.05 18.24 15.49 83.29 
Median 22.00 30.00 18.00 16.00 81.00 
Minimum 11.00 12.00 9.00 6.00 42.00 
Maximum 30.00 35.00 25.00 20.00 110.00 
Std. Deviation 4.97 6.39 4.07 3.64 17.76 
Variance 24.66 40.80 16.59 13.26 315.31 
Mean Difference 5.19 4.76 4.30 3.08 17.33 
 
Independent-Samples Mann-Whitney U Test 
Mann-Whitney U 290.00 396.50 292.50 359.50 305.50 
Z-score -4.78 -3.68 -4.70 -4.10 -4.55 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 
Table 6-6: The distribution and statistical analysis of the four subscales and total scores of the PAQL 
between the two normal hearing and ototoxic groups of cancer children. 
 Independent-samples Mann-Whitney test U was used. There was a highly significant difference between 
the groups in all categories. 
6.1.2 Discussion of the effects of ototoxicity of the quality of 
life on children:  
Cancer is considered to be one of the most life threatening diseases of the century. The UK 
World Cancer Research Fund (WCRF) reports a prevalence of around 12.7 million cancer 
cases per year worldwide, which is estimated to rise to 21 million by the year 2030, with the 
UK reported to have the 22
nd
 highest overall rate of cancer in the world (www.wcrf-uk.org). 
With the marked advances in the research, healthcare, pharmaceuticals, technology and 
many fields related to the diagnosis and management of cancer, the survival rate from this 
disease has significantly improved with statistical reports such as those from the National 
Cancer Institute in the US stating that >80% of patients diagnosed at childhood or 
adolescence survive their initial disease (http://seer.cancer.gov/faststats). This in turn has 
meant, as with CF patients, that more emphasis is placed on trying to preserve the patients’ 
quality of life as opposed to just keeping them alive. Chemotherapy is an extremely 
important method of treatment for a wide variety of tumours. However it can lead to 
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ototoxicity as a side effect, with the platinum-based group of drugs such as cisplatin and 
high-dose carboplatin, being the most well documented ototoxic chemotherapeutics (Schell 
et al., 1989, Parsons et al., 1998, Punnett et al., 2004, Bertolini et al., 2004, Kushner et al., 
2006). The hearing loss is especially detrimental in children as it also affects speech and 
language development, educational progression, social interaction and communication, 
psychological wellbeing and overall quality of life.       
In this study records of 219 children with cancer who were exposed to potentially ototoxic 
chemotherapeutic agents were reviewed with the aim of recruiting a group of them with 
evidence of ototoxicity and a matching group with normal hearing in order to assess the 
effect this added hearing disability has on Quality of Life measures. The 15Q parent-proxy 
version of the HUI3 and the 22Q PAQL questionnaire were administered. 78 families 
responded. 
Retrospective assessment of the data of the children with cancer showed that they had a wide 
range of tumour types all requiring the administration of at least one type of potentially 
ototoxic chemotherapeutic agents e.g. cisplatin, in addition to exposure to head and neck 
radiotherapy. Radiotherapy is also potentially ototoxic and is reported to have a synergistic 
effect when combined with chemotherapy (Kortmann et al., 2000, Miettinen et al., 1997, 
Schell et al., 1989, Walker et al., 1989). Platinum agents are known to be effective against a 
variety of childhood malignancies including certain brain tumours, such medulloblastomas; 
solid tumours, such as neuroblastomas and germ cell tumours (Doz et al., 1993, Gaynon, 
1994, Ettinger et al., 1994), which were all seen in this study cohort.  This data showed that 
48% of the children demonstrated evidence of ototoxicity when post-exposure audiological 
assessments were performed and that 80% of those had high-frequency sloping SNHLs 
characteristic of ototoxicity. This prevalence of ototoxicity is similar to several other studies 
reporting prevalences ranging from 34-62% (Kortmann et al., 2000, Kushner et al., 2006, 
Laverdiere et al., 2005, Packer et al., 1994), which significantly increased to 80-100% when 
associated with high risk factors such as young age, cumulative dosage, brain tumours and 
concomitant use of CNS radiation. A large proportion of the children showed evidence of 
progressive worsening of their hearing status on repeated testing emphasizing the need for 
repeated audiological monitoring of these patients (Table 6-3). At GOSH change in 
management is made if Brock grade 2 levels of hearing loss are reached. This may be the 
reason why only 48% of the children had ototoxicity despite having all the high risk factors 
just mentioned which would potentially increase this prevalence to up to 100%.  The 
progressive worsening of hearing that was seen in these children has also been reported by 
Bertolini et al. who showed that 5% of the 120 children exposed to cisplatin and/or 
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carboplatin had at least Brock’s grade 2 hearing loss before the end of treatment, which rose 
to 44% after more than 2 years of long-term follow up. Al-Khatib et al. also showed a 33% 
worsening in the audiograms of cisplatin-exposed patients with long-term follow-up for 
periods ranging from 1.5 to 6.6 years (median of 3.4 years). They, as well as several others, 
also recommended long-term audiological surveillance even after cessation of treatment 
(Bertolini et al., 2004, Al-Khatib et al., 2010, Einarsson et al., 2010, Sivaprakasam et al., 
2011) 
The 78 recruited children were aged between 5-15 years with 54% of them lying within the 
6-10 years age category. There was a good match between the group with normal hearing 
(n=37) and the group with ototoxicity (n=41) in terms of age, gender, tumour type, 
chemotherapy exposure and recorded additional disabilities. 63% of the group with 
ototoxicity had mild-moderate HF sloping SNHL and 73% were wearing hearing aids. 
Despite this match, scores of the single attributes of ‘hearing’ and ‘cognition’ and the overall 
multi-attribute utility score of HRQL of the HUI3 questionnaire all showed a significant 
difference between the two groups with children in the ototoxicity group having HRQL 
utility scores as low a -0.264, which is considered a level worse than death  (Table 6-4, Table 
6-5, and Figure 6-2). In addition to that, all the PAQL subscales and the overall QoL scores 
of the group with ototoxicity were also significantly lower than the group with normal 
hearing (Figure 6-3 and Table 6-6). Therefore, results of both questionnaires demonstrated 
that the additional hearing loss disability had the significant effect of reducing the overall 
health-related quality of life (HRQL) and overall quality of life (QoL) of children who are 
already facing the extensive range of difficulties associated with being a cancer patient. 
There is limited data in the literature investigating the impact that hearing loss has on the 
QoL of cancer survivors therefore the findings of this current study are significant. These 
limited studies are presented below. There is more evidence in the literature on the 
significant affect of permanent childhood hearing loss (PCHI) on quality of life. This is also 
related to the outcomes of the current study as the ototoxicity in these children would be 
considered a cause of PCHI.    
On comparing the health status and HRQL preference-based outcomes, using the HUI3, of 
7-9 years old children with bilateral permanent childhood hearing impairment (PCHI) with 
their normal hearing peers, Petrou et al. found that they scored significantly lower on 6 of the 
8 single-attribute utility scores of the HUI3: vision, hearing, speech, ambulation, dexterity 
and cognition with significantly lower multi-attribute utility scores as well (Petrou et al., 
2007).  Wake et al. used the 28-item parent-proxy Child Health Questionnaire measure of 
HRQL to assess the difference between a cohort of 7-8 year-old children with a varying 
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range of severities of congenital hearing loss that were fitted with hearing aids or cochlear 
implants and normal hearing children of the same age cohort. They found that the hearing 
loss cohort scored significantly poorer in 6 of the scales (Behaviour, Mental health, 
Role/Social-Physical, Parent Impact-time, Parent Impact-Emotional and Family Activities) 
in addition to poorer overall Psychosocial Summary scores when compared with their 
normal hearing peers (Wake et al., 2004). Edwards et al. had devised the PAQL to assess the 
quality of life to deaf children wearing cochlear implants and specifically assess the added 
impact of having additional needs, such as learning or physical difficulties. They showed 
that the children with added disabilities had poorer scores in three of the four subscales 
(Communication and independence, Emotional well-being and Acceptance by peers) yet also 
showed that both groups of children benefited significantly from having cochlear implants 
which were shown to improve their overall QoL (Edwards et al., 2012). This PAQL was a 
good tool to use in the current study because it is a disease-specific quality of life measure 
and as expected was able to demonstrate the significant impact of ototoxicity on all four 
subscales.  
Regarding the limited literature related to the effect of hearing loss on QoL in cancer 
survivors, Gurney et al. undertook a survey of 8-17 years-old long-term neuroblastoma (NB) 
survivors.  The parent-proxy and self-reported Pediatric Quality of Life Inventory 4.0 was 
used which showed that the NB survivors with hearing loss had twice the risk of having 
academic learning difficulties, such as reading and math skills, and psychosocial problems 
compared to their normal-hearing counterparts (Gurney et al., 2007). Laverdiere et al. who 
had also assessed the long-term complications of NB survivors (7.06 years median follow-up 
from diagnosis) showed that 62% of the children complained of hearing loss. Cisplatin 
exposure increased the risk for hearing loss (OR 9.74, 95% CI: 0.9-101.6) (Laverdiere et al., 
2005). Barr et al. assessed the HRQL of children with Wilm's tumour and those with NB 
using the parent-proxy HUI Mark 2 and Mark 3 questionnaires. Children with Wilm's 
tumours generally have a better prognosis and less exposure to platinum compounds. 84% of 
the eligible 93 families responded and scores were worse in the NB survivors for the single 
attributes for ‘hearing’ and ‘speech’ utility scores and for the overall multi-attribute HRQL 
scores when compared to the Wilm's tumour survivors (Barr et al., 2000). These findings are 
all in agreement with the outcomes in the current study. The worsening in the hearing 
attribute is expected and confirms that the questions representing this attribute are able to 
detect the effect of the mild to moderate hearing loss seen in the bigger proportion of the 
children in the ototoxic group. However, the worsening in the cognition and overall multi-
attribute utility scores confirm the findings of the previous research discussed here which 
shows that the effect of hearing loss extends to affect the children’s cognitive function, 
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educational abilities and overall psychosocial development. This supports the 
recommendation to effectively manage the hearing loss caused by ototoxicity through early 
detection and rehabilitation.        
In recognizing the significant effect of long-term (≥ 2years post treatment) complications of 
management of paediatric malignancies, a multidisciplinary panel of experts developed “The 
Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, 
Adolescent, and Young Adult Cancers”. These guidelines were intended to increase 
awareness of these late complications and advocate standardized follow-up care. A series of 
complimentary patient educational material (“Health Links”) were also developed. Hearing 
loss was recognized as one of these complications recognized to affect the academic, speech 
and language, social and emotional well-being of children and adolescent cancer survivors. 
The Guidelines, and related Health Links, can all be downloaded at 
www.survivorshipguidelines.org. (Eshelman et al., 2004, Grewal et al., 2010, Landier et al., 
2004). 
6.1.2.1 Limitations of the study: 
Limitations of this study included the achieved response rate. Responses were obtained from 
78/219 of the potential candidates contacted, which respresents a response rate of 36%. 
Despite this being a common problem in questionnaire studies especially when targeting 
significantly unwell subjects, the lower response rate may bias the outcomes as the 64% non-
respondents may have done so for several reasons. This may include families where 
ototoxicity had less of an impact on the QoL of their children. However the similar response 
rate of the non-ototoxic group and ototoxic group (37 vs. 41 responses) helps overcome this 
to a certain extent.  Another limitation of the study was that parent-proxy questionnaires 
were used and so the children themselves were not directly reporting the effect of their 
disease on their QoL. The effect perceived by the parents might be different from that 
perceived by the children themselves. A recommendation for future work may include 
repeating this study with the actual patient forms of the questionnaires and contact the older 
children and adults surviving cancer. It would also be interesting to confirm whether the 
same effect on the QoL would be recorded for the children with CF with ototoxicity. One of 
the reasons for choosing the children with cancer for this was because they already had a 
dedicated ototoxicity monitoring service at GOSH and therefore at retrospective review of 
records of disease management and audiological assessment was possible. It was also 
possible to have an adequate sample size to have enough power to detect a significant effect 
if it existed. As the children with CF did not have a similar service this was not possible. CF 
is a chronic disorder where the child is unwell from birth or early in childhood then 
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throughout their lives. Parents are used to their children developing repeated complications 
and know that their children’s life is under threat all the time. In addition, there is also a 
significant impact on their educational and psychosocial development due to the need for 
repeated hospitalization and therefore the impact of ototoxicity on the QoL may be more 
significant. It would be interesting to compare the outcomes of these QoL measures for this 
group with the children with cancer where the disease is usually more acute and parents have 
a shorter time to deal with the psychological and physical stress of discovering that their 
previously healthy child is having a life-threatening condition.  A recommendation for future 
research would be to repeat this study with CF children and compare the results with the 
cancer children in order to put in place individualized rehabilitation plans that are aimed at 
addressing the specific needs of each patient group if they were found to be different.   
6.1.3 Conclusion: 
In conclusion, this study has added to the limited literature assessing the effect of the hearing 
loss disability on the quality of life of children and adolescents surviving cancer. The use of 
generic HRQL (HUI3) questionnaires helps compare this effect with a wide variety of 
conditions and confirm its impact on health status. The use of the dedicated disease specific 
questionnaire such as the PAQL specifically assesses the effect of childhood deafness on the 
quality of life (QoL) of children and so highlights this impact in more detail compared to the 
generic tools. Both questionnaires were shown to effectively detect a significant difference 
between the two groups of non-ototoxic vs. ototoxic cancer survivors. This study has shown 
that ototoxicity had a significant effect on the hearing and cognition attributes of the HUI3 
questionnaire in addition to a general worsening of the overall multi-attribute scores. It also 
showed that all four subscales of the PAQL questionnaire were significantly worse. These 
subscales included Communication and independence, Emotional well-being and Peer 
comparisons and Acceptance indicating that the handicap caused by the hearing loss 
extended much further than the hearing disability itself. These finding supported previous 
research showing that hearing loss exacerbates the deficits in the developmental, academic, 
psychosocial, emotional and physical well-being of cancer survivors with documented long-
term effects recognized. Therefore this study augments the recommendations previously 
made for increased awareness and better standardized and effective management of this 
disability in these children in order to improve their quality of life.     
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6.2 Survey of UK Oncology, Audiology and CF 
services to assess current practice of auditory 
monitoring for ototoxicity 
The previous study showed that hearing loss due to ototoxicity had a significant effect on the 
quality of life of children who are already unwell such as those with cancer or CF. This 
highlights the importance of early detection and monitoring for ototoxicity with the aim to 
prevent or avoid further deterioration of hearing. Providing the clinicians with the ability to 
make informed decisions regarding change in treatment management can do this. This study 
aimed to assess current UK practice in relation to monitoring for ototoxicity from the 
perspective of oncology and CF clinicians and those of the audiologists. This would help 
identify areas of weakness that can aid in devising an informed plan for improvement of 
service provision.  
The UCL Opinio online survey tool was used to collect data for questionnaires specifically 
designed to suit each of the three target populations in term of their area of expertise and 
knowledge. The target professionals were those working in oncology, as they manage 
patients with cancer who are exposed to ototoxic chemotherapy; those working in CF units 
as they manage CF patients exposed to ototoxic antibiotics; and those working in audiology 
as they are the professionals providing the auditory monitoring to both patient groups and 
any others exposed to ototoxicity.  The hyperlink to each applicable survey was sent to the 
related clinicians through the mailing lists of the relevant professional bodies as described in 
the methods section 3.6.2. The questionnaires aimed to document current practice in 
ototoxicity monitoring and address questions like: 1) Are clinicians aware of the need to 
monitor hearing? 2) Are they following guidelines for referral, testing and correct 
identification of ototoxicity? 3) Is there uniformity in this service provision? 4) Do 
individual clinics have a pipeline for monitoring and options for change in management and 
rehabilitation? If they do, are these criteria adhered to? The responses to all the questions 
were presented below.  
6.2.1.1 Characteristic features of respondents:  
Responses were received from 56 oncology, 133 audiology and 33 CF unit clinical staff. As 
it was possible to obtain a list of all 48 CF units through the CF Trust 2010 registry 
(www.cftrust.org.uk) the lead clinician from each unit was identified and was sent the 
invitation to complete the questionnaire. Therefore a response rate of 33/48 (69%) could be 
calculated. Due to the significantly larger number of oncology and audiology professionals 
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all over the UK and the portal used to reach them, it was not possible to approach them in the 
same way, making it impossible to calculate a response rate or to confirm exactly which 
hospitals were involved.  
Responses were received from members from all three professions representing all regions 
of the UK as seen in Figure 6-4. The clinical roles are represented in Table 6-7 for the 
oncology and audiology surveys; all the CF respondents represented the clinical leads of the 
UK CF services, as these were the only ones approached. Audiology professionals (including 
audiologists and audiological scientists) represented 90.2% of the respondents while doctors 
(including Audiovestibular physicians and ENT surgeons) accounted for only 8.3%. On the 
other hand, for the oncology survey, doctors (oncologists) constituted 53.6% whereas nurses 
constituted 41.1% of the 56 respondents. Twenty- eight (84.9%) of the CF centers cared for 
over 100 CF patients at any given time whereas only five (15.2%) stated that their patient 
cohort ranged from 50-100 patients. The categorization of the type of services delivered was 
also shown in Table 6-7 and shows a good representation of paediatric and adults services 
within each profession.   
 
Figure 6-4: Regional distribution of respondents from the three professions. 
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 Audiology (N=133),  
n (%) of respondents 
Oncology (N=56), 
n (%) of respondents 
CF units (N=33),  
n (%) of respondents 
Clinical roles    
Audiological professional 120 (90.3%)  -   - 
Doctor 11   (8.3%)
a
 30 (53.6%)
b
 33 (100%)
c
 
Nurse 1     (0.8%) 23 (41.1%)  - 
Other 3     (2.3%)
d
 3   (5.4%)
e
  - 
    
Program type
1
   
Paediatric 90   (67.7%) 33 (58.9%) 24 (72.7%) 
Adult 105 (79.0%) 28 (50.0%) 14 (42.4%) 
Other specialist centre 6     (4.5%) 2   (3.6%)  - 
a,b,c Doctors referred to: a AVM & ENT; b Oncologists; c CF Respiratory consultants respectively 
d, e Others included:  d neonatal consultant, student audiologist & oncologist; e radiographer, pharmacist & shared 
care doctor  
Program type1: Respondents were asked to tic 'all options that applied' therefore percentages are not intended to 
equal 100%. 
Table 6-7: Clinical and Program characteristics of respondents. 
6.2.1.2 Confirmation of ototoxic drug intake:  
Several questions were added to the oncology and CF services surveys in order to achieve a 
better understanding of the clinicians’ awareness of their patients’ exposure to ototoxic 
medications, confirm the type of ototoxic drugs patients are exposed to and to assess if 
monitoring of therapeutic drug levels constitutes part of their regular practice. Table 6-8 
shows the oncology respondents’ answers to these questions. Most of the respondents 
reported that up to 75% of their patients are exposed to potentially ototoxic 
chemotherapeutics with the highest percentage (39.3%) reporting that 26-50% of their 
patients are exposed. This confirms that ototoxicity is a complication that can affect these 
patients and therefore something that the clinicians should be aware of. Cisplatin and 
carboplatin (or drug protocols including these drugs) were identified as first line treatment 
options by 94.6% and 78.6% of respondents respectively. Exposure to head and neck 
radiotherapy, known to exacerbate the ototoxic effect of chemotherapy, was also reported by 
58.9% of the respondents. It was interesting to note that 44 (78.5%) of the oncology 
respondents were either not sure or confirmed that therapeutic drug monitoring (TDM) was 
not carried out with chemotherapeutics. TDM is performed to avoid sub-therapeutic or toxic 
levels being reached. This is not the case for aminoglycosides, which are monitored by all 
the responding CF clinicians (Table 6-9).  Therefore TDM for chemotherapy may not be part 
of general practice.   Tobramycin was reported (97.0%) as the first choice aminoglycoside 
used to combat pulmonary exacerbations in CF patients and is commonly administered using 
extended interval (once or twice daily) dosing.    
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 Oncology (N=56), 
n (%) of respondents 
% Patients exposed to ototoxic chemotherapy 
76-100% 1   (1.8%) 
51-75% 13 (23.2%) 
26-50% 22 (39.3%) 
0-25% 20 (35.7%) 
Cisplatin/Cisplatin-based protocol as 1st line treatment? 
Yes 53 (94.6%)
a
 
No 3   (5.4%) 
Carboplatin/Carboplatin-based protocol as 1st line treatment? 
Yes 44 (78.6%)
b
 
No 12 (21.4%) 
Patients receive Head & Neck Radiotherapy? 
Yes 33 (58.9%) 
No 23 (41.1%) 
How are therapeutic drug levels monitored? 
Measure a peak and a trough level 2   (3.6%) 
Measure trough level only 10 (17.9%) 
Measure a single level at a specified time 1   (1.8%) 
I'm not sure 25 (44.6%) 
They’re not measured! 19 (33.9%) 
a Treatment for neuroblastoma, hepatoblastoma, osteosarcoma, medulloblastoma, GIT 
tumours & solid tumours 
b Treatment for neuroblastoma, hepatoblastoma, high-risk Wilm's tumour & brain tumours 
 
Table 6-8: Oncology respondents’ estimation of their patients’ exposure and monitoring to ototoxic chemo 
and radiotherapy. 
 CF units (N=32)
a
,  
n (%) of respondents 
Which iv AG is used as 1st line treatment of pulmonary exacerbations 
Tobramycin 32 (97.0%) 
Amikacin 2   (6.1%) 
Frequency of administration? 
Once daily 21 (65.6%) 
Twice daily 10 (31.3%) 
Three times daily 1   (3.1%) 
How are therapeutic drug levels monitored? 
Measure a peak and a trough level 12 (37.5%) 
Measure trough level only 19 (59.4%) 
Other 1   (3.1%)
b
 
a One respondent consistently didn't answer these questions hence N=32 
b The respondent specified that a peak and trough measure is taken with dose 3 then a peak measurement is made 
on day 10.  
Table 6-9: CF clinician respondents’ estimation of their patients’ exposure and monitoring to ototoxic 
aminoglycosides.  
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6.2.1.3 Ototoxicity monitoring: 
All three surveys included a direct question asking if patients received monitoring of 
auditory function for ototoxicity. As shown in Figure 6-5, 63.9% of the audiology (n=85); 
69.6% of the oncology (n=39); and 69.7% of the CF clinicians (n=23) said that they did 
monitor hearing for signs of ototoxicity. The audiology and oncology surveys also asked 
whether they believe that ototoxicity monitoring is a priority. Interestingly, 68.4% (n=91) of 
the audiology respondents and 80.4% (n=45) of the oncology respondents confirmed that 
they do consider it to be a priority, which are more responses than those that actually 
perform monitoring. This indicates that even some of the respondents who are not involved 
in monitoring ototoxicity in their patients still acknowledge its importance. On the other 
hand, a significant minority of professional groups, 31.6% (n=42) of audiology and 19.6% 
(n=11) of oncology respondents felt that it was not a priority for their patients.  When asked 
whether other forms of monitoring for toxicities was carried out, 61.6% of the audiology 
respondents said that none were carried out and of the other 26% that chose the ‘Other 
monitoring’ option 18/26 (69%) stated that they either ‘didn’t know’ or were ‘not sure’ 
whether any other monitoring was performed or not (Figure 6-6). On the other hand, 83.9% 
of the oncology respondents confirmed that monitoring for nephrotoxicity was carried out 
and the 60.6% who chose the ‘other monitoring’ option mainly stated that monitoring for 
cardiac toxicities and other adverse effects on the CTCAE register were monitored. Both 
professionals indicated that limited monitoring for vestibulotoxicity was carried out (≤10% 
in both groups).     
When the services that do undertake monitoring were asked whether their patients were 
assessed within a dedicated ototoxicity monitoring clinic 81.2% of audiology (n=69) and 
64.1% of the oncology (n=25) respondents confirmed that testing was not performed in a 
dedicated ototoxicity clinic, which would create difficulties in tracking patients’ monitoring 
within appropriate timelines, performing more specialized testing such as high frequency 
audiometry or even being able to properly audit this service in order to make 
recommendations for improvements. When asked where the auditory assessments are 
undertaken, all three professional groups confirmed that they were overwhelmingly 
conducted at their local audiology departments [97.7% audiology (n=83); 94.9% oncology 
(n=37); and 82.0% CF respondents (n=18)]. Only 17.7% of the audiology (n=15) and 2.6% 
of the oncology respondents (n=1) reported that testing could be conducted at the patients’ 
bedside on the hospital ward and even less are undertaken in a community setting. The CF 
clinicians didn’t report this similar small proportion and stated that the remaining 14% and 
5% of the testing was performed in the local ENT departments or specialist Audiovestibular 
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clinics respectively. This indicates limited access of the commonly unwell cancer or CF 
patients who are not able to come to outpatients’ audiology clinics.   
 
 
Only 4 respondents from the CF survey did not answer this question, all the rest gave an answer (Yes/No). 
Figure 6-5: Distribution of responses of the three professions confirming whether they do or do not 
monitor their patients’ hearing for signs of ototoxicity.   
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Figure 6-6: Percentage of respondents confirming if other forms of monitoring for toxicities is carried out. 
Criteria for referral for monitoring: 
An important set of questions was related to assessing the criteria for referral of patients for 
auditory monitoring. Figure 6-7 and Figure 6-8 show the distribution of responses. The CF 
responses were presented separately as different response choices were offered in their 
survey compared to the audiology and oncology respondents. ‘Patients receiving repeated 
doses of ototoxic medication’ was the most frequently selected referral criteria by both 
audiology (55.3%) and oncology (66.7%) respondents; whereas the CF service respondents 
indicated that patients complaining of hearing loss, tinnitus or dizziness were the most 
frequently selected criteria for referral (90.9%, 72.7% and 68.2% respectively). Only 
referring patients when they start complaining of a hearing or a balance problem was also a 
common referral criterion for the audiology and oncology respondents (32.9% and 25.6% 
respectively). A very limited number of any of the three professions indicated that all their 
patients are monitored. CF service respondents (31.8%) also indicated that patients with poor 
renal function or those with positive family history or known genetic susceptibility to 
ototoxicity were referred.  
A follow up question was given in the audiology and oncology surveys asking them ‘if 
formal referral criteria didn’t exist, what in their clinical judgment would be the criteria for 
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referral for monitoring?’ Figure 6-9 summarizes the comments of the audiology (n=38) and 
oncology (n=9) respondents who commented on this question.  Interestingly the highest 
percentage (36%) confirmed that a baseline testing at diagnosis then repeated testing after 
every 2-3 cycles/courses, whereas some stated that only children should be referred and 
several audiologists confirmed that they didn’t know what criteria the oncologists used. 
Respondents were asked to tic 'all options that applied' therefore percentages are not intended to equal 100%. 
Figure 6-7: Response of Audiology (n=85) and Oncology (n=39) respondents to: “What are the criteria 
used for referring patients for auditory monitoring”. 
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C/O, Complaining of; iv AGs, Intravenous aminoglycosides. Respondents were asked to tic 'all options that 
applied' therefore percentages are not intended to equal 100%. 
Figure 6-8: Response of CF respondents (n=23) to: “What are the criteria used for referring patients for 
auditory monitoring?” 
 
Figure 6-9: Professional opinions from audiologists and oncologists in regards to when patients should be 
referred for monitoring in the case of absence of referral criteria. 
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Auditory monitoring for ototoxicity: 
Table 6-10 shows results of several questions covered in this section. On assessing whether 
there is a protocol defining which tests to use for ototoxicity monitoring, 52.9% of the 
audiology (n=45) and 25.6% of the oncology (n=10) respondents stated that there is no 
protocol and that tests are determined on a patient-by-patient basis, with another 17.7% and 
12.8% of each of the two professionals respectively stating that they don’t know. 
Surprisingly 61.5% of the oncology (n=24) respondents believed that there is a protocol 
compared to 29.4% of the audiologists (n=25).  
A significant 70.6% of the audiology respondents stated that they didn’t know whether 
patients received counseling prior to receiving ototoxic treatment or not and indicated a lack 
of awareness or involvement in this aspect of ototoxicity monitoring. Another 24.7% of the 
audiology respondents stated that patients did receive counseling but many of them 
confirmed that the oncologists/managing physicians provided this. Only 3 audiologists said 
that they provided information in relation to the side effects of ototoxic medications and how 
this should be managed, with another few indicating that patients were provided with leaflets 
or written information by the oncologists. On the other hand, 79.5% of the oncology 
respondents confirmed that counseling is provided but the comments (n=28) provided 
suggested this is often in the form of just informing patients that ototoxicity is a potential 
side effect. Several comments included ‘side effects are mentioned at the time of consent’; 
‘routine part of consent for chemotherapy’; ‘patients are warned of it only’; while some gave 
a bit more detail such as ‘We tell all patients that the treatment will cause transient tinnitus 
and some degree of hearing loss’ or ‘told may reduce hearing and will be repeatedly tested’.  
In regards to confirmation if baseline testing is conducted prior to the start of ototoxic 
medications, 50.6% of the audiologists (n=43) and 76.9% % of the oncologists (n=30) stated 
that it was performed however the remaining proportions of both groups confirmed that it 
was either only done some of the time or not at all.   
Again, there was a large variation in opinions as to how frequently the monitoring was 
performed. Some said within the course of treatment, others said when patients report 
symptoms such as hearing loss or tinnitus but the highest percentage of audiologists (40%) 
chose the ‘Other’ option where they gave comments like ‘As and when requested by the 
referring clinician’ or ‘at the referring consultant’s discretion’ or ‘don’t know’. These 
comments indicated the possible lack of knowledge and the seemingly ad hoc basis by which 
clinicians refer patients from the audiologists’ perspective.  The same applied when the 
question as to how long ototoxicity monitoring continues following cessation of treatment 
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was posed. A large variation between audiologists’ responses ranged between ‘it doesn’t 
continue after cessation of treatment’ to ‘up to 6-12 months later’. However the ‘Other’ 
option was again chosen by the highest proportion (40%) that specified that they were either 
‘not sure’; ‘variable with no consistency’ or ‘as requested by the oncologist’.  
The same question regarding how often the monitoring was performed was also posed in the 
oncology and CF surveys. Contrary to the audiologists’ responses the majority of oncology 
(69.2%) said that monitoring was performed within or after each course of treatment. This 
included nine respondents (23.1%) stating that they would only be tested when they start 
complaining of hearing loss or tinnitus and another nine (23.1%) choosing the ‘other’ option 
and specifying that monitoring is performed as per guidelines/protocol and others specifying 
a frequency of every two cisplatin-containing regimens.  The highest proportion of CF 
clinicians (52.4%) stated that auditory assessment was only performed when patients start 
complaining of hearing loss, another 28.6% said monitoring was done after every 10-12 
courses and another 19.1% specified that it was done annually. A smaller proportion of 
oncology respondents (15.4%) compared to the audiologists reported that monitoring does 
not continue after cessation of treatment. Most of them reported that monitoring does 
continue but responses varied in regards to the duration, ranging between 3-6 months, 12 
months, 5 years or even 10 years post-treatment. A significant proportion of respondents that 
provided comments (n=17) confirmed that surveillance continues mainly when hearing loss/ 
tinnitus was present during treatment with only one respondent saying ‘not sure’. 
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Audiology (N=85),  
n (%) 
Oncology (N=39),  
n (%) 
Is there a protocol defining which audiological tests to use? 
 
Yes 25 (29.4%) 24 (61.5%) 
No-Testing required is on a patient-by-patient basis 45 (52.9%) 10 (25.6%) 
I don't know 15 (17.7%) 5 (12.8%) 
Do patients receive counseling prior to receiving potentially ototoxic medications? 
 
I don't know 60 (70.6%) 5   (12.8%) 
No 4   (4.7%) 3   (7.7%) 
Yes 21 (24.7%) 31 (79.5%) 
Is baseline testing performed before/at start of medication? 
 
Yes 43 (50.6%) 30 (76.9%) 
No 5   (5.9%) 4   (10.3%) 
Sometimes 37 (43.5%) 5   (12.8%) 
How often is auditory monitoring done?  
 
Within a course of treatment  26 (30.6%) 24 (61.5%) 
After each course of treatment 29 (22.4%) 3   (7.7%) 
After two or more courses of treatment 3   (3.5%) 4   (10.3%) 
When patient reports symptoms 23 (27.1%) 9   (23.1%) 
Other 34 (40.0%) 9   (23.1%) 
How long does monitoring continue after cessation of treatment? 
 
It doesn't continue 29 (34.1%) 6   (15.4%) 
Up to 3-6 months following cessation 10 (11.8%) 3   (7.7%) 
Up to 6-12 months following cessation 12 (14.1%) 13 (33.3%) 
Other 34 (40.0%) 17 (43.6%) 
Table 6-10: Responses from audiology and oncology respondents that do perform auditory monitoring 
regarding the monitoring set-up.   
The CF survey did not include these questions. 
There was a general agreement between all three professionals that standard pure-tone 
audiometry (0.25-8 kHz) was the most commonly used audiological test used for ototoxicity 
monitoring (Table 6-11) followed by tympanometry to exclude middle ear disease.  All 
professionals confirmed that when certain tests were performed at baseline testing they were 
repeated at the follow-up monitoring. However it is worth noting that the percentage of 
responses made by the oncology respondents for each of the audiological test procedures is 
very small, which may be an indication of their limited knowledge of these tests and 
identification of which ones are used (Table 6-11). Unfortunately, extended high frequency 
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audiometry (EHFA) and DPOAEs, which were shown to be more effective at early detection 
of ototoxicity, were not as commonly used as hoped (EHFA: in 17.7%, 12.8% and 22.7%; 
DPOAEs: in 23.5%, 2.6% and 13.6% of each of the three professions). A follow up question 
asking respondents to specify the highest frequency tested confirmed that frequencies up to 
and including 8kHz were the commonest as reported by 27/43 audiology respondents and 
4/9 oncology respondents. Two audiologists stated that they did have the facilities for EHFA 
but was deemed unnecessary, as changes in these higher frequencies would not prompt 
changes in management. A total of 15/43 and only 1/9-audiology and oncology respondents 
respectively said that they test higher frequencies ranging up to 10 to 20 kHz (1/6
th
 octave 
intervals). Four respondents indicated that they didn’t know the extent of frequencies tested.  
 
Audiology (N=85), 
n (%) 
 
Oncology (n=39), 
n (%) 
CF clinicians (N=22), 
n (%) 
PTA, including VRA/play audiometry 
(250Hz-8kHz) 
64 (75.3%) 14 (35.9%) 19 (86.4%) 
EHFA; including VRA/play audiometry 
(above 8kHz) 
15 (17.7%) 5   (12.8%) 5   (22.7%) 
TEOAEs 21 (24.7%) 1   (2.6%) 3   (13.6%) 
DPOAEs 20 (23.5%) 1   (2.6%) 3   (13.6%) 
Tympanometry  46 (54.1%) 11 (28.2%) 1   (4.5%) 
ART 8   (9.4%) 3   (7.7%) N/A 
ABR; neurological 1   (1.2%) 1   (2.6%) N/A 
ABR; threshold 8   (9.4%) 1   (2.6%) N/A 
Speech audiometry  5   (5.9%) 5   (12.8%) N/A 
VRA, Visual Reinforcement Audiometry; ABR, Auditory Brainstem Response; ART, Acoustic reflex thresholds; 
N/A, not applicable as this choice wasn’t offered on the CF survey. Respondents were asked to tic 'all options 
that applied' therefore percentages are not intended to equal 100%. 
Table 6-11: Distribution of responses to “What audiological testing is conducted for ototoxicity 
monitoring?” 
Patient management:  
The final section of the surveys aimed to assess how evidence of ototoxicity, shown through 
auditory monitoring, affects the medical management of patients. When asked if there is a 
protocol used to identify when changes in auditory status become clinically significant, 
43.5% of the oncology (n=17) respondents confirmed that a published protocol was used but 
just under half of them (48.7%) where either not sure or said there was no protocol and that 
clinical judgment was used. Contrary to that, the highest proportion 83.4% of the audiology 
(n=71) respondents were either not sure or used clinical judgment, with a much smaller 
percentage (21.1%) confirming there is a departmental or published protocol used (Figure 
6-10). The follow up question asked respondents to specify what audiological results may 
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lead to change in medical management. A summary of the comments added by the audiology 
and oncology respondents is shown in Figure 6-11. Many audiologists stated that the 
decision to change management was not up to them especially because they are non-medical. 
Many comments included comments such as: ‘not for me to say. I'm not a clinician’; ‘Not 
known. Decisions not made by technician’ and ‘decision of oncologist not audiologist’. 
More audiologists quoted specific threshold shifts, as seen in Figure 6-11, than the oncology 
respondents. Mainly audiologists mentioned ASHA criteria whereas oncologists mainly 
mentioned Brock’s criteria. Several audiologists wrote detailed comments such as: ‘Any 
significant change (considered as 20dB alteration at single frequency, or 10dB at contiguous 
frequencies) should be reported by Audiology to Oncologists as potentially important. 
Clearly whether action is taken will depend upon treatment aims (palliative/curative). 
Regarding adults: Audiological results should be discussed with patient before making 
recommendations’.  
 
Figure 6-10: Distribution of responses to the question: “Is there a protocol used to identify when changes 
in auditory status become clinically significant?” 
Figure 6-12 shows the responses of the oncologists as to what changes would be made. A 
majority of 79.9% (n=31) confirmed that they would change the ototoxic treatment.  All the 
CF clinicians (100%, n=22) confirmed that results of auditory monitoring confirming 
occurrence of ototoxicity changes their antibiotic management. Figure 6-13 shows what 
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actions they would take. The highest proportion stated that they would stop or avoid using 
aminoglycosides when ototoxicity occurs, with others specifying that they would reduce 
dosage or number of courses by using alternative antibiotics such as colistin or folomycin. 
Others said they would avoid intravenous AGs but replace them with nebulized AGs such as 
TOBI. They were also asked if they undertake genetic screening of all their patients for the 
mitochondrial DNA mutation A1555G in the 12S rRNA gene, which is known to increase 
susceptibility to aminoglycoside ototoxicity. Only 19.2% CF clinicians (n=5) said they did 
screen their patients whereas the majority 80.8% (n=21) confirmed that they didn’t.  
 
Figure 6-11: Distribution of respondents’ comments to the question: “What changes in audiological results 
should prompt consideration or an actual change in medical management?” 
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Figure 6-12: Distribution of oncology respondents’ response to question: ‘What changes would be made if 
auditory monitoring shows evidence of ototoxicity?’ 
 
Figure 6-13: Distribution of CF clinicians’ comments to the question: “What changes do you implement to 
your medical management if auditory monitoring shows evidence of ototoxicity?” 
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6.2.2 Discussion of survey study of current UK service 
provision: 
The 1994 ASHA guidelines for audiological management of individuals receiving 
cochleotoxic drug therapy emphasized that a basic program of audiological monitoring for 
ototoxicity requires the following components: “(a) specific criteria for identification of 
toxicity, (b) timely identification of at-risk patients, (c) pre-treatment counseling regarding 
potential cochleotoxic effects, (d) valid baseline measures (pre-treatment or early in 
treatment), (e) monitoring evaluations at sufficient intervals to document progression of 
hearing loss or fluctuation in sensitivity, and (f) follow-up evaluations to determine post-
treatment effects” (ASHA, 1994a). Similar UK guidelines do not yet exist. On the contrary, 
to emphasise the relatively limited interest in ototoxicity monitoring in clinical practice the 
only two recommendations made within a 102-page document by the UK CF trust on 
‘Antibiotic treatment in cystic fibrosis’ were “(a) consideration should be given to an 
annual pure tone audiogram in patients receiving frequent courses of an aminoglycoside and 
(b) that the use of an aminoglycoside should be restricted to alternate courses of intravenous 
antibiotics, where the patient’s clinical condition permits in order to reduce cochlear and 
vestibular toxicity” (UK CF Trust, 2009).  
The current study underwent a survey of oncology, CF and audiology services in the UK in 
order to assess how often ototoxicity monitoring is performed and how effectively the 
ASHA components above are implemented.  Review of the literature had shown that no 
previous surveys of oncology and audiology services had been published with the exception 
of one pilot study of two centres in South Africa (de Andrade, 2009). However, there were 
two previous UK surveys of CF centres (Tan et al., 2002, Smyth and Campbell, 2013, Smyth 
and Campbell, 2014) and another four from the USA and Australia (Phillips and Bell, 2001, 
Soulsby et al., 2009, Van Meter et al., 2009, Prescott, 2011, Prescott, 2014) that briefly 
assessed ototoxicity monitoring as part of overall surveys investigating current practice in 
aminoglycoside usage and monitoring in CF patients in each of these countries.   
There was a relatively good response from 133 Audiology, 56 Oncology and 33 CF 
respondents representing all regions of the UK (Figure 6-4) and representing both paediatric 
and adults services (Table 6-7). Both oncology and CF respondents acknowledged that their 
patients receive potentially ototoxic treatments such as cisplatin, carboplatin and head & 
neck radiotherapy in the case of oncology patients and aminoglycoside antibiotics, mainly 
extended interval dosing of tobramycin, in the case of CF patients (Table 6-8 and Table 6-9). 
A once daily tobramycin regimen was also confirmed as the first line treatment in most of 
the UK CF centres by the survey study on prescribing practice of i.v. AGs in UK CF centres. 
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This survey also showed that many centres have stopped gentamicin prescription (Smyth and 
Campbell, 2014). Tobramycin was also confirmed as the most commonly used regimen in 
adult US CF programs where it is also dosed at 10 mg/kg/d every 24 hours using an infusion 
over 30-60 mins (Prescott, 2014). 
The most encouraging piece of information obtained from all three surveys was the positive 
responses from 63.9% of the audiology, 69.6% of the oncology and 69.7% of the CF 
respondents confirming that their patients do receive auditory monitoring for ototoxicity 
(Figure 6-5). This was a significant improvement over the responses from the Tan et al. 
survey which showed that only 3/23 (13%) of the responding UK CF centres routinely 
assessed hearing function using only standard pure-tone audiometry. Van Meter et al. 
reported that 22/51 (43%) of the US CF Foundation-accredited care centres and affiliated 
programs (CFFACCs) administering once-daily tobramycin therapy routinely performed 
audiometric evaluations and Prescott (2014) confirmed that around one-half of the 68 US CF 
adult centres responding to his survey used audiometry to monitor ototoxicity even though 
all of them monitored for nephrotoxicity using serum creatinine measurements. Similarily, 
Phillips and Bell reported in their 1999 survey that only 4/26 (15%) of the Australian CF 
centres monitored their patients for ototoxicity/vestibulotoxicity which was reported to have 
improved to 17/27 (63%) eight years later in the repeated survey by Soulsby et al. (Phillips 
and Bell, 2001, Soulsby et al., 2009, Tan et al., 2002, Van Meter et al., 2009, Prescott, 2014). 
In the current study, monitoring for other toxicities, especially nephrotoxicity, was common 
as it was reported by 83.9% of the oncology respondents. This was in line with previous 
studies that reported that renal function was measured in 18/23 (78%) of UK CF centers 
(Tan et al., 2002), in 51/51 (100%) of US CFFACCs (Van Meter et al., 2009), and in 26/27 
(96%) of the Australian CF centers (Soulsby et al., 2009).   
Conversely, all three professional groups reported variability in practice in relation to all 
aspects of this monitoring service, which highlighted the main problem facing its adequate 
provision in light of absence of agreed UK guidelines. In relation to the ‘timely identification 
and referral of at-risk patients’; patients receiving repeated doses of ototoxic medication and 
patients complaining of hearing or balance problems were the two most common criteria 
used for referring patients for auditory monitoring (Figure 6-7 and Figure 6-8). The 
distribution of answers shown in Figure 6-9, of oncology and audiology respondents as to 
what should be the referral criteria in their professional opinion highlights the wide 
variability in these opinions with a few stating that only paediatric patients should be 
referred, some audiologists confirming that they didn’t know how oncologists decide, and 
only 27% stating that all patients exposed to ototoxic chemo/radiotherapy should be referred. 
  221 
One of the main purposes of auditory monitoring for ototoxicity is early detection of minor 
changes to cochlear function in order to inform the managing clinicians to implement 
changes in the drug regimens, if possible, aiming to prevent further hearing damage (Durrant 
et al., 2009). Referring patients after exposure to repeated courses or after cochlear damage 
has extended from the higher frequencies to the lower frequencies associated with speech 
understanding and communication, defies the main aim of monitoring. In this case, 
monitoring becomes a tool for management of side effects of the treatment and not for early 
prevention of hearing damage.  
Only around half of the audiologists confirmed that baseline testing is conducted before the 
start of medication with the remaining proportion stating that baseline recording is either 
done some of the time or not at all (Table 6-10). It is imperative to keep in mind that ototoxic 
medications are not administered in isolation from other damaging effects to the ear. 
Exposure to noise, infections, and trauma, ageing or even to other ototoxic drugs or 
environmental chemicals causes synergistic damage to the inner ear (Laurell and Borg, 1986, 
Fechter et al., 2007, Rybak, 1992). Therefore baseline recording in addition to good history 
taking to identify these risk factors is essential not just to confirm that evidence of hearing 
loss from post-treatment assessments are attributed to the ototoxic drug exposure but to help 
in further protection of the patients’ hearing by identifying how often monitoring should 
occur or even whether use of this ototoxic drug should be avoided from the start. This also 
brings us to the important topic of pre-treatment counseling. Even though it was expected, it 
was disturbing to record that 75.3% of the audiology respondents either didn’t know or 
didn’t believe that patients received counseling prior to receipt of potentially ototoxic 
medications. This is an indication that audiology professionals are not involved in this 
process even though their specialist training and knowledge best places them to be able to 
have a very active role in that aspect. This can be through taking the relevant history; 
providing patients/their parents with the correct information regarding the prevalence, 
warning signs, symptoms of ototoxicity from the specific drugs they will be exposed to; and 
advising them on what to do if unavoidable permanent hearing loss does occur to maintain 
the most effective hearing and communication possible through rehabilitation (hearing aids/ 
assistive listening devices/cochlear implants) and good communication tactics. This lack of 
involvement in patient counseling or lack of ownership of the whole ototoxicity monitoring 
process by the audiology respondents may possibly be attributed to the fact that most of the 
audiology professionals in the UK are not medically qualified (90.3% of the respondents 
identified themselves as audiological professionals i.e. audiologists or audiological scientists 
with only 8.3% AVM or ENT doctors). As they mainly work in consultant-led services, they 
probably do not believe that patient management is part of their role. This was evident from 
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some of the comments made such as ‘not for me to say. I'm not a clinician’ or ‘Not known. 
Decisions not made by technicians’. This, in addition to other discrepancies between 
audiologists’ and clinicians’ responses, displays a unilateral relationship between them 
where the audiologists receive the referrals, they perform the tests as requested and they send 
the results back with no sense of partnership or ownership of the process.   The American 
Academy of Audiology has published a position statement and clinical guideline on 
ototoxicity monitoring in 2009 to specifically focus attention on the fact that audiologists are 
best placed to take the lead in developing ototoxicity monitoring programs as their 
professional training equips them to achieve their two main objectives of preventing or 
minimizing hearing loss, through early identification, and helping patients maintain the most 
effective hearing and communication possible should hearing loss occur (Durrant et al., 
2009).  The majority of oncologists (79.5%) confirmed that they provide counseling to their 
patients but many of their comments showed this was limited to mentioning hearing 
loss/tinnitus as possible side effects as part of the consent process. Again this highlights that 
audiologists can offer so much more to this part of the program.  
There were mixed levels of agreement between audiologists and oncology or CF clinicians 
regarding the frequency and timing of audiological monitoring before, during and post-
treatment; whether there was a protocol to specify which audiological tests to perform or 
whether it was determined on a patient-by-patient basis, or what criteria for ototoxicity are 
used to advocate change in management (Table 6-10 & Figure 6-10).  The lack of generally 
agreed protocols and guidelines again increases the uncertainty of all the professionals 
involved and weakens their ability to make best use of the outcomes of monitoring. It also 
highlights that patients may be at risk of receiving inappropriate and variable monitoring 
depending mainly on their local clinicians’ awareness of the significance of ototoxicity and 
its impact of their quality of life and on their relationship with the local audiology service.    
A significant proportion of the audiology and CF respondents confirmed that standard PTA 
was the most commonly used audiological test used in monitoring followed by 
tympanometry. Most of the respondents indicated that there is no set protocol of audiological 
tests for ototoxicity monitoring and that testing is not differentiated from a routing test 
battery of basic audiological assessments. This misses opportunities for early detection and 
prevention of hearing loss.  
Additionally, the very limited percentage of responses made by the oncology respondents to 
any of the audiological test procedures (the highest percentage being 35.9% for standard 
PTA with much lower responses for the other options) (Table 6-11) may be an indication of 
lack of knowledge of which audiological tests are actually performed for their patients. This 
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is a very significant outcome as it is common practice that audiologists normally perform 
assessments and then just adds the test results (e.g. a copy of the audiogram, tympanograms, 
DP-gram or speech test) to the patients’ clinical notes with no reporting/explanation of these 
results or recommendations for action. If oncologists don’t know what audiological tests are 
performed how are they interpreting the output of these tests in the clinical notes and how 
are they changing their management accordingly? It is also clear from the audiologists’ 
comments to several questions that they do not normally have direct communication with the 
clinicians. As these were the responses of the 39 oncology respondents that confirmed that 
ototoxicity monitoring is performed in their service and as this is a very small percentage of 
overall oncology workforce, which is reported in the Royal College of Radiologists’ (RCR) 
2011 census to be 1,118 clinicians (Radiologists, 2011), the question that may be posed 
could be:  Is that a real indication of very limited interest in this area of patient management?  
The use of EHFA and DPOAEs were sparsely reported. These tests have been repeatedly 
shown to detect ototoxic cochlear damage earlier than standard audiometry (Al-Malky et al., 
2011, Beahan et al., 2012, Fausti et al., 1992a, Fausti et al., 1993, Fausti et al., 2003, Knight 
et al., 2007, Stavroulaki et al., 2002). These procedures were also shown to be less effected 
by low frequency environmental noise and therefore more efficacious for bedside testing in 
quiet hospital rooms/ community settings especially when using portable equipment, which 
is now widely commercially available (Gordon et al., 2005, Gorga et al., 2000b, Konrad-
Martin, 2005a). Therefore these tests can be very effective in monitoring and early detection 
of auditory changes in ill patients who cannot be repeatedly transported to audiology 
departments especially if they were based in different hospitals or are too far from patients’ 
homes. Responses from the three surveys indicated that most patients are tested in the local 
audiology departments with only 17.7% of audiology, 2.6% of oncology and none of the CF 
respondents reporting that bedside testing is performed. DPOAEs have the added advantage 
of being a very quick objective test and therefore do not require patient cooperation. This 
allows testing for quite unwell children and adults. As shown by the DPOAE repeatability 
study (section 4.2) deterioration in DPOAE amplitudes of  > 7.5 dB SPL, which was also 
reported by Beattie et al., indicates the criteria that should be used to identify evidence of 
cochlear damage when using this test as an ototoxicity monitoring tool (Beattie et al., 2003). 
EHFA may not be recordable in all patients such as elderly patients, where presbyacusis 
characteristically affects higher frequencies more (Wiley et al., 1998), and such as young 
children (<7 years old) due to lower test-retest reliability (Beahan et al., 2012). Therefore, 
from the outcomes of this survey and through review of the related literature, I am 
recommending the use of a screening protocol consisting of a test battery of EHF audiometry 
sensitive range of ototoxicity (SRO) measurements and DPOAEs as an accessible, sensitive 
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and cost-effective monitor or sensitive early detection of ototoxicity especially in unwell 
patients.  
The respondents also showed variability in the reported results criteria for ototoxicity with 
the oncologists specifying that they follow published criteria quoting Grade 2 Brock’s 
criteria and the audiologists quoting the ASHA criteria (Figure 6-10 and Figure 6-11). Both 
oncology and CF respondents indicated that they would change their management if 
evidence of ototoxicity were recorded (Figure 6-12 and Figure 6-13). It is important for all 
parties involved to use the same ototoxicity grading criteria in order to maintain consistent 
adherence to guideline and management of patients. Brock’s Grade 2 hearing loss is 
equivalent to a >40dB hearing loss at 4 and 8kHz which is already a significant hearing loss 
especially in children. It is known that even mild to moderate hearing losses in children will 
affect their educational progress and speech and language development (Grewal et al., 2010, 
Park et al., 2013). The recommended modification to the Brock’s scale such as those made 
by Chang and Chinosornvatana or the International Society of Pediatric Oncology Boston 
(SIOP) Boston Ototoxicity Criteria are more appropriate criteria to use for early detection of 
ototoxicity because they take into account mild (>20 dB) levels of hearing loss (Brock et al., 
2012a, Chang and Chinosornvatana, 2010). A clearly agreed grading system and grade at 
which change in management is considered has to be defined by both the audiologists and 
managing clinicians.   
6.2.2.1 Limitations of the study: 
The main limitation of this study was the method through which professionals were 
approached. Lead clinicians of each of the 48 CF centers identified through the ‘CF Trust 
registry reports’ allowed for the calculation of a center response rate of 33/48 (69%), which 
was excellent at confirming an adequate representation of UK services, but it limited 
responses to only the lead clinician of each center. Previous literature and clinical experience 
confirms that other team members such as specialist oncology/CF nurses and pharmacists 
undertake key roles in recording drug regimens, identifying planned treatments and 
arranging baseline and monitoring assessments (Durrant et al., 2009). The audiology and 
oncology professionals were contacted through mailing lists of relevant professional bodies 
such the BAA, the Children’s Cancer and Leukaemia group or the UK Oncology Nursing 
Society and through personal communications. This guaranteed that wide ranges of 
professionals in the two fields (consultants, registrars, nurses, pharmacists and 
audiologists/scientists) were approached. Even though this allowed for recruitment of a 
wider range of healthcare professionals, it did not allow for a calculation of a response rate 
or for identification of how well each profession is represented to confirm whether the 
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results are an accurate representation of current UK practice or not.  The audiology response 
of 133 was relatively high but it was not possible to assess why only 56 oncology 
professionals responded even though the survey could have been potentially sent to hundreds 
of people. It was not possible to estimate exactly how many professionals received the email, 
how many deleted the message without even considering to read it, how many wanted to 
complete the survey but were too busy or didn’t because they don’t perform monitoring or 
whether this was a true reflection of the significant lack of interest of oncology professionals 
in ototoxicity monitoring.  It was only after the survey was complete that a document of a 
2011 UK clinical oncology workforce census conducted by the Royal College of 
Radiologists (RCR) was discovered. It reported that the overall workforce included 1,118 
clinicians (consultants, specialist registrars and other grades) within 59 UK centers 
(Radiologists, 2011). A repeat of the survey targeting each center may allow for calculation 
of a response rate and estimation of how well UK services are represented. Davis et al. 
estimated that there is an excess of 3000 professionals working in the audiology services 
(Davis et al., 2007) however there is no official workforce census to date.   A BAA 
Audiology 2013 census is the first census to be undertaken to assess the audiology workforce 
in the UK. An online questionnaire was sent to audiology professionals through the BAA 
mailing list over the month of October 2013. However, the outcomes of this census have not 
been published to-date. 
The other limitation of the study was the inability to match the audiology services to the 
corresponding oncology and CF services, in order to directly compare responses of both ends 
of each service, because the anonymity of the respondents was maintained. It was also not 
possible to confirm whether more than one respondent from the same hospital had completed 
the questionnaire. However, the data presented in Figure 6-4 confirms that the three 
professional groups represented most of the UK regions.  
6.2.3 Conclusions: 
Hearing loss due to ototoxic medications is potentially preventable but only if all healthcare 
professionals involved in managing exposed patients play an active role in preventing it 
through a robust audiological monitoring service. This study aimed to survey healthcare 
professionals to assess the current UK provision of ototoxicity monitoring services. Due to 
the lack of clear UK-wide guidelines for the audiological monitoring of ototoxicity, there 
were significant variations in all aspects of the monitoring services provided and in the 
perceptions of the audiology professionals compared to the oncology and CF clinicians. The 
high response confirming that monitoring is performed was encouraging but there was a 
wide variation in the criteria for referral; the audiological tests used and the frequency of 
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monitoring; the grading criteria to confirm ototoxicity; and the options for change in 
management once evidence of ototoxicity is provided. The two main aims of ototoxicity 
monitoring services is early identification of initial signs of ototoxicity and then adequate 
management by informing the managing clinicians to modify treatment to prevent further 
damage or by maintaining communication abilities through audiological rehabilitation in 
case permanent damage could not be avoided. As recommended in the AAA position 
statement for ototoxicity monitoring (Durrant et al., 2009), audiologists are best placed to 
take the lead in initiating and implementing adequate ototoxicity monitoring services but this 
will only be possible through establishing strong working links with the clinicians involved 
and through establishing a UK-wide program where clear roles, responsibilities and patient 
care pathways are defined.     
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 Summary and General Discussion Chapter 7:
7.1 Recap of research aims: 
This research had the overall aim of furthering the understanding of different aspects of 
ototoxicity in children to enable recommendations for development of better but realistic 
guidelines for monitoring and management of ototoxicity and for making recommendations 
for future research in this field.  
The research undertaken was presented within three main themes.  
Theme A focused on audiological assessment for detection of ototoxicity. It aimed to assess 
the prevalence of ototoxicity in children with CF exposed to AGs and to evaluating the 
performance of the different audiological tools in order to define the best test battery that can 
detect early signs of ototoxicity. A further control study was done to gauge the impact of 
certain factors on DPOAE testing and which were considered to have an affect on its ability 
to be used as an effective auditory monitoring tool. It analyzed the effect of probe removal 
and re-insertion on the repeatability of recordings in ears of school-aged children.  
Theme B focused on causation. Results of the audiological assessments of AG exposed 
children with CF showed a dichotomy in the hearing test results of these children with some 
showing completely normal hearing and others showing evidence of ototoxicity. This 
dichotomy could partially but not completely be explained by the cumulative exposure to 
repeated courses of AGs. Within this theme potential risk factors within the children’s 
history were examined for significant associations with the occurrence of ototoxicity. In 
addition, genetic investigations were performed to assess if certain genetic mutations were 
associated with increased susceptibility to ototoxicity in some of the children within this 
patient cohort and therefore offer a possible explanation for the observed dichotomy. Even 
though the sample size investigated was not large enough to provide significant outcomes 
with enough power, it provided a good pilot study to raise specific research questions. For 
example, if this association was established should consideration be made as to whether or 
not it would be useful to advocate screening to identify these mutations before patients are 
exposed to AGs? Should more investigations into other genetic candidate or modifying 
genes be pursued? Is there a need for more investigation into the penetrance of A1555G 
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mutations when patients are exposed to AGs? Do drug-metabolizing genes have a role in 
increasing susceptibility to AG ototoxicity?  
Theme C focused on the clinical impact of ototoxic hearing loss on patients. It aimed at 
assessing the impact of hearing loss on the quality of life of paediatric cancer survivors 
compared to their corresponding normal hearing peers. Significant outcomes would highlight 
the importance of early detection, management and ultimately prevention of ototoxicity in 
these children. The second aim within this theme was to assess the current service provision 
for auditory monitoring for ototoxicity in the UK from the perspective of both the audiology 
professionals and the oncology and CF clinicians. The overall aim here was to assess how 
much of the published recommendations and guidelines are actually applied clinically and 
whether the absence of agreed national UK guidelines has an impact on these services.       
7.2 Summary of findings 
Studies within Theme A discussed several aspects of auditory assessment of ototoxicity. 
The auditory function was examined in the children with CF who were one of the population 
groups of interest in this research. The fact that the results showed that 21.4% of the tested 
subjects had evidence of ototoxicity, is a very significant finding as this equates to a ratio of 
1:4/5 children with CF exposed to AGs. This is a much higher prevalence than previously 
reported in the literature for paediatric CF patients and is closer to the reported prevalence 
for adults (Mulheran et al., 2001, Mulherin et al., 1991, Mulrennan et al., 2009, O'Donnell et 
al., 2010, Prayle et al., 2010, Smyth and Bhatt, 2012, Tan and Bunn, 2000). This stresses the 
importance of monitoring for ototoxicity in this patient group, which was not the case at 
GOSH and was shown to be quite varied and inconsistent in services all over the UK, as 
shown from the results of the survey study in Theme C. It was also observed that a clear 
dichotomy existed in the hearing status of these children, where some had completely normal 
hearing while others had high frequency SNHL attributed to ototoxicity. The study also 
emphasized the benefits of using both EHF PTA and DPOAEs as a complementary test 
battery for ototoxicity monitoring as opposed to the commonly used standard PTA especially 
when testing children. EHF PTA was shown to identify the highest number of children with 
evidence of ototoxicity and therefore was considered as the gold standard for testing. The 
DPOAEs have the significant advantage of being objective, quick and non-invasive but in 
the current study did not show a drop in amplitudes in a number of children where EHF PTA 
thresholds had increased. This could be attributed to the fact that the DPOAE recordings 
made only covered frequencies up to 8 kHz and not the extended higher frequencies assessed 
through EHF PTA. However, two control studies were undertaken with normal hearing 
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individuals to assess other possible factors that may affect the accuracy of DPOAE 
recordings and its use as an effective auditory monitoring tool. 
These control study showed that DPOAE recording in the ears of school-aged children is 
robust and repeatable even when performed in a quiet non-sound proof room. It was shown 
that removal and re-insertion of the OAE probe does not significantly affect the repeatability 
of DPOAE recordings as long as it’s inserted carefully. It also showed that a minimal change 
of >11.1 and >7.5 dB SPL for the lower and higher frequencies respectively on repeated 
DPOAE recordings is required when monitoring for ototoxicity to establish a true shift in 
auditory function and which can not be attributed with 95% confidence to an error of 
measurement. These findings helped to confirm that DPOAE testing could be effectively 
used as an auditory monitoring tool for detection of ototoxicity especially when used for 
serial recordings. Here, the baseline pre-exposure DPOAE amplitude recordings would be 
used as the control measurement for each subject and a drop in amplitudes >11.1 and >7.5 
dB SPL for the lower and higher frequencies respectively at post-exposure recordings would 
be an indication of OHC damage within the inner ear. DPOAE have the advantage of being a 
quick, non-invasive and accurate object measure of inner ear function.  
Theme B studies that focused on causation of ototoxicity and assessed possible risk factors 
that can be used to explain the observed dichotomy in hearing outcomes of the children with 
CF. The first study showed that high exposure to ototoxic medications like AGs is the most 
significant, but not exclusive, risk factor for ototoxicity and highlighted the non-linear 
relationships between age, exposure, lung function and possible genetic predispositions to 
ototoxicity. It also stressed that waiting for children to start complaining of hearing problems 
is not an appropriate referral criteria for auditory monitoring and that a monitoring protocol 
should be put in place commencing with baseline recordings before the start of treatment. 
The second study within this theme assessed the role of some genetic variants / mutations in 
increasing susceptibility to ototoxicity in the CF children exposed to aminoglycosides. These 
findings will be discussed further in the general discussion below.  
Theme C studies focused on assessment of the clinical impact of hearing loss due to 
ototoxicity and on evaluating the current UK practice in auditory monitoring for ototoxicity. 
The first study showed that both the generic HUI3 HRQL and disease-specific PAQL 
(specific for assessing paediatric deafness) parent-proxy questionnaires proved that there was 
a significant deterioration in the HRQL and QoL of the cancer children with ototoxic hearing 
loss compared to those with normal hearing. Scores of the single attributes of ‘hearing’ and 
‘cognition’ and the overall multi-attribute utility score of HRQL of the HUI3 questionnaire 
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all showed a significant difference between the two groups in addition to all the PAQL 
subscales and the overall QoL scores. It highlighted the impact hearing loss has on children’s 
speech and language development, social and psychological well-being and educational 
progress, which again stresses on the need for a strong ototoxicity monitoring protocol for 
patients involved.  
The second survey study within this theme assessed the current status of auditory monitoring 
service provision in the UK. It highlighted the variability in many aspects of provision of this 
service within and between the three professional groups targeted in this survey. It showed 
that there was evidence of limited awareness and/or agreement of responsibilities of team 
members so that audiologists’ roles were underutilized for counseling and rehabilitation and 
clinicians had limited understanding of the criteria for ototoxicity and test battery used to 
diagnose it. There were no generally agreed criteria for when, how often and what 
audiological tools should be used to monitor for ototoxicity. There were no agreed criteria 
for what audiological outcomes should be used to advocate change in management and no 
provision to monitoring patients outside the outpatients’ audiology department even if the 
child was too unwell to reach it. Recommendations included the development of UK-wide 
clinical guidelines and professional education programmes, as advocated by the WHO 
(1994), to increase the profile and standardisation of ototoxicity monitoring in clinical 
practice.  
Overall, all the studies within the three themes confirmed findings of previous research 
studies that stressed that ototoxicity was a significant cause of hearing loss especially in the 
more vulnerable patient groups such as children with CF or cancer that have to be repeatedly 
exposed to ototoxic medications. Theme A studies confirmed that a test battery including 
EHF PTA and DPOAE testing, which is preceded by tympanometric assessment of middle 
ear function, would constitute an effective auditory monitoring battery especially when pre-
and-post exposure serial recordings could be regularly performed.  The importance of using 
agreed specific criteria for identification of ototoxicity and defining at what stage a change in 
medical management should be implemented was stressed. The newly developed SIOP 
Boston grading system was recommended as a good grading tool for the degree of 
ototoxicity as there is more international agreement to use it, the lower audiometric threshold 
shifts of >20dB are considered and it is simple and easy to follow by all professionals 
involved. It was also concluded that more work was still needed to implement all the 
recommendations of this current and previous research regarding the auditory monitoring 
and management of ototoxicity in these different patient groups.     
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7.3 General Discussion & Recommendations for 
future work and practical applications 
7.3.1 Significance of monitoring for ototoxicity in 
susceptible patient populations 
All three themes of this research have directly or indirectly stressed the importance of 
monitoring for ototoxicity especially in vulnerable patient groups such as children exposed 
to repeated and well-established permanently ototoxic agents as cisplatin and 
aminoglycosides. The survey study in Theme C established that services in the UK are still 
far from achieving this goal and the best way forward is for national guidelines to be agreed 
between all parties. 
Presentation of the results of the clinical observational study to the whole CF team at GOSH 
highlighting that 1 in 4 of their patients have evidence of ototoxicity in addition to the efforts 
made to bring the CF unit and Audiology services together and the enthusiastic support of 
the two consultants involved has now allowed the establishment of an ototoxicity monitoring 
service for the CF children at GOSH. This service has just recently been set up and hopefully 
will be reviewed and improved once it becomes embedded more as an integral part of the 
management of CF patients.  Appendices 9.9, 9.10, 9.11 and 9.12 include the protocols, 
pathways and paperwork that I prepared as part of this work in order to help set up this 
service. The need for increased awareness of the use of appropriate auditory monitoring tools, 
criteria for referral and for defining ototoxicity, assessment times, clearly defined roles, good 
effective lines of communication between professionals, and individualized patient 
management plans are all essential components needed for a monitoring service to be 
successful. 
7.3.2 Recommendations for achieving an ideal ototoxicity 
monitoring protocol: 
Based on the outcomes and clinical experience acquired from all the studies involved in this 
research and on the review of the related literature the following points are the ones that I 
believe would aid in developing an effective ototoxicity monitoring protocol: 
1. Clear awareness by all clinicians of common / established ototoxic drugs. This study 
only focused on aminoglycosides and cisplatin but there are many others involved 
including other antibiotics such as vancomycin, other chemotherapeutic agents such 
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as vincristine, chelating agents used in thalassaemia patients such as desferoxamine, 
antimalarials such as quinine and diuretics such a furosemide.  
2. Clear identification of patient groups that are at a higher risk of repeated exposure to 
ototoxic medications. This includes patients with cancer, CF, TB, renal disorders, 
and infectious diseases in intensive care units etc.  
3. Clear identification of key contacts within each team – this confirms that there are 
clearly identified personnel within the relevant departments (whether consultant, 
specialist nurse or audiologist) who can be contacted in relation to any queries in 
relation to the monitoring program as a whole or in relation to a specific patient.  
4. Awareness of the clinicians involved in managing these patient groups of the need to 
start monitoring the hearing of these patients before or just after patients are first 
exposed to these medications. Baseline auditory recordings for chemotherapeutics 
should be done before or within 48 hours of the first dose and for aminoglycosides 
before or within the first 72 hours of the first dose as recommended by ASHA 
(ASHA, 1994a).  
5. Accurate recording of drug history – dates of intake of courses; type, dose and mode 
of administration of any medication. This would allow for clear identification of 
ototoxic medications, confirm cumulative exposure and identify any other 
medications that may interact or have a synergistic effect with these ototoxic drugs.    
6. Providing patients with information – e.g. through a pamphlet on the related drug, its 
effect on the ear and ototoxicity monitoring service provided. 
7. Audiologists’ role and importance of leadership role in this service. Audiological 
professionals have to actively initiate this partnership with clinicians, providing 
them with clear detailed information on the service they can provide and providing 
evidence-based information regarding all aspects of the monitoring protocol.  
8. Counseling: role of clinician and audiologist. Counseling does not just involve 
informing the patient that one of the side effects of this drug includes hearing loss as 
part of the consent procedure. It involved this plus clarifying points like letting the 
patient know the early warning signs such as tinnitus or difficulty in hearing in 
background noise, know that the only way to identify early damage is by regular 
auditory monitoring which starts as baseline testing before commencement of 
treatment and explaining what steps will be taken if ototoxicity is identified. These 
steps could include making changes in the medication if possible, more regular 
auditory monitoring, and referral back to audiology for management of any 
significant permanent hearing loss through amplification on other methods of 
rehabilitation. It has to be clear who and when provides this information and that 
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both clinicians and audiology professionals provide similar non-contradictory 
information.    
9. Good communication links between clinicians and audiologists: clinicians should 
get clear reports of the outcomes of monitoring and know who to contact if more 
clarification is required, audiologists should also know the key members of the 
clinical team (consultant, specialist nurse, registrar).  
10. Setup of dedicated ototoxicity clinics. This allows for the use of a specific 
ototoxicity monitoring test battery that is different from that used in the standard 
ENT clinics. Here tympanometry, EHF audiometry and DPOAE testing will be 
performed for all patients. A dedicated clinic will also allow clear identification for 
these patients as they would be allocated specific identifier codes that can allow 
retrieval of all their repeated monitoring data and for easier auditing of this service 
and putting in place measures to improve the service if needed.   
11. Having a clear and agreed patient care pathway that both clinicians and audiologists 
are aware of.  
12. Referral points: Baseline testing, then if there is limited capacity for monitoring 
during or at the end of each course of medication- regular annual monitoring as long 
as the patient is not complaining of any hearing loss or tinnitus and has normal 
audiological test results. Monitoring to increase to during and after every course if 
any evidence of ototoxicity is discovered. Post-treatment monitoring after cessation 
of treatment for late onset hearing loss (over 3 and 6 months then 1, 2 and 5 year 
intervals)  
13. Criteria for identification of ototoxicity: there need to be clear aims for the 
monitoring service: a) early identification should prompt closer monitoring; b) a set 
cut-off point should be agreed where change in management should be advocated. 
The use of one agreed grading classification such as the SIOP Boston ototoxicity 
scale where if a specific grade on this scale were reached the clinician would initiate 
change in treatment.   
14. All professionals involved should be aware of risk factors that can increase 
susceptibility to ototoxicity such as extreme age, renal impairment, previous 
exposure to this ototoxic medication, concomitant exposure to other ototoxic drugs, 
noise exposure and genetic predisposition to ensure that closer monitoring or 
avoidance of this medication should be done.  
15. Clinicians should decide on different options for change in management that could 
be possible for their patient cohorts. They should be clear on whether they can 
change the medication, decrease dosage, change dosing regimenn, change route of 
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administration (e.g. from systemic to topical routes such as nebulized) or even 
completely replace it with another non-ototoxic alternative drug if possible. 
16. Clear pathway of referral to audiology rehabilitation services for fitting of hearing 
aids or cochlear implants etc. if ototoxic SNHL has occurred.  
17. Facilitating access to monitoring for very ill unwell patients that have difficulty 
reaching audiology departments. 
18. Professional education and training: training healthcare personnel during their basic 
and continuing professional education training regarding types and rational use of 
ototoxic drugs, importance of monitoring and ability to interpret audiological 
assessments will help raise awareness and improve management. The outcomes of 
the survey study in Theme C had highlighted the need for this training for all 
professionals involved. This has been advocated for a long time even by the WHO 
(WHO, 1994). Audiologists and Otolaryngologists could provide the leadership in 
introducing and supporting these training programs. Professional education can also 
be advocated through publication of well-designed high quality research in peer-
reviewed journals on this topic.  
7.3.3 Role of risk factors and genetic susceptibility in 
increasing the prevalence of ototoxicity 
As technology improves, the availability, ease and value of performing genetic tests shows 
increases. The challenge is to identify the genetic variances or mutations that are 
significantly associated with increased susceptibility to specific ototoxic medications or 
those that have a significant role in modifying the phenotypic presentation of hearing loss. In 
this research a significant correlation between the two drug-metabolizing gene variants 
(rs12201199 TPMT and rs4646316 COMT) and AG ototoxicity could not be found. 
Previous research had shown a significant correlation with these variants and cisplatin 
ototoxicity through association analysis (Ross et al., 2009, Pussegoda et al., 2013) but this 
correlation was then shown to be non-significant when this work was replicated by another 
research group (Yang et al., 2013).  However the basic concept behind the Ross et al. study 
of trying to identify gene variations in the top 220 key genes involved in the adsorption, 
distribution, metabolism and elimination (ADME) of drugs that are significantly associated 
with increased prevalence in ototoxicity is a valid and logical approach to discovering these 
links. The ability to genotype for thousands of SNPs in these genes using as single assay 
such as the Illumina GoldenGate assay that Ross et al. used is an excellent example of how 
this research can be easily applied to different medications, in this case AGs instead of 
cisplatin, as long as we have the appropriate patient cohorts to test. The availability of even 
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more advanced techniques such as next generation genome sequencing, and improvements in 
fields such as pharmacogenomics, where evaluation of different mechanisms of actions of 
drugs on cells is revealed through gene expression (Roukos, 2010), makes the goal towards 
personalized medicine, better understanding of genotype-phenotype relationships and 
developments of biomarkers for disease seem more possible. Therefore, based on the 
negative outcomes of the current study the recommendation for future work is either to 
completely abandon this hypothesis altogether or to take a step back and not try to establish a 
link with the TPMT and COMT variants but to replicate the Ross et al. assay of all 1,949 
SNPs in the 220 drug-metabolizing genes. Here a genetic association study with ototoxicity 
from AGs but in a much larger cohort of children with CF with any of the other drug-
metabolizing genes would be undertaken in search for significant associations. This should 
be undertaken in addition to focusing on establishing the pathway for this effect if one was 
discovered.  
As for the A1555G 12S rRNA mutation two children of the 67 children with CF were 
discovered to carry the mutation. This was not enough to explain the causation for the 
dichotomy in hearing observed in this study group but did offer an explanation for the 
significant hearing loss seen after exposure to only three i.v. AG courses in one of these two 
children. This finding was in line with previous literature that showed that this mutation 
increases susceptibility to ototoxicity even after exposure to the first dose of AG. The two 
main outcomes of this study were the discovery that one of these children had normal 
hearing despite documented evidence of exposure to AGs. The other was the suspicion that 
this mutation is more prevalent in patients with cystic fibrosis as prevalence here represented 
a 15-fold increase when compared with the commonly reported 0.2% prevalence in UK and 
other populations. The same suspicion was also raised by Conrad et al. when they identified 
2/157 (1.3%) cases of adults with CF. This was a driver to test more patients. A total of 105 
samples were collected but only the two A1555G children that were discovered in the first 
sample collection were confirmed to carry this mutation. However, this study did not aim to 
perform an association study or to assess prevalence. If this were the aim it would be 
recommended to conduct a wide scale multi-center study in order to identify the true 
prevalence of this mutation in CF patients. The latest CF Trust registry report has stated that 
there are 10,078 people with CF registered in the UK (UK CF Trust, 2013). A large-scale 
multi-center UK study sequencing the mtDNA 12S rRNA gene will help identify the true 
prevalence of the A1555G mutation and identify other new or known mutations/variants 
within the 12S rRNA and tRNA mitochondrial genes that are associated with AG ototoxicity. 
Patients with CF would be a very good population to investigate AG ototoxicity as 
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documented evidence of intake of i.v and nebulized aminoglycosides is already collated 
making a genotype-phenotype association study more feasible.  
The discovery that one of the two children carrying the A1555G mutation had normal 
hearing, which was confirmed twice using a full audiological test battery, has raised two 
issues. The first was that it questioned the true penetrance of this mutation, which was 
reported by many researchers to be 100% when patients are exposed to AGs as it is 
considered to be a major modifying factor in increasing expression of this mutation.  The 
other issue is that it supported a recommendation to screen all CF patients for this mutation 
before they are exposed to aminoglycosides. This was because this normal hearing may still 
be considered as a temporary condition and that late onset hearing loss can still occur months 
or years after cessation of treatment. Therefore early identification may help prevent the 
occurrence of hearing loss soon after exposure or later on after cessation of treatment. 
Bitner-Glindzicz et al. and Chen et al. reported that 18/9371 (0.19%) and 6/865 (0.6%) 
respectively of the newborns and 19/7350 (0.26%) of the adult 44-45 year olds tested by 
Rahman et al. that genotyped positively for the A1555G mutation all had within normal 
hearing thresholds confirming that the mutation alone is not enough for the hearing loss 
phenotype to be expressed and that AG exposure plays a major role in increasing this 
expression. They all recommended that it would be both practical and cost-effective to 
complement auditory monitoring for ototoxicity with genetic screening for this mutation for 
prevention of hearing loss by avoiding intake of AGs if possible or at least closer, more 
prolonged monitoring of these patients for early detection and discovery of any late-onset 
hearing loss that may affect these patients following the exposure to AGs (Rahman et al., 
2012, Chen et al., 2011, Bitner-Glindzicz et al., 2009). 
Investigating genetic susceptibility to AG ototoxicity is an important area of research aiming 
at understanding individual variances, explaining the dichotomy in outcomes, identifying 
patients at higher risk and ultimately devising preventative and curative measures. The 
A1555G mutation, along with other mtDNA variants, is established as a genetic cause of 
increased susceptibility to AG ototoxicity in addition to non-syndromic deafness. However 
investigating the effect of this mutation on different populations and designing studies where 
the patient inclusion criteria are not defined by the phenotypic presentation of hearing 
impairment may help establish a better understanding of the true penetrance of this mutation 
and possible ‘protective’ effects of disorders such as CF on the prevalence of this condition. 
CF patients are repeatedly exposed to aminoglycosides and therefore they could benefit from 
pharmacogenetic testing for the A1555G mutation but this should not be implemented until a 
strong evidence base for proof of protection from ototoxicity, assessment of effect of 
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avoidance of first-line treatments on morbidity and cost-effectiveness is established. 
Conversly, it should be noted that the pharmacoeconomic analysis made by Veenstra et al. 
assessing the potential impact of pharmacogenomics testing on clinical, patient and 
economic outcomes in CF patients (Veenstra et al., 2007) were based on lower prevalence 
rates of the A1555G mutation (Bitner-Glindzicz et al., 2009, Rahman et al., 2012) than are 
currently presented in this study and therefore genetic screening may be more cost effective 
than previously reported.  
7.3.4 Developing an audiological screening protocol using 
EHF screening PTA and portable DPOAE 
Results of studies within the three themes of this research and of those of multiple previous 
studies have confirmed that in order to implement an effective ototoxicity monitoring 
service; repeated audiological testing using a comprehensive test battery, clear criteria for 
grading for ototoxicity, options for change in management and introduction of auditory 
rehabilitation and good multi-disciplinary communication are all required. The Theme C 
survey has confirmed that patients are almost always only tested in audiology departments. 
Many of the patients needing ototoxicity monitoring are usually very ill patients, especially 
when they are children or elderly. They would probably have very limited ability to move to 
the outpatients audiology departments, even if they were hospitalized, and would also have 
limited ability to cooperate effectively to respond to prolonged audiological objective tests. 
In addition to this, many of the audiology departments are not based in the same 
buildings/location housing the cancer or CF centers e.g. the London University College 
London Hospital (UCLH) does not have a dedicated audiology department and therefore 
patients needing this service are referred to the Royal National Nose, Throat & Ear Hospital 
(RNTNE) which is another hospital within this trust but is about twenty minutes away from 
its site. Ill patients would need to be transported by ambulance on a wheel chair or trolley to 
the other hospital. All this means that effective repeated auditory monitoring for ototoxicity 
might not be practically feasible for many of the patients that most need it.  
The recommendation is to develop a quick validated audiological test battery that can be 
used in a hospital  (clinic/ward) or home setting that can be used for repeated testing of these 
patients for early signs of ototoxicity and only when these are detected would the patient 
need to be referred for more comprehensive monitoring within the audiology department.  
I have already performed a pilot study with 32 CF children and 32 cancer children to validate 
the outcomes of a screening test battery using a 25dB five-frequency (8, 10, 12.5,14 and 16 
kHz) sweep using a portable high frequency audiometer and a high frequency DPOAE (2-8 
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kHz f2 frequency) using a portable hand-help Otodynamics Otoport device. Results were 
validated against the available comprehensive audiological tests performed at the audiology 
department within soundproof booths. Analysis of the results has shown the screening test 
battery to have a similar level of sensitivity and specificity to the comprehensive test battery 
and is even more superior than standard audiometry results alone at identifying children with 
ototoxicity. Further work is required to confirm these finding and recommend the use of this 
protocol. 
Other research groups have also made similar recommendations. Fausti et al. have developed 
a new automated portable screening high frequency audiometer, which they called the OtoID 
(Jacobs et al., 2012). This machine does not have FDA approval yet but experimental results 
have shown that it can be used effectively of monitor ototoxicity of adult patients in the 
veterans’ hospital or even from the comfort of their own home. The same research group 
have also published extensively on the sensitive range of ototoxicity (SRO) where an 
individualized, one-octave wide sensitive frequency range separated by 1/6th-octave 
intervals from the highest limit of hearing would be used to detect early signs of ototoxicity 
(Fausti et al., 2003, Konrad-Martin et al., 2010). Therefore screening auditory monitoring 
may offer a good solution for increasing access to regular repeated auditory monitoring and 
should be more utilized in the future.   
7.3.5 Investigating a possible otoprotective role of the CFTR 
gene mutation against ototoxicity  
Mulheran el al. had suggested that the less than expected prevalence of ototoxicity in CF 
patients exposed to repeated courses of AGs might be caused by a possible otoprotective role 
of the CFTR mutation in the inner ear (Mulheran et al., 2001). The relatively large numbers 
of children in the audiological study of CF children (Theme A) of this research within the 
high-exposure group that had exceptionally good hearing 14/25 (Figure 4-5) supports this 
hypothesis. Further investigation is needed to establish the effect of the CFTR mutation on 
the inner ear and assess whether this affects the mechanism of entry or accumulation of AGs 
in the inner ear cells or in some way affects the apoptotic cell death pathways initiated by 
these drugs. Homma et al. have shown the CFTR interacts with prestin (SLC26A5) in the 
lateral wall of the OHCs and that both the mRNA and protein of CFTR are present in the 
OHCs with CFTR localizing in both the apical and lateral membranes. As the OHCs at the 
basal turn of the cochlea are one of the first cells affected by ototoxic drugs like 
aminoglycosides and cisplatin, it is important to investigate what other proteins it affects in 
these cells and whether it is involved in the mechano-electrical transduction channels at the 
apical ends of the OHCs as this is the route of entry of the ototoxic drugs.   A possible study 
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could be through ‘assessing the expression of the CFTR gene in OHCs and inner ear hair 
cells (IHCs) in a mouse model’ or through ‘comparing the uptake of AGs by the OHCs or 
IHCs in a CFTR Knock-out mouse vs. a mouse with a normal CFTR gene’.  
7.3.6 Other recommendations for future work include: 
 Assessing the sensitivity of DP-gram amplitude recordings vs. DP input/output 
function vs. high-frequency DPOAE testing as monitoring tools for early detection 
of ototoxicity 
 Investigating the difference in prevalence of ototoxicity following exposure to 
different types of AGs 
 Investigating the prevalence, quality of monitoring and rehabilitation of 
aminoglycoside vestibular ototoxicity   
 Investigating the effectiveness of different otoprotection agents as D-methionine, 
glutathione, N-acetylcysteine, amifostine, ebselen, sodium thiosulphate, aspirin, 
oxidizing agents in otoprotection against AG ototoxicity 
7.4 Conclusion: 
The work presented in this thesis has covered several different aspects of research into 
ototoxicity. Ototoxicity is a very important preventable cause of inner ear damage. Some of 
the research questions raised here have been addressed by previous research. Others still 
need more investigation. One important aspect that was quite clear to me from studying 
aspects of audiological monitoring and causation versus studying clinical impact and current 
practice is that there seems to be a wide gap between the extensive body of published 
research in this field and the actual implementation and integration of the outcomes of this 
research into clinical practice to provide direct benefit to patients. Despite the great benefit 
that clinicians provide to their patients there is an increased need for translational research 
that can transfer the established scientific outcomes into measures of patient management. 
There is a need for national and international guidelines for ototoxicity monitoring and a 
need for audiology professionals to have a stronger role in increasing awareness, 
implementing and supporting clinicians in dealing with this very important preventable 
cause of hearing loss.    
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 Appendices: Chapter 9:
9.1 Appendix 1:  High frequency measurements 
made by Otodynamics to generate correction 
factors for the high frequency DPOAE recordings.  
High frequency correction for DP stimulus levels 
On the DPOAE stimulus level issue: 
The frequency response of a number of our probes (n=14) in an Occluded ear simulator (IEC 
60318-4 B&K 4157) was measured using a HP Spectrum Analyzer. 
 
 
The results were used to construct a correction table for frequencies above 5kHz. 
The correction table is used by V6 to allow the appropriate extra drive to the speaker. 
Recorded level on V6/Ez Screen may still be lower than the target due to standing waves in 
the ear canal. 
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9.2 Appendix 2: HUI3 Questionnaire  
The Health Utilities Index Mark 3 (HUI3) 
Instructions: This set of questions asks about your child’s day-to-day health. You may feel 
that some of these questions do not apply to you, but it is important that we ask the same 
questions of everyone. Please read each question and consider your answers carefully. For 
each question, please select one answer that best describes your child’s usual level of ability 
or disability. Please indicate the selected answer by marking (X) the box beside the answer. 
A few of the questions are similar to others; please excuse the apparent overlap, and answer 
each question independently. Thank you. 
 
1. Which one of the following best describes your child’s usual ability to see well enough to see 
pictures in a book? 
□ Able to see well enough without glasses or contact lenses 
□ Able to see well enough with glasses or contact lenses 
□ Unable to see well enough even with glasses or contact lenses 
□ Unable to see at all 
 
2. Which one of the following best describes your child’s usual ability to see well enough to recognize 
you across the room? 
□ Able to see well enough without glasses or contact lenses 
□ Able to see well enough with glasses or contact lenses 
□ Unable to see well enough even with glasses or contact lenses 
□ Unable to see at all 
 
3. Which one of the following best describes your child’s usual ability to hear what is said in a group 
conversation with at least three other people? 
□ Able to hear what is said without a hearing aid or cochlear implant 
□ Able to hear what is said with a hearing aid or cochlear implant 
□ Unable to hear what is said, even with a hearing aid or cochlear implant 
□ Unable to hear what is said, but don’t wear a hearing aid or cochlear implant 
□ Unable to hear at all 
 
4. Which one of the following best describes your child’s usual ability to hear what is said in a 
conversation with one other person in a quiet room? 
□ Able to hear what is said without a hearing aid or cochlear implant 
□ Able to hear what is said with a hearing aid or cochlear implant 
□ Unable to hear what is said, even with a hearing aid or cochlear implant 
□ Unable to hear what is said, but don’t wear a hearing aid or cochlear implant 
□ Unable to hear at all 
 
5. Which one of the following best describes your child’s usual ability to be understood when 
speaking the same language with strangers? 
□ Able to be understood completely 
□ Able to be understood partially 
□ Unable to be understood 
□ Unable to speak at all 
 
6. Which one of the following best describes your child’s usual ability to be understood when 
speaking with people who know him/her well? 
□ Able to be understood completely 
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□ Able to be understood partially 
□ Unable to be understood 
□ Unable to speak at all 
 
7. Which one of the following best describes how your child usually feels? 
□ Happy and interested in life 
□ Somewhat happy 
□ Somewhat unhappy 
□ Very unhappy 
□ So unhappy that life is not worthwhile 
 
8. Which one of the following best describes your child’s usual level of pain and discomfort? 
□ Free of pain and discomfort 
□ Mild to moderate pain that prevents no activities 
□ Moderate pain that prevents a few activities 
□ Moderate pain that prevents some activities 
□ Severe pain that prevents most activities 
 
9. Which one of the following best describes your usual child’s ability to get around? 
□ Able to walk, bend, lift, jump and run normally for age 
□ Walks, bends, lifts, jumps or runs with some limitations but does not require 
Help 
□ Requires mechanical equipment (such as canes, crutches, braces or wheelchair) to walk or get 
around independently 
□ Requires the help of another person to walk or get around and requires mechanical equipment as 
well 
□ Unable to control or use arms and legs 
 
10. Which one of the following best describes your child’s usual ability to use his/her hands and 
fingers? Note: Special tools refer to hooks for buttoning clothes, gripping devices for opening jars or 
lifting small items, and other devices to compensate for limitations of hands or fingers 
□ Full use of two hands and ten fingers 
□ Limitations in the use of hands or fingers, but do not require special tools or help of another person 
□ Limitations in the use of hands or fingers, independent with the use of special tools (do not require 
the help of another person) 
□ Limitations in use of hands or fingers, require the help of another person for some tasks (not 
independent even with use of special tools) 
□ Limitations in use of hands of fingers, require the help of another person for most tasks (not 
independent even with use of special tools) 
□ Limitations in use of hands or fingers require the help of another person for all tasks (not 
independent even with use of special tools) 
 
11. Which one of the following best describes your child’s usual ability to remember things? 
□ Able to remember most things 
□ Somewhat forgetful 
□ Very forgetful 
□ Unable to remember anything at all 
 
12. Which one of the following best describes your child’s usual ability to think and solve day-to-day 
problems? 
□ Able to think clearly and solve day-to-day problems normally for age 
□ Have a little difficulty when trying to think and solve day-to-day problems 
□ Have some difficulty when trying to think and solve day-to-day problems 
□ Have great difficulty when trying to think and solve day-to-day problems 
□ Unable to think or solve day-to-day problems 
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9.3 Appendix 3: HUI Mark 3 (HUI3) Classification System.  
From: Health Qual Life Outcomes. 2003; 1: 54. Published online 2003 October 16. doi: 10.1186/1477-7525-1-54 (Horsman et al., 2003) 
ATTRIBUTE LEVEL DESCRIPTION 
VISION 1 
Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, without glasses or 
contact lenses. 
 2 Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, but with glasses. 
 3 
Able to read ordinary newsprint with or without glasses but unable to recognize a friend on the other side of the street, even with 
glasses. 
 4 
Able to recognize a friend on the other side of the street with or without glasses but unable to read ordinary newsprint, even with 
glasses. 
 5 Unable to read ordinary newsprint and unable to recognize a friend on the other side of the street, even with glasses. 
 6 Unable to see at all. 
HEARING 1 Able to hear what is said in a group conversation with at least three other people, without a hearing aid. 
 2 
Able to hear what is said in a conversation with one other person in a quiet room without a hearing aid, but requires a hearing aid 
to hear what is said in a group conversation with at least three other people. 
 3 
Able to hear what is said in a conversation with one other person in a quiet room with a hearing aid, and able to hear what is said 
in a group conversation with at least three other people, with a hearing aid. 
 4 
Able to hear what is said in a conversation with one other person in a quiet room, without a hearing aid, but unable to hear what 
is said in a group conversation with at least three other people even with a hearing aid. 
 5 
Able to hear what is said in a conversation with one other person in a quiet room with a hearing aid, but unable to hear what is 
said in a group conversation with at least three other people even with a hearing aid. 
 6 Unable to hear at all. 
SPEECH 1 Able to be understood completely when speaking with strangers or friends. 
 2 
Able to be understood partially when speaking with strangers but able to be understood completely when speaking with people 
who know me well. 
 3 Able to be understood partially when speaking with strangers or people who know me well. 
 4 Unable to be understood when speaking with strangers but able to be understood partially by people who know me well. 
 5 Unable to be understood when speaking to other people (or unable to speak at all). 
AMBULATION 1 Able to walk around the neighbourhood without difficulty, and without walking equipment. 
 2 Able to walk around the neighbourhood with difficulty; but does not require walking equipment or the help of another person. 
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 3 Able to walk around the neighbourhood with walking equipment, but without the help of another person. 
 4 Able to walk only short distances with walking equipment, and requires a wheelchair to get around the neighbourhood. 
 5 
Unable to walk alone, even with walking equipment. Able to walk short distances with the help of another person, and requires a 
wheelchair to get around the neighbourhood. 
 6 Cannot walk at all. 
DEXTERITY 1 Full use of two hands and ten fingers. 
 2 Limitations in the use of hands or fingers, but does not require special tools or help of another person. 
 3 Limitations in the use of hands or fingers, is independent with use of special tools (does not require the help of another person). 
 4 
Limitations in the use of hands or fingers, requires the help of another person for some tasks (not independent even with use of 
special tools). 
 5 
Limitations in use of hands or fingers, requires the help of another person for most tasks (not independent even with use of 
special tools). 
 6 
Limitations in use of hands or fingers, requires the help of another person for all tasks (not independent even with use of special 
tools). 
EMOTION 1 Happy and interested in life. 
 2 Somewhat happy. 
 3 Somewhat unhappy. 
 4 Very unhappy. 
 5 So unhappy that life is not worthwhile. 
COGNITION 1 Able to remember most things, think clearly and solve day-to-day problems. 
 2 Able to remember most things, but have a little difficulty when trying to think and solve day-to-day problems. 
 3 Somewhat forgetful, but able to think clearly and solve day-to-day problems. 
 4 Somewhat forgetful, and have a little difficulty when trying to think or solve day-to-day problems. 
 5 Very forgetful, and have great difficulty when trying to think or solve day-to-day problems. 
 6 Unable to remember anything at all, and unable to think or solve day-to-day problems. 
PAIN 1 Free of pain and discomfort. 
 2 Mild to moderate pain that prevents no activities. 
 3 Moderate pain that prevents a few activities. 
 4 Moderate to severe pain that prevents some activities. 
 5 Severe pain that prevents most activities. 
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9.4 Appendix 4: Paediatric Quality of Life 
Questionnaire 
Please rate how concerned or worried you have felt about your child in the following areas, 
over the past month. Please put a tick in the appropriate box for each item, and don’t leave 
out any items. 
 
How concerned or worried have you felt about: 
 
           Not at all              A little            Moderately                   Very               Extremely 
                       Concerned            concerned           concerned                    concerned       concerned  
      
1. How well your child is able 
to cope academically 
 
2. Your child’s ability to join in  
play-time activities at school or  
nursery 
 
3. How your child gets along with  
children of the same age 
 
4. How well your child is able to  
communicate with family members 
 
5. The extent to which your child  
Is teased or bullied by peers 
 
6. The way your child looks; his/her 
appearance  
 
7. How much your child is able to  
join in indoor activities and games  
at home 
 
8. How well your child is able to  
communicate with other relatives 
 
9. The extent to which your child  
gets frustrated or angry 
 
10. How anxious your child has felt 
about going to school or nursery 
 
11. The extent to which your child 
argues or fights with peers 
 
12. Your child’s ability to make new  
friends and keep the friendship 
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How concerned or worried have you felt about: 
 
     
    Not at all          A little           Moderately           Very            Extremely 
          Concerned      concerned               concerned       concerned           concerned 
 
 
13. How well your child is able to  
cope with visiting a friend,  
without you there 
 
14. Your child’s ability to  
communicate with peers in 
school or nursery 
 
15. How sad or miserable your  
child has felt 
 
16. Your child’s ability to join in  
sports and physical activities 
 
17. How tearful or easily upset  
your child has been 
 
18. Your child’s ability to cope  
with everyday life 
 
19. The extent to which your child  
has felt over-anxious or panicky 
 
20. How well your child is able to  
communicate with peers outside  
school 
 
21. The extent to which your child  
is easily frightened 
 
22. The extent to which your child  
is able to be independent, do  
things for him/herself  
(as appropriate for their age) 
 
 
Overall, do you think your child’s quality of life has improved as a result of having  
 
hearing aids? Yes   No N/A 
 
If yes, to what extent has it improved? 
 
                A little                           Moderately   Very much 
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Finally: 
Please could you now provide the following information? 
 
 
Your child’s age …………………… 
 
 
Does your child attend school?   nursery? 
 
 
How long has your child had hearing aids? ……………….Years ………… Months 
 
 
Your child’s gender Male   Female 
 
 
Your child’s ethnic background   ……………………………………………………. 
 
 
Does your child have any disabilities or learning difficulties in addition to their deafness? 
 
Yes                    No 
 
 
If yes, please describe: ………………………………………………… 
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9.5 Appendix 5: PAQL Items 
PAQL items: (Edwards et al., 2012) 
o A.1. Communication and independence 
How well your child is able to communicate with family members 
How well your child is able to communicate with other relatives 
How well your child is able to cope with visiting a friend, without you there 
Your child's ability to communicate with peers in school or nursery 
How well your child is able to communicate with peers outside school 
The extent to which your child is able to be independent (as appropriate for their 
age) 
o A.2. Emotional well-being 
The extent to which your child gets frustrated or angry 
How anxious your child has felt about going to school or nursery 
How sad or miserable your child has felt 
How tearful or easily upset your child has been 
Your child's ability to cope with everyday life 
The extent to which your child has felt over-anxious or panicky 
The extent to which your child is easily frightened 
o A.3. Peer comparisons 
How well your child is able to cope academically 
Your child's ability to join in playtime activities at school or nursery 
How well you child gets along with children of the same age 
How much your child is able to join in indoor activities and games at home 
o A.4. Acceptance by peers 
The extent to which your child is teased or bullied by peers 
The way your child looks; his/her appearance 
The extent to which your child argues or fights with peers 
Your child's ability to make friends and keep the friendship 
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9.6 Appendix 6: Online survey questionnaire for 
UK Audiologists 
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9.7 Appendix 7: Online survey questionnaire for 
UK Oncologists 
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9.8 Appendix 8: Online survey questionnaire for 
UK CF Clinicians  
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9.9 Appendix 9: Plan for ototoxicity monitoring 
pathway developed for CF children at GOSH 
Flow Chart for Audiological Assessment for Ototoxicity: 1st Trial of Ototoxicity 
Monitoring Pathway: 
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9.10 Appendix 10: GOSH Ototoxicity referral form 
 
  
  
  
Referral Form for Ototoxicity 
monitoring of CF patients 
  
  
DEPARTMENT 
Audiovestibular Medicine & 
Cystic Fibrosis Unit, 
Great Ormond Street Hospital, 
London 
  
Referral Form for Audiological Assessment for Cystic Fibrosis Unit Patients 
  
Please complete the form and sent to the Audiology Department in the internal mail. 
 
Please affix patient ID label: 
MRN Number: …………………………… 
Surname: ………………………………… 
Name: …………………………………… 
DOB: …………………………………… 
Sex: ……………………………………… 
  
 
1. Administered antibiotics in the past year: 
…………………………………………………………………………………………
…………………………………………………………………………………………
……………… 
2. Type of Aminoglycoside received: 
  
  Tobramycin                    Amikacin               Gentamicin                 Other 
  
3. Has child had a hearing assessment for ototoxicity monitoring before? 
  
   YES                                            NO 
  
  
  
 Reason for referral: Please tick as appropriate 
  
  
Child has history of intake of Aminoglycosides at Annual 
Review (regardless of number of courses given) 
  
Child/parent has auditory concerns (hearing loss/tinnitus) – 
in review clinic/ward 
  
Any staff concerns about hearing– in review clinic/ward 
  
G. Al-Malky- CF unit Referral Form For Hearing Assessment v1. 
March 1, 2013 
   
Details of referring doctor: 
Referrer’s Name (Print clearly): 
…………………………………………………. 
Consultant: ………………………………. 
Contact Number/Bleep: …………….. 
Date of referral: ………………………….. 
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9.11 Appendix 11: GOSH Ototoxicity post-
assessment feedback report 
 
  
  
  
Audiology Report for 
Ototoxicity monitoring of 
CF patients 
  
  
DEPARTMENT 
Audiovestibular Medicine & Cystic 
Fibrosis Unit, 
Great Ormond Street Hospital, 
London 
       Hearing Assessment Report: 
Ototoxicity Monitoring Service for CF Unit 
Please affix patient ID label: 
MRN Number: ……………………………………….. 
Surname: ……………………………………………….. 
Name: …………………………………………………… 
DOB: ……………………………………………………… 
Sex: ………………………………………………………. 
  
 Summary Report: (see results enclosed) 
 Otoscopy:            Clear                   Non-occluding wax 
  
Tympanometry (middle ear analysis): 
  
                             Normal               Otitis Media with Effusion (OME)/ Negative Pressure 
  
Standard Audiometry (0.5 – 8kHz):     Rt:           Lt:            Both: 
Description: ………………………………………………... 
  
  Normal     HF Hearing Loss –Stable           HF HL - 
Deterioration  
  
Extended High-Frequency (HF) Audiometry (9 – 16kHz):      Rt:            Lt:           
 Both: 
  
 Normal             HL – Stable                   HL – Deterioration 
(>20dB) 
  
Distortion-Product Otoacoustic emissions (DPOAE-monitor inner ear OHC function) 
  
 Present             Absent        Deterioration 
                     
 Recommendation: 
  
Repeat assessment after 6 months 
  
Repeat assessment after intake of next aminoglycoside course 
  
Refer to Local / GOSH Audiology for hearing aids 
  
Genetic test to exclude mtDNA A1555G mutation 
  
 Date: ……………………………………….. 
Audiologist: ………………………………. 
Contact Number/Bleep: …………….. 
New patient assessment: 
Existing patient monitoring: 
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9.12 Appendix 12: Ototoxicity monitoring protocol 
prepared for the CF patients at GOSH 
 
PROTOCOL FOR OTOTOXICITY MONITORING OF CYSTIC FIBROSIS (CF) 
PATIENTS 
(AUDGOSH-2) 
Ototoxicity is ‘drug-related inner ear damage’ which results in auditory and/or vestibular 
dysfunction that is often permanent. Symptoms of ototoxicity include tinnitus, dizziness, and 
difficulty understanding speech in noise. The main therapeutic drug groups causing 
permanent ototoxicity include aminoglycoside antibiotics used to treat life-threatening 
infections and chemotherapeutic drugs as cisplatin and carboplatin.  
Initial ototoxic drug exposure typically affects cochlear regions coding the high frequencies. 
Continued exposure results in a spread of damage to progressively lower frequencies. 
Unfortunately, ototoxic hearing loss may go unnoticed by patients, especially children, until 
a communication problem becomes apparent, signifying that hearing loss within the 
frequency range important for speech understanding has already occurred. Similarly, by the 
time a patient complains of dizziness, permanent vestibular system damage probably has 
already occurred. Because symptoms of ototoxicity are poorly correlated with drug dosage, 
peak serum levels, and other toxicities, the only way to detect ototoxicity is by assessing 
auditory and vestibular function directly (Konrad-Martin, 2005a). The risk of hearing loss is 
estimated to be 1.7% per course of aminoglycoside in CF patients with evidence of presence 
of a cumulative effect following repeated exposure especially when >10 courses are 
administered (Mulheran et al., 2001) 
This document is aimed at presenting an auditory monitoring protocol for children with CF 
who are exposed to repeated courses of aminoglycosides and other potentially ototoxic 
antibiotics prescribed to combat chronic pseudomonas aeruginosa chest infections. A 
separate document for ototoxicity monitoring of vestibular function will be prepared in due 
course.   
 
1 POLICY AND SCOPE 
1.1 To provide a high quality, objective and accurate service for the audiological 
monitoring of patients with CF for signs of ototoxicity 
1.2 The main purpose of this monitoring is to detect ototoxicity early in order to provide 
an opportunity for the managing clinicians to make informed decisions about making 
adjustments the therapeutic treatment in order to minimize or prevent hearing loss 
requiring rehabilitation, without compromising their overall care.  
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1.3 To contribute to the protection and prevention of further damage to the hearing 
function of these children and to set in place early auditory rehabilitation 
management of hearing loss during and after treatment. This in turn will help 
improve the overall quality of life of these patients.  
1.4 To provide audiologists and clinical staff opportunities to counsel patients and their 
families regarding ototoxicity-induced hearing loss, tinnitus, and dizziness, 
communication strategies, and the synergistic effects of noise and ototoxic damage. 
 
2 AVAILABILITY 
2.1 Patients will be booked into agreed Audiology slots under Dr Tony Sirimanna’s care. 
2.2 Every effort will be made to provide timely referral service for baseline and post-
treatment auditory monitoring provided that: 
 Equipment is free 
 Staff are available 
 Patient is able to undergo the assessment 
 
3 STAFF REQUIREMENT 
3.1 Auditory monitoring should be undertaken by suitable trained and qualified staff of the 
following grades:  Audiological/Clinical Scientist, AfC Band 6 and above. Peer review 
of results by Band 7 audiologist and above. 
3.2 An audiological physician or senior registrar in Audiological Medicine should 
undertake analysis and follow up of the results. 
 
4 MANAGEMENT OF PATIENT – PATIENT JOURNEY 
4.1 Referral received by Audiologist from the CF specialist nurse following coordination of 
requests from members of the CF unit team or the Badger/other hospital ward if a 
patient is admitted for administration of an intravenous (iv) aminoglycoside course.  
4.2 Request for the baseline audiological monitoring should be initiated before the 
administration of or exposure to ototoxic agents. When pre-exposure testing is not 
performed for some reason, monitoring should be initiated within the first 72 hours of 
administration of the first dose of aminoglycoside as recommended by ASHA's 
"Guidelines for the Audiologic Management of Individuals Treated with Cochleotoxic 
Drug Therapy" (1994), based in part on the results of large clinical studies. 
4.3 Baseline audiological recordings for any child born in years ≥2006 can also be retrieved 
by an audiologist from the NHSP eSP database through the local services.  
4.4 Post-treatment audiological monitoring should be performed within the final days of 
completion of each aminoglycoside course (usually lasting 14 days) before the patient is 
discharged from the hospital or before that if the patient complains of any auditory 
symptoms.   
4.5 Monitoring and appropriate referrals for further auditory and vestibular testing also are 
warranted any time a patient reports increased hearing difficulties, tinnitus, aural 
fullness, or dizziness. Retesting to confirm significant changes can reduce false positive 
rates, which is recommended by ASHA (1994). Post-treatment evaluations at the 6-8 
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week post-treatment follow-up visit are necessary to confirm that hearing is stable 
because ototoxic hearing loss can occur up to 6 months following drug exposure. 
4.6 Targeted Diagnostic assessment: 
An audit assessing the feasibility and cost effectiveness of post-treatment monitoring 
of patients after each antibiotic course will be undertaken six months after the start 
of this service. If this shows a significant degree of difficulty or results obtained that 
a cumulative ototoxic affect is more evident instead of an acute post-treatment effect 
from intake of a single course, then a targeted assessment protocol should be 
followed including the minimum of following risk criteria: 
1. History of intake of ≥10 i.v. aminoglycoside courses. 
2. Regular repeated intake of 3-4 aminoglycoside courses per year 
3. Presence of any parental/carer concern regarding hearing/balance 
function 
4. History of intake of additional concomitant ototoxic medications (e.g. 
Diuretics as furosemide or chemotherapeutic medications as cisplatin) 
or exposure to loud noise, which may have a synergistic effect.      
These criteria should be revised or more added in agreement between the service leads 
of both departments.  
4.7  CF Outpatient clinic or Ward audiological screening: 
A research pilot study will be undertaken to investigate the sensitivity and specificity of 
using portable audiological equipment to perform quick screening of a limited number of 
specific high frequencies using high-frequency audiometry (8-10-12-14 kHz) and DPOAEs 
(on 3-8 kHz) for post-treatment assessment. This study will aim to confirm if this screening 
is effective in detecting early signs of ototoxicity so that only these patients will then be sent 
to the audiological medicine department for complete assessment and follow-up.  
If this screening procedure proves effective- the ototoxicity monitoring protocol will be 
revised to include this as a permanent step in assessing and triaging patients for referral for 
full audiological assessment.   
 
5 TEST TIME 
The time allocated for the baseline testing of each subject is 45 minutes. This should include: 
   Tympanometry and ART recordings to assess middle ear function 
  Standard (0.25-8 kHz) Audiometry using calibrated equipment and TDH39 
headphones 
  High-Frequency (9-16 kHz) Audiometry using calibrated equipment and Sennheiser 
HDA200 headphones  
 DPOAE recording (diagnostic bilateral DP-gram recordings of f2 frequencies 1-8 
kHz)   
A shortened pared-down version of these tests assessing the higher frequencies ≥2 kHz 
should be performed during the post-treatment assessments. Comparison with the baseline 
recordings should be made to assess if ototoxicity has occurred according to the ASHA 
criteria of ototoxicity (1994).  
6 Auditory assessment should include the following: 
 History taking: to include current and previous history of exposure to 
aminoglycosides, type and route of administration of the drug, duration of 
exposure, any audiological complaints (tinnitus or hearing loss), exposure to 
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other potential ototoxic drugs e.g. vancomycin or other antibiotics, diuretics or 
chemotherapeutic drugs.  
 Otoscopy, Tympanometry and acoustic reflex testing: to exclude existence of 
external and middle ear disease.   
 Standard pure-tone Audiometry (0.25 – 8 kHz)   
 High-frequency pure-tone audiometry using the dedicated circumaural 
headphones e.g. Sennheiser HDA200 high frequency earphones  (up to 16kHz) 
Audiometric techniques for standard and high-frequency testing are age 
dependent 
o Visual Reinforcement audiometry (VRA) should be used for children 
aged 6-30 months 
o Play audiometry should be used for children >36 months 
o Conventional audiometry (as with adults – pressing the button) can be 
used for children ≥5 years.  
 Distortion-product evoked otoacoustic emissions (DPOAEs) 
 Other tests may be considered if needed e.g. ABR threshold estimation, speech 
audiometry. 
o Equipment should be calibrated every six - twelve months traceable to the National 
Physical Laboratory. 
o Suitable accommodation with enough room to perform the test safely and comfortably 
(for both patient and tester): 
o Ambient noise <30 dBA 
o Adequate seating for parent and child 
o Tidy room with absence of sources of distraction/cues (extra play audiometry toys 
should be stored away in a cupboard). talk loudly.  {A baseline measurement of 
ambient noise  
7 Criteria for ototoxicity: 
For serial audiograms, ASHA (1994) developed criteria for a clinically significant 
hearing change based on results of large clinical research studies which reported 
normal test-retest variability in healthy subjects not receiving ototoxic drugs, and to 
a limited extent on receiver-operating characteristics (ROC) curves, constructed for 
threshold shift data obtained in drug- or noise-exposed individuals to record 
sensitivity and specificity of these data (Konrad-Martin, 2005b).  
These criteria include:  
 >20 dB pure-tone threshold shift at one frequency,  
 OR >10 dB shift at two consecutive test frequencies,  
 OR threshold response shifting to "no response" at three consecutive test 
frequencies.  
 
Change must be confirmed by retest. 
The ASHA guidelines for ototoxicity monitoring emphasize the increased test 
sensitivity achieved using extended high-frequency monitoring to detect ototoxicity. 
Test-retest differences for extended-high-frequency thresholds using modern 
equipment are generally reported to be within ±10 dB for frequencies between 9 and 
14 kHz. False positive rates indicating a change in extended-high-frequency 
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thresholds in subjects that were not exposed to ototoxic drugs is low in young and 
older adults, even when thresholds are tested on the hospital ward under controlled 
conditions. 
Extended-high-frequency sensitivity can be monitored in older children; however, 
test-retest variability is generally poorer in young children which will likely result in 
lower sensitivity and higher false positive rates compared to adults. Consequently, 
additional information provided by DPOAE objective testing in young children is 
very valuable (Konrad-Martin et al., 2010, Beahan et al., 2012). 
 
8 Safety and Health Precautions 
o All procedures should ensure the safety of the patient, audiologist, and others who 
participate in the clinical process and adhere to the standard precautions (e.g., 
prevention of bodily injury and transmission of infectious disease). 
 
o Decontamination, cleaning, disinfection, and sterilization of multiple-use equipment 
before reuse are carried out according to facility-specific infection control policies 
and procedures and according to manufacturer's instructions. The audiologist 
performing electrodiagnostic test procedures is familiar with facility-specific 
emergency medical protocols and adheres to all hospital, state, and federal 
regulations. 
 
o CF patients are more vulnerable to developing chronic infections with resistant 
organisms as MRSA and therefore all the necessary levels of decontamination 
should be employed. CF patients with MRSA should be tested at the end of the 
clinic and tympanometry should not be performed. The filter on the DPOAE probe 
should be removed and the probe disinfected. Level 2 disinfection of the room 
should be undertaken after completion of the tests.  
 
9 POST TEST MANAGEMENT 
Interpretation of the assessment may indicate one or more of the following: 
 Normal auditory system function 
 Significant change in auditory system function 
 Existence, type, and degree of auditory dysfunction with or without significant 
change 
Evaluation may result in one or more of the following: 
 Discharge and/or recommendations for routine follow-up 
 Feedback for the CF team to inform management 
 Referral for audiological rehabilitation evaluation 
 Referral for tinnitus evaluation and management 
 Referral to other professionals or vestibular testing 
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10 Documentation and dedicated database 
 Documentation must contain identifying and pertinent background information to 
include identification of ototoxic agents, assessment results, and patient condition 
before, during, and after the tests (including patient reactions), interpretation, 
prognosis, and specific recommendations. 
 An electronic database of all CF patients should be developed and maintained with 
information regularly fed back to the CF team.   
 Annual audit of the service should be performed to inform improvement of the 
service and allow its rollout to other trusts managing CF patients and other 
susceptible patient groups. 
 
11 MONITORING OF STANDARDS: 
11.1  Internal Procedure 
11.1.1 Monitoring of appointment times and waiting lists every 6 months. 
Results logged in audit manual. 
11.1.2 Monitoring of referral rates every 12 months. 
11.1.3 Monitoring of adherence to protocol (test and report writing) every 
12 months by observation of person running the test. The assessor 
should be Band 7 Scientist or audiologist and above. Non-
compliance to protocol should be logged, action plan developed for 
tester if needed (including training required if necessary).  
11.1.4 Peer review of test results and early accurate identification of 
occurrence of ototoxicity. 
11.1.5 Any deviation from the standard is to be brought to the attention of 
the clinical physician/scientist. These will then be brought up at the 
next audit meeting. 
 
Second  version:  Created November 2012 by Ghada Al-Malky. 
APPENDIX I - PROTOCOL PROBLEMS AND CHANGES 
DATE COMMENTS 
Nov 2012 
 
Minor edits (GAM, RS and TS) 
March 2013 Minor edit of Flow chart (GAM) 
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Flow chart for Ototoxicity Monitoring protocol: 
 
 
  
If early signs of ototoxicity detected using ASHA criteria 
Referral to CF unit for modification of 
treatment 
Audiological rehabilitation for 
amplification/tinnitus councelling 
 
Diagnostic post-treatment  review at 
end of every subsequent i.v. AG course 
 
If normal hearing maintained 
Continue monitoring using targeted monitoring criteria 
Canditate for post-treatment  auditory screening in CF 
clinic/ward 
Follow-up auditory monitoring post-treatment 
should be performed at the end of i.v. AG course before discharge from ward and  at 6/8 week follow-up review clinic 
IF POSSIBLE: Baseline auditory monitoring in AVM Dept. (Tymps/ART, PTA (0.25-16kHz), DPOAE (1-8kHz)  
should be performed before/within 1st 72 hours of intake of 
1st dose of AG 
NHSP screening data can be retrieved from the eSP database 
if born >2006 
Clinical Fellow send referral for via internal mail to Audiology 
Audiologist books appointment on the dedicated clinic slots 
for Dr TS after checking next CF clinic appt for patient on 
PIMS 
Add patient to ototoxicity monitoring database 
CF child with respiratory infection in need of i.v. AGs 
Request for baseline audiological assessment by CF team (in AR clinic/ward)-Clinical Fellow/Registrar to confirm need 
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9.13 Appendix 13: Multivariate analysis for potential 
risk factors related to Theme B study 1: 
  Coefficient                95% CI p-value 
Standard Audiometry       
PTA 0.5 kHz 0.81 (-1.60, 3.22) 0.511 
PTA 1 kHz -1.99 (-4.40, 0.42) 0.107 
PTA 2 kHz -3.16 (-5.57, -0.75) 0.01 
PTA 4 kHz -2.1 (-4.51, 0.31) 0.089 
PTA 8 kHz 2.94                        ( 0.53,  5.35) 0.017 
Age (years) -0.24 (-0.83, 0.34) 0.415 
Male 0.53 (-3.79, 4.85) 0.812 
Low Exposed <10 AG Course 3.9 (-5.04, 12.83) 0.396 
High Exposed ≥10 AG Course 10.7 ( 1.44,  19.96) 0.027 
Amikacin Courses 0.87 ( 0.50,  1.24) <0.01 
Tobramycin Courses 0.29 (-0.41, 0.99) 0.424 
Gentamicin Courses 0.24 (-0.40, 0.88) 0.461 
FEV1 Average -0.03 (-0.18, 0.11) 0.648 
Years Of iv Intake -0.41 (-0.93, 0.12) 0.135 
Concomitant Vancomycin 0.7 (-0.20, 1.59) 0.135 
Concomitant Cisplatin  -2.42        (-13.11, 8.28) 0.66 
EHF Audiometry       
PTA 9 kHz 3.03 (-0.22, 6.28) 0.068 
PTA 10 kHz 1.72 (-1.53, 4.97) 0.299 
PTA 11.8 kHz 3.74 ( 0.49,  6.99) 0.024 
PTA 12.5 kHz 3.4 ( 0.15,  6.65) 0.04 
PTA 14 kHz 2.96 (-0.29, 6.21) 0.075 
PTA 16 kHz 0.72 (-2.53, 3.97) 0.666 
Age (years) 0.19 (-0.61, 0.99) 0.65 
Male 0.99 (-4.94, 6.92) 0.744 
Low Exposed <10 AG Course 2.8 (-10.88, 16.47) 0.69 
High Exposed ≥10 AG Course 18.97 ( 4.81,  33.14) 0.011 
Amikacin Courses 1.52 ( 1.01,  2.03) <0.01 
Tobramycin Courses 0.75 (-0.21, 1.71) 0.132 
Gentamicin Courses 0.64 (-0.23, 1.52) 0.156 
FEV1 Average -0.08 (-0.29, 0.12) 0.42 
Years Of iv Intake -0.92 (-1.64, -0.20) 0.015 
Concomitant Vancomycin 2 ( 0.77,  3.23) 0.002 
Concomitant Cisplatin  9.28 (-5.40, 23.97) 0.22 
DPOAEs         
1.0 kHz 3.79         ( 2.01,  5.57)          <0.01 
1.3 kHz 7.72 ( 5.94,  9.50) <0.01 
1.6 kHz 12.11 (10.33,  13.88) <0.01 
2.0 kHz 13.23 (11.45,  15.01) <0.01 
2.5 kHz 12.74 (10.96,  14.52) <0.01 
3.0 kHz 13.87 (12.09,  15.65) <0.01 
4.0 kHz 16.12 (14.34,  17.90) <0.01 
5.0 kHz 18.59 (16.81,  20.36) <0.01 
6.3 kHz 13.52 (11.74,  15.30) <0.01 
8.0 kHz 0.16 (-1.62, 1.94) 0.86 
Age (years) 0.37 ( 0.04,  0.70) 0.034 
Male -3.29 (-5.73, -0.85) 0.011 
Low Exposed <10 AG Course 0.86 (-4.18, 5.90) 0.739 
High Exposed ≥10 AG Course -2.04 (-7.29, 3.22) 0.45 
Amikacin Courses -0.23 (-0.46, -0.01) 0.048 
Tobramycin Courses -0.52 (-0.91, -0.12) 0.013 
Gentamicin Courses 0.02 (-0.34, 0.38) 0.923 
FEV1 Average -0.02 (-0.10, 0.07) 0.717 
Years Of iv Intake 0.27 (-0.03, 0.57) 0.078 
Concomitant Vancomycin -0.91 (-2.10, 0.29) 0.142 
Concomitant Cisplatin  -2.38 (-8.35, 3.60) 0.439 
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Table 5-9-1: Multivariable linear mixed models analysis applied for each of the audiometry and DPOAE 
testing methods in relation to explored risk factors.  
Factors in bold are significant at p<0.05. (This data was analyzed and presented within this table by Mr. 
Manolis Bagkeris – statistician at ICH with gratitude)  
 
Further analysis was performed by the ICH statistician using Multivariable linear mixed 
models applied for each of the testing methods, Standard PTA, EHF PTA and DPOAE to 
quantify the association of these different possible risk factors on the response levels at 
different frequencies. This allowed modeling the trajectories of hearing level (dB) change 
according to frequency and adjusting for the possible risk factors, taking into account the 
repeated measures at different frequencies from different ears within person (Table 
5-9-1).  For the Standard PTA, frequency 2kHz was significant coefficient change of -3.16 
dB HL (95% CI: -5.57 to -0.75; p=0.010) with every unit change in hearing, and frequency 
8kHz with increased coefficient by 2.94 dB HL (95% CI: 0.53 to 5.35; p=0.017), whereas 
coefficient 0.87 (0.50, 1.24); p<0.01 represents the significant increase in hearing thresholds 
(dBHL) achieved per unit increase of Amikacin. For EHF PTA significant increase was 
reported for the 11.8 and 12.5 kHz frequencies at 3.74 dB HL (95% CI: 0.49 to 6.99; 
p=0.024) and 3.40 dB HL (95% CI: 0.15 to 6.65; p=0.040) respectively. High exposure to 
AGs (≥10 courses- highest increase of 18.97 coefficient, 95% CI: 4.81 to 33.14), greater 
intake of Amikacin, longer years of exposure and intake of concomitant Vancomycin were 
shown to be significantly associated risk factors at p=0.011, <0.01, 0.015 and 0.002 
respectively. For DPOAEs significant changes were reported for all f2 frequencies ranging 
between 1.0 – 6.3 kHz at p<0.01 where the children’s older age, male gender, greater intake 
of Amikacin and greater intake of Tobramycin were shown to be significantly associated 
with reduced DPOAE amplitude levels (p=0.034, 0.011, 0.048 and 0.013 respectively).  
This analysis was undertaken, as the statistician believed that adding all the frequency 
responses within each of the three audiological tools into this multivariable linear mixed 
model takes advantage of the richness of the data collected rather than just depending on the 
binary analysis of identifying ‘non-ototoxic’ versus ‘ototoxic’ groups from each of these 
tools as presented in the Kappa analysis in Table 4-2, Table 4-3 and Table 4-4 or in the chi-
square analysis in Table 5-1. The criteria for ototoxicity was applied to each frequency tested 
by the three tools rather than to the overall outcome of each of the tests. However, in my 
opinion this analysis seemed to provide some outcomes that are contradictory to those 
previously presented. In this analysis only the 8kHz frequency outcomes from standard 
audiometry showed a statistically significant coefficient change, which was expected from 
previous analysis, yet for the EHF audiometry only the 11.8 and 12.0 kHz frequency were 
significant. This was not expected as data presented in Figure 4-1 and Figure 4-2, which 
showed the clear difference in thresholds across all EHF audiometry responses at all 9 to 16 
kHz frequencies, and from the ANOVA statistical analysis which showed: ‘The audiometric 
thresholds did not differ significantly between the groups at the lower frequencies (≤4 kHz) 
but differed significantly from one another at p<0.05 for frequencies 8 to 16 kHz with 
related t-tests when Bonferroni adjustment was made for the number of comparisons.’ 
(Section: 4.1.1.2). The analysis of the DPOAE responses was even more divergent from 
previous analysis as it showed that all f2 frequencies (except for 8kHz) tested showed 
significant coefficient changes that were much larger than the standard or the EHF 
audiometry data (i.e. coefficient values range of 3.79 -18.59 for DPOAEs vs. 0.72 - 3.74 for 
EHF PTA).  This was different from the DPOAE amplitude and SNR data presented in 
Figure 4-6and Figure 4-7 respectively and in the kappa analysis presented in Table 4-3 and 
Table 4-4. These results had shown that even though the DPOAE results were generally in 
agreement with the audiometric data, the sensitivity of the EHF audiometry to detection of 
ototoxicity was higher than with DPOAE.  
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